{"docstore/data": {"cb06e274-8f84-4c07-9959-21d8a2b43e39": {"__data__": {"id_": "cb06e274-8f84-4c07-9959-21d8a2b43e39", "embedding": null, "metadata": {"page_label": "223", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fed750a1-344b-4cc1-a9e3-43aa3e2a9dc8", "node_type": "4", "metadata": {"page_label": "223", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "2c06566c26b06f23f8a52f8179455fda5323aa20a2e62522f72e39de74ef022b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2955d200-3d69-4c09-98e8-670107036db7", "node_type": "1", "metadata": {"page_label": "223", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1842f7d5f9f60310bb15d2ac3d9ca82dc109a917b48a62097eb3ba12c048a62c", "class_name": "RelatedNodeInfo"}}, "hash": "55572bc0c153f2cdf5bafd96fcbc0dd77ad880d41ff9d0eb2dba2ca2f9715d6e", "text": "nature publishing group 223\n\u00a9 2015 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGYPRACTICE GUIDELINES\n      Hereditary gastrointestinal (GI) cancer syndromes represent a \nphenotypically diverse group of disorders that exhibit distinct patterns of inheritance in an individual\u2019s progeny. Over the past few decades, the expansion of fami lial cancer registries and ad-\nvancement in genomics have led to the development of clinical diagnostic criteria for specifi  c hereditary syndromes as well as \nthe discovery of multiple genes in which germline mutations predispose individuals to syndrome-associated neoplastic mani-festations. Th  is guideline fi  rst discusses essential elements of a \npatient\u2019s personal and family history that allow for risk assess-ment for potential inherited cancer susceptibility. It then ad-dresses the currently most well-characterized GI cancer suscep-tibility syndromes: Lynch syndrome (LS), familial adenomatous polyposis (FAP), attenuated familial adenomatous polyposis (AFAP),  MUTYH  -associated polyposis (MAP), Peutz\u2013Jeghers syndrome (PJS), juvenile polyposis syndrome (JPS), Cowden \nsyndrome (CS), serrated (hyperplastic) polyposis syndrome, hereditary pancreatic cancer, and hereditary gastric cancer. For each of these syndromes, we outline diagnostic criteria and in-dications for genetic evaluation, describe the currently known associated underlying genes, an d make recommendations for \nsurveillance and management of at-risk individuals and those found to carry a defi  nitive disease-causing mutation. Finally, we \ndiscuss the elements of informed consent that must accompany genetic evaluation as well as currently evolving genetic testing technologies that may change how genetic testing is conducted in the near-term future.\n  Each section of the document presents summary statements, \nthe key recommendations related to the section topic, followed by a summary of the supporting evidence ( Tables 1 and 2 ).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2955d200-3d69-4c09-98e8-670107036db7": {"__data__": {"id_": "2955d200-3d69-4c09-98e8-670107036db7", "embedding": null, "metadata": {"page_label": "223", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fed750a1-344b-4cc1-a9e3-43aa3e2a9dc8", "node_type": "4", "metadata": {"page_label": "223", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "2c06566c26b06f23f8a52f8179455fda5323aa20a2e62522f72e39de74ef022b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb06e274-8f84-4c07-9959-21d8a2b43e39", "node_type": "1", "metadata": {"page_label": "223", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "55572bc0c153f2cdf5bafd96fcbc0dd77ad880d41ff9d0eb2dba2ca2f9715d6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4474d413-46ca-44b4-9c40-f05b8cc604be", "node_type": "1", "metadata": {"page_label": "223", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "0295503c522f9f8e1a973d7e95701875691057af0af189cb865fcd7c0275858b", "class_name": "RelatedNodeInfo"}}, "hash": "1842f7d5f9f60310bb15d2ac3d9ca82dc109a917b48a62097eb3ba12c048a62c", "text": "A                                              ACG Clinical Guideline: Genetic Testing and \nManagement of Hereditary Gastrointestinal Cancer Syndromes\n        S a p n a      S y n g a l    ,    M D ,  M P H ,  F A C G    1   ,      2   ,      3      ,      R a n d a l l  E .      B r a n d    ,    M D ,  F A C G    4    ,      J a m e s  M .      C h u r c h    ,    M D ,  F A C G    5   ,      6   ,      7    ,     Francis M.     Giardiello   ,   MD   8    ,  \n    Heather L.     Hampel   ,   MS, CGC   9     a n d      R a n d a l l  W.      B u r t    ,    M D ,  F A C G    10   \n                                                                                                                   This guideline presents recommendations for the management of patients with hereditary gastrointestinal cancer \nsyndromes. The initial assessment is the collection of a family history of cancers and premalignant gastrointestinal conditions and should provide enough information to develop a preliminary determination of the risk of a familial predisposition to cancer. Age at diagnosis and lineage (maternal and/or paternal) should be documented for all diagnoses, especially in \ufb01  rst- and second-degree relatives. When indicated, genetic testing for a germline mutation \nshould be done on the most informative candidate(s) identi\ufb01  ed through the family history evaluation and/or tumor \nanalysis to con\ufb01  rm a diagnosis and allow for predictive testing of at-risk relatives. Genetic testing should be \nconducted in the context of pre- and post-test genetic counseling to ensure the patient\u2019s informed decision making. Patients who meet clinical criteria for a syndrome as well as those with identi\ufb01  ed pathogenic germline mutations \nshould receive appropriate surveillance measures in order to minimize their overall risk of developing syndrome-speci\ufb01  c cancers.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4474d413-46ca-44b4-9c40-f05b8cc604be": {"__data__": {"id_": "4474d413-46ca-44b4-9c40-f05b8cc604be", "embedding": null, "metadata": {"page_label": "223", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fed750a1-344b-4cc1-a9e3-43aa3e2a9dc8", "node_type": "4", "metadata": {"page_label": "223", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "2c06566c26b06f23f8a52f8179455fda5323aa20a2e62522f72e39de74ef022b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2955d200-3d69-4c09-98e8-670107036db7", "node_type": "1", "metadata": {"page_label": "223", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1842f7d5f9f60310bb15d2ac3d9ca82dc109a917b48a62097eb3ba12c048a62c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d57064e5-bb9f-4b7e-a278-8da8bcb5f388", "node_type": "1", "metadata": {"page_label": "223", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "8f7d024556432ddb095cb9c43181f8570da399382e146f54795f41cfaa25ee99", "class_name": "RelatedNodeInfo"}}, "hash": "0295503c522f9f8e1a973d7e95701875691057af0af189cb865fcd7c0275858b", "text": "This guideline speci\ufb01  cally discusses genetic testing and management of Lynch syndrome, familial \nadenomatous polyposis (FAP), attenuated familial adenomatous polyposis (AFAP),  MUTYH  -associated polyposis \n(MAP), Peutz\u2013Jeghers syndrome, juvenile polyposis syndrome, Cowden syndrome, serrated (hyperplastic) polyposis syndrome, hereditary pancreatic cancer, and hereditary gastric cancer.\n   Am J Gastroenterol   2015; 110:223\u2013262; doi: 10.1038/ajg.2014.435; published online 3 February 2015 \n   1   Brigham and Women\u2019s Hospital ,  Boston ,  Massachusetts ,  USA   ;     2   Dana Farber Cancer Institute ,  Boston ,  Massachusetts ,  USA   ;     3   Harvard Medical School ,  Boston , \n Massachusetts ,  USA   ;     4   Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center ,  Pittsburgh , \n Pennsylvania ,  USA   ;     5   Department of Colorectal Surgery, Cleveland Clinic ,  Cleveland ,  Ohio ,  USA   ;     6   Sanford R Weiss, MD, Center for Hereditary Colorectal Neoplasia, \nCleveland Clinic Foundation ,  Cleveland ,  Ohio ,  USA   ;     7   Digestive Disease Institute, Cleveland Clinic Foundation ,  Cleveland ,  Ohio ,  USA   ;     8   Johns Hopkins University \nSchool of Medicine ,  Baltimore ,  Maryland ,  USA   ;     9   Department of Internal Medicine, Ohio State University ,  Columbus ,  Ohio ,  USA   ;     10   Huntsman Cancer Institute, \nUniversity of Utah School of Medicine ,  Salt Lake City ,  Utah ,  USA   .   Correspondence:      Sapna Syngal, MD, MPH, FACG,   Dana Farber Cancer Institute ,  450 Brookline \nAvenue, Dana 1124 ,  Boston ,  Massachusetts   02215 ,  USA .", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d57064e5-bb9f-4b7e-a278-8da8bcb5f388": {"__data__": {"id_": "d57064e5-bb9f-4b7e-a278-8da8bcb5f388", "embedding": null, "metadata": {"page_label": "223", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fed750a1-344b-4cc1-a9e3-43aa3e2a9dc8", "node_type": "4", "metadata": {"page_label": "223", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "2c06566c26b06f23f8a52f8179455fda5323aa20a2e62522f72e39de74ef022b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4474d413-46ca-44b4-9c40-f05b8cc604be", "node_type": "1", "metadata": {"page_label": "223", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "0295503c522f9f8e1a973d7e95701875691057af0af189cb865fcd7c0275858b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1ebd309-4ec7-4ba8-bdba-a489ece0dae1", "node_type": "1", "metadata": {"page_label": "224", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "d9694a19b3a86f84b4ce4e29be0102fef0944880ab6fd60cad867cb257cfee87", "class_name": "RelatedNodeInfo"}}, "hash": "8f7d024556432ddb095cb9c43181f8570da399382e146f54795f41cfaa25ee99", "text": "E-mail:  sapna_syngal@dfci.harvard.edu  \n   Received     12     September     2014  ;     accepted     10     December     2014   CME\nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1ebd309-4ec7-4ba8-bdba-a489ece0dae1": {"__data__": {"id_": "d1ebd309-4ec7-4ba8-bdba-a489ece0dae1", "embedding": null, "metadata": {"page_label": "224", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d03c26b4-5937-40d1-a094-9520d1ab61a8", "node_type": "4", "metadata": {"page_label": "224", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1c82003ede3187962d975d3bd5e55ac91c034b3a493fea7789598a4cec4e4c3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d57064e5-bb9f-4b7e-a278-8da8bcb5f388", "node_type": "1", "metadata": {"page_label": "223", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "8f7d024556432ddb095cb9c43181f8570da399382e146f54795f41cfaa25ee99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c12dc3d-c112-4002-bd73-d1565c54fece", "node_type": "1", "metadata": {"page_label": "224", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "8620a9023889fce4d72d6769cfd8cb61051c028d61879d588e3b077ad391d1b3", "class_name": "RelatedNodeInfo"}}, "hash": "d9694a19b3a86f84b4ce4e29be0102fef0944880ab6fd60cad867cb257cfee87", "text": "Syngal  et al.  \nThe American Journal of GASTROENTEROLOGY VOLUME 110 | FEBRUARY 2015    www.amjgastro.com 224\n Table 1  .     Summary statements \n  Standard for minimal cancer family history assessment in gastrointestinal (GI) practice   \n   A family history of cancer and premalignant GI conditions that provides suf\ufb01  cient information to develop a preliminary determi nation of the risk of a familial \npredisposition to cancer should be obtained for all patients being evaluated in outpatient gastroenterology and endoscopy pract ices. \n   Essential elements of a family history include presence and type of cancer diagnoses in \ufb01  rst- and second-degree relatives, and  presence and (ideally) type \nof polyps in \ufb01  rst-degree relatives; age and lineage should be noted for each diagnosis. \n  Lynch syndrome (LS)   \n  All newly diagnosed colorectal cancers (CRCs) should be evaluated for mismatch repair de\ufb01  ciency. \n   Analysis may be done by immunohistochemical testing for the  MLH1/MSH2/MSH6/PMS2   proteins and/or testing for microsatellite instability. Tumors that \ndemonstrate loss of  MLH1   should undergo BRAF testing or analysis for  MLH1   promoter hypermethylation. \n   Individuals who have a personal history of a tumor showing evidence of mismatch repair de\ufb01  ciency (and no demonstrated BRAF mutation or hypermethylation of \n MLH1)  , a known family mutation associated with LS, or a risk of \u22655% chance of LS based on risk prediction models should undergo gene tic evaluation for LS. \n   Genetic testing of patients with suspected LS should include germline mutation genetic testing for the  MLH1  ,  MSH2  ,  MSH6  ,  PMS2  , and/or  EPCAM   genes \nor the altered gene(s) indicated by immunohistochemical (IHC) testing.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c12dc3d-c112-4002-bd73-d1565c54fece": {"__data__": {"id_": "6c12dc3d-c112-4002-bd73-d1565c54fece", "embedding": null, "metadata": {"page_label": "224", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d03c26b4-5937-40d1-a094-9520d1ab61a8", "node_type": "4", "metadata": {"page_label": "224", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1c82003ede3187962d975d3bd5e55ac91c034b3a493fea7789598a4cec4e4c3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1ebd309-4ec7-4ba8-bdba-a489ece0dae1", "node_type": "1", "metadata": {"page_label": "224", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "d9694a19b3a86f84b4ce4e29be0102fef0944880ab6fd60cad867cb257cfee87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "854b4134-fa1e-4e23-9fbd-11ff8ae104ca", "node_type": "1", "metadata": {"page_label": "224", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "40fd279e09f94d871b957868a38e3e548b710c54dee31e86a7cf527f7fdda353", "class_name": "RelatedNodeInfo"}}, "hash": "8620a9023889fce4d72d6769cfd8cb61051c028d61879d588e3b077ad391d1b3", "text": "Adenomatous polyposis syndromes   \n   Familial adenomatous polyposis (FAP)/MUTYH-associated polyposis/attenuated polyposis   \n    Individuals who have a personal history of >10 cumulative colorectal adenomas, a family history of one of the adenomatous polyp osis syndromes, or a \nhistory of adenomas and FAP-type extracolonic manifestations (duodenal/ampullary adenomas, desmoid tumors (abdominal>peripheral ), papillary thyroid \ncancer, congenital hypertrophy of the retinal pigment epithelium ((CHRPE), epidermal cysts, osteomas) should undergo assessment  for the adenomatous \npolyposis syndromes. \n   Genetic testing of patients with suspected adenomatous polyposis syndromes should include  APC  and  MUTYH   gene mutation analysis. \n  Hamartomatous polyposis syndromes   \n   Peutz\u2013Jeghers syndrome (PJS)   \n    Individuals with perioral or buccal pigmentation and/or two or more histologically characteristic gastrointestinal hamartomatou s polyp(s) or a family history \nof PJS should be evaluated for PJS. \n   Genetic evaluation of a patient with possible PJS should include testing for  STK11   mutations. \n   Juvenile polyposis syndrome (JPS)   \n   Individuals with \ufb01  ve or more juvenile polyps in the colorectum or any juvenile polyps in other parts of the GI tract should undergo evaluation for JPS. \n   Genetic evaluation of a patient with possible JPS should include testing for  SMAD4   and  BMPR1A   mutations. \n   Cowden syndrome (PTEN hamartoma tumor syndrome)   \n   Individuals with multiple gastrointestinal hamartomas or ganglioneuromas should be evaluated for Cowden syndrome and related conditions. \n   Genetic evaluation of a patient with possible Cowden syndrome should include testing for  PTEN   mutations.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "854b4134-fa1e-4e23-9fbd-11ff8ae104ca": {"__data__": {"id_": "854b4134-fa1e-4e23-9fbd-11ff8ae104ca", "embedding": null, "metadata": {"page_label": "224", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d03c26b4-5937-40d1-a094-9520d1ab61a8", "node_type": "4", "metadata": {"page_label": "224", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1c82003ede3187962d975d3bd5e55ac91c034b3a493fea7789598a4cec4e4c3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c12dc3d-c112-4002-bd73-d1565c54fece", "node_type": "1", "metadata": {"page_label": "224", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "8620a9023889fce4d72d6769cfd8cb61051c028d61879d588e3b077ad391d1b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87a6f675-a8d6-432a-a4b6-88658a2391f2", "node_type": "1", "metadata": {"page_label": "224", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "91328e06477a035cb83565cbfab4e1866895c71411448c5580e8226a8df728c7", "class_name": "RelatedNodeInfo"}}, "hash": "40fd279e09f94d871b957868a38e3e548b710c54dee31e86a7cf527f7fdda353", "text": "Serrated/hyperplastic polyposis syndrome   \n    Individuals who meet at least one of the following criteria have the clinical diagnosis of serrated polyposis syndrome (SPS): ( i) at least 5 serrated polyps \nproximal to the sigmoid colon with \u22652 of these being >10 mm; (ii) any number of serrated polyps proximal to the sigmoid colon i n an individual who has \na \ufb01  rst-degree relative (FDR) with serrated polyposis; and (iii) >20 serrated polyps of any size, distributed throughout the la rge intestine. \n    A clear genetic etiology has not yet been de\ufb01  ned for SPS, and therefore genetic testing is currently not routinely recommended  for SPS patients; testing \nfor  MUTYH   mutations may be considered for SPS patients with concurrent adenomas and/or a family history of adenomas. \n  Hereditary pancreatic cancer   \n    Individuals should be considered to be at risk for familial pancreatic adenocarcinoma if they (i) have a known genetic syndrome  associated with pancreatic \ncancer, including hereditary breast\u2013-ovarian cancer syndrome, familial atypical multiple melanoma and mole syndrome (FAMMM), PJ S, LS, or other gene \nmutations associated with an increased risk of pancreatic adenocarcinoma; or (ii) have two relatives with pancreatic adenocarci noma, where one is a FDR; \n(iii) have three or more relatives with pancreatic cancer; or (iv) have a history of hereditary pancreatitis. \n    Genetic testing of patients with suspected familial pancreatic cancer should include analysis of  BRCA1/2  ,  CDKN2A  ,  PALB2  , and  ATM . Evaluation for PJS, \nLS, and hereditary pancreatitis-associated genes should be considered if other component personal and/or family history criteri a are met for the syndrome.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87a6f675-a8d6-432a-a4b6-88658a2391f2": {"__data__": {"id_": "87a6f675-a8d6-432a-a4b6-88658a2391f2", "embedding": null, "metadata": {"page_label": "224", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d03c26b4-5937-40d1-a094-9520d1ab61a8", "node_type": "4", "metadata": {"page_label": "224", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1c82003ede3187962d975d3bd5e55ac91c034b3a493fea7789598a4cec4e4c3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "854b4134-fa1e-4e23-9fbd-11ff8ae104ca", "node_type": "1", "metadata": {"page_label": "224", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "40fd279e09f94d871b957868a38e3e548b710c54dee31e86a7cf527f7fdda353", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc477908-57ae-495f-bd09-079fe77a6b72", "node_type": "1", "metadata": {"page_label": "225", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "b130cfbe924b2379c7730f6f9cc6f402556f9d118f0b6ea72e9642ba36997ea4", "class_name": "RelatedNodeInfo"}}, "hash": "91328e06477a035cb83565cbfab4e1866895c71411448c5580e8226a8df728c7", "text": "Hereditary gastric cancer   \n   Hereditary diffuse gastric cancer (HDGC)   \n    Individuals with (i) \u22652 cases of diffuse gastric cancer, with at least one diagnosed at <50 years; (ii) \u22653 cases of documented diffuse cancer in \ufb01  rst- or \nsecond degree relatives independent of age of onset; (iii) diffuse gastric cancer diagnosed at <40 years; (iv) a personal or fa mily history of diffuse gastric \ncancer and lobular breast cancer with one diagnosed at <50 years should be evaluated for HDGC. \n   Genetic testing of individuals who ful\ufb01  ll HDGC clinical criteria should include analysis of  CDH1   mutations. \nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc477908-57ae-495f-bd09-079fe77a6b72": {"__data__": {"id_": "cc477908-57ae-495f-bd09-079fe77a6b72", "embedding": null, "metadata": {"page_label": "225", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "2fa71731-7e72-4fac-af86-8692b3ae2854", "node_type": "4", "metadata": {"page_label": "225", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "0e9204c37f2956a59c281022feae0d35914b2a7c34ed4c87892ee9464d0f93a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87a6f675-a8d6-432a-a4b6-88658a2391f2", "node_type": "1", "metadata": {"page_label": "224", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "91328e06477a035cb83565cbfab4e1866895c71411448c5580e8226a8df728c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63a265be-89a6-469f-af2c-54d215aa08fb", "node_type": "1", "metadata": {"page_label": "225", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "e871f50b03c14a407dc53facce722417bedcad43d9919debc32f1840dcf9bd01", "class_name": "RelatedNodeInfo"}}, "hash": "b130cfbe924b2379c7730f6f9cc6f402556f9d118f0b6ea72e9642ba36997ea4", "text": "Hereditary GI Cancer Syndromes\n\u00a9 2015 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY\n 225\n Table 2  .     Summary of recommendations \n  Lynch syndrome (LS)   \n   1. In individuals at risk for or affected with LS, screening for colorectal cancer by colonoscopy should be performed at least every 2 years, beginning \nbetween ages 20 and 25 years. Annual colonoscopy should be considered in con\ufb01  rmed mutation carriers (strong recommendation, moderate quality of \nevidence for screening, and very low quality of evidence for annual surveillance and age of initiation). \n   2. Colectomy with ileorectal anastomosis (IRA) is the preferred treatment of patients affected with LS with colon cancer or col onic neoplasia not controllable \nby endoscopy. Segmental colectomy is an option in patients unsuitable for total colectomy if regular postoperative surveillance  is conducted (conditional \nrecommendation, moderate quality of evidence). \n   3. Hysterectomy and bilateral salpingo-oophorectomy should be offered to women who are known LS mutation carriers and who have \ufb01  nished child bearing, \noptimally at age 40\u201345 years (conditional recommendation, low quality of evidence). \n   4. Screening for endometrial cancer and ovarian cancer should be offered to women at risk for or affected with LS by endometria l biopsy and transvaginal \nultrasound annually, starting at age 30 to 35 years before undergoing surgery or if surgery is deferred (conditional recommenda tion, very low quality of \nevidence). \n   5. Screening for gastric and duodenal cancer can be considered in individuals at risk for or affected with LS by baseline esoph agogastroduodenoscopy \n(EGD) with gastric biopsy at age 30\u201335 years, and treatment of  H. pylori   infection when found. Data for ongoing regular surveillance are limited, but \nongoing surveillance every 3\u20135 years may be considered if there is a family history of gastric or duodenal cancer (conditional recommendation, very low \nquality of evidence). \n   6.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63a265be-89a6-469f-af2c-54d215aa08fb": {"__data__": {"id_": "63a265be-89a6-469f-af2c-54d215aa08fb", "embedding": null, "metadata": {"page_label": "225", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "2fa71731-7e72-4fac-af86-8692b3ae2854", "node_type": "4", "metadata": {"page_label": "225", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "0e9204c37f2956a59c281022feae0d35914b2a7c34ed4c87892ee9464d0f93a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc477908-57ae-495f-bd09-079fe77a6b72", "node_type": "1", "metadata": {"page_label": "225", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "b130cfbe924b2379c7730f6f9cc6f402556f9d118f0b6ea72e9642ba36997ea4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de8f7c17-8877-4658-a464-bd0838881033", "node_type": "1", "metadata": {"page_label": "225", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "14b01570e33c1c00b20c3fba8d82e7a11967fe64be801cadb47bb7e73f99dafe", "class_name": "RelatedNodeInfo"}}, "hash": "e871f50b03c14a407dc53facce722417bedcad43d9919debc32f1840dcf9bd01", "text": "6. Screening beyond population-based recommendations for cancers of the urinary tract, pancreas, prostate, and breast is not re commended unless there \nis a family history of the speci\ufb01  c cancers (conditional recommendation, low quality of evidence). \n   7. Although data suggest that daily aspirin may decrease the risk of colorectal and extracolonic cancer in LS, currently the ev idence is not suf\ufb01  ciently robust \nor mature to make a recommendation for its standard use (conditional recommendation, moderate quality of evidence). \n  Adenomatous polyposis syndromes   \n   Familial adenomatous polyposis (FAP)/MUTYH-associated polyposis (MAP)/attenuated polyposis   \n   8. In individuals at risk for or affected with the classic AP syndromes, screening for colorectal cancer by annual colonoscopy or \ufb02  exible sigmoidoscopy \nshould be performed, beginning at puberty. In families with attenuated familial adenomatous polyposis (AFAP) or MAP, surveillan ce should be by \ncolonoscopy (strong recommendation, moderate quality of evidence). \n   9. Absolute indications for immediate colectomy in FAP, AFAP, and MAP include: documented or suspected cancer or signi\ufb01  cant sy mptoms. Relative \nindications for surgery include the presence of multiple adenomas >6 mm, a signi\ufb01  cant increase in adenoma number, and inability to adequately survey the \ncolon because of multiple diminutive polyps (strong recommendation, low quality of evidence). \n   10. Screening for gastric and proximal small bowel tumors should be done using upper endoscopy including duodenoscopy starting at age 25\u201330 years. \nSurveillance should be repeated every 0.5\u20134 years depending on Spigelman stage of duodenal polyposis: 0=4 years; I=2\u20133 years, I I=1\u20133 years, III=6\u201312 \nmonths, and IV=surgical evaluation. Examination of the stomach should include random sampling of fundic gland polyps.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de8f7c17-8877-4658-a464-bd0838881033": {"__data__": {"id_": "de8f7c17-8877-4658-a464-bd0838881033", "embedding": null, "metadata": {"page_label": "225", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "2fa71731-7e72-4fac-af86-8692b3ae2854", "node_type": "4", "metadata": {"page_label": "225", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "0e9204c37f2956a59c281022feae0d35914b2a7c34ed4c87892ee9464d0f93a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63a265be-89a6-469f-af2c-54d215aa08fb", "node_type": "1", "metadata": {"page_label": "225", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "e871f50b03c14a407dc53facce722417bedcad43d9919debc32f1840dcf9bd01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdf19d33-e750-4aa6-9e49-0069d820ec64", "node_type": "1", "metadata": {"page_label": "225", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "116c3b16e7cbf952779534ed225191062482b5f85ec05ddf26394d4bb4e54343", "class_name": "RelatedNodeInfo"}}, "hash": "14b01570e33c1c00b20c3fba8d82e7a11967fe64be801cadb47bb7e73f99dafe", "text": "Examination of the stomach should include random sampling of fundic gland polyps. Low-grade  dysplasia is \ncommon in fundic gland polyps, and surgery should be reserved for high-grade dysplasia or cancer (strong recommendation, very l ow quality of \nevidence). \n   11. Annual thyroid screening by ultrasound should be recommended to individuals affected with FAP, MAP, and attenuated polyposi s (conditional recom-\nmendation, low quality of evidence). \n   12. Biannual screening should be offered to affected infants until age 7 years with \u03b1 -fetoprotein and ultrasounds (conditional recommendation, very low \nquality of evidence). \n   13. Postsurgical surveillance should include yearly endoscopy of rectum or ileal pouch, and examination of an ileostomy every 2  years (strong recommenda-\ntion, low quality level of evidence). \n  Hamartomatous polyposis syndromes   \n   Peutz\u2013Jeghers syndrome (PJS)   \n   14. Surveillance in affected or at-risk PJS patients should include monitoring for colon, stomach, small bowel, pancreas, breas t, ovary, uterus, cervix, \nand testes cancers. Risk for lung cancer is increased, but no speci\ufb01  c screening has been recommended. It would seem wise to consider annual chest \nradiograph or chest computed tomography (CT) in smokers (conditional recommendation, low quality of evidence). \n   Juvenile polyposis syndrome (JPS)   \n   15. Surveillance of the gastrointestinal (GI) tract in affected or at-risk JPS patients should include screening for colon, sto mach, and small bowel cancers \n(conditional recommendation, very low quality of evidence). \n   16. Colectomy and ileorectal anastomosis or proctocolectomy and ileal pouch-anal anastomosis is indicated for polyp-related sym ptoms, or when the polyps \ncannot be managed endoscopically (conditional recommendation, low quality of evidence). \n   17. Cardiovascular examination for and evaluation for hereditary hemorrhagic telangiectasia should be considered for  SMAD4   mutation carriers \n(conditional recommendation, very low quality of evidence).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdf19d33-e750-4aa6-9e49-0069d820ec64": {"__data__": {"id_": "fdf19d33-e750-4aa6-9e49-0069d820ec64", "embedding": null, "metadata": {"page_label": "225", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "2fa71731-7e72-4fac-af86-8692b3ae2854", "node_type": "4", "metadata": {"page_label": "225", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "0e9204c37f2956a59c281022feae0d35914b2a7c34ed4c87892ee9464d0f93a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de8f7c17-8877-4658-a464-bd0838881033", "node_type": "1", "metadata": {"page_label": "225", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "14b01570e33c1c00b20c3fba8d82e7a11967fe64be801cadb47bb7e73f99dafe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05d70c96-e99a-49a7-8c15-cd4f4ce6f6b7", "node_type": "1", "metadata": {"page_label": "226", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "8fd7512aeca413b85d9dcb11e2e0270cd86ac1db3bda0fb1cbb7fa792794bee1", "class_name": "RelatedNodeInfo"}}, "hash": "116c3b16e7cbf952779534ed225191062482b5f85ec05ddf26394d4bb4e54343", "text": "Cowden syndrome (PTEN hamartoma tumor syndrome)   \n   18. Surveillance in affected or at-risk Cowden syndrome patients should include screening for colon, stomach, small bowel, thyr oid, breast, uterine, kidney, \nand skin (melanoma) cancers (conditional recommendation, low quality of evidence). \nTable 2 continued on following page\nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05d70c96-e99a-49a7-8c15-cd4f4ce6f6b7": {"__data__": {"id_": "05d70c96-e99a-49a7-8c15-cd4f4ce6f6b7", "embedding": null, "metadata": {"page_label": "226", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f97a245a-22f1-48a5-8820-a409dcc5d14a", "node_type": "4", "metadata": {"page_label": "226", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "aa5b3ae7d0b06f498047e5c4deb1c9c2bda250381e27c36a66e83072b1e4a2e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdf19d33-e750-4aa6-9e49-0069d820ec64", "node_type": "1", "metadata": {"page_label": "225", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "116c3b16e7cbf952779534ed225191062482b5f85ec05ddf26394d4bb4e54343", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdaafdfd-7e6b-4488-93eb-894a0f7b7a57", "node_type": "1", "metadata": {"page_label": "226", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "94c477817048efe2a6c869a2d24d0659b57c23183bb7fcb9deac57a60a103e01", "class_name": "RelatedNodeInfo"}}, "hash": "8fd7512aeca413b85d9dcb11e2e0270cd86ac1db3bda0fb1cbb7fa792794bee1", "text": "Syngal  et al.  \nThe American Journal of GASTROENTEROLOGY VOLUME 110 | FEBRUARY 2015    www.amjgastro.com 226\n Table 2  .     Continued \n   Serrated/hyperplastic polyposis syndrome   \n   19. Patients with serrated polyposis should undergo colonoscopies every 1\u20133 years with attempted removal of all polyps >5 mm di ameter (conditional \nrecommendation, low quality of evidence). \n   20. Indications for surgery for serrated polyposis syndrome (SPS) include an inability to control the growth of serrated polyps , or the development of cancer. \nColectomy and ileorectal anastomosis is a reasonable option given the risks of metachronous neoplasia (conditional recommendati on, low quality of evi-\ndence). \n   21. There is no evidence to support extracolonic cancer surveillance for SPS at this time. Screening recommendations for family  members are currently \nunclear pending further data and should be individualized based on results of baseline evaluations in family members (condition al recommendation, very \nlow quality of evidence). \n  Hereditary pancreatic cancer   \n   22. Surveillance of individuals with a genetic predisposition for pancreatic adenocarcinoma should ideally be performed in expe rienced centers utilizing \na multidisciplinary approach and under research conditions. These individuals should be known mutation carriers from hereditary  syndromes associated \nwith increased risk of pancreatic cancer (Peutz\u2013Jeghers, hereditary pancreatitis, familial atypical multiple melanoma and mole syndrome (FAMMM)) or \nmembers of familial pancreatic cancer kindreds with a pancreatic cancer affected \ufb01  rst-degree relative. Because of a lower relative risk for pancreatic adeno-\ncarcinoma development in  BRCA1  ,  BRCA2  ,  PALB2  ,  ATM , and LS families, surveillance should be limited to mutation carriers with a \ufb01  rst or second-degree \nrelative affected with pancreatic cancer (conditional recommendation; very low quality of evidence). \n   23.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdaafdfd-7e6b-4488-93eb-894a0f7b7a57": {"__data__": {"id_": "bdaafdfd-7e6b-4488-93eb-894a0f7b7a57", "embedding": null, "metadata": {"page_label": "226", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f97a245a-22f1-48a5-8820-a409dcc5d14a", "node_type": "4", "metadata": {"page_label": "226", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "aa5b3ae7d0b06f498047e5c4deb1c9c2bda250381e27c36a66e83072b1e4a2e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05d70c96-e99a-49a7-8c15-cd4f4ce6f6b7", "node_type": "1", "metadata": {"page_label": "226", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "8fd7512aeca413b85d9dcb11e2e0270cd86ac1db3bda0fb1cbb7fa792794bee1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6f1e6f7-5dc7-4653-a92a-ad0ac99f6431", "node_type": "1", "metadata": {"page_label": "226", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "29c507cdafcc4db65a3919968ae20bc38e7eb164e32b8f9b0b5285ac25e06926", "class_name": "RelatedNodeInfo"}}, "hash": "94c477817048efe2a6c869a2d24d0659b57c23183bb7fcb9deac57a60a103e01", "text": "23. Surveillance for pancreatic cancer should be with endoscopic ultrasound (EUS) and/or magnetic resonance imaging (MRI) of th e pancreas annually \nstarting at age 50 years, or 10 years younger than the earliest age of pancreatic cancer in the family. Patients with PJS shoul d start surveillance at age \n35 years (conditional recommendation, very low quality of evidence). \n   24. Because of the increased risk for pancreatic cancer development when compared with a pancreatic cyst in the sporadic settin g, cystic lesion(s) of the \npancreas detected during surveillance of a hereditary pancreatic cancer-prone family member requires evaluation by centers expe rienced in the care of \nthese high-risk individuals. Determining when surgery is required for pancreatic lesions is dif\ufb01  cult and is best individualized after multidisciplinary assess-\nment (conditional recommendation, low quality of evidence). \n  Hereditary gastric cancer   \n   Hereditary diffuse gastric cancer   \n   25. Management for patients with hereditary diffuse gastric cancer should include: (i) prophylactic gastrectomy after age 20 ye ars (>80% risk by age 80); \n(ii) breast cancer surveillance in women beginning at age 35 years with annual mammography and breast MRI and clinical breast e xamination every 6 \nmonths; and (iii) colonoscopy beginning at age 40 years for families that include colon cancer (conditional recommendation, low  quality of evidence). \n Table 3  .     GRADE (Grading of Recommendations Assessment, \nDevelopment and Evaluation) system of evidence and strength of recommendation \n High  Further research is very unlikely to change our con\ufb01  dence in \nthe estimate of effect. \n Moderate  Further research is likely to have an important impact on \nour con\ufb01  dence in the estimate of effect and may change the \nestimate. \n Low  Further research is very likely to have an important impact on \nour con\ufb01  dence in the estimate of effect and is likely to change \nthe estimate. \n Very low  Any estimate of the effect is very uncertain.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6f1e6f7-5dc7-4653-a92a-ad0ac99f6431": {"__data__": {"id_": "d6f1e6f7-5dc7-4653-a92a-ad0ac99f6431", "embedding": null, "metadata": {"page_label": "226", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f97a245a-22f1-48a5-8820-a409dcc5d14a", "node_type": "4", "metadata": {"page_label": "226", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "aa5b3ae7d0b06f498047e5c4deb1c9c2bda250381e27c36a66e83072b1e4a2e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdaafdfd-7e6b-4488-93eb-894a0f7b7a57", "node_type": "1", "metadata": {"page_label": "226", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "94c477817048efe2a6c869a2d24d0659b57c23183bb7fcb9deac57a60a103e01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3395afff-957c-47f1-9f7b-12039009ba12", "node_type": "1", "metadata": {"page_label": "226", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "8bfae5b08a1fa8b98d6ecd90a026b8405a3b5946eb9dfdbc0a588ac8dd8dc3c5", "class_name": "RelatedNodeInfo"}}, "hash": "29c507cdafcc4db65a3919968ae20bc38e7eb164e32b8f9b0b5285ac25e06926", "text": "Very low  Any estimate of the effect is very uncertain. search of MEDLINE via the OVID interface using the MeSH \nterm \u201chereditary cancer syndrome\u201d limited to clinical trials, reviews, guidelines, and meta-analysis for the years 1966\u20132013 was performed to develop the document and create summary statements and recommendations. \u201cSummary statements\u201d and \u201crecommendations\u201d are distinguished by whether it was possi-ble to address the quality of evidence supporting the statements based on an objective grading system. An objective measure that provides assessment of the strength of data regarding prognos-tic indicators does not currently exist, and similarly, \u201cmother-hood\u201d statements (such as the importance of obtaining a family history) that are based on sound clinical judgment are oft  en not \nsubject to systematic clinical studies as they are understood to refl ect sound clinical practice. Th  e summary statements there-\nfore refl  ect consensus opinion by the authors and a thorough \nliterature review that refl  ects expert opinion by leaders in the \nfi eld and other consensus guidelines. For management recom-\nmendations, where alternative strategies are and should be subject to rigorous assessment, the GRADE (Grading of Recom-mendations Assessment, Development and Evaluation) system was used to grade the strength of recommendations and the quality of evidence ( 1 ). An explanation of the quality of evi-dence and strength of recommendations is shown in  Table 3  . \nTh e quality of evidence, which infl  uences the strength of the recommendation, ranges from \u201chigh\u201d (further research is very \nunlikely to change our confi  dence in the estimate of eff  ect) to \n\u201cmoderate\u201d (further research is likely to have an important impact on our confi  dence in the estimate of eff  ect and may \nchange the estimate) to \u201clow\u201d (further research is very likely to have an important impact on our confi  dence in the estimate of \neff ect and is likely to change the estimate), and to \u201cvery low\u201d (any \nestimate of eff  ect is uncertain).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3395afff-957c-47f1-9f7b-12039009ba12": {"__data__": {"id_": "3395afff-957c-47f1-9f7b-12039009ba12", "embedding": null, "metadata": {"page_label": "226", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f97a245a-22f1-48a5-8820-a409dcc5d14a", "node_type": "4", "metadata": {"page_label": "226", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "aa5b3ae7d0b06f498047e5c4deb1c9c2bda250381e27c36a66e83072b1e4a2e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6f1e6f7-5dc7-4653-a92a-ad0ac99f6431", "node_type": "1", "metadata": {"page_label": "226", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "29c507cdafcc4db65a3919968ae20bc38e7eb164e32b8f9b0b5285ac25e06926", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07abcf04-c899-41b8-9bec-abe37e501058", "node_type": "1", "metadata": {"page_label": "227", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "4f13d7b4bed5368f25fc1e1be4709baec821ab2ab073658eb420849ae98648ec", "class_name": "RelatedNodeInfo"}}, "hash": "8bfae5b08a1fa8b98d6ecd90a026b8405a3b5946eb9dfdbc0a588ac8dd8dc3c5", "text": "Th  e strength of a recommenda-\ntion is graded as strong when the desirable eff  ects of an inter-\nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07abcf04-c899-41b8-9bec-abe37e501058": {"__data__": {"id_": "07abcf04-c899-41b8-9bec-abe37e501058", "embedding": null, "metadata": {"page_label": "227", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "febe9185-c2fa-4b8e-95c6-c8a33f8ce111", "node_type": "4", "metadata": {"page_label": "227", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c087115aea423ec06255e80b525f77557d63fb3c91e56e182c22f63df9fa1fe7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3395afff-957c-47f1-9f7b-12039009ba12", "node_type": "1", "metadata": {"page_label": "226", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "8bfae5b08a1fa8b98d6ecd90a026b8405a3b5946eb9dfdbc0a588ac8dd8dc3c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d82365eb-6434-41f1-87ab-a32788a8a18a", "node_type": "1", "metadata": {"page_label": "227", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "e45efcefec198238f27f65c1e9377d0ecbdcf7f17f9f948b0fe096b060a7aead", "class_name": "RelatedNodeInfo"}}, "hash": "4f13d7b4bed5368f25fc1e1be4709baec821ab2ab073658eb420849ae98648ec", "text": "Hereditary GI Cancer Syndromes\n\u00a9 2015 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY\n 227\nvention clearly outweigh the undesirable eff  ects and is graded as \nconditional when uncertainty exists about the trade-off  s.\n  Th e fi eld of cancer genetics poses some challenges with respect \nto the GRADE system. Because of the rarity of the syndromes, and the relatively recent discovery of cancer susceptibility genes, data regarding long-term outcomes regarding optimal manage-ment strategies at this time ar e limited to observational studies. \nRandomized clinical trials, which are the gold standard of systems such as GRADE, are diffi   cult to conduct in rare diseases, where \nthe main objective outcome, reduction in cancer mortality, takes \nyears to assess and large patient numbers. Th  e reader, therefore, \nshould take the assessments of quality of evidence with caution\u2014the oft  en \u201clow\u201d or \u201cvery low\u201d quality gradings refl  ect primarily a \nlack of available data and not that the quality of studies conducted thus far has been poor.\n   STANDARDS FOR MINIMAL CANCER FAMILY HISTORY \nASSESSMENT IN GI PRACTICE\n   Summary statements\n\u2022     A family history of cancer and premalignant GI conditions \nthat provides suffi   cient information to develop a prelimi-\nnary determination of the risk of a familial predisposition to cancer should be obtained for all patients being evaluated in outpatient gastroenterology and endoscopy practices. \n\u2022    Essential elements of a family history include presence \nand type of cancer diagnoses in fi  rst- and second-degree \nrelatives, and presence and (ideally) type of polyps in fi  rst-\ndegree relatives; age and lineage should be noted for each diagnosis. \n     Summary of evidence\n  Approximately 5\u201310% of cancers are attributable to a hereditary \ncancer predisposition syndrome. Identifying those patients who have an inherited cancer predisposition syndrome has signifi  cant \nbenefi  t to both the patient and at-risk relatives.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d82365eb-6434-41f1-87ab-a32788a8a18a": {"__data__": {"id_": "d82365eb-6434-41f1-87ab-a32788a8a18a", "embedding": null, "metadata": {"page_label": "227", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "febe9185-c2fa-4b8e-95c6-c8a33f8ce111", "node_type": "4", "metadata": {"page_label": "227", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c087115aea423ec06255e80b525f77557d63fb3c91e56e182c22f63df9fa1fe7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07abcf04-c899-41b8-9bec-abe37e501058", "node_type": "1", "metadata": {"page_label": "227", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "4f13d7b4bed5368f25fc1e1be4709baec821ab2ab073658eb420849ae98648ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55824f6b-09db-4aa6-9a22-ea52f55843a1", "node_type": "1", "metadata": {"page_label": "227", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "cdb63af424085991bc3c9754c3c2d39f823eb4bc38053b6ca0c2aa5db4d9de2e", "class_name": "RelatedNodeInfo"}}, "hash": "e45efcefec198238f27f65c1e9377d0ecbdcf7f17f9f948b0fe096b060a7aead", "text": "For the index \npatient, the diagnosis of a hereditary cancer syndrome has impli-cations for his/her surveillance strategy for multiple component tumors in terms of age of initiation and intervals between surveil-lance exams, and may lead to the consideration of prophylactic surgery or more extensive surgery in the case of neoplasia devel-opment. Th  e diagnosis of an inheri ted syndrome also has signifi  -\ncant implications for management of the patient\u2019s immediate and extended family.\n  Features of a patient\u2019s personal history may be the initial clue to \nthe possibility of an inherited predisposition to cancer. Hallmark features, whose specifi  cs are outlined in detail in the remainder of \nthis guideline, include early age at onset of polyps or cancer and \nunusual numbers or histologies of cancers or premalignant condi-tions. Family history is the other key component to the identifi  ca-\ntion of those individuals who may have an inherited predisposition to malignancy or who are at increased risk for additional primary cancers.\n  Th e goal of any cancer family history, in combination with \nthe patient\u2019s personal history, is to provide enough information to make a preliminary determination about whether the patient \nmay have a familial predisposition to cancer, may benefi  t from \ngenetic counseling and possibly testing for underlying cancer sus-ceptibility genes, or may not need genetic counseling and testing, but still require more intensive surveillance than the average- or moderate-risk patient. As there is currently no clear evidence base to defi  ne how family history should be taken or what con-\nstitutes the right amount of information for an initial cancer screening family history, an expert panel was recently convened \nto defi  ne how and what to collect for a family cancer history ( 2 ). \nTh e panel agreed that although the gold standard family history \nis the comprehensive, three-generation pedigree used in medical genetics, counseling, and research settings, this evaluation is time consuming and not feasible in genera l medical practice. For most \npatients, family history of cancer and premalignant conditions in \nclose relatives is most relevant.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55824f6b-09db-4aa6-9a22-ea52f55843a1": {"__data__": {"id_": "55824f6b-09db-4aa6-9a22-ea52f55843a1", "embedding": null, "metadata": {"page_label": "227", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "febe9185-c2fa-4b8e-95c6-c8a33f8ce111", "node_type": "4", "metadata": {"page_label": "227", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c087115aea423ec06255e80b525f77557d63fb3c91e56e182c22f63df9fa1fe7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d82365eb-6434-41f1-87ab-a32788a8a18a", "node_type": "1", "metadata": {"page_label": "227", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "e45efcefec198238f27f65c1e9377d0ecbdcf7f17f9f948b0fe096b060a7aead", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5fbf8c2-3522-4942-974b-d2b2e5043896", "node_type": "1", "metadata": {"page_label": "227", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "ed49db4204582f2a07e0fe931e2e27532ef2138f96998ddea8d8d4da52f2496f", "class_name": "RelatedNodeInfo"}}, "hash": "cdb63af424085991bc3c9754c3c2d39f823eb4bc38053b6ca0c2aa5db4d9de2e", "text": "Guidelines for consideration of genetic risk assessment, such as the NCCN Clinical Guidelines in \nOncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian, ( 3 ) focus on fi  rst- and second-degree relatives, although \nthey may optionally incorporate family history in third-degree relatives. Th  us, family history of cancer in fi  rst-degree (parents, \nchildren, and siblings) and second-degree (grandparents, aunts/uncles, nieces/nephews, grandchildren, and half-siblings) rela-tives is oft  en suffi   cient to assess a patient\u2019s empiric risk of com-\nmon cancers or a cancer patient\u2019s risk of a second primary cancer. Relatives\u2019 age at cancer or polyp diagnosis should also be assessed \nbecause this factors into both genetic risk assessment guidelines \nand cancer screening recommendations. Maternal and paternal \nlineages should be assessed separately. Accuracy of self-reported cancer family history in fi  rst-degree relatives (FDRs) has been \nshown to be >75% for most cancers, including colorectal, breast, ovarian, and pancreatic cancers. Studies have shown a decrease in the accuracy of reported family history in more distant relatives, ranging from 50 to 80% depending on the cancer ( 4,5 ). Hence, the routine review of family medical records, although not required during family history collection, can be helpful in particular cases where the cancer site is in question.\n     LYNCH SYNDROME (LS)\n   Tumor testing and indications for genetic testing\n   Summary statements  \n   1  .   All newly diagnosed colorectal cancers (CRCs) should be \nevaluated for mismatch repair defi  ciency. \n   2  .   Analysis may be done by immunohistochemical testing for \nthe  MLH1/MSH2/MSH6/PMS2   proteins and/or testing for \nmicrosatellite instability (MSI). Tumors that demonstrate \nloss of  MLH1   should undergo BRAF testing or analysis for \n MLH1   promoter hypermethylation. \n   3  .", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5fbf8c2-3522-4942-974b-d2b2e5043896": {"__data__": {"id_": "c5fbf8c2-3522-4942-974b-d2b2e5043896", "embedding": null, "metadata": {"page_label": "227", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "febe9185-c2fa-4b8e-95c6-c8a33f8ce111", "node_type": "4", "metadata": {"page_label": "227", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c087115aea423ec06255e80b525f77557d63fb3c91e56e182c22f63df9fa1fe7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55824f6b-09db-4aa6-9a22-ea52f55843a1", "node_type": "1", "metadata": {"page_label": "227", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "cdb63af424085991bc3c9754c3c2d39f823eb4bc38053b6ca0c2aa5db4d9de2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bd15618-7230-4774-8b05-cad67a4861e2", "node_type": "1", "metadata": {"page_label": "228", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "89381a0cd650371c6fcad69bbf45f5ef4658b1c279bd9fa85dce4ec282e8d3e0", "class_name": "RelatedNodeInfo"}}, "hash": "ed49db4204582f2a07e0fe931e2e27532ef2138f96998ddea8d8d4da52f2496f", "text": "3  .   Individuals who have a personal history of a tumor \nshowing evidence of mismatch repair defi  ciency (and no \ndemonstrated BRAF mutation or hypermethylation of  MLH1)  , a known family mutation associated with LS, or a \nrisk of \u22655% chance of LS based on risk prediction models should undergo genetic evaluation for LS. \nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bd15618-7230-4774-8b05-cad67a4861e2": {"__data__": {"id_": "4bd15618-7230-4774-8b05-cad67a4861e2", "embedding": null, "metadata": {"page_label": "228", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c6a21ca2-90e1-4c65-bdff-b803654ec46f", "node_type": "4", "metadata": {"page_label": "228", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c9a78ed0e805130f1d3798c1ea4c8f99ed93879f1253b9c7906bc704e3b8f69c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5fbf8c2-3522-4942-974b-d2b2e5043896", "node_type": "1", "metadata": {"page_label": "227", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "ed49db4204582f2a07e0fe931e2e27532ef2138f96998ddea8d8d4da52f2496f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8597bfbe-72e4-4d0c-80b0-ea9c53f07f8c", "node_type": "1", "metadata": {"page_label": "228", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "e5ca209d9bde3d69f1ff78595ada046533f80fe27fbb81e9200b254c5c5135eb", "class_name": "RelatedNodeInfo"}}, "hash": "89381a0cd650371c6fcad69bbf45f5ef4658b1c279bd9fa85dce4ec282e8d3e0", "text": "Syngal  et al.  \nThe American Journal of GASTROENTEROLOGY VOLUME 110 | FEBRUARY 2015    www.amjgastro.com 228\nsensitivity of the clinical criteria in identifying mutation carriers. \nIn families where LS is a consideration, and no tumor sample is available for analysis, direct germline testing of an unaff  ected \nat-risk individual whose risk is calculated to be \u22655% based on the PREMM1,2,6 risk prediction model (accessible at  http://premm.dfci.harvard.edu/ ) is a strategy that has been demonstrated to be cost eff  ective in improving health outcomes ( 26 ). Th  e complex-\nity of clinical criteria may be diffi   cult to apply in clinical practice. \nA simple, validated three-question tool may be used as a quick \ninitial screen in busy practices to identify which patients need \nfurther risk assessment ( 27 ) ( Table 4  ).\n     Surveillance and management of CRC\n   Recommendation   \n    1.  In individuals at risk for or aff  ected with LS, screening for CRC \nby colonoscopy should be performed at least every 2 years, beginning between ages 20 and 25 years. Annual colonoscopy should be considered in confi  rmed mutation carriers (strong \nrecommendation, moderate quality of evidence for screening, and very low quality of evidence for annual surveillance and age of initiation).\n    \nSummary of evidence   \n    Th e precursor lesion for a LS-related CRC is an adenomatous \npolyp that is oft  en proximal and can occasionally be fl  at rather \nthan elevated/polypoid and likely to demonstrate villous features, high-grade dysplasia, and a preponderance of tumor-infi  ltrat-\ning lymphocytes ( 28 ). Th  e historical term nonpolyposis CRC \nwas intended to diff  erentiate this condition from FAP in which \npatients develop hundreds of adenomas. LS patients develop few (usually <10) early-onset adenomas, but the adenoma\u2013carcinoma sequence appears to be accelerated in LS with polyp to cancer dwell times estimated at 35 months compared with 10\u201315 years in sporadic cancer ( 29 ).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8597bfbe-72e4-4d0c-80b0-ea9c53f07f8c": {"__data__": {"id_": "8597bfbe-72e4-4d0c-80b0-ea9c53f07f8c", "embedding": null, "metadata": {"page_label": "228", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c6a21ca2-90e1-4c65-bdff-b803654ec46f", "node_type": "4", "metadata": {"page_label": "228", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c9a78ed0e805130f1d3798c1ea4c8f99ed93879f1253b9c7906bc704e3b8f69c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bd15618-7230-4774-8b05-cad67a4861e2", "node_type": "1", "metadata": {"page_label": "228", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "89381a0cd650371c6fcad69bbf45f5ef4658b1c279bd9fa85dce4ec282e8d3e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c66dd567-cce5-4bd8-a6af-6889c238978a", "node_type": "1", "metadata": {"page_label": "228", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1a688dfd55ff6419b45e1d8a0b7cf67d6cdc81a6ae2c32086b60d8fb9c4a11b7", "class_name": "RelatedNodeInfo"}}, "hash": "e5ca209d9bde3d69f1ff78595ada046533f80fe27fbb81e9200b254c5c5135eb", "text": "Reports of lifetime risks of CRC for  MLH1   \nand  MSH2   gene mutation carriers range from 22 to 74% ( 30\u201335 ) \n( Table 5  ). Lower risk for colorectal malignancy has been found in \nwomen, but not in men with  MSH6   mutations (30% vs. 69% cu-\nmulative risk by age 70 years, respectively), compared with  MLH1   \nand  MSH2   carriers ( 36 ). CRC risk is reported to be lower in one \nstudy of 99  PMS2   mutation carriers, with an estimated cumulative \nrisk of 15\u201320% by age 70 years. ( 37 ). Th  e mean age of CRC diag-\nnosis in LS patients is 44\u201361 years ( 8,12,38,39 ) compared with 69 years in sporadic cases of CRC ( 40 ).\n  CRC prevention in LS families is guided by the distinctive \ncharacteristics of these malignancies, including the younger age of presentation, right-sided colorectal predominance, and rapid polyp growth with shorter dwell time before malignant conversion. \nEvidence for the eff  ectiveness of colorectal screening in decreas-\ning CRC mortality has been documented in studies by J\u00e4rvinen  et \nal.  ( 41\u201343 ) ( Table 6  ). Individuals at risk for LS who took up colo-\nnoscopic surveillance had 65% ( P =0.003) less death from CRC \ncompared with those who refused surveillance. Update of this Finnish study that analyzed colonoscopic surveillance in LS muta-tion carriers found no diff  erence in CRC death between mutation \ncarriers and mutation-negative relatives ( 43 ). Dove-Edwin  et al.        Summary of evidence   \n    LS, the most common cause of inherited CRC, is an autosomal-\ndominant condition defi  ned by the presence of a germline mu-\ntation in a DNA mismatch repair gene (or  EPCAM  ). It was of-\nten previously referred to as hereditary nonpolyposis colorectal cancer. LS tumors are associated with changes in the length of nucleotide repeat sequences of tumor DNA, termed MSI.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c66dd567-cce5-4bd8-a6af-6889c238978a": {"__data__": {"id_": "c66dd567-cce5-4bd8-a6af-6889c238978a", "embedding": null, "metadata": {"page_label": "228", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c6a21ca2-90e1-4c65-bdff-b803654ec46f", "node_type": "4", "metadata": {"page_label": "228", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c9a78ed0e805130f1d3798c1ea4c8f99ed93879f1253b9c7906bc704e3b8f69c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8597bfbe-72e4-4d0c-80b0-ea9c53f07f8c", "node_type": "1", "metadata": {"page_label": "228", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "e5ca209d9bde3d69f1ff78595ada046533f80fe27fbb81e9200b254c5c5135eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d90953d-8363-4f31-a021-82049fc4b9cc", "node_type": "1", "metadata": {"page_label": "228", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "10d8e0a8b2a139ca2d4cdc13e5ec225b26953bfc861153569d29cc3e93f67422", "class_name": "RelatedNodeInfo"}}, "hash": "1a688dfd55ff6419b45e1d8a0b7cf67d6cdc81a6ae2c32086b60d8fb9c4a11b7", "text": "MSI results from defective mismatch repair and is associated with loss of expression of the  MLH1  ,  MSH2  ,  MSH6  , and/or  PMS2   \nproteins that can be detected by immunohistochemical (IHC) \nanalysis. Multiple international studies have demonstrated that the prevalence of MSI in population-based series of CRC rang-es from 7 to 19% ( 6\u201310 ). Th  e sensitivity of MSI testing among \nthose with  MLH1   or  MSH2   mutations is 80\u201391%, and is 55\u201377% \namong those with  MSH6   or  PMS2   mutations; the specifi  city of \nMSI testing is 90% ( 11 ). Th  e sensitivity of IHC testing, regard-\nless of the MMR gene involved, is 83% and the specifi  city is 89% \n( 11 ). MSI and IHC results are highly correlated ( 9,12 ), and as protein staining is oft  en easier to perform than DNA analysis \nin a clinical setting, it may be a more feasible option for wide-spread MSI screening. In order to facilitate surgical planning, tumor testing on suspected CRC should be performed on pre-operative biopsy specimens if possible. For individuals whose IHC indicates loss of the MLH1 protein, determination of the mechanism of loss should be pursued as an additional screening step, and this may be done by analysis for a BRAF mutation or promoter hypermethylation studies. Almost no LS tumors carry a BRAF mutation, whereas 68% of those without LS do ( 11 ). Individuals who demonstrate evidence of MMR defi  ciency, in-\ndependent of somatic  MLH1   silencing, should undergo genetic \ntesting.\n     Genetic etiology\n   Summary statement   \n\u2022       Genetic testing of patients with suspected LS should include \ngermline mutation genetic testing for the  MLH1  ,  MSH2  , \n MSH6  ,  PMS2  , and/or  EPCAM   genes ( 13\u201323 ), or the altered \ngene(s) indicated by IHC testing.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d90953d-8363-4f31-a021-82049fc4b9cc": {"__data__": {"id_": "4d90953d-8363-4f31-a021-82049fc4b9cc", "embedding": null, "metadata": {"page_label": "228", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c6a21ca2-90e1-4c65-bdff-b803654ec46f", "node_type": "4", "metadata": {"page_label": "228", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c9a78ed0e805130f1d3798c1ea4c8f99ed93879f1253b9c7906bc704e3b8f69c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c66dd567-cce5-4bd8-a6af-6889c238978a", "node_type": "1", "metadata": {"page_label": "228", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1a688dfd55ff6419b45e1d8a0b7cf67d6cdc81a6ae2c32086b60d8fb9c4a11b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d58abcdd-60d5-4e33-b098-c0d33480cce9", "node_type": "1", "metadata": {"page_label": "229", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "5ef235fa617dd2d67fcb3fc709388fe4c18931833164d6dcd4bb157458448138", "class_name": "RelatedNodeInfo"}}, "hash": "10d8e0a8b2a139ca2d4cdc13e5ec225b26953bfc861153569d29cc3e93f67422", "text": "Summary of evidence   \n    In 1993, genome-wide linkage analysis in several large families \nwith autosomal-dominant CRC and the demonstration of associ-ated tumor MSI led to the subsequent cloning of the mismatch repair genes  MLH1   and  MSH2  , followed by  MSH6  ,  PMS2  , and \n EPCAM   ( 13\u201323 ). Multiple large international population-based \nseries have demonstrated that MMR gene mutations account for 1\u20133% of newly diagnosed CRC cases ( 6,7,9,10,12 ). LS should be considered in individuals whose tumors show evidence of MMR defi ciency as discussed above (without the presence of a  BRAF   \nmutation or  MLH1   promoter hypermethylation), and those \nwhose personal and/or family history fullfi  ll the Amsterdam cri-\nteria, Bethesda Guidelines, or who have a \u22655% risk of carrying a germline mutation based on available prediction models ( 24,25 )( Table 4  ). Th e computational models all appear to outperform \nexisting clinical guidelines ( 25 ), primarily because of limited \nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d58abcdd-60d5-4e33-b098-c0d33480cce9": {"__data__": {"id_": "d58abcdd-60d5-4e33-b098-c0d33480cce9", "embedding": null, "metadata": {"page_label": "229", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6ebbc63c-01f4-4e3e-b230-558532555d08", "node_type": "4", "metadata": {"page_label": "229", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "36235f90c8eb388118ae8eb190264efc5ae1f8ead068cfebfcee722bca165250", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d90953d-8363-4f31-a021-82049fc4b9cc", "node_type": "1", "metadata": {"page_label": "228", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "10d8e0a8b2a139ca2d4cdc13e5ec225b26953bfc861153569d29cc3e93f67422", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "620f4262-e455-4c54-8d98-30b7839bf517", "node_type": "1", "metadata": {"page_label": "229", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "a22fd5bffa1fddbd0a54fd63e1fdb6d8c5737fa368e69bdf7c790646a40a0119", "class_name": "RelatedNodeInfo"}}, "hash": "5ef235fa617dd2d67fcb3fc709388fe4c18931833164d6dcd4bb157458448138", "text": "Hereditary GI Cancer Syndromes\n\u00a9 2015 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY\n 229\nsurveillance of MMR germline mutation-positive patients, consid-\neration should be given to annual colonoscopy, as several studies have demonstrated CRC development with surveillance intervals that are between 1 and 2 years ( 29,47 ). In carriers of deleterious  MSH6   and  PMS2   mutations, the risk of CRC is less and age of diag-\nnosis later ( 37,49 ) than in patients with  MLH1 and MSH2   muta-\ntions. In these aff  ected individuals, consideration could be given \nto starting surveillance at age 25\u201330 in  MSH6   and  PMS2   carriers \n( 24 ), unless an early-onset cancer exists in a given family; however, ( 44 ) reported the results of a prospective observational study of \ncolonoscopy surveillance of members in hereditary nonpolyposis colorectal cancer or LS families, revealing a 72% decrease in mor-tality from CRC in those undergoing screening. In several stud-ies ( 45\u201348 ), more frequent colonoscopy screening (\u22642 years) was associated with an earlier stage of CRC at diagnosis and less CRC than less frequent colonoscopy. At least every 2-year colonoscopic surveillance of LS patients is supported by the data above and the rapid adenoma\u2013carcinoma sequence reported in these patients. In  Table 4  .     Amsterdam criteria, revised Bethesda guidelines, and colorectal cancer risk assessment tool \n  Amsterdam criteria I   ( 24 ) \n  At least three relatives with colorectal cancer (CRC); all of the following criteria should be present: \n   One should be a \ufb01  rst-degree relative of the other two; \n   At least two successive generations must be affected; \n   At least one of the relatives with CRC must have received the diagnosis before the age of 50 years; \n   Familial adenomatous polyposis should be excluded; \n   Tumors should be veri\ufb01  ed by pathologic examination.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "620f4262-e455-4c54-8d98-30b7839bf517": {"__data__": {"id_": "620f4262-e455-4c54-8d98-30b7839bf517", "embedding": null, "metadata": {"page_label": "229", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6ebbc63c-01f4-4e3e-b230-558532555d08", "node_type": "4", "metadata": {"page_label": "229", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "36235f90c8eb388118ae8eb190264efc5ae1f8ead068cfebfcee722bca165250", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d58abcdd-60d5-4e33-b098-c0d33480cce9", "node_type": "1", "metadata": {"page_label": "229", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "5ef235fa617dd2d67fcb3fc709388fe4c18931833164d6dcd4bb157458448138", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "041848d4-e1e1-4d6f-b15d-6580c31c7ea2", "node_type": "1", "metadata": {"page_label": "229", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "650d9b22c20c013f477f6e0a19c09b0d8f049d93581ad0635effc6335945bd32", "class_name": "RelatedNodeInfo"}}, "hash": "a22fd5bffa1fddbd0a54fd63e1fdb6d8c5737fa368e69bdf7c790646a40a0119", "text": "Amsterdam criteria II   ( 24 ) \n   At least three relatives must have a cancer associated with Lynch syndrome (colorectal, cancer of the endometrium, small bowel,  ureter, or renal\u2013pelvis); all \nof the following criteria should be present: \n   One must be a \ufb01  rst-degree relative of the other two; \n   At least two successive generations must be affected; \n   At least one relative with cancer associated with Lynch syndrome (LS) should be diagnosed before age 50; \n   Familial adenomatous polyposis should be excluded in the CRC case(s) (if any); \n   Tumors should be veri\ufb01  ed whenever possible. \n  Revised Bethesda guidelines   ( 24 ) \n  Tumors from individuals should be tested for microsatellite instability (MSI) in the following situations: \n   CRC diagnosed in a patient who is younger than 50 years of age \n   Presence of synchronous, or metachronous, colorectal or other LS-related tumors  a  , regardless of age \n   CRC with MSI-high histology  b   diagnosed in a patient who is younger than 60 years of age \n   CRC diagnosed in a patient with one or more \ufb01  rst-degree relatives with an LS-related cancer, with one of the cancers being d iagnosed under age 50 years \n   CRC diagnosed in a patient with two or more \ufb01  rst- or second-degree relatives with LS-related cancer regardless of age \n  Colorectal cancer risk assessment tool    c   \n  (Patient who answers yes to any question should have more comprehensive family history evaluation) \n   1. Do you have a \ufb01  rst-degree relative (mother, father, brother, sister, or child) with any of the following conditions diagn osed before age 50? \n    Colon or rectal cancer \n    Cancer of the uterus, ovary, stomach, small intestine, urinary tract (kidney, ureter, bladder), bile ducts, pancreas, or bra in \n   2. Have you had any of the following conditions diagnosed before age 50 years? \n    Colon or rectal cancer \n    Colon or rectal polyps \n   3. Do you have three or more relatives with a history of colon or rectal cancer?", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "041848d4-e1e1-4d6f-b15d-6580c31c7ea2": {"__data__": {"id_": "041848d4-e1e1-4d6f-b15d-6580c31c7ea2", "embedding": null, "metadata": {"page_label": "229", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6ebbc63c-01f4-4e3e-b230-558532555d08", "node_type": "4", "metadata": {"page_label": "229", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "36235f90c8eb388118ae8eb190264efc5ae1f8ead068cfebfcee722bca165250", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "620f4262-e455-4c54-8d98-30b7839bf517", "node_type": "1", "metadata": {"page_label": "229", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "a22fd5bffa1fddbd0a54fd63e1fdb6d8c5737fa368e69bdf7c790646a40a0119", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6dcf6419-715b-4a0e-851d-53b3954ad845", "node_type": "1", "metadata": {"page_label": "230", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1a62ee9998ad8fc4da3698c9d12295da8d891a1831c713e19f733011be034404", "class_name": "RelatedNodeInfo"}}, "hash": "650d9b22c20c013f477f6e0a19c09b0d8f049d93581ad0635effc6335945bd32", "text": "Do you have three or more relatives with a history of colon or rectal cancer? \n  (This includes parents, brothers, sisters, children, grandparents, aunts, uncles, and cousins) \n   a   Lynch syndrome-related cancers include colorectal, endometrial, gastric, ovarian, pancreas, ureter and renal pelvis, biliary tr act, brain (usually glioblastoma), small \nintestinal cancers, as well as sebaceous gland adenomas and keratoacanthomas.  \n   b   Presence of tumor-in\ufb01  ltrating lymphocytes, Crohn\u2019s-like lymphocytic reaction, mucionous/signet-ring differentiation, or medull ary growth pattern.  \n   c   Adapted with permission from Kastrinos  et al.   ( 27 ).  \nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6dcf6419-715b-4a0e-851d-53b3954ad845": {"__data__": {"id_": "6dcf6419-715b-4a0e-851d-53b3954ad845", "embedding": null, "metadata": {"page_label": "230", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fe5bec53-1f2b-4c3c-829c-8495787e9122", "node_type": "4", "metadata": {"page_label": "230", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1194874b42d1b016f11537bc665cd233b9211f3b0a8fd5e01702648cddbacdea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "041848d4-e1e1-4d6f-b15d-6580c31c7ea2", "node_type": "1", "metadata": {"page_label": "229", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "650d9b22c20c013f477f6e0a19c09b0d8f049d93581ad0635effc6335945bd32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd92a56f-d2d6-42f2-859a-b5ecdab1521b", "node_type": "1", "metadata": {"page_label": "230", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "5a0ebb17c5621bba5ad009a1c2bdd17b8a5a3745189aba0745e763e49c439602", "class_name": "RelatedNodeInfo"}}, "hash": "1a62ee9998ad8fc4da3698c9d12295da8d891a1831c713e19f733011be034404", "text": "Syngal  et al.  \nThe American Journal of GASTROENTEROLOGY VOLUME 110 | FEBRUARY 2015    www.amjgastro.com 230\nthis approach of gene-specifi  c alterations in surveillance has not \nbeen evaluated in clinical studies.\n    Recommendation   \n    2.  Colectomy with ileorectal anastomosis (IRA) is the preferred \ntreatment of patients aff  ected with LS with colon cancer or \ncolonic neoplasia not controllable by endoscopy. Segmental colectomy is an option in patients unsuitable for total colec-tomy if regular postoperative surveillance is conducted (condi-tional recommendation, moderate quality of evidence).\n    \nSummary of evidence   \n    Th e treatment for patients with CRC or premalignant polyps that \ncannot be removed by colonoscopy is subtotal colectomy with IRA. A high rate of metachronous CRC (16% at 10 years; 41% at 20 years) is noted in LS patients who have undergone segmental surgical resection of the initial CRC in several retrospective stud-ies ( 48,50,51 ). A standard low anterior resection or abdominal perineal resection may be performed to treat rectal cancers in LS patients, although the residual colon is at high risk of metachro-nous neoplasia. Y ounger patients may be off  ered a total procto-\ncolectomy and ileal pouch anal anastomosis (IPAA), or ileos-tomy. A recent retrospective study of 79 LS patients with rectal \ncancer who had undergone proctectomy found a cumulative risk of metachronous colon cancer to be 19% at 10 years, 47% at 20 years, and 69% at 30 years aft  er surgical resection ( 51 ). Th  e risk \nof metachronous cancer is substantially abated if extensive colec-tomy is performed (0\u20133.4%) ( 48,50,51 ).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd92a56f-d2d6-42f2-859a-b5ecdab1521b": {"__data__": {"id_": "cd92a56f-d2d6-42f2-859a-b5ecdab1521b", "embedding": null, "metadata": {"page_label": "230", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fe5bec53-1f2b-4c3c-829c-8495787e9122", "node_type": "4", "metadata": {"page_label": "230", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1194874b42d1b016f11537bc665cd233b9211f3b0a8fd5e01702648cddbacdea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6dcf6419-715b-4a0e-851d-53b3954ad845", "node_type": "1", "metadata": {"page_label": "230", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1a62ee9998ad8fc4da3698c9d12295da8d891a1831c713e19f733011be034404", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c09b5ca2-f7f4-4baa-8cb6-cc280465f100", "node_type": "1", "metadata": {"page_label": "230", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "b4cea3f8ba461e74218d3b74a4ca2fb9bada8c1295f779955b2ee9ccd2109353", "class_name": "RelatedNodeInfo"}}, "hash": "5a0ebb17c5621bba5ad009a1c2bdd17b8a5a3745189aba0745e763e49c439602", "text": "In a Dutch study, no diff  erence in global quality of life was noted \nbetween 51 LS patients who underwent partial colectomy and 53 patients who underwent subtotal colectomy, although functional outcome (stool frequency, stool-related aspects, social impact) was \nworse aft  er subtotal colectomy than aft  er partial colectomy ( 52 ). \nA comparison of life expectancy gained performing total colec-\ntomy vs. hemicolectomy in LS patients at ages 27, 47, and 67 years \nby Markov modeling was 2.3, 1, and 0.3 years, respectively. Th  ese \ninvestigators concluded that total colectomy is the preferred treat-ment in LS but hemicolectomy may be an option in older indi-viduals. Consideration for less extensive surgery may be given in patients who are >60\u201365 years of age.\n  Th e option of prophylactic colectomy should be discussed with \nmutation carriers who have an endoscopically normal colon as an alternative to surveillance. Although rarely chosen, it may be attractive to patients from families where the prevalence of colon cancer is very high, or for whom colonoscopy is diffi   cult. Direct \ncomparative studies of extensive surgery vs. annual or biennial surveillance have not been conducted, and are unlikely be insti-tuted because of the multitude patient-dependent factors that aff ect comorbidities and quality of life.\n     Surveillance and management of extracolonic malignancies\n   Gynecologic malignancies   \n     Recommendations   \n    3.  Hysterectomy and bilateral salpingo-oophorectomy should be \noff ered to women who are known LS mutation carriers and who \nhave fi  nished child bearing, optimally at age 40\u201345 years (con-\nditional recommendation, low quality of evidence).\n  4.  Screening for endometrial cancer (EC) and ovarian cancer should \nbe off  ered to women at risk for or aff  ected with LS by endome-\ntrial biopsy and transvaginal ultrasound annually, starting at age 30 to 35 years before undergoing surgery or if surgery is deferred (conditional recommendation, very low quality of evidence). Table 5  .", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c09b5ca2-f7f4-4baa-8cb6-cc280465f100": {"__data__": {"id_": "c09b5ca2-f7f4-4baa-8cb6-cc280465f100", "embedding": null, "metadata": {"page_label": "230", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fe5bec53-1f2b-4c3c-829c-8495787e9122", "node_type": "4", "metadata": {"page_label": "230", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1194874b42d1b016f11537bc665cd233b9211f3b0a8fd5e01702648cddbacdea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd92a56f-d2d6-42f2-859a-b5ecdab1521b", "node_type": "1", "metadata": {"page_label": "230", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "5a0ebb17c5621bba5ad009a1c2bdd17b8a5a3745189aba0745e763e49c439602", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "802d5db0-e454-406b-bac6-6546cb040436", "node_type": "1", "metadata": {"page_label": "230", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "7978d8f7e79138f0c0346431628fd3af909fc72942a3a24c13bc260008434598", "class_name": "RelatedNodeInfo"}}, "hash": "b4cea3f8ba461e74218d3b74a4ca2fb9bada8c1295f779955b2ee9ccd2109353", "text": "Table 5  .     Cumulative risks of colorectal cancer in hereditary colorectal cancer syndromes \n  Syndrome    Gene    Risk    Average age of \ndiagnosis (years)    References  \n Sporadic cancer    4.8%  69  SEER( 303 ) \n Lynch syndrome   MLH1/MSH2    M: 27\u201374% \n F: 22\u201361%  27\u201360  ( 30\u201335,38 ) \n    MSH6    M: 22\u201369% \n F: 10\u201330% \n M/F: 12%  50\u201363  ( 31,36,49,64 ) \n    PMS2    M: 20% \n F: 15%  47\u201366  ( 37 ) \n Familial adenomatous polyposis (FAP)   APC   100%  38\u201341  ( 81,123,126,316 ) \n Attenuated FAP   APC   69%  54\u201358  ( 88,90,126,317\u2013319 ) \n  MUTYH  -associated polyposis   MUTYH    43\u2013100%  48\u201350  ( 109,126,134,135,319 ) \n Juvenile polyposis   SMAD4   \n  BMPR1A    38\u201368%  34\u201344  ( 126,220 )( 320\u2013323 ) \n Peutz\u2013Jeghers syndrome   STK11    39%  42\u201346  ( 126,196,197 ) \n Cowden syndrome   PTEN    9\u201316%  44\u201348  ( 224,235,236,324 ) \n Serrated polyposis syndrome  Not known  ~>50%  48  ( 243,254 ) \n F, female; M, male.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "802d5db0-e454-406b-bac6-6546cb040436": {"__data__": {"id_": "802d5db0-e454-406b-bac6-6546cb040436", "embedding": null, "metadata": {"page_label": "230", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fe5bec53-1f2b-4c3c-829c-8495787e9122", "node_type": "4", "metadata": {"page_label": "230", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1194874b42d1b016f11537bc665cd233b9211f3b0a8fd5e01702648cddbacdea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c09b5ca2-f7f4-4baa-8cb6-cc280465f100", "node_type": "1", "metadata": {"page_label": "230", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "b4cea3f8ba461e74218d3b74a4ca2fb9bada8c1295f779955b2ee9ccd2109353", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ec04b63-1847-481f-b2be-0982f04d6e0e", "node_type": "1", "metadata": {"page_label": "231", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "69b5303c4090db54edea0977170e97a93637a8bdf54606f0b4f495980c4e7242", "class_name": "RelatedNodeInfo"}}, "hash": "7978d8f7e79138f0c0346431628fd3af909fc72942a3a24c13bc260008434598", "text": "Downloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ec04b63-1847-481f-b2be-0982f04d6e0e": {"__data__": {"id_": "2ec04b63-1847-481f-b2be-0982f04d6e0e", "embedding": null, "metadata": {"page_label": "231", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "487f0446-65f4-4882-ab3e-bed2586a8214", "node_type": "4", "metadata": {"page_label": "231", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "d5f694ac7e1216367363179d34fe8b69da80ed504c6f7e5509f4c9ada651f178", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "802d5db0-e454-406b-bac6-6546cb040436", "node_type": "1", "metadata": {"page_label": "230", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "7978d8f7e79138f0c0346431628fd3af909fc72942a3a24c13bc260008434598", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c71a7b5-0e2f-4924-b857-0bfebc4c6fec", "node_type": "1", "metadata": {"page_label": "231", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "cba0f0bdd8544d75f708bcb0b572d574173cb1757c51e8c73e33267377462070", "class_name": "RelatedNodeInfo"}}, "hash": "69b5303c4090db54edea0977170e97a93637a8bdf54606f0b4f495980c4e7242", "text": "Hereditary GI Cancer Syndromes\n\u00a9 2015 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY\n 231\n Table 6  .     Studies of colorectal screening in hereditary colorectal cancer (CRC) syndromes \n  Study (year)    Reference    Subjects    Design    Findings  \n  Lynch syndrome   \n  J\u00e4rvinen  et al.   (1995)  ( 42 )  252 At-risk individuals \nfrom 20 of 22 families with MMR mutations.  Observational: all invited for colono-\nscopy screening; 133 had q 3-year colonoscopy, 118 declined.  62% Less CRC in screened ( P =0.03).  \n Tumor stage more favorable in screened.  \n No deaths in screened vs. 5 deaths in non-\nscreened. \n  J\u00e4rvinen  et al.   (2000)  ( 41 )  252 At-risk individuals \nfrom 20 of 22 families with MMR mutations.  Observational: follow-up of J\u00e4rvinen \n et al.   (1995) study  62% reduction in CRC in screened ( P =0.02).  \n No deaths from CRC in screened vs. 9 deaths \nin nonscreened. \n   De Vos tot Nederveen \nCappel  et al.   (2002)  ( 48 )  857 Members of 114 \nHNPCC- or MMR-positive families.  Observational: tumor stage with \nmore frequent (\u22642 years) vs. less frequent colonoscopy; 10-year risk of CRC with partial vs. subtotal colectomy.  Earlier stage CRC with more frequent colono-\nscopy.  15.7% risk of CRC with partial vs. 3.4% with \nsubtotal colectomy at 10 years. \n   Dove-Edwin  et al.   \n(2005)  ( 44 )  554 At-risk members of \n290 families with HNPCC or MMR mutations.  Prospective observational: evalua-\ntion of ef\ufb01  cacy of colonoscopy.  Estimated 72% decrease in CRC death in \nscreened individuals.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c71a7b5-0e2f-4924-b857-0bfebc4c6fec": {"__data__": {"id_": "9c71a7b5-0e2f-4924-b857-0bfebc4c6fec", "embedding": null, "metadata": {"page_label": "231", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "487f0446-65f4-4882-ab3e-bed2586a8214", "node_type": "4", "metadata": {"page_label": "231", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "d5f694ac7e1216367363179d34fe8b69da80ed504c6f7e5509f4c9ada651f178", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ec04b63-1847-481f-b2be-0982f04d6e0e", "node_type": "1", "metadata": {"page_label": "231", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "69b5303c4090db54edea0977170e97a93637a8bdf54606f0b4f495980c4e7242", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c1011a6-d692-4e0b-b417-76e94f50be55", "node_type": "1", "metadata": {"page_label": "231", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "72f5d4170a6979cf28df0cca4b8c15772de807a8ed6fadea54365571de1a0112", "class_name": "RelatedNodeInfo"}}, "hash": "cba0f0bdd8544d75f708bcb0b572d574173cb1757c51e8c73e33267377462070", "text": "Estimated 72% decrease in CRC death in \nscreened individuals. \n  J\u00e4rvinen  et al.   (2009)  ( 43 )  242 MMR mutation-\npositive and 367 muta-tion-negative subjects.  Observational: cancer incidence/\nsurvival of 11.5-year follow-up of colonoscopy surveillance  No increase in cancer mortality in mutation-\npositive vs. -negative individuals. \n  Familial adenomatous polyposis (FAP)  \n \n  Vasen  et al.   (1990)  ( 325 )  230 Con\ufb01  rmed FAP \ncases  Observational: compared colorectal \ncancer rates in symptomatic cases vs. family members identi\ufb01  ed via \nscreening  47% of the symptomatic cases had CRC at a \nmean age of 35 years compared with 4% at 24 years \n  Bjork  et al.   (2000)  ( 128 )  195 Subjects with FAP  Observational: evaluation of rectal \ncancer morbidity and mortality after colectomy with ileorectal anastomo-sis (IRA)  The cumulative risk of rectal cancer 20 years \nafter an IRA was 12.1%. There was a 7% cumulative risk of mortality. \n  Jarvinen (1992)  ( 82 )  251 Affected subjects \nfrom 81 FAP families  Observational: evaluation of the \neffects of family screening on the occurrence of colorectal cancer by comparing cases diagnosed during family screening (call-up group) and symptomatic probands  65.5% Of probands had colorectal cancer \ncompared with 6.6% of the call-up cases. The call-up group had a signi\ufb01  cantly increased \nlifetime cumulative survival from age 31 years. \n  MUTYH-associated polyposis (MAP)   \n   Nascimbeni  et al.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c1011a6-d692-4e0b-b417-76e94f50be55": {"__data__": {"id_": "0c1011a6-d692-4e0b-b417-76e94f50be55", "embedding": null, "metadata": {"page_label": "231", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "487f0446-65f4-4882-ab3e-bed2586a8214", "node_type": "4", "metadata": {"page_label": "231", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "d5f694ac7e1216367363179d34fe8b69da80ed504c6f7e5509f4c9ada651f178", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c71a7b5-0e2f-4924-b857-0bfebc4c6fec", "node_type": "1", "metadata": {"page_label": "231", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "cba0f0bdd8544d75f708bcb0b572d574173cb1757c51e8c73e33267377462070", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc56f9ed-1fc1-45e9-a954-56dbe740f786", "node_type": "1", "metadata": {"page_label": "231", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "8525c595238b4af624be848c616f34fd44e6acf2781b5bc831ff38636c54ad55", "class_name": "RelatedNodeInfo"}}, "hash": "72f5d4170a6979cf28df0cca4b8c15772de807a8ed6fadea54365571de1a0112", "text": "(2010)  ( 326 )  14  MUTYH-  positive \nsubjects  Retrospective observational: to \nevaluate the risk of cancer or severe polyposis of the rectal stump after total colectomy  11 Cases underwent total colectomy with \nileorectal anastomosis and yearly proctoscopic surveillance; no patient developed rectal cancer during surveillance (median duration: 5 years). \n  Nielsen  et al.   (2010)  ( 327 )  147 Cases and 272 \nmatched controls  Retrospective: compared survival \nbetween cases with MAP colorectal cancer and matched controls with colorectal cancer from the general population  Five-year survival was higher for the MAP \ncolorectal subjects (78% vs. 63%). Survival remained better after adjusting for differences between the groups (hazard ration of 0.48). \n  Peutz\u2013Jeghers syndrome (PJS; see    Table 8  ) \n  Juvenile polyposis   \n  Oncel  et al.   (2005)  ( 223 )  13 Juvenile polyposis \ncases \n Retrospective: to evaluate the \nlong-term outcomes of the surgery in JPS cases who present with symptomatic colonic polyps  Eleven presented with rectal bleeding initially. \nFive of 10 patients who had initial rectum-preserving surgery required subsequent proctectomy; a total of 8 cases had their rectum removed during the study period. Following their ultimate operations, \ufb01  ve \npatients required multiple polypectomies for recurrent pouch/rectal polyps. \n  Cowden syndrome   \n  Heald  et al.   (2010)  ( 224 )  127 PTEN mutation \ncarriers  Retrospective: to describe the \ngastrointestinal phenotype in a prospective series of PTEN mutation carriers.  Sixty-nine cases had 1 or more endoscopies \nand polyps were present in 64 (93%). Of the 64, half had hyperplastic polyps and 24 had both upper and lower gastrointestinal (GI) polyps; 9 (13%) cases had colorectal cancer at age <50 years.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc56f9ed-1fc1-45e9-a954-56dbe740f786": {"__data__": {"id_": "fc56f9ed-1fc1-45e9-a954-56dbe740f786", "embedding": null, "metadata": {"page_label": "231", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "487f0446-65f4-4882-ab3e-bed2586a8214", "node_type": "4", "metadata": {"page_label": "231", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "d5f694ac7e1216367363179d34fe8b69da80ed504c6f7e5509f4c9ada651f178", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c1011a6-d692-4e0b-b417-76e94f50be55", "node_type": "1", "metadata": {"page_label": "231", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "72f5d4170a6979cf28df0cca4b8c15772de807a8ed6fadea54365571de1a0112", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f463496b-27cc-4727-ba1e-786e7aeddbc8", "node_type": "1", "metadata": {"page_label": "232", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "6d6f66e95eb6f4f4b3e83bd387f8e2896b31e61a98133735212f1f80d255b283", "class_name": "RelatedNodeInfo"}}, "hash": "8525c595238b4af624be848c616f34fd44e6acf2781b5bc831ff38636c54ad55", "text": "Table 6 continued om following page\nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f463496b-27cc-4727-ba1e-786e7aeddbc8": {"__data__": {"id_": "f463496b-27cc-4727-ba1e-786e7aeddbc8", "embedding": null, "metadata": {"page_label": "232", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1dfd9907-68af-43c3-b265-7f4569dd82a8", "node_type": "4", "metadata": {"page_label": "232", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "577138abc6b787a593937362a016cd6457b011de5cee2253c9373418c27a6020", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc56f9ed-1fc1-45e9-a954-56dbe740f786", "node_type": "1", "metadata": {"page_label": "231", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "8525c595238b4af624be848c616f34fd44e6acf2781b5bc831ff38636c54ad55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "141b9542-6952-46d6-8405-bf80bc361419", "node_type": "1", "metadata": {"page_label": "232", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "6c269400d315bcccd1b4d9565ed2f75707be9f0ff0f661888fc65c64778f1a10", "class_name": "RelatedNodeInfo"}}, "hash": "6d6f66e95eb6f4f4b3e83bd387f8e2896b31e61a98133735212f1f80d255b283", "text": "Syngal  et al.  \nThe American Journal of GASTROENTEROLOGY VOLUME 110 | FEBRUARY 2015    www.amjgastro.com 232\nyears, and treatment of  H elicobacter  pylori   infection when \nfound. Data for ongoing regular surveillance are limited, but ongoing surveillance every 3\u20135 years may be considered if there is a family history of gastric or duodenal cancer (conditional recommendation, very low quality of evidence).\n  6.  Screening beyond population-based recommendations for can-\ncers of the urinary tract, pancreas, prostate, and breast is not rec-ommended unless there is a family history of the specifi  c cancers \n(conditional recommendation, low quality of evidence).\n    \nSummary of evidence  \n    Th e impact of a family history of extracolonic cancers on other \nat-risk relatives has not been systematically studied. Some studies show clustering of extracolonic cancers in families, whereas oth-ers have not (discussed when available in section below for indi-vidual cancers). In clinical practice, decision making regarding \nsurveillance for extracolonic cancers is generally done on a case-\nby-case basis, taking into account cancer history in at-risk fi  rst- \nand second-degree relatives on the aff  ected side of the family.\n  Some studies have estimated the lifetime risk of gastric cancer \nin LS to be as high as 13%, but it is currently much lower in North America and Western Europe. A carefully conducted time trend study of gastric cancer found an 8.0% and 5.3% lifetime risk of this malignancy in males and females with MMR gene mutation, respectively, and lack of familial clustering ( 61 ). Th  e majority of \ngastric cancers in LS patients appear to be histologically classifi  ed \nas intestinal type ( 61,62 ), and, consequently, potentially amenable to endoscopic surveillance. Th  ere are no studies that have evalu-\nated the eff  ectiveness of screening and surveillance for gastric can-\ncer in LS patients.\n  Th e lifetime risk for small bowel cancer ranges from 0.4 to \n12.0% ( 31,34,53,54,63,64 ).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "141b9542-6952-46d6-8405-bf80bc361419": {"__data__": {"id_": "141b9542-6952-46d6-8405-bf80bc361419", "embedding": null, "metadata": {"page_label": "232", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1dfd9907-68af-43c3-b265-7f4569dd82a8", "node_type": "4", "metadata": {"page_label": "232", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "577138abc6b787a593937362a016cd6457b011de5cee2253c9373418c27a6020", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f463496b-27cc-4727-ba1e-786e7aeddbc8", "node_type": "1", "metadata": {"page_label": "232", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "6d6f66e95eb6f4f4b3e83bd387f8e2896b31e61a98133735212f1f80d255b283", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d6ed2bb-755a-41c9-bb05-b466c2676786", "node_type": "1", "metadata": {"page_label": "232", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "f208f254f81a2c434bcf2403cbdda238cadf1caa3a14cf0c61d17b23dbe9f465", "class_name": "RelatedNodeInfo"}}, "hash": "6c269400d315bcccd1b4d9565ed2f75707be9f0ff0f661888fc65c64778f1a10", "text": "Th  e majority of small bowel cancers \nin a LS cohort were located in the duodenum or ileum ( 65 ) and within the reach of EGD and colonoscopy with dedicated ileal intubation. Studies of small bowel screening in LS patients are lacking. However, one screening investigation of 35 gene muta-\ntion carriers found that 2 had jejunal adenomas and 1 had a \njejunal cancer ( 66 ) ( Table 8  ). Six additional patients had capsule \nendoscopy images of uncertain clinic relevance, prompting fur-ther invasive investigation in fi  ve patients. A recent publication \nsuggested that routine surveillance of the small bowel in LS was not cost effi   cient ( 55 ).\n  Estimates of the lifetime risk of urinary tract cancer in LS range \nfrom 0.2 to 25%, depending on the study and which urinary tract     Summary of evidence  \n    EC is the second most common cancer occurring in LS. Esti-\nmates of the cumulative lifetime risk of EC in LS patients range from 15 to 71%, with variability depending on specifi  c gene \nmutation ( 31,33,35\u201337,49 ) ( Table 7  ); reports of age at diagnosis \nof this malignancy are clearly a decade or more younger than \nsporadic EC but range from 48 to 54 years ( 31,33,35\u201337,49 )( Table 7  ). Estimates of the cumulative lifetime risk of ovarian \ncancer in LS patients ranges from 3.4 to 22% ( 31,38,53\u201355 ) ( Table 7  ).\n  Because of the worrisome cumulative risk of EC, several annual \nscreening modalities have been proposed including pelvic exams, transvaginal ultrasound, endometrial sampling, and CA 125 test-ing. Few studies of these interventions have been conducted and there is currently no evidence of survival benefi  t from EC surveil-\nlance ( Table 8  ). Decrease in death from EC screening may be dif-\nfi cult to prove as 75% of LS patients with EC present with stage 1 \ndisease and have an 88% 5-year survival rate.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d6ed2bb-755a-41c9-bb05-b466c2676786": {"__data__": {"id_": "4d6ed2bb-755a-41c9-bb05-b466c2676786", "embedding": null, "metadata": {"page_label": "232", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1dfd9907-68af-43c3-b265-7f4569dd82a8", "node_type": "4", "metadata": {"page_label": "232", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "577138abc6b787a593937362a016cd6457b011de5cee2253c9373418c27a6020", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "141b9542-6952-46d6-8405-bf80bc361419", "node_type": "1", "metadata": {"page_label": "232", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "6c269400d315bcccd1b4d9565ed2f75707be9f0ff0f661888fc65c64778f1a10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9a8ad4b-4793-40e6-9d04-18e7afa681c5", "node_type": "1", "metadata": {"page_label": "232", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "ec8fcc752a7fadf49dbbe1676028ae583b70c70aaf9ce3c34076a6981d2c7565", "class_name": "RelatedNodeInfo"}}, "hash": "f208f254f81a2c434bcf2403cbdda238cadf1caa3a14cf0c61d17b23dbe9f465", "text": "Transvaginal ultra-sound has poor sensitivity and specifi  city for the diagnosis of EC in \nthis population ( 56,57 ). However, endometrial sampling appears useful in identifying some asymptomatic patients with EC and those with premalignant endometrial lesions ( Table 8  ). Currently, \nno studies on the eff  ectiveness of ovarian screening are available \nfor women in LS families.\n  One retrospective study of 315 women with MMR muta-\ntions who did and did not have hysterectomy and oophorectomy revealed no cancers in the surgical group compared with a 33% and 5.5% rate of uterine and ovarian cancer, respectively, in the nonsurgical group ( 58 ). Cost-eff  ectiveness analysis modeling of \ngynecological screening vs. prophy lactic gynecological surgery \n(hysterectomy and bilateral salpingo-oophorectomy) in a theo-retical population of 30-year-old women with LS revealed that prophylactic surgery had lower cost and higher quality-adjusted life-years ( 59 ). An additional modeling study evaluated multiple screening and surgical strategies. Th  is investigation concluded that \nannual screening starting at age 30 years followed by prophylactic \nsurgery at age 40 years was the most eff  ective gynecologic cancer \nprevention strategy, but incremental benefi  t over prophylactic sur-\ngery at age 40 years alone was attained at substantial cost ( 60 ).\n    \nRecommendations   \n    5.  Screening for gastric and duodenal cancer can be considered in \nindividuals at risk for or aff  ected with LS by baseline esophago-\ngastroduodenoscopy (EGD) with gastric biopsy at age 30\u201335  Table 6  .     Studies of colorectal screening in hereditary colorectal cancer (CRC) syndromes \n  Study (year)    Reference    Subjects    Design    Findings  \n   Sessile serrated polyposis syndrome   \n   Boparai  et al.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9a8ad4b-4793-40e6-9d04-18e7afa681c5": {"__data__": {"id_": "f9a8ad4b-4793-40e6-9d04-18e7afa681c5", "embedding": null, "metadata": {"page_label": "232", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1dfd9907-68af-43c3-b265-7f4569dd82a8", "node_type": "4", "metadata": {"page_label": "232", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "577138abc6b787a593937362a016cd6457b011de5cee2253c9373418c27a6020", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d6ed2bb-755a-41c9-bb05-b466c2676786", "node_type": "1", "metadata": {"page_label": "232", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "f208f254f81a2c434bcf2403cbdda238cadf1caa3a14cf0c61d17b23dbe9f465", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de2eebaa-da1a-4d63-bc17-3faf7f0291ff", "node_type": "1", "metadata": {"page_label": "233", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "ca319267153c131edf568eac26ec3a8de8892ae40cc6e905a056c6ef19d23bfa", "class_name": "RelatedNodeInfo"}}, "hash": "ec8fcc752a7fadf49dbbe1676028ae583b70c70aaf9ce3c34076a6981d2c7565", "text": "(2010)  ( 259 )  77 Hyperplastic polyposis \nsyndrome cases  Retrospective: to describe the clinical \nand pathological features of a large hyperplastic polyposis syndrome (HPS) cohort  In a mean follow-up period of 5.6 years, 1,984 \npolyps were identi\ufb01  ed. Colorectal cancer was \nidenti\ufb01  ed in 27 cases; 22 were diagnosed at initial colonoscopy. Four of the 5 interval CRCs were detected in diminutive serrated polyps (4\u201316 mm). \nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de2eebaa-da1a-4d63-bc17-3faf7f0291ff": {"__data__": {"id_": "de2eebaa-da1a-4d63-bc17-3faf7f0291ff", "embedding": null, "metadata": {"page_label": "233", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "671cda4e-8944-448f-8054-6c718ccd0db3", "node_type": "4", "metadata": {"page_label": "233", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c60ad437c62c9ec957cfc9653ff4274b9a5400e153273fbd839790821780897b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9a8ad4b-4793-40e6-9d04-18e7afa681c5", "node_type": "1", "metadata": {"page_label": "232", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "ec8fcc752a7fadf49dbbe1676028ae583b70c70aaf9ce3c34076a6981d2c7565", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4ac0b38-79c2-4ebb-8ce4-26f3ded5092b", "node_type": "1", "metadata": {"page_label": "233", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "d453b3b288005d8d235767940c76d0f5a7cc30bf6339ae27d992d85fb587cdac", "class_name": "RelatedNodeInfo"}}, "hash": "ca319267153c131edf568eac26ec3a8de8892ae40cc6e905a056c6ef19d23bfa", "text": "Hereditary GI Cancer Syndromes\n\u00a9 2015 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY\n 233\n Table 7  .     Cumulative risks of extracolorectal cancer in hereditary colorectal cancer syndromes \n  Cancer site    General population \nrisk   a     Syndrome risk    Average age of \ndiagnosis (years)    References  \n  Lynch syndrome   \n  Endometrium \n  General population  2.7%  65  SEER ( 328 ) \n   MLH1/MSH2    14\u201354%  48\u201354  ( 30,31,33,35,36,38 ) \n   MSH6    16\u201371%  53\u201354  ( 31,36,49 ) \n   PMS2    15%  49\u201350  ( 37 ) \n  Stomach  <1%  0.2\u201313%  49\u201355  ( 31,34,49,53\u201355,61,63,64 ) \n  Ovary  1.4%  3.4\u201322%  42\u201354  ( 31,36\u201338,49,53\u201355,63,64,67 ) \n  Hepatobiliary tract  <1%  0.02\u20134%  54\u201357  b    ( 31,55,63,67 ) \n  Urinary tract  <1%  0.2\u201325.5%  52\u201357  ( 31,37,49,53\u201355,63,64,67 ) \n  Small bowel  <1%  0.4\u201312%  46\u201351  ( 31,34,53\u201355,64 ) \n  Brain/central nervous system  <1%  1.2\u20133.7%  50\u201355  ( 53,55,63,64 ) \n  Sebaceous neoplasm  <1%  9%  c    51\u201354  ( 329\u2013331 ) \n  Pancreas  1.5%  0.4\u20133.7%  51.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4ac0b38-79c2-4ebb-8ce4-26f3ded5092b": {"__data__": {"id_": "e4ac0b38-79c2-4ebb-8ce4-26f3ded5092b", "embedding": null, "metadata": {"page_label": "233", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "671cda4e-8944-448f-8054-6c718ccd0db3", "node_type": "4", "metadata": {"page_label": "233", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c60ad437c62c9ec957cfc9653ff4274b9a5400e153273fbd839790821780897b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de2eebaa-da1a-4d63-bc17-3faf7f0291ff", "node_type": "1", "metadata": {"page_label": "233", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "ca319267153c131edf568eac26ec3a8de8892ae40cc6e905a056c6ef19d23bfa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff31a775-0515-49df-a20e-07f9aa15f925", "node_type": "1", "metadata": {"page_label": "233", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "f983e8b0b44e05398bf122cfed98e8cbf66a2407588392211522369f7a4fc44d", "class_name": "RelatedNodeInfo"}}, "hash": "d453b3b288005d8d235767940c76d0f5a7cc30bf6339ae27d992d85fb587cdac", "text": "5%  0.4\u20133.7%  51.5\u201356.5  b    ( 33,53,271 ) \n  Prostate  15.3%  9\u201330%  59\u201360  ( 54,76,332 ) \n  Breast (female)  12.3%  1.5\u201318%  46\u201352  ( 53,54,75 ) \n  Familial adenomatous polyposis(FAP)   \n  Small bowel (duodenum/periampullary)  <1%  3\u201310%  44  \n 50\u201352  b    ( 81,126,127,138,144,146,316,333 ) \n  Stomach  <1%  <1%  49  ( 126,138,316 ) \n  Pancreas  1.5%  1.7%  50  b    ( 126,138,334 ) \n  Thyroid  1.1%  2%  25\u201333  ( 126,138,171,172,316,334,335 ) \n  Liver (hepatoblastoma)  <1%  1\u20132%  Most often occurs in \nthe \ufb01  rst 5 years of life  ( 126,138,173 ) \n  Brain/central nervous system  <1%  1\u20132%  15\u201321  ( 126,138,336\u2013338 ) \n  Attenuated FAP   \n  Small bowel (duodenum/periampullary)  <1%  4\u201312%  60  ( 90,126 ) \n  Thyroid  1.1%  1\u20132%  26  ( 90,126 ) \n  MUTYH-associated polyposis   \n  Small bowel (duodenum)  <1%  4%  61   b    ( 126,174 ) \n  Stomach  <1%  1%  38   b    ( 126,174 ) \n  Juvenile polyposis   \n   Upper gastrointestinal (GI) cancer \n(stomach, pancreas,", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff31a775-0515-49df-a20e-07f9aa15f925": {"__data__": {"id_": "ff31a775-0515-49df-a20e-07f9aa15f925", "embedding": null, "metadata": {"page_label": "233", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "671cda4e-8944-448f-8054-6c718ccd0db3", "node_type": "4", "metadata": {"page_label": "233", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c60ad437c62c9ec957cfc9653ff4274b9a5400e153273fbd839790821780897b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4ac0b38-79c2-4ebb-8ce4-26f3ded5092b", "node_type": "1", "metadata": {"page_label": "233", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "d453b3b288005d8d235767940c76d0f5a7cc30bf6339ae27d992d85fb587cdac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c01f901-fcef-4551-9052-b1b98f364fc9", "node_type": "1", "metadata": {"page_label": "234", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "e5077d5cee8379a7089d21649bc87cafdc657cfb970bddfa69364d0f8daad653", "class_name": "RelatedNodeInfo"}}, "hash": "f983e8b0b44e05398bf122cfed98e8cbf66a2407588392211522369f7a4fc44d", "text": "pancreas, and small bowel)  \u2014  21%  c    54  ( 126,183,321 ) \n  Peutz\u2013Jeghers syndrome   \n  Stomach  <1%  29%  30\u201340  ( 196,197 ) \n  Small bowel  <1%  13%  37\u201342  ( 196,197 ) \n  Pancreas  1.5%  11\u201336%  41\u201352  ( 194,196,197,339 ) \n  Breast  12.4%  32\u201354%  37\u201359  ( 194,196,197 ) \n   Ovarian (mostly SCTAT (sex cord tumor \nwith annular tubules))  1.6%  21%  28  ( 197 ) \n  Uterus  2.7%  9%  43  ( 196,197 ) \n  Cervix (adenoma malignum)  <1%  10%  34\u201340  ( 197,340 ) \nTable 7 continued on following page\nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c01f901-fcef-4551-9052-b1b98f364fc9": {"__data__": {"id_": "4c01f901-fcef-4551-9052-b1b98f364fc9", "embedding": null, "metadata": {"page_label": "234", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a81e88e8-aa74-4a71-82ae-177cdcfcf648", "node_type": "4", "metadata": {"page_label": "234", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "82bab5dd0516e5bd25a5bb44de435b99cc8579120b1993101404b590aca08c6f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff31a775-0515-49df-a20e-07f9aa15f925", "node_type": "1", "metadata": {"page_label": "233", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "f983e8b0b44e05398bf122cfed98e8cbf66a2407588392211522369f7a4fc44d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56c8371c-0e48-4e67-8af5-74f3d90f822f", "node_type": "1", "metadata": {"page_label": "234", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "90f5653559cd4f5e97b146d1215a0fbc6fd4d893f0eff1876e3e3210d4d84527", "class_name": "RelatedNodeInfo"}}, "hash": "e5077d5cee8379a7089d21649bc87cafdc657cfb970bddfa69364d0f8daad653", "text": "Syngal  et al.  \nThe American Journal of GASTROENTEROLOGY VOLUME 110 | FEBRUARY 2015    www.amjgastro.com 234\nis 2.0- to 2.5-fold the general population risk ( 54,76 ); however, the \neff ectiveness of intensive screening beyond population recommen-\ndations has not been evaluated.\n      Prevention strategies\n   Diet, exercise, smoking, and supplements   .     A prospective analysis \nof 386 patients with LS undergoing surveillance revealed that cur-rent smokers had an increased risk of colorectal adenomas com-pared with past smokers and never smokers (hazard ratio of 6.1 vs. 3.0 vs. 1, respectively ( 77 ). Excess body weight (body mass in-dex >25 kg/m \n2 ) has been shown to be associated with an elevated \nrisk (hazard ratio of 8.7 compared with normal weight) of colo-rectal adenomas in men with LS in the same cohort; an elevated risk was not found in women with a high body mass index ( 78 ).\n     Chemoprevention\n   Recommendation   \n    7.  Although data suggest that daily aspirin may decrease the risk \nof colorectal and extracolonic cancer in LS, currently the evi-dence is not suffi   ciently robust or mature to make a recom-\nmendation for its standard use (conditional recommendation, moderate quality of evidence).\n    \nSummary of evidence  \n    Resistant starch and aspirin have been assessed as chemopre-\nventive agents in patients with LS. Th  e Colorectal/Adenoma/\nCarcinoma Prevention Programme 2 (CAPP2) was a rand-omized placebo-controlled trial with a two-by-two design in-vestigating the eff  ect of resistant starch (Novelose) 30 g per day \nand aspirin 600 mg per day taken for up to 4 years on develop-ment of colorectal adenoma and cancer ( 79 ). Th  is study rand-\nomized 727 participants to starch or placebo and 693 between aspirin and placebo.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56c8371c-0e48-4e67-8af5-74f3d90f822f": {"__data__": {"id_": "56c8371c-0e48-4e67-8af5-74f3d90f822f", "embedding": null, "metadata": {"page_label": "234", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a81e88e8-aa74-4a71-82ae-177cdcfcf648", "node_type": "4", "metadata": {"page_label": "234", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "82bab5dd0516e5bd25a5bb44de435b99cc8579120b1993101404b590aca08c6f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c01f901-fcef-4551-9052-b1b98f364fc9", "node_type": "1", "metadata": {"page_label": "234", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "e5077d5cee8379a7089d21649bc87cafdc657cfb970bddfa69364d0f8daad653", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4f71330-654b-4a21-a5ae-7faab9cdd2f1", "node_type": "1", "metadata": {"page_label": "234", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c32ee831709d86ef3584d82b8ecdedb8d633483334882c8268be310275558d16", "class_name": "RelatedNodeInfo"}}, "hash": "90f5653559cd4f5e97b146d1215a0fbc6fd4d893f0eff1876e3e3210d4d84527", "text": "Th  e use of resistant starch, aspirin, or both cancers are included (transitional cell carcinoma of the ureter, \nrenal pelvis, and bladder) ( 31,53,54,63,64,67 ). Currently, a dearth of literature on screening for urinary cancer in LS patients exists. One retrospective study evaluating screening for urinary cancer by urine cytology in individuals in hereditary nonpolyposis colorectal \ncancer or LS families found a poor (29%) sensitivity in diagnos-\ning cancer in asymptomatic patients and production of many false positive results requiring invasive investigation ( 68 ) ( Table 8  ). \nScreening has not been shown to be eff  ective with urine cytology \nand urinalysis for microscopic hematuria for urinary cancer in the general population and in groups at higher risk for bladder can-cer from environmental factors ( 69,70 ). Th  e benefi  t of ultrasound \nscreening is unknown. In summary, limited data exist to advocate urinary screening.\n  Th e risk of pancreatic cancer (PC) in LS patients was noted \nto be elevated in two cohort studies. In one study, the standard-ized incidence ratio for PC was 10.7 (95% confi  dence interval, \n2.7\u201347.7), with a 10-year cumulative risk of 0.95% ( 71 ), and the other study reported a 8.6-fold increase (95% confi  dence inter-\nval, 4.7\u201315.7), with cumulative risk of 3.7% by age 70 years ( 72 ). Th e benefi  t of screening for PC in LS has not been evaluated. \nAn international pancreas consensus panel recommended that, based on expert opinion, mismatch repair gene mutation carri-ers with one aff  ected FDR should be considered for annual PC \nsurveillance with magnetic resonance imaging (MRI) and/or \nendoscopic ultrasound based on early data in other cohorts with \ncomparable risk ( 73 ).\n  Th ere are confl  icting data regarding the risk of several other \nextracolonic cancers in patients with LS. Th  e relationship between \nLS and breast cancer is unclear.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4f71330-654b-4a21-a5ae-7faab9cdd2f1": {"__data__": {"id_": "f4f71330-654b-4a21-a5ae-7faab9cdd2f1", "embedding": null, "metadata": {"page_label": "234", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a81e88e8-aa74-4a71-82ae-177cdcfcf648", "node_type": "4", "metadata": {"page_label": "234", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "82bab5dd0516e5bd25a5bb44de435b99cc8579120b1993101404b590aca08c6f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56c8371c-0e48-4e67-8af5-74f3d90f822f", "node_type": "1", "metadata": {"page_label": "234", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "90f5653559cd4f5e97b146d1215a0fbc6fd4d893f0eff1876e3e3210d4d84527", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9ac43ff-a56a-49ae-8e24-54eb1b4c7409", "node_type": "1", "metadata": {"page_label": "235", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "4c54e8b7b87e175deeef16ec17affca3634eb88ec35ec4af71c69b98b28d328e", "class_name": "RelatedNodeInfo"}}, "hash": "c32ee831709d86ef3584d82b8ecdedb8d633483334882c8268be310275558d16", "text": "Th  e relationship between \nLS and breast cancer is unclear. Although a small increase in life-time breast cancer risk of 18% has been found ( 54,74 ), most clinic-based registry reports have not demonstrated this consistently ( 55,75 ). In two recent studies the relative risk of prostate cancer  Table 7  .     Continued \n  Cancer site    General population \nrisk   a     Syndrome risk    Average age of \ndiagnosis (years)    References  \n  Testicular (Sertoli cell tumor)  <1%  9%  6\u20139  ( 196,197 ) \n  Lung  6.9%  7\u201317%  47  ( 194,196,197 ) \n  Cowden syndrome   \n  Breast  12.4%  25\u201385%  38\u201346  ( 184,235,236,341\u2013343 ) \n  Thyroid  1.1%  3\u201338%  31\u201338  b    ( 184,235,236,342\u2013345 ) \n  Endometrium  2.7%  5\u201328%  25  d    ( 184,228,235,236 ) \n  Kidney (renal cell)  1.6%  15\u201334%  40  d    ( 183,224,225,235,346,347 ) \n  Melanoma  2  6%  3  e    ( 183,224,225,235,346,347 ) \n   a   SEER, 2013 ( 328 ).  \n   b   Median age.  \n   c   Incidence.  \n   d   Onset of risk.  \n   e   Youngest age of onset.  \nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9ac43ff-a56a-49ae-8e24-54eb1b4c7409": {"__data__": {"id_": "b9ac43ff-a56a-49ae-8e24-54eb1b4c7409", "embedding": null, "metadata": {"page_label": "235", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "06ea3c36-f840-4e59-b835-99394dbf217e", "node_type": "4", "metadata": {"page_label": "235", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "80229b45892221e15e5e019a8ca79e201711dcbfac0c6fa59073c51d2a8834d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4f71330-654b-4a21-a5ae-7faab9cdd2f1", "node_type": "1", "metadata": {"page_label": "234", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c32ee831709d86ef3584d82b8ecdedb8d633483334882c8268be310275558d16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1f26ad7-da83-482e-8443-f5bac68bec65", "node_type": "1", "metadata": {"page_label": "235", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "34e70ceec0c4a6fcc640317ef6c73ea153a94779e4bf995b228b0d69cb7ec97b", "class_name": "RelatedNodeInfo"}}, "hash": "4c54e8b7b87e175deeef16ec17affca3634eb88ec35ec4af71c69b98b28d328e", "text": "Hereditary GI Cancer Syndromes\n\u00a9 2015 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY\n 235\n Table 8  .     Studies of extracolonic cancer screening in hereditary colorectal cancer syndromes \n  Organ    Study (years)    Reference    Subjects    Design    Findings  \n  Lynch syndrome (LS)   \n   Endometrial \nand ovarian  Dove-Edwin  et al.   \n(2002)  ( 56 )  292 Women from hereditary \nnonpolyposis colorectal cancer (HNPCC) or HNPCC-like families.  Observational: all offered \ntransvaginal ultrasounds.  Two cases of endometrial cancer (EC) pre-\nsented with symptoms, neither detected by ultrasound. \n   Rijcken  et al.   (2003)  ( 348 )  41 Women with MMR muta-\ntions or ful\ufb01  lled Amsterdam \nI criteria followed for median of 5 years.  Observational: all offered \nannual pelvic exam, trans-vaginal ultrasound, CA-125.  17 Of 179 ultrasounds gave reason for \nendometrial sampling with 3 premalignant lesions noted; one interval endometrial cancer presented symptomatically. \n   Renkonen-Sinisalo \n et al.   (2007)  ( 57 )  175 Women with MMR \nmutations.  Observational: all offered \ntransvaginal ultrasound and endometrial biopsy.  14 cases of EC; 11 diagnosed by surveillance. \nBiopsy diagnosed 8 of 11 EC and 14 cases of premalignant hyperplasia.  Ultrasound indicated 4 EC cases but missed \n6 others.  4 case of ovarian cancer, none found by \nultrasound. \n   Lecuru  et al.   (2008)  ( 349 )  62 Women (13 with MMR \nmutation, 49 met Amsterdam II criteria).  Observational: annual \nhysteroscopy and endometrial biopsy.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1f26ad7-da83-482e-8443-f5bac68bec65": {"__data__": {"id_": "e1f26ad7-da83-482e-8443-f5bac68bec65", "embedding": null, "metadata": {"page_label": "235", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "06ea3c36-f840-4e59-b835-99394dbf217e", "node_type": "4", "metadata": {"page_label": "235", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "80229b45892221e15e5e019a8ca79e201711dcbfac0c6fa59073c51d2a8834d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9ac43ff-a56a-49ae-8e24-54eb1b4c7409", "node_type": "1", "metadata": {"page_label": "235", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "4c54e8b7b87e175deeef16ec17affca3634eb88ec35ec4af71c69b98b28d328e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48f93b99-d093-4b32-9f6c-a5367ff12847", "node_type": "1", "metadata": {"page_label": "235", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "9e68d993daa2c2f710a0740a915d7c332457e5e37742d8cd52aae5b47526e9c0", "class_name": "RelatedNodeInfo"}}, "hash": "34e70ceec0c4a6fcc640317ef6c73ea153a94779e4bf995b228b0d69cb7ec97b", "text": "Observational: annual \nhysteroscopy and endometrial biopsy.  3 Malignancies in 3 patients with abnormal \nbleeding; 3 cases of hyperplasia in asympto-matic patients; hysteroscopy 100% sensitive for cancer or hyperplasia. \n   Gerritzen  et al.   \n(2009)  ( 350 )  100 Women from families \nwith MMR mutation.  Observational: annual trans-\nvaginal ultrasound, CA-125, endometrial sampling.  3 Atypical hyperplasias and 1 endometrial \ncancer diagnosed. One stage III ovarian cancer developed despite ultrasound. \n   Stuckless  et al.\n  \n(2013)  ( 351 )  174 Women with MSH2 gene \nmutation.  Case\u2013control: Cases:54 \npatient with at least one screening exam (transvaginal, endometrial biopsy, or CA-125 test); Controls: matched women without screening.  Stage I/II cancer diagnosed in 92% of \nscreened patients compared with 71% in control group ( P =0.17). \n Two of three deaths in the screened group \nfrom ovarian cancer. \n   Stuckless  et al.   \n(2012)  ( 46 )  322 MSH2 mutation carriers.  Observational: cancer \nincidence and survival in 152 screened vs. 170 not screened by colonoscopy.  Median age to CRC later in screened vs. \nnonscreened.  Survival statistically improved in screened vs. \nnonscreened. \n   Schmeler  et al.   \n(2006)  ( 58 )  315 Women with MMR \nmutation with and without gynecological surgery.  Retrospective: risk of uterine \nand ovarian cancer in patients with and without prophylactic/ clinically indicated gyneco-logical surgery.  No uterine or ovarian cancer in surgery group \nvs. 33 and 5% cancer respectively in nonsur-gery group. \n  Gastric  Renkonen-Sinisalo \n et al.   (2002)  ( 352 )  73 Patients with MMR \nmutation; 32 MMR mutation-negative family members.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48f93b99-d093-4b32-9f6c-a5367ff12847": {"__data__": {"id_": "48f93b99-d093-4b32-9f6c-a5367ff12847", "embedding": null, "metadata": {"page_label": "235", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "06ea3c36-f840-4e59-b835-99394dbf217e", "node_type": "4", "metadata": {"page_label": "235", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "80229b45892221e15e5e019a8ca79e201711dcbfac0c6fa59073c51d2a8834d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1f26ad7-da83-482e-8443-f5bac68bec65", "node_type": "1", "metadata": {"page_label": "235", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "34e70ceec0c4a6fcc640317ef6c73ea153a94779e4bf995b228b0d69cb7ec97b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eafe4a13-9bed-40bc-b8a4-751a7724b3a3", "node_type": "1", "metadata": {"page_label": "235", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "f09f54b7dd09ecb6797490c9bb89e668d2632e7b46efc8711c443bc357c10deb", "class_name": "RelatedNodeInfo"}}, "hash": "9e68d993daa2c2f710a0740a915d7c332457e5e37742d8cd52aae5b47526e9c0", "text": "Observational: \n Upper endoscopy with gastric \nbiopsies.  In MMR gene-positive patients,  H. pylori   in \n26%, atrophy 14%, intestinal metaplasia 14%. No statistical difference between gene-positive and -negative groups. \n  Small bowel  Saurin  et al.   (2010)  ( 66 )  35 Patients with MMR \nmutations.  Observational: \n Capsule endoscopy and \ncomputed tomographic (CT) enteroclysis screening of small bowel.  Small bowel neoplasms were found in 8.6% of \ncases (1 patient with jejunal carcinoma and 2 with jejunal adenoma).  Capsule endoscopy found all lesions; CT ent-\neroscopy found cancer but missed adenomas. \n  Urinary tract  Myrhoj  et al.\n  (2008)  ( 68 )  977 At-risk individuals in \nfamilies suspected to have HNPCC/LS.  Observational: \n Retrospective review of \nscreening urine cytology (UC) and diagnosis of urinary cancer.  0.1% Of UC exams lead to diagnosis of \nurothelial tumor.  10\u00d7 more UC exams lead to false-positive \ndiagnosis.  Sensitivity of UC was 29%. \n  Familial adenomatous polyposis (FAP)   \n  Duodenum  Bulow  et al.   (2004)  ( 144 )  367 FAP cases  Prospective: to describe the \nlong-term natural history of duodenal adenomatosis in FAP and evaluate the indications for prophylactic duodenal surveillance  65% Of cases had duodenal adenomas \non their \ufb01  rst endoscopy. The cumulative \nincidence of duodenal carcinoma was 4.5% at 57 years; cases with Spigelman stage IV ad-enomatosis on initial endoscopy were at higher risk compared with those with stages 0\u2013III \n   Biasco  et al.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eafe4a13-9bed-40bc-b8a4-751a7724b3a3": {"__data__": {"id_": "eafe4a13-9bed-40bc-b8a4-751a7724b3a3", "embedding": null, "metadata": {"page_label": "235", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "06ea3c36-f840-4e59-b835-99394dbf217e", "node_type": "4", "metadata": {"page_label": "235", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "80229b45892221e15e5e019a8ca79e201711dcbfac0c6fa59073c51d2a8834d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48f93b99-d093-4b32-9f6c-a5367ff12847", "node_type": "1", "metadata": {"page_label": "235", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "9e68d993daa2c2f710a0740a915d7c332457e5e37742d8cd52aae5b47526e9c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "476dc7cf-48eb-42f4-ba53-de43ad766c9e", "node_type": "1", "metadata": {"page_label": "236", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "d4b8712f3d2933165fd046d31c444ac634cad81abe95cbbd43b09cb3b4c657ae", "class_name": "RelatedNodeInfo"}}, "hash": "f09f54b7dd09ecb6797490c9bb89e668d2632e7b46efc8711c443bc357c10deb", "text": "(2006)  ( 353 )  50 FAP cases  Prospective: to evaluate the \npresence and severity of pre-cancerous duodenal mucosal lesions  86% Of cases had duodenal lesions at the end \nof the study compared with 38% at \ufb01  rst endos-\ncopy. Eleven subjects developed stage IV disease and had endoscopic or surgical resection. \nTable 8 continued on following page\nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "476dc7cf-48eb-42f4-ba53-de43ad766c9e": {"__data__": {"id_": "476dc7cf-48eb-42f4-ba53-de43ad766c9e", "embedding": null, "metadata": {"page_label": "236", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d01648cf-3d66-490f-a813-395c0a26c02d", "node_type": "4", "metadata": {"page_label": "236", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "b3f90638e98fbaed083bff0888957fc30e02906b3d9bb038b6654162238474ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eafe4a13-9bed-40bc-b8a4-751a7724b3a3", "node_type": "1", "metadata": {"page_label": "235", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "f09f54b7dd09ecb6797490c9bb89e668d2632e7b46efc8711c443bc357c10deb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c968e55d-c2fa-485e-8999-c7081f68652e", "node_type": "1", "metadata": {"page_label": "236", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "fff6ef129e0888d93bc16e33e93ee4cd2486cb4fa39964930f8e82a8bd6add39", "class_name": "RelatedNodeInfo"}}, "hash": "d4b8712f3d2933165fd046d31c444ac634cad81abe95cbbd43b09cb3b4c657ae", "text": "Syngal  et al.  \nThe American Journal of GASTROENTEROLOGY VOLUME 110 | FEBRUARY 2015    www.amjgastro.com 236\nnoted to be eff  ective (75 mg a day) in sporadic CRC chemopre-\nvention.\n  Th e CAPP3 trial is currently underway to establish the optimum \ndose and duration of aspirin treatment. Although data exist to sug-gest that aspirin may decrease the risk of colorectal and extraco-lonic cancer in LS, currently the evidence is not suffi   ciently robust \nor mature to make a recommendation for its standard use.\n     Adenomatous polyposis syndromes\n   Familial adenomatous polyposis/ MUTYH  -associated polyposis/\nattenuated polyposis indications for genetic evaluation \n  Summary statement   \n\u2022       Individuals who have a personal history of >10 cumulative \ncolorectal adenomas, a family history of one of the adeno-matous polyposis syndromes, or a history of adenomas and FAP-type extracolonic manifestations (duodenal/ampullary adenomas, desmoid tumors (abdominal>peripheral), papil-lary thyroid cancer, congenital hypertrophy of the retinal pig-ment epithelium, epidermal cysts, osteomas) should undergo assessment for the adenomatous polyposis syndromes. had no eff  ect on the incidence of colorectal neoplasia in LS car-\nriers over a mean follow-up period of 29 months. Th  e CAPP2 \ninvestigators subsequently evaluated the long-term eff  ect of \n600 mg of aspirin usage on CRC development ( 80 ). At a mean follow-up of 55.7 months, intention-to-treat analysis of time to fi rst CRC showed a hazard ratio of 0.63 (95% confi  dence \ninterval, 0.35\u20131.13,  P =0.12). An intention-to-treat analysis of \nall LS cancers (colorectal, endometrial, ovarian, pancreatic, small bowel, gallbladder, ureter, stomach, kidney, and brain) revealed a protective eff  ect of aspirin vs.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c968e55d-c2fa-485e-8999-c7081f68652e": {"__data__": {"id_": "c968e55d-c2fa-485e-8999-c7081f68652e", "embedding": null, "metadata": {"page_label": "236", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d01648cf-3d66-490f-a813-395c0a26c02d", "node_type": "4", "metadata": {"page_label": "236", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "b3f90638e98fbaed083bff0888957fc30e02906b3d9bb038b6654162238474ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "476dc7cf-48eb-42f4-ba53-de43ad766c9e", "node_type": "1", "metadata": {"page_label": "236", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "d4b8712f3d2933165fd046d31c444ac634cad81abe95cbbd43b09cb3b4c657ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22d59266-a885-46e5-a73d-35b3c1781020", "node_type": "1", "metadata": {"page_label": "236", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "dbc76a54b6fda16c7711ab93c313d5b144386bcf930eec1386d3922c633c4b57", "class_name": "RelatedNodeInfo"}}, "hash": "fff6ef129e0888d93bc16e33e93ee4cd2486cb4fa39964930f8e82a8bd6add39", "text": "placebo (hazard ratio, \n0.65; 95% confi  dence interval, 0.42\u20131.00,  P =0.05). During the \nintervention, adverse events did not diff  er between aspirin and \nplacebo groups.\n  Th e CAPP2 trial has several limitations. First, ascertainment \nof the end point, CRC, was not standardized, and more intensive colonoscopic evaluation could have occurred in the aspirin group than in the non-aspirin group because of more frequent adverse eff ects aft  er intervention. Second, the extracolonic cancers did not \nundergo molecular evaluation to assess whether they were related to the germline MMR mutation. In addition, the dose of daily aspirin utilized in the CAPP2 trial is signifi  cantly higher than that  Table 8  .     Continued \n  Organ    Study (years)    Reference    Subjects    Design    Findings  \n  Thyroid  Jarrar  et al.   (2011)  ( 354 )  192 FAP cases  Prospective: to clarify the \nincidence of thyroid cancer in patients with FAP  38% Of cases had thyroid nodules and 2.6% \nhad thyroid cancer. Clinical history and neck examination did not detect any of the cancers \n  Peutz\u2013Jeghers syndrome (PJS)   \n    Gastrointesti-\nnal (GI) tract  Latchford  et al.   \n(2011)  ( 355 )  63 PJS cases from \n48 pedigrees  Retrospective review: to \nassess outcomes from GI sur-veillance in patients with PJS  Baseline investigations were done in 12 sub-\njects. The rest of the patients were followed for a median of 10 years and 776 procedures were performed. Of the 2,461 polypectomies done, 6 polyps contained atypia or dysplasia; there were two cases of perforation following resection of polyps >2 cm. No luminal GI cancers were diagnosed. \n  Small bowel  Brown  et al.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22d59266-a885-46e5-a73d-35b3c1781020": {"__data__": {"id_": "22d59266-a885-46e5-a73d-35b3c1781020", "embedding": null, "metadata": {"page_label": "236", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d01648cf-3d66-490f-a813-395c0a26c02d", "node_type": "4", "metadata": {"page_label": "236", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "b3f90638e98fbaed083bff0888957fc30e02906b3d9bb038b6654162238474ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c968e55d-c2fa-485e-8999-c7081f68652e", "node_type": "1", "metadata": {"page_label": "236", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "fff6ef129e0888d93bc16e33e93ee4cd2486cb4fa39964930f8e82a8bd6add39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7cb7d23e-c478-4dcd-ba8b-dce5cab26a19", "node_type": "1", "metadata": {"page_label": "236", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "7978d8f7e79138f0c0346431628fd3af909fc72942a3a24c13bc260008434598", "class_name": "RelatedNodeInfo"}}, "hash": "dbc76a54b6fda16c7711ab93c313d5b144386bcf930eec1386d3922c633c4b57", "text": "No luminal GI cancers were diagnosed. \n  Small bowel  Brown  et al.   (2006)  ( 356 )  19 Adult PJS cases  Prospective: to evaluate the \nperformance of capsule endoscopy in small bowel surveillance of adults with PJS vs. barium follow-through  Capsule endoscopy detected more signi\ufb01  cant \npolyps than barium follow-through but seemed less reliable for accurately sizing 1\u20132 cm polyps. \n   Gupta  et al.   (2010)  ( 357 )  19 Adult PJS cases  Prospective: to assess the \nutility of magnetic resonance (MR) enterography compared with capsule endoscopy for small bowel polyp detection in PJS  All cases underwent both procedures. MR \nenterography detected large polyps (>15 mm) missed in three patients by capsule endosco-py. Size assessments of large polyps appeared more reproducible with MR enterography. \n  Pancreas  Poley  et al.   (2009)  ( 358 )  44 Individuals at high risk of \ndeveloping pancreatic cancer (2 PJS cases)  Prospective: to investigate the \nuse of endoscopic ultrasound for screening individuals at high risk of developing pancreatic cancer  Initial screening detected an asymptomatic \nmass lesion in 3 cases (6.8%) and premalig-nant intraductal papillary mucinous neoplasm (IPMN)-like lesions in 16%. \n  Cowden syndrome   \n  Thyroid  Milas  et al.   (2012)  ( 345 )  225 PTEN mutative-positive \ncases  Retrospective: to characterize \nCowden syndrome-associated malignant and benign thyroid disease  32 Cases (14%) had thyroid cancer (mostly \npapillary type) at a median age of 35 years. Initial thyroid ultrasound in 16 of 25 subjects revealed thyroiditis/goiters in all >13 years of age.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7cb7d23e-c478-4dcd-ba8b-dce5cab26a19": {"__data__": {"id_": "7cb7d23e-c478-4dcd-ba8b-dce5cab26a19", "embedding": null, "metadata": {"page_label": "236", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d01648cf-3d66-490f-a813-395c0a26c02d", "node_type": "4", "metadata": {"page_label": "236", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "b3f90638e98fbaed083bff0888957fc30e02906b3d9bb038b6654162238474ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22d59266-a885-46e5-a73d-35b3c1781020", "node_type": "1", "metadata": {"page_label": "236", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "dbc76a54b6fda16c7711ab93c313d5b144386bcf930eec1386d3922c633c4b57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8e8c46d-dd70-4e40-a9b7-e1bdb1591c3a", "node_type": "1", "metadata": {"page_label": "237", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "23cf9ebad5d282ea85ec8fef29adb18fd934aeeb574dcadc82441758047894a4", "class_name": "RelatedNodeInfo"}}, "hash": "7978d8f7e79138f0c0346431628fd3af909fc72942a3a24c13bc260008434598", "text": "Downloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8e8c46d-dd70-4e40-a9b7-e1bdb1591c3a": {"__data__": {"id_": "e8e8c46d-dd70-4e40-a9b7-e1bdb1591c3a", "embedding": null, "metadata": {"page_label": "237", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "90a489b0-c353-465c-8d7d-6417983ac5ab", "node_type": "4", "metadata": {"page_label": "237", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "e3a51d40f1bb123e1313c4d5a2ebf08c2449d8df9298e604072bda79c2a7380c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7cb7d23e-c478-4dcd-ba8b-dce5cab26a19", "node_type": "1", "metadata": {"page_label": "236", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "7978d8f7e79138f0c0346431628fd3af909fc72942a3a24c13bc260008434598", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebcbf99d-187e-4cd3-b16e-08da3f4349c8", "node_type": "1", "metadata": {"page_label": "237", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "99209f906885c0ba37dd08cf1c558d568b3c18324478d29d45c3761a547ae5ad", "class_name": "RelatedNodeInfo"}}, "hash": "23cf9ebad5d282ea85ec8fef29adb18fd934aeeb574dcadc82441758047894a4", "text": "Hereditary GI Cancer Syndromes\n\u00a9 2015 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY\n 237\n     Summary of evidence   \n    Th ere are three known hereditary syndromes where inheritance \nof germline mutations produces enhanced colorectal carcinogen-esis, manifested by early age of onset of multiple colorectal adeno-mas with the potential for early development of CRC: FAP , AFAP and MAP .\n  FAP is the defi  ned by the presence of \u2265100 synchronous colorec-\ntal adenomas inherited in an autosomal-dominant manner. Esti-mates of the prevalence of FAP vary from 1 in 6,850 to 1 in 31,250 \nlive births (2.29 to 3.2 cases per 100,000 individuals) ( 81\u201387 ). Th  e \nfrequency is fairly constant throughout the world, with men and women being aff  ected equally.\n  Patients with 10 to 99 synchronous adenomas have oligopoly-\nposis or AFAP . AFAP is defi  ned by <100 adenomas at presentation \ninherited in an autosomal-dominant pattern. Patients with AFAP have fewer adenomas than those with typical FAP , averaging 25 polyps in one study and exhibiting a more proximal colonic pre-ponderance than in typical FAP ( 88\u201390 ). However, the polyp num-ber is extremely variable within many kindreds.\n  In 2002, an attenuated polyposis syndrome was described in \nthree siblings aff  ected with multiple adenomas and/or CRC inher-\nited in an autosomal-recessive pattern ( 91 ). Th  is recessive condi-\ntion is referred to as MAP and is characterized by an increased risk for CRC and multiple adenomatous polyps that can mimic FAP or AFAP .\n  Th ere are two settings in which to consider genetic testing for \nthe adenomatous polyposes syndromes: (i) testing an individual \nwith a phenotype suggestive of one of the polyposes, but where \nthe clinical diagnosis is not certain, and (ii) testing relatives of a patient with a known germline mutation.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebcbf99d-187e-4cd3-b16e-08da3f4349c8": {"__data__": {"id_": "ebcbf99d-187e-4cd3-b16e-08da3f4349c8", "embedding": null, "metadata": {"page_label": "237", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "90a489b0-c353-465c-8d7d-6417983ac5ab", "node_type": "4", "metadata": {"page_label": "237", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "e3a51d40f1bb123e1313c4d5a2ebf08c2449d8df9298e604072bda79c2a7380c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8e8c46d-dd70-4e40-a9b7-e1bdb1591c3a", "node_type": "1", "metadata": {"page_label": "237", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "23cf9ebad5d282ea85ec8fef29adb18fd934aeeb574dcadc82441758047894a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a953f635-57e9-4769-87ed-42498732ead0", "node_type": "1", "metadata": {"page_label": "237", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "2d4be10cc8e586175db7aef1682a3c36d85c425a11285014f930943989c9571e", "class_name": "RelatedNodeInfo"}}, "hash": "99209f906885c0ba37dd08cf1c558d568b3c18324478d29d45c3761a547ae5ad", "text": "Th  e fi rst setting is usually \ndefi ned as a patient with \u226510 cumulative adenomas, or sometimes \nsuggestive extracolonic manifestations, but no known family his-tory of an underlying pathogenic mutation. Genetic testing in this setting should be comprehensive and the absence of a mutation does not defi  nitively rule out a clinical diagnosis if the phenotype \nis striking. In the second setting, relatives of an individual with a known pathogenic mutation are tested for the presence or absence of that particular mutation. A positive test indicates the diagnosis of a syndrome, whereas a negative test (absence of mutation) rules it out and establishes that the individual is not at a syndromic risk for cancer and polyps.\n      Genetic etiology\n   Summary statement   \n\u2022       Genetic testing of patients with suspected adenomatous \npolyposis syndromes should include  APC   and  MUTYH   gene \nmutation analysis. \n     Summary of evidence   \n    FAP arises from germline mutations of the  APC   gene on chro-\nmosome 5q21 ( 92,93 ). FAP is dominantly inherited and is close to 100% penetrant. Up to one-third of newly diagnosed cases not belonging to previously identified families appear to represent either  de novo   germline mutations or mosaicism \n( 81,94\u201398 ).   APC   is a tumor suppressor gene; thus, gene inactivation occurs \nonly aft  er both alleles are mutationally damaged. In FAP , one allele \nis inherited in a mutated form. Adenoma formation is initiated when the second allele is damaged or lost by a somatic event. Th  e \nprogression of adenoma to carcinoma aft  er  APC   inactivation is \nsimilar in FAP and the sporadic setting in that mutations accu-mulate in additional relevant genes including K- ras ,  p53 , a gene \nor genes on chromosome 18, and possibly others ( 99 ). Although mutations have been found scattered throughout the  APC   gene, \nmost are located in the 5\u0374 end of exon 15, oft  en called the  mutation \ncluster region   ( 100,101 ).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a953f635-57e9-4769-87ed-42498732ead0": {"__data__": {"id_": "a953f635-57e9-4769-87ed-42498732ead0", "embedding": null, "metadata": {"page_label": "237", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "90a489b0-c353-465c-8d7d-6417983ac5ab", "node_type": "4", "metadata": {"page_label": "237", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "e3a51d40f1bb123e1313c4d5a2ebf08c2449d8df9298e604072bda79c2a7380c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebcbf99d-187e-4cd3-b16e-08da3f4349c8", "node_type": "1", "metadata": {"page_label": "237", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "99209f906885c0ba37dd08cf1c558d568b3c18324478d29d45c3761a547ae5ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccf1017f-6468-4128-b21b-e83bf9c9e9c9", "node_type": "1", "metadata": {"page_label": "237", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "5a82324d9d6baad7b53bc433635a8d98c6a1d37bff25ed06ee1b280e989a12c4", "class_name": "RelatedNodeInfo"}}, "hash": "2d4be10cc8e586175db7aef1682a3c36d85c425a11285014f930943989c9571e", "text": "Th  e location of mutations in the  APC   gene \ncorrelate to some degree with colonic adenoma number, desmoid tumor occurrence, and congenital hypertrophy of the retinal pig-ment epithelium ( 102 ). Individuals with >1,000 polyps exhibit mutations in the mid-portion of the gene ( 102,103 ).\n  AFAP arises from  APC   mutations at either the far proximal (5\u0374) \nend of the gene, the far distal (3\u0374) end of the gene, or in certain locations of exon 9 ( 90,102 ). Whole or partial gene deletions may also give an attenuated phenotype.\n  MAP is a recessively inherited syndrome due to biallelic \n(homozygous or compound heterozygous)  MUTYH   mutations. \n MUTYH   is a base excision repair gene involved in DNA oxida-\ntive damage repair whose protein repairs oxidative damage to the DNA ( 91 ). Failure of base excision repair results in CG\u2013AT trans-versions in multiple genes, including  APC   and  KRAS   ( 91,104,105 ). \nPolyp and cancer predisposition occur with germline  MUTYH   \nmutations, but somatic  MUTYH   mutations do not appear to play \na role in the pathogenesis of colon cancer ( 106,107 ). Th  e two most \nprevalent  MUTYH   mutations, occurring in >80% of individuals of \nEuropean ancestry with MAP , are two missense mutations Y179C and G396D (previously referred to as Y165C and G382D, respec-tively) ( 91,104,106,108\u2013110 ). Other population-specifi  c  MUTYH   \nmutations have been found ( 107 ). Approximately 90% of \u201cwest-ern\u201d population MAP patients have at least one of these two muta-tions; however, many other distinct  MUTYH   mutations have been \nreported ( 107 ).\n  MAP is most commonly found in patients presenting with \n20 to 99 adenomas ( 107,111 ).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccf1017f-6468-4128-b21b-e83bf9c9e9c9": {"__data__": {"id_": "ccf1017f-6468-4128-b21b-e83bf9c9e9c9", "embedding": null, "metadata": {"page_label": "237", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "90a489b0-c353-465c-8d7d-6417983ac5ab", "node_type": "4", "metadata": {"page_label": "237", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "e3a51d40f1bb123e1313c4d5a2ebf08c2449d8df9298e604072bda79c2a7380c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a953f635-57e9-4769-87ed-42498732ead0", "node_type": "1", "metadata": {"page_label": "237", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "2d4be10cc8e586175db7aef1682a3c36d85c425a11285014f930943989c9571e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cde14d95-96fd-4412-9428-83d1e6099c75", "node_type": "1", "metadata": {"page_label": "238", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "bec84dff40643ce0fe1c1617e35cf8646f69ccb5166a11490c24d5144cbae644", "class_name": "RelatedNodeInfo"}}, "hash": "5a82324d9d6baad7b53bc433635a8d98c6a1d37bff25ed06ee1b280e989a12c4", "text": "Biallelic  MUTYH   mutations are \nfound in 7.5% to 12.5% of patients with >100 adenomas in whom a disease-causing  APC   mutation is not found ( 104,112 ) \nand in 16 to 40% of patients with 15 to 99 colonic adenomas but not FAP ( 104,108,109,113,114 ). Although biallelic muta-tions have been found in individuals with early-onset CRC and few to no polyps, and in individuals with <10 adenomas with-out CRC, this is relatively uncommon ( 115 ). MAP was found in 0 out of 400 individuals with <4 adenomas, 2 of 444 (0.5%) unselected CRCs, and 0 out of 62 MSI high CRCs ( 112 ). Similar \nfrequencies among patients with polyps and CRCs have been \nfound in other studies. In a study from Finland, 0.4% of 1,042 population-based CRC cases had biallelic  MUTYH   mutations \n( 110 ). All those with mutations were found to have adenomas, ranging from 3 to 100. In a large (2,239 cases and 1,845 con-trols) population-based case\u2013control study from Scotland, 0.8% of CRC cases <55 years old and 0.54% of all cases had biallelic mutations ( 116 ).\nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cde14d95-96fd-4412-9428-83d1e6099c75": {"__data__": {"id_": "cde14d95-96fd-4412-9428-83d1e6099c75", "embedding": null, "metadata": {"page_label": "238", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d6049be2-6741-4b9a-962b-62d6b721da5e", "node_type": "4", "metadata": {"page_label": "238", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1ddd2ca6f259a6125e44abaaa5119d4f709b2f8e3302bcb66a35770c0643b9dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccf1017f-6468-4128-b21b-e83bf9c9e9c9", "node_type": "1", "metadata": {"page_label": "237", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "5a82324d9d6baad7b53bc433635a8d98c6a1d37bff25ed06ee1b280e989a12c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f49add44-9e6f-4958-9ffa-7f2e1824d60c", "node_type": "1", "metadata": {"page_label": "238", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "4a45cc6d9d6f5c0c0ab78c0b599d2920324c62f039deaafddf4d54d7528eca1d", "class_name": "RelatedNodeInfo"}}, "hash": "bec84dff40643ce0fe1c1617e35cf8646f69ccb5166a11490c24d5144cbae644", "text": "Syngal  et al.  \nThe American Journal of GASTROENTEROLOGY VOLUME 110 | FEBRUARY 2015    www.amjgastro.com 238\nthe St Marks FAP registry in London ( 81 ). Polyps begin to ap-\npear most oft  en in the second or third decade of life. Th  e mean \nage of polyp occur rence is 15.9 years (range, 8\u201334 years) ( 119 ). Adenomatous polyps are usually distributed evenly throughout the colon, with a slight distal colonic excess. Th  e size of the pol-\nyps depends on the stage at which the patient is examined. Even in fully developed cases, however, 90% of adenomas are <0.5 cm in diameter, and <1% of polyps are >1 cm. Polyps may either carpet the colon with myriad small lesions or occur as more \ndistinct and somewhat larger lesions. Striking heterogeneity of \npolyp number and growth rate has been observed ( 120 ). His-topathology demonstrates tubula r adenomas, indistinguishable \nfrom common or sporadic adenomas. Villous and tubulovillous histologies are also seen, but much less frequently and usually in larger polyps. A histologic feature of FAP not observed in the general population is dysplastic or adenomatous epithelial cells in single crypts or even portions of single crypts. Th  ese are called \nmicroadenomas and are oft  en seen in FAP biopsy specimens of \nnormal-appearing mucosa ( 81 ). Budding of dysplastic epitheli-um from normal crypts can be observed and aberrant crypt foci have been reported to occur with increased frequency in FAP ( 121 ). Th  ese lesions are similar to microadenomas but are identi-\nfi ed with methylene blue staining of the colonic mucosal surface.\n  Colonic adenocarcinoma is the inevitable consequence of FAP \nunless the colon is removed.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f49add44-9e6f-4958-9ffa-7f2e1824d60c": {"__data__": {"id_": "f49add44-9e6f-4958-9ffa-7f2e1824d60c", "embedding": null, "metadata": {"page_label": "238", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d6049be2-6741-4b9a-962b-62d6b721da5e", "node_type": "4", "metadata": {"page_label": "238", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1ddd2ca6f259a6125e44abaaa5119d4f709b2f8e3302bcb66a35770c0643b9dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cde14d95-96fd-4412-9428-83d1e6099c75", "node_type": "1", "metadata": {"page_label": "238", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "bec84dff40643ce0fe1c1617e35cf8646f69ccb5166a11490c24d5144cbae644", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ee8fc74-4fad-4193-aa12-5b53ca22fbef", "node_type": "1", "metadata": {"page_label": "238", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "81847b8ffc79b738c63a91a7f1de8dd89f88fcc8370b490060d1252c74a9b91c", "class_name": "RelatedNodeInfo"}}, "hash": "4a45cc6d9d6f5c0c0ab78c0b599d2920324c62f039deaafddf4d54d7528eca1d", "text": "Th  ere is a 25% incidence of colon \ncancer in newly diagnosed FAP patients, not belonging to known families, that remains common because of the high frequency of \n de novo   germline mutations ( 94,122 ). In the St Mark\u2019s series, the \naverage age at cancer diagnosis was 39 years. By 45 years of age, 87% had developed cancer, and by 50 years, it increased to 93%. Colon cancer has been reported as early as 9 years of age, although the occurrence of malignancy before adolescence is very unusual. Multiple colonic malignancies were present in \u223c 48% of those with \ncancer (41% synchronous and 7% metachronous). Of the malig-nancies, 84% were at or distal to the splenic fl  exure, a fraction \nalmost identical to that found in their series of random colorectal malignancies at that time. Average life expectancy aft  er diagnosis \nof cancer was 2.6 years.\n  Th e generally accepted colon screening guideline for children at \nrisk for classic FAP is every 1- to 2-year sigmoidoscopy beginning at 10 to 12 years of age ( 123\u2013127 ). Th  ose initially screened at an \nolder age should probably have colonoscopy for the fi  rst examina-\ntion. If surgery is delayed longer than a year aft  er polyps emerge, \nannual colonoscopy should be used for surveillance.\n  Colon screening with subsequent surgery decreases and almost \neliminates mortality from large bowel malignancy in FAP ( 127\u2013130 ). Survival is remarkably improved in relatives of probands who undergo screening ( 82,85,86,129,131 ).\n  In AFAP , the emergence of adenomas and cancer is delayed 10 to \n20 years compared with typical FAP . Th  e cumulative risk of CRC in \nAFAP by age 80 years in two large carefully studied kindreds was estimated to be 69%, with an average age at cancer diagnosis of 58 years (range, 29\u201381 years) ( 90 ). In another study, the average age at symptomatic presentation was 52 years ( 132 ).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ee8fc74-4fad-4193-aa12-5b53ca22fbef": {"__data__": {"id_": "3ee8fc74-4fad-4193-aa12-5b53ca22fbef", "embedding": null, "metadata": {"page_label": "238", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d6049be2-6741-4b9a-962b-62d6b721da5e", "node_type": "4", "metadata": {"page_label": "238", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1ddd2ca6f259a6125e44abaaa5119d4f709b2f8e3302bcb66a35770c0643b9dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f49add44-9e6f-4958-9ffa-7f2e1824d60c", "node_type": "1", "metadata": {"page_label": "238", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "4a45cc6d9d6f5c0c0ab78c0b599d2920324c62f039deaafddf4d54d7528eca1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "963b95c8-00f9-4576-a88d-382fef51ce00", "node_type": "1", "metadata": {"page_label": "238", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "cd0cad03b4ee535ff67373a7da679c57919298df622922bfcec502c4ec540f70", "class_name": "RelatedNodeInfo"}}, "hash": "81847b8ffc79b738c63a91a7f1de8dd89f88fcc8370b490060d1252c74a9b91c", "text": "In another study, the average age at symptomatic presentation was 52 years ( 132 ). For AFAP , colono-scopy should always be used for screening, in view of more proxi-  Monoallelic  MUTYH   mutations are found in 1 to 2% of the \ngeneral population ( 107 ). Monoallelic  MUTYH   mutation carri-\ners may have a slightly elevated risk of CRC, although the precise magnitude of the increased risk is currently unclear; most stud-ies estimate a 1.5\u20132-fold risk above the general population ( 107 ). Th ere is currently no consensus regarding the management of \nmonoallelic carriers as data are limited. An option for clinicians at the current time is to manage monoallelics as individuals with a FDR with CRC, off  ering colonoscopy as a surveillance modal-\nity every 5 years, beginning 10 years earlier than the earliest CRC \ndiagnosis.\n  Polymerase-proofreading associated polyposis is a newly \ndescribed syndrome and only a few families have been character-ized ( 117 ). Its phenotype includes oligo-adenomatous polyposis and an early age of onset of colorectal and EC. In a recent study of 858 familial/early-onset CRC cases and polyposis, one known  POLE   germline mutation and one new  POLD1   mutation were \nidentifi  ed ( 118 ). Polymerase proofreading-associated polyposis is \ndominantly inherited and penetrance appears high.\n  Patients with clinical suspicion of an adenomatous polyposis \nsyndrome should have genetic counseling and testing for germline mutations in  APC   and  MUTYH  . Failure to identify a mutation \nin an index case does not rule out the diagnosis of adenomatous polyposis, as mutations cannot be found in all families. If testing is negative, and clinical suspicion remains high, testing for other possible underlying genes should be considered. Failure to fi  nd a \nmutation means that all close relatives must still be screened as if \nthey have FAP .\n  Finding a mutation confi  rms the diagnosis of adenomatous \npolyposis and allows relatives to be tested with a high degree of accuracy.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "963b95c8-00f9-4576-a88d-382fef51ce00": {"__data__": {"id_": "963b95c8-00f9-4576-a88d-382fef51ce00", "embedding": null, "metadata": {"page_label": "238", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d6049be2-6741-4b9a-962b-62d6b721da5e", "node_type": "4", "metadata": {"page_label": "238", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1ddd2ca6f259a6125e44abaaa5119d4f709b2f8e3302bcb66a35770c0643b9dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ee8fc74-4fad-4193-aa12-5b53ca22fbef", "node_type": "1", "metadata": {"page_label": "238", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "81847b8ffc79b738c63a91a7f1de8dd89f88fcc8370b490060d1252c74a9b91c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3725859c-104c-4065-ab66-186b172b7a06", "node_type": "1", "metadata": {"page_label": "239", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "89d71da3d6a61fe74c8a728fbcf5a05223669a8024f09e59fe7c4ff1acb85327", "class_name": "RelatedNodeInfo"}}, "hash": "cd0cad03b4ee535ff67373a7da679c57919298df622922bfcec502c4ec540f70", "text": "Once an aff  ected patient has been genotyped, all at-risk \nrelatives can be screened for the mutation.\n     Surveillance and management of CRC and polyps\n   Recommendation   \n    8.  In individuals at risk for or aff  ected with the classic AP syn-\ndromes, screening for CRC by annual colonoscopy or fl  exible \nsigmoidoscopy should be performe d, beginning at puberty. In \nfamilies with AFAP or MAP , surveillance should be by colonos-copy (strong recommendation, moderate quality of evidence).\n    \nSummary of evidence   \n    Colon screening should be performed in those with a clinical \nor genetic diagnosis of FAP or in FDRs of those with FAP if genetic testing is uninformative or has not been done. In fami-lies where no mutation can be found, all at-risk relatives must undergo endoscopic screening. Colonoscopy should begin at \npuberty, or whenever there are suggestive symptoms such as \nchronic diarrhea, rectal bleeding, or abdominal pain. Flexible sigmoidoscopy is also reasonable in families with classic FAP , until a polyp is found. If this is proved to be an adenoma, full colonoscopy should be done. During colonoscopy, polyp num-ber, size, and distribution should be recorded, and several polyps should be biopsied. Th  e average age of FAP diagnosis in patients \npresenting with symptoms is 35.8 years (range, 4\u201372 years) in \nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3725859c-104c-4065-ab66-186b172b7a06": {"__data__": {"id_": "3725859c-104c-4065-ab66-186b172b7a06", "embedding": null, "metadata": {"page_label": "239", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "78617b07-b153-4000-9df0-5f080884cea0", "node_type": "4", "metadata": {"page_label": "239", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c53995ae163e1677d75979f5254acb8bc921c2a330433286423e6bf5de604e87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "963b95c8-00f9-4576-a88d-382fef51ce00", "node_type": "1", "metadata": {"page_label": "238", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "cd0cad03b4ee535ff67373a7da679c57919298df622922bfcec502c4ec540f70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8a053e7-f657-4e43-af93-4e2d05bd3915", "node_type": "1", "metadata": {"page_label": "239", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "eb1638bc0c06f9718fbbef900c31571a71fa19d4f31484c3cac910756c7e0d7a", "class_name": "RelatedNodeInfo"}}, "hash": "89d71da3d6a61fe74c8a728fbcf5a05223669a8024f09e59fe7c4ff1acb85327", "text": "Hereditary GI Cancer Syndromes\n\u00a9 2015 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY\n 239\nmal colonic polyp distribution. Onset of examination in AFAP can \nreasonably be delayed until the late teens to mid-20s and be per-formed every 1 to 2 years.\n  MAP patients commonly have between 20 and 99 polyps \n( 107,111 ) and rarely have >500, although the colonic phenotype can vary ( 107,112,113 ). CRC was found to be present in patients with an MAP diagnosis in \u223c 60% of cases ( 107 ). CRCs in MAP \nhave been predominantly distal colonic in some studies ( 105 ) and proximal in others ( 133 ). In eight population-based studies, \n28 of 79 (35%) MAP cases with CRC had no concurrent polyps, \nwhereas 17 (22%) had <10 adenomas ( 107 ). Th  e risk of CRC by age \n50 years is 19% and by age 60 years is 43%, with an average age of onset of 48 years ( 107,134,135 ). Although the predominant polyp type in patients with MAP is an adenoma, multiple hyperplastic and/or sessile serrated polyps (also referred to as sessile serrated adenomas) may occur. In a small study of 17 patients with MAP , 8 (47%) had at least one hyperplastic and/or sessile serrated polyp, 3 (~18%) met criteria for serrated polyposis (previously referred to as hyperplastic polyposis, see Serrated polyposis section below for additional details), and 1 patient had over 100 hyperplastic and sessile serrated polyps ( 136 ). Treatment of MAP follows the same principles as AFAP . Th  e disease may be managed endoscopically \nwith at least yearly colonoscopy. If the polyps become endoscopi-cally uncontrollable, then colectomy is indicated. Currently, there is no consensus as to whether monoallelic  MUTYH   mutations \nwarrant increased CRC screening.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8a053e7-f657-4e43-af93-4e2d05bd3915": {"__data__": {"id_": "f8a053e7-f657-4e43-af93-4e2d05bd3915", "embedding": null, "metadata": {"page_label": "239", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "78617b07-b153-4000-9df0-5f080884cea0", "node_type": "4", "metadata": {"page_label": "239", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c53995ae163e1677d75979f5254acb8bc921c2a330433286423e6bf5de604e87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3725859c-104c-4065-ab66-186b172b7a06", "node_type": "1", "metadata": {"page_label": "239", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "89d71da3d6a61fe74c8a728fbcf5a05223669a8024f09e59fe7c4ff1acb85327", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40e38f1f-79db-4e41-92c0-2443ac6a0220", "node_type": "1", "metadata": {"page_label": "239", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "62d3e5b47a9dfaddf7cbcd1767a3817fd968447379088a9a74edf4ae6dc4b34c", "class_name": "RelatedNodeInfo"}}, "hash": "eb1638bc0c06f9718fbbef900c31571a71fa19d4f31484c3cac910756c7e0d7a", "text": "No recommendations for treatment or surveillance of patients \nwith polymerase proofreading-associated polyposis have been \nmade because the frequency of polyps, cancer, and the extraco-lonic phenotype have yet to be determined, but the options of close endoscopic surveillance and colectomy seem reasonable.\n    \nRecommendation   \n    9.  Absolute indications for immediate colorectal surgery in FAP , \nAFAP , and MAP include: documented or suspected cancer or signifi  cant symptoms. Relative indications for surgery include \nthe presence of multiple adenomas >6 mm, a signifi  cant in-\ncrease in adenoma number, the presence of an adenoma with high-grade dysplasia, and inability to adequately survey the co-lon because of multiple diminutive polyps (strong recommen-dation, low quality of evidence).\n   Summary of evidence  \n    Development of colon cancer in classic FAP is inevitable if the \ncolon is not removed. An appropriately timed colectomy remains the cornerstone of colon cancer prevention in FAP ( 127,137,138 ). Prophylactic surgery can be planned at a suitable time (late teens \nto early twenties), based on the risk of cancer posed by the polyp \nburden. Indications for early surgery include polyps >10 mm diameter, polyps with high-grade dysplasia, marked increases in polyp number from one exam to the next, and symptoms. Surgical options are colectomy with IRA (for <20 rectal and <1,000 colonic adenomas) and proctocolectomy with IPAA (for severe or pro-fuse adenomas, >20 rectal adenomas, and >1,000 colonic adeno-mas). A laparoscopic approach is now oft  en used for both surgical approaches. Conversion from IRA to IPAA may occasionally be \nneeded because of development of numerous or advanced rectal adenomas. Proctocolectomy with ileostomy is rarely needed.  APC   \nmutation location, allowing prediction of severity of rectal poly-posis and likelihood of future completion proctectomy, has been suggested as a factor to consider in determining which procedure should be done ( 139 ).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40e38f1f-79db-4e41-92c0-2443ac6a0220": {"__data__": {"id_": "40e38f1f-79db-4e41-92c0-2443ac6a0220", "embedding": null, "metadata": {"page_label": "239", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "78617b07-b153-4000-9df0-5f080884cea0", "node_type": "4", "metadata": {"page_label": "239", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c53995ae163e1677d75979f5254acb8bc921c2a330433286423e6bf5de604e87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8a053e7-f657-4e43-af93-4e2d05bd3915", "node_type": "1", "metadata": {"page_label": "239", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "eb1638bc0c06f9718fbbef900c31571a71fa19d4f31484c3cac910756c7e0d7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b355d4a5-913e-4c83-98e7-d9f2db353259", "node_type": "1", "metadata": {"page_label": "239", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "4e448659ebcc71cd27fb9f56ef3d3d178e7781e07f8b075b54f5834b8a4048f6", "class_name": "RelatedNodeInfo"}}, "hash": "62d3e5b47a9dfaddf7cbcd1767a3817fd968447379088a9a74edf4ae6dc4b34c", "text": "Colectomy with IRA is a single-stage procedure with slightly \nless morbidity than the IPAA surgery, but some rectal cancer risk \nremains and yearly proctoscopy is essential ( 139,140 ). Even aft  er \ntotal proctocolectomy and IPAA, adenomas and cancers may occur in the anal transition zone and in the pouch itself; lifelong endoscopic surveillance is required ( 141\u2013143 ). Possible morbidi-ties from either surgery include increased bowel frequency and incontinence. Pouch surgery is asso ciated with some loss of fertil-\nity in women and some loss of sexual function in men.\n  Patients with AFAP can oft  en be managed for many years with \ncolonoscopic polypectomy and may possibly never need colec-tomy ( 90 ). If surgical resection is indicated, AFAP patients can almost always undergo colectomy and IRA because of rectal spar-ing of polyps. Aft  er colectomy with IRA in a large series of patients \nwith AFAP , an average of 3.4 recurrent polyps (range, 0\u201329) and only one cancer was found in the postcolectomy rectal remnant over a mean follow-up of 7.8 years (range, 1\u201334 years) ( 90 ).\n  Similar to AFAP , FAP , and some multiple adenoma patients, sub-\ntotal colectomy with close subsequent surveillance would seem to be the best option for MAP patients with relative rectal sparing. \nRestorative proctocolectomy is indicated if the rectum is substan-\ntially involved.\n      Surveillance and management of extracolonic malignancies\n   Recommendations   \n    10.  Screening for gastric and proximal small bowel tumors should \nbe done using upper endoscopy including duodenoscopy starting at age 25\u201330 years. Surveillance should be repeated every 0.5\u20134 years depending on Spigelman stage of duode-nal polyposis: 0=4 years; I=2\u20133 years, II=1\u20133 years, III=6\u201312 months, and IV=surgical evaluation. Examination of the stom-ach should include random sampling of fundic gland polyps.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b355d4a5-913e-4c83-98e7-d9f2db353259": {"__data__": {"id_": "b355d4a5-913e-4c83-98e7-d9f2db353259", "embedding": null, "metadata": {"page_label": "239", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "78617b07-b153-4000-9df0-5f080884cea0", "node_type": "4", "metadata": {"page_label": "239", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c53995ae163e1677d75979f5254acb8bc921c2a330433286423e6bf5de604e87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40e38f1f-79db-4e41-92c0-2443ac6a0220", "node_type": "1", "metadata": {"page_label": "239", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "62d3e5b47a9dfaddf7cbcd1767a3817fd968447379088a9a74edf4ae6dc4b34c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4117715-e302-48f9-b207-05a4488f6893", "node_type": "1", "metadata": {"page_label": "240", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "fcbd39fbb85e48d13ab170e0f4f4858b0d6c661d54d3307f13b6c16a5a2fa50d", "class_name": "RelatedNodeInfo"}}, "hash": "4e448659ebcc71cd27fb9f56ef3d3d178e7781e07f8b075b54f5834b8a4048f6", "text": "Examination of the stom-ach should include random sampling of fundic gland polyps. Low-grade dysplasia is common in fundic gland polyps, and surgery should be reserved for high-grade dysplasia or cancer (strong recommendation, very low quality of evidence).\n  11.  Annual thyroid screening by ultrasound should be recom-\nmended to individuals aff  ected with FAP , MAP , and attenu-\nated polyposis (conditional recommendation, low quality of evidence).\n  12.  Biannual screening should be off  ered to aff  ected infants annu-\nally until age 7 years with \u03b1 -fetoprotein and ultrasounds (con-\nditional recommendation, very low quality of evidence).\n    \nSummary of evidence   \n    Th e phenotype of FAP includes benign and malignant neoplasms \nin other organs. Other organs commonly aff  ected include the \nthyroid (with papillary thyroid cancer), adrenal (non functioning adenomas), the small intestine (adenomas or carcinoma), bones \nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4117715-e302-48f9-b207-05a4488f6893": {"__data__": {"id_": "d4117715-e302-48f9-b207-05a4488f6893", "embedding": null, "metadata": {"page_label": "240", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "997b874e-d73a-4f57-a490-73f63810361c", "node_type": "4", "metadata": {"page_label": "240", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "0df52806f7db5cf11613b49bf74bb4f4366f3c98739baa6c583d852bf7517fab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b355d4a5-913e-4c83-98e7-d9f2db353259", "node_type": "1", "metadata": {"page_label": "239", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "4e448659ebcc71cd27fb9f56ef3d3d178e7781e07f8b075b54f5834b8a4048f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8eed13dc-c2ce-4f73-b415-a0e666fd4528", "node_type": "1", "metadata": {"page_label": "240", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "9ee713439931e3eb0cd1dc1bef81deaac7f415494c03050202903828b3872464", "class_name": "RelatedNodeInfo"}}, "hash": "fcbd39fbb85e48d13ab170e0f4f4858b0d6c661d54d3307f13b6c16a5a2fa50d", "text": "Syngal  et al.  \nThe American Journal of GASTROENTEROLOGY VOLUME 110 | FEBRUARY 2015    www.amjgastro.com 240\n(osteomas), retina (congenital hypertrophy of the retinal pig-\nmented epithelium), and skin (epidermoid cysts). However, the most common causes of death in FAP aft  er CRC are duodenal or \nampullary cancer and desmoid disease.\n  Endoscopically visible duoden al adenomas are found in more \nthan half of FAP patients ( 101,144,145 ). Th  e lifetime risk for duo-\ndenal cancer is 3 to 5%, but in some series it has been even higher ( 81,101,127,144,146 ). Th  e age of duodenal cancer diagnosis ranges \nfrom 17 to 81 years, with a mean between 45 and 52 years. Approx-imately half of duodenal cancers are ampullary or periampullary, whereas others are elsewhere in the duodenum ( 147 ). Duodenal cancer is one of the leading causes of death in FAP patients who have had prophylactic colectomy ( 147\u2013150 ).\n  Adenomas beyond the duodenum may occur throughout the \nsmall bowel but are concentrated for the most part in the proximal jejunum (50% of cases) and distal ileum (20% of cases) ( 151\u2013153 ). Th e polyps are most commonly 1 to 10 mm in diameter and multi-\nple. Most duodenal polyps cluster around the ampulla, although in some patients there are small adenomas scattered throughout the duodenum. Adenomas may progress, oft  en slowly, and there is evi-\ndence of an adenoma\u2013carcinoma sequence similar to that observed in the colon ( 101 ). Adenomas sometimes grow large, exhibit vil-lous histology and increasing degrees of dysplasia, and may cause symptoms. A scoring system has been developed to evaluate the severity of duodenal polyposis and is now widely applied as the Spi-gelman staging system ( 154 ) ( Table 9  ).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8eed13dc-c2ce-4f73-b415-a0e666fd4528": {"__data__": {"id_": "8eed13dc-c2ce-4f73-b415-a0e666fd4528", "embedding": null, "metadata": {"page_label": "240", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "997b874e-d73a-4f57-a490-73f63810361c", "node_type": "4", "metadata": {"page_label": "240", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "0df52806f7db5cf11613b49bf74bb4f4366f3c98739baa6c583d852bf7517fab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4117715-e302-48f9-b207-05a4488f6893", "node_type": "1", "metadata": {"page_label": "240", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "fcbd39fbb85e48d13ab170e0f4f4858b0d6c661d54d3307f13b6c16a5a2fa50d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1eca0253-e991-45ab-80e3-a72c880b2edd", "node_type": "1", "metadata": {"page_label": "240", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c83c9b270d64c70f712081b33ac663eaa22ccf6beb677a2516db2edb965c8ccc", "class_name": "RelatedNodeInfo"}}, "hash": "9ee713439931e3eb0cd1dc1bef81deaac7f415494c03050202903828b3872464", "text": "Th e risk for duodenal cancer \nincreases to 36% within 10 years for Spigelman stage IV patients ( 155 ). Th  e risk of exhibiting Spigelman stage IV duodenal polyposis \nis 43% by age 60 years and 50% by age 70 years ( 156 ). Patients with Spigelman Stage IV duodenal adenomatosis are candidates for a pancreas-preserving duodenectomy. Th  is is much less morbid than \na Whipple procedure and patients have a better quality of life. If there is a strong suspicion of cancer, then a Whipple is necessary.\n  Gastric fundic gland polyps are also common but gastric \nadenomas are rare and in western countries gastric cancer is uncommon. Gastric polyps occur in 23 to 100% of FAP patients ( 101,126,144,157 ). In the gastric fundus and body, the polyps are most oft  en fundic gland polyps, considered hamartomas. Th  ese \npolyps are histologically seen to consist of simple hyperplasia of the fundic glands with microcysts. Endoscopically, the polyps are multiple sessile lesions, most oft  en 1 to 10 mm in diameter, and \nare the same color as surrounding mucosa ( 158 ). Considerable variation in size and number is observed. Th  e polyps are some-\ntimes so numerous that they coalesce, forming areas of irregular, \nmatted surface mucosa. Fundic gland polyps rarely cause symp-toms. Almost half of FAP patients with fundic gland polyps will \nhave superfi  cial dysplasia in some of those polyps ( 159 ). Although \nthey are considered nonneoplastic, fundic gland polyps may rarely progress to cancer ( 160\u2013162 ). Adenomatous polyps occur in the stomach of \u223c 10% of patients with FAP . Th  ey are most oft  en con-\nfi ned to the antrum but are occasionally found in the body and \nfundus.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1eca0253-e991-45ab-80e3-a72c880b2edd": {"__data__": {"id_": "1eca0253-e991-45ab-80e3-a72c880b2edd", "embedding": null, "metadata": {"page_label": "240", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "997b874e-d73a-4f57-a490-73f63810361c", "node_type": "4", "metadata": {"page_label": "240", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "0df52806f7db5cf11613b49bf74bb4f4366f3c98739baa6c583d852bf7517fab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8eed13dc-c2ce-4f73-b415-a0e666fd4528", "node_type": "1", "metadata": {"page_label": "240", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "9ee713439931e3eb0cd1dc1bef81deaac7f415494c03050202903828b3872464", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bca38d1-1786-47de-aa73-096e654656ce", "node_type": "1", "metadata": {"page_label": "240", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "7978d8f7e79138f0c0346431628fd3af909fc72942a3a24c13bc260008434598", "class_name": "RelatedNodeInfo"}}, "hash": "c83c9b270d64c70f712081b33ac663eaa22ccf6beb677a2516db2edb965c8ccc", "text": "( 163,164 ) Th  e lifetime risk for gastric cancer in FAP is \n\u223c 0.6%, believed both from fundic gland polyps and adenomatous \npolyps ( 138 ). Table 9  .     Duodenal adenomatosis staging system  a   \n  Polyps    1 Point    2 Points    3 Points  \n Number  <4  5\u201320  >20 \n Size  0\u20134 mm  5\u201310 mm  >10 \n Histology  Tubular  Tubulovillous  Villous \n Dysplasia  Mild  Moderate  Severe \n Spigelman stage  Total points  Frequency of surveillance \n  Recommended duodenal surveillance frequency    b   \n 0  0  Every 4 years \n I  \u22644  Every 2\u20133 years \n II  5\u20136  Every 1\u20133 years \n III  7\u20138  Every 6\u201312 months \n IV  9\u201312  Expert surveillance every 3- 6 months \n     Surgical evaluation \n     Complete mucosectomy or duodenectomy or \nWhipple procedure if duodenal papilla is involved \n   a   Adapted from ref. ( 154 ).  \n   b   Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk  Assessment: Colorectal V.1.2014. \n2014 National Comprehensive Cancer Network ( 24 ) The NCCN Guidelines and illustrations herein may not be reproduced in any form for any purpose without the \nexpress written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN. org. NATIONAL COMPREHENSIVE \nCANCER NETWORK, NCCN, NCCN GUIDELINES, and all other NCCN content are trademarks owned by the National Comprehensive Cancer Net work.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bca38d1-1786-47de-aa73-096e654656ce": {"__data__": {"id_": "6bca38d1-1786-47de-aa73-096e654656ce", "embedding": null, "metadata": {"page_label": "240", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "997b874e-d73a-4f57-a490-73f63810361c", "node_type": "4", "metadata": {"page_label": "240", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "0df52806f7db5cf11613b49bf74bb4f4366f3c98739baa6c583d852bf7517fab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1eca0253-e991-45ab-80e3-a72c880b2edd", "node_type": "1", "metadata": {"page_label": "240", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c83c9b270d64c70f712081b33ac663eaa22ccf6beb677a2516db2edb965c8ccc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d047ad8-e150-41c6-a26f-08da210c40b2", "node_type": "1", "metadata": {"page_label": "241", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "6241dfb350b9ba65274b3c0f41fa15c9fd7129c7e0af5fe170c9caafce3a1e40", "class_name": "RelatedNodeInfo"}}, "hash": "7978d8f7e79138f0c0346431628fd3af909fc72942a3a24c13bc260008434598", "text": "Downloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d047ad8-e150-41c6-a26f-08da210c40b2": {"__data__": {"id_": "1d047ad8-e150-41c6-a26f-08da210c40b2", "embedding": null, "metadata": {"page_label": "241", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6f57cb37-f096-446b-8a86-6ad463f80904", "node_type": "4", "metadata": {"page_label": "241", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "7cd563418e2cb4f40d599c7a8ab80518453d33b80b393f872bb255079b8fc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bca38d1-1786-47de-aa73-096e654656ce", "node_type": "1", "metadata": {"page_label": "240", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "7978d8f7e79138f0c0346431628fd3af909fc72942a3a24c13bc260008434598", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ae82f89-dd88-48e9-855f-a46e5d60769f", "node_type": "1", "metadata": {"page_label": "241", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "8e07dc3592d83b252ef0b2656cec58dd3dd1561eca56b1a2f684a1a5dd9a331f", "class_name": "RelatedNodeInfo"}}, "hash": "6241dfb350b9ba65274b3c0f41fa15c9fd7129c7e0af5fe170c9caafce3a1e40", "text": "Hereditary GI Cancer Syndromes\n\u00a9 2015 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY\n 241\nScreening with every 3- to 6-month serum \u03b1 -fetoprotein and liver \nultrasound for the fi  rst 5 to 10 years in FAP patients has been sug-\ngested but is still debated. A family history of hepatoblastoma may be an indication to do this from age 6 months to 6 years. A decision to perform hepatoblastoma screening mandates genetic testing in infancy to see if the child carries the mutation.\n    Desmoid tumors\n  Screening is not done for desmoids, but evaluation is done for \npalpable masses and a full work-up for suggestive symptoms. \nPeriodic abdominal imaging is not generally recommended, but preoperative abdominal CT scan before colectomy may be con-sidered if desmoids have been an issue in family members.\n  Th e lifetime risk of extracolonic tumors in MAP is not as well \ndefi ned as the colorectal phenotype. In a large study of 276 MAP \npatients, 17% had extracolonic lesions, with an estimated 38% life-time risk of extracolonic malignancy that is approximately double \nthe risk in the general population ( 174 ). Similar to FAP and AFAP , the lifetime risk of duodenal cancer in MAP has been estimated to be 4% ( 174 ). Although gastric lesions have been found in up to 11% of patients with MAP , data are currently lacking to support an increased risk of gastric cancer ( 107 ).\n  Other cancers such as endometrial, breast, ovarian, bladder, var-\nious skin, and thyroid have been reported in patients with MAP ( 107 ), although it is still not clear whether the lifetime risk for these malignancies is increased. Although rare, other fi  ndings seen in \npatients with MAP have included sebaceous gland adenomas, car-\ncinomas and epitheliomas, lipomas, congenital hypertrophy of the \nretinal pigment epithelium, osteomas, desmoid tumors, epider-moid cysts, and pilomatrixomas ( 107 ).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ae82f89-dd88-48e9-855f-a46e5d60769f": {"__data__": {"id_": "7ae82f89-dd88-48e9-855f-a46e5d60769f", "embedding": null, "metadata": {"page_label": "241", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6f57cb37-f096-446b-8a86-6ad463f80904", "node_type": "4", "metadata": {"page_label": "241", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "7cd563418e2cb4f40d599c7a8ab80518453d33b80b393f872bb255079b8fc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d047ad8-e150-41c6-a26f-08da210c40b2", "node_type": "1", "metadata": {"page_label": "241", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "6241dfb350b9ba65274b3c0f41fa15c9fd7129c7e0af5fe170c9caafce3a1e40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ae9e58f-ac3a-4c28-b1b0-a229da57fbc8", "node_type": "1", "metadata": {"page_label": "241", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "fddd68d30f8d1d8d30ff2742e9b558b2f0700c67323d678c584fe752ef2cfd88", "class_name": "RelatedNodeInfo"}}, "hash": "8e07dc3592d83b252ef0b2656cec58dd3dd1561eca56b1a2f684a1a5dd9a331f", "text": "Surveillance and disease management of the colon in MAP should be similar to patients with multiple adenomas, AFAP , and FAP ( 166 ).\n  In women with a  POLD1   mutation, pelvic ultrasound and selec-\ntive endometrial biopsy may be considered as the  POLD1   variant \nhas been associated with endometrial and possibly brain tumors.\n   \nRecommendation   \n    13.  Postsurgical surveillance should include yearly endoscopy \nof rectum or ileal pouch, and examination of an ileostomy every 2 years (strong recommendation, low quality level of evidence).\n    \nSummary of evidence   \n    Adenomas may develop in the ileal pouch aft  er colectomy with \nIPAA surgery, or they may develop in the small segment of re-maining rectal epithelium aft  er restorative proctocolectomy \n( 175\u2013177 ). Th  ere appears to be a small but real risk for cancer in \nthe ileal pouch ( 177\u2013179 ). Advanced dysplasia and cancer may \noccur at the anal transition zone, either from rectal tissue unex-pectedly remaining with ileo-anal anastomosis or from the short segment of rectum oft  en remaining with restorative proctocolec-\ntomy ( 143,150,180 ).\n  A ft er colectomy or proctocolectomy, endoscopic surveillance \nof the rectum or ileal pouch should continue yearly. Concerning polyposis in the rectum (large adenomas, high-grade dysplasia,   Upper GI screening has not been demonstrated to improve \nprognosis but is nonetheless reco mmended in view of the cancer \nrisk and expectation that mortality can be improved ( 127,144\u2013147,156,165 ). Standard upper endoscopy should be supplemented with a side-viewing instrument to visualize the duodenal papilla. Duodenal screening should begin at age 25\u201330 years and con-tinue for life, with a frequency determined by the severity of the duodenal polyposis as measured by the Spigelman score.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ae9e58f-ac3a-4c28-b1b0-a229da57fbc8": {"__data__": {"id_": "0ae9e58f-ac3a-4c28-b1b0-a229da57fbc8", "embedding": null, "metadata": {"page_label": "241", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6f57cb37-f096-446b-8a86-6ad463f80904", "node_type": "4", "metadata": {"page_label": "241", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "7cd563418e2cb4f40d599c7a8ab80518453d33b80b393f872bb255079b8fc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ae82f89-dd88-48e9-855f-a46e5d60769f", "node_type": "1", "metadata": {"page_label": "241", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "8e07dc3592d83b252ef0b2656cec58dd3dd1561eca56b1a2f684a1a5dd9a331f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7287a59-a6af-411e-b079-a77191b4a239", "node_type": "1", "metadata": {"page_label": "241", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "79db73aaa367ec3544d63c993a78b7cd24d907eaaed5826be73dd260d98eba03", "class_name": "RelatedNodeInfo"}}, "hash": "fddd68d30f8d1d8d30ff2742e9b558b2f0700c67323d678c584fe752ef2cfd88", "text": "A 0.5\u20134-year interval for examination is given as follows: (i) every 4 years \nfor Spigelman stage 0; (ii) every 2\u20133 years for stage I disease; (iii) \nevery 1\u20133 years for stage II disease; (iv) every 6\u201312 months for stage III disease; and (v) for stage IV disease: surgical evaluation, expert surveillance every 3\u20136 months and complete mucosectomy or duodenectomy, or Whipple procedure if duodenal papilla is involved ( 101,127 ). Another approach to screening is every 3-year endoscopy if adenomas are not found and annually if they are. Th  e \nstomach should be examined during endoscopy and any polyps judged to be of concern because of size, color, or gross appearance biopsied. Th  e role of examination of the small bowel beyond reach \nof the upper endoscope by computed tomography (CT) enterog-raphy, push or balloon enteroscopy, or capsule endoscopy if upper endoscopy demonstrates severe duodenal polyposis is uncertain ( 153 ).\n  In contrast to colorectal polyps and cancer, the expression of \nupper GI polyps, both gastric and duodenal, does not appear to be attenuated in number, age at emergence, or cancer risk in AFAP compared with FAP ( 89,162 ); therefore, EGD surveillance should also be performed at age 25\u201330 years, and continued according to the rules stated for classical FAP .\n  Given that the risk of duodenal cancer in MAP is similar to that \nof AFAP and FAP , upper GI endoscopy with added side-viewing duodenoscopy should be considered, starting at around age 30 years and repeated at intervals similar to AFAP and FAP , again depending on duodenal fi  ndings ( 166 ).\n     Gallbladder, bile ducts, and pancreas\n  Both adenomatous change and cancer have been reported in the \ngallbladder, bile ducts, and pancreas ( 138,151,167\u2013170 ). Biliary and pancreatic duct obstructions have arisen from both benign and malignant lesions.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7287a59-a6af-411e-b079-a77191b4a239": {"__data__": {"id_": "c7287a59-a6af-411e-b079-a77191b4a239", "embedding": null, "metadata": {"page_label": "241", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6f57cb37-f096-446b-8a86-6ad463f80904", "node_type": "4", "metadata": {"page_label": "241", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "7cd563418e2cb4f40d599c7a8ab80518453d33b80b393f872bb255079b8fc55f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ae9e58f-ac3a-4c28-b1b0-a229da57fbc8", "node_type": "1", "metadata": {"page_label": "241", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "fddd68d30f8d1d8d30ff2742e9b558b2f0700c67323d678c584fe752ef2cfd88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5fc137e-6b97-4966-adc3-10aff0b6b23c", "node_type": "1", "metadata": {"page_label": "242", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "0c46b8dfa6ac2f1cc8f8507801dce2e7e263b5e400579e35f03e7ff025936f8d", "class_name": "RelatedNodeInfo"}}, "hash": "79db73aaa367ec3544d63c993a78b7cd24d907eaaed5826be73dd260d98eba03", "text": "Biliary and pancreatic duct obstructions have arisen from both benign and malignant lesions. Th  e cancer risks are shown in  Table 7  . \nTh ere are no surveillance strategies that are currently recom-\nmended for these malignancies.\n    Extraintestinal malignancies\n  Up to 12% of FAP patients have thyroid cancer and 80% have \nnodular thyroid ( 171 ). Th  e mean age of diagnosis of thyroid \ncancer is 28 years, ranging from 12 to 62 years ( 172 ). A female \npreponderance is observed, and the histology is predominantly \npapillary, commonly with a cribriform\u2013morular pattern. Annual thyroid ultrasound is recommended for thyroid screening in FAP ( 171 ).\n  Hepatoblastoma occurs in 1.6% of FAP patients, exhibits a male \npredominance, and associates somewhat with mutations in the 5\u00b4 end of the  APC   gene. Th  is malignancy most oft  en occurs in \nthe fi  rst 5 years of life, with some risk up to 15 years of age ( 173 ). \nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5fc137e-6b97-4966-adc3-10aff0b6b23c": {"__data__": {"id_": "c5fc137e-6b97-4966-adc3-10aff0b6b23c", "embedding": null, "metadata": {"page_label": "242", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d096f65b-91df-4cab-9a1a-6a2c13173042", "node_type": "4", "metadata": {"page_label": "242", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "b0973f7fb44f7f6840d805871d316033d7ff0f6dfa7fca44f26f57e1903879c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7287a59-a6af-411e-b079-a77191b4a239", "node_type": "1", "metadata": {"page_label": "241", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "79db73aaa367ec3544d63c993a78b7cd24d907eaaed5826be73dd260d98eba03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "340de4aa-0fe2-4627-a123-4f5f617bb42e", "node_type": "1", "metadata": {"page_label": "242", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "ff7c663b506906fdb8c5d2260db168e108bfad0ac3c4d342b24f1da004cabad4", "class_name": "RelatedNodeInfo"}}, "hash": "0c46b8dfa6ac2f1cc8f8507801dce2e7e263b5e400579e35f03e7ff025936f8d", "text": "Syngal  et al.  \nThe American Journal of GASTROENTEROLOGY VOLUME 110 | FEBRUARY 2015    www.amjgastro.com 242\nfrequency by segment is: stomach, 24%; small bowel, 96%; colon, \n27%; and rectum, 24% ( 183,186 ). Polyp sizes range from 0.1 to 3 cm in diameter. Polyp growth begins in the fi  rst decade of life, \nbut patients typically do not develop symptoms until the second or third decade ( 187,188 ). Symptoms arise from larger polyps that may infarct, ulcerate, bleed, and cause intestinal obstruction and intussusception, usually in the small intestine.\n      Genetic etiology\n   Summary statement   \n\u2022       Genetic evaluation of a patient with possible PJS should \ninclude testing for  STK11   mutations. \n     Summary of evidence   \n    PJS arises from mutations of the  STK11   gene, a tumor suppressor \nseronine/threonine kinase gene, previously called  LKB1  , on chro-\nmosome 19p ( 182,183 ). Up to 94% of PJS families have mutations of  STK11   with up to a third of disease causing mutations repre-\nsenting large deletions ( 189,190 ). Approximately 25% of newly diagnosed PJS patients represent  de novo   mutations ( 183 ). Th  ere \ndo not appear to be genotype\u2013phenotype correlations with mu-tation location in the  STK11   gene ( 191 ). Once a disease-causing \nmutation is identifi  ed in a patient with PJS, other family members \nshould undergo mutation-specifi  c testing to determine whether \nthe disease is present or absent so that appropriate surveillance can be undertaken.\n     Surveillance and management\n   Recommendation   \n    14.  Surveillance in aff  ected or at-risk PJS patients should include \nmonitoring for colon, stomach, small bowel, pancreas, breast, ovary, uterus, cervix, and testes cancers. Risk for lung cancer is increased, but no specifi  c screening has been recommended.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "340de4aa-0fe2-4627-a123-4f5f617bb42e": {"__data__": {"id_": "340de4aa-0fe2-4627-a123-4f5f617bb42e", "embedding": null, "metadata": {"page_label": "242", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d096f65b-91df-4cab-9a1a-6a2c13173042", "node_type": "4", "metadata": {"page_label": "242", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "b0973f7fb44f7f6840d805871d316033d7ff0f6dfa7fca44f26f57e1903879c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5fc137e-6b97-4966-adc3-10aff0b6b23c", "node_type": "1", "metadata": {"page_label": "242", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "0c46b8dfa6ac2f1cc8f8507801dce2e7e263b5e400579e35f03e7ff025936f8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d50ab8a-5677-4ffd-a5e6-6fb2f805f095", "node_type": "1", "metadata": {"page_label": "242", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "bed43e42b73f423d78894e1a7ffb2f166ee400b3b6f8d1da784c380f82752617", "class_name": "RelatedNodeInfo"}}, "hash": "ff7c663b506906fdb8c5d2260db168e108bfad0ac3c4d342b24f1da004cabad4", "text": "Risk for lung cancer is increased, but no specifi  c screening has been recommended. It \nwould seem wise to consider annual chest radiograph or chest CT in smokers (conditional recommendation, low quality of evidence).\n    \nSummary of evidence   \n    Numerous studies and reviews have now reported a high risk of \nboth GI and extraintestinal cancer in PJS ( 126,182,183,185,192\u2013197 ). Individual risks by cancer site are given in  Tables 5 and 7 .\nTh e malignant risk in PJS includes colorectal, breast, pancre-\natic, gynecological, small bowel, lung, and gastroesophageal cancers in that order of risk ( 198 ). Th  e overall risk of devel-\noping any cancer at ages 20, 30, 40, 50, 60, and 70 years was 1%, 3%, 19%, 32%, 63%, and 81% respectively. In terms of spe-cifi c cancers, estimated lifetime risks are 39% for colorectal, \n29% for gastric, 13% for small bowel 24\u201354% for breast, 21% for ovary, 10\u201323% for cervix, 9% for uterus, 9% for testicular, 7\u201317% for lung, and 11\u201336% for pancreas ( 196 ). Distinctive tu-mors in women with this condition include ovarian sex cord tumors with annular tubules that are benign, although \u223c 20% \nbecome malignant; mucinous tumors of the ovary; and well-diff erentiated adenocarcinomas of the uterine cervix, called >20 adenomas) is treated either by polypectomy or proctectomy. \nPouch polyposis can be treated by polypectomy or chemopreven-tion with sulindac. Ileostomies shou ld be checked every 2 years as \nadenomas and even cancer can develop on the stoma.\n     Prevention strategies\n  Much attention and eff  ort has been given to examining chemopre-\nvention for colonic and duodenal polyps in FAP ( 127 ).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d50ab8a-5677-4ffd-a5e6-6fb2f805f095": {"__data__": {"id_": "6d50ab8a-5677-4ffd-a5e6-6fb2f805f095", "embedding": null, "metadata": {"page_label": "242", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d096f65b-91df-4cab-9a1a-6a2c13173042", "node_type": "4", "metadata": {"page_label": "242", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "b0973f7fb44f7f6840d805871d316033d7ff0f6dfa7fca44f26f57e1903879c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "340de4aa-0fe2-4627-a123-4f5f617bb42e", "node_type": "1", "metadata": {"page_label": "242", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "ff7c663b506906fdb8c5d2260db168e108bfad0ac3c4d342b24f1da004cabad4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa75e4a2-58ab-4f47-8711-93fcf4007f00", "node_type": "1", "metadata": {"page_label": "242", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "afd03a0e05a1d3dc3e519bf9968e4f73946b4ecbed0bac3edcf6cfb2ef360d9d", "class_name": "RelatedNodeInfo"}}, "hash": "bed43e42b73f423d78894e1a7ffb2f166ee400b3b6f8d1da784c380f82752617", "text": "Consider-able regression and prevention of colonic and rectal adenomas \nhas been demonstrated with sulindac, but cancer prevention is \nless certain. Celecoxib appears to have a more modest eff  ect in \nthe colon and rectum, but some eff  ect in duodenal adenoma \nregression as well. Celecoxib was approved for use in the United States for several years for FAP , but this indication has now been removed. Concern over cardiovascular side eff  ects of long-term \ncyclooxygenase-2 (COX-2) inhibitors has dampened enthusiasm for their use in FAP . In view of the uncertainty of cancer preven-tion with sulindac, it is not considered a substitute for colec-tomy but has shown utility in rectal surveillance by substantially decreasing the number of adenomas needing removal at periodic examination. Chemoprevention studies examining nonsteroidal anti-infl  ammatory drugs and other agents continue in the hopes \nthat colectomy might be delayed.\n    Hamartomatous polyposis syndromes\n   Peutz\u2013Jeghers syndrome   \n     Indications for genetic testing  \n     Summary statement  \n\u2022     Individuals with perioral or buccal pigmentation and/or \ntwo or more histologically characteristic GI hamartomatous polyp(s) or a family history of PJS should be evaluated for PJS. \n    \nSummary of evidence  \n  PJS is an autosomal-dominantly inherited syndrome that includes histologically distinctive hamartomatous polyps of the GI tract and characteristic mucocutaneous pigmentation ( 181\u2013184 ). Its incidence is estimated at between 1 in 50,000 and 1 in 200,000 births ( 185 ). Th  e mucocutaneous melanin pigment spots are seen \nin >95% of cases. Th  ey are 1 to 5 mm in diameter and most com-\nmonly occur in the perioral area and on the buccal mucosa (94%). Pigment spots on the lips are distinctive in that they cross the vermilion border and are oft  en much darker and more densely \nclustered than common freckles.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa75e4a2-58ab-4f47-8711-93fcf4007f00": {"__data__": {"id_": "fa75e4a2-58ab-4f47-8711-93fcf4007f00", "embedding": null, "metadata": {"page_label": "242", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d096f65b-91df-4cab-9a1a-6a2c13173042", "node_type": "4", "metadata": {"page_label": "242", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "b0973f7fb44f7f6840d805871d316033d7ff0f6dfa7fca44f26f57e1903879c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d50ab8a-5677-4ffd-a5e6-6fb2f805f095", "node_type": "1", "metadata": {"page_label": "242", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "bed43e42b73f423d78894e1a7ffb2f166ee400b3b6f8d1da784c380f82752617", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1818f55-b1ab-4b0f-bbdd-1c5ea96c12ad", "node_type": "1", "metadata": {"page_label": "243", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "777d6de277a861817f7148c31b2d449ff2cb282d2ea6d0e6f346f27bd4e96eaf", "class_name": "RelatedNodeInfo"}}, "hash": "afd03a0e05a1d3dc3e519bf9968e4f73946b4ecbed0bac3edcf6cfb2ef360d9d", "text": "Th  ese spots also occur on the \nface, forearms, digits, palms, soles, perianal area, and rarely on the intestinal mucosa. Th  e pigment appears in infancy and may fade \nwith age, but less so on the buccal mucosa. GI polyps occur in 88 to 100% of patients. PJS polyps are histologically distinct. Th  ey are \nnondysplastic, have normal overlying epithelium specifi  c to the GI \nsegment in which they are found, and exhibit an arborizing pat-tern of growth with muscularis mucosae extending into branch-ing fronds of the polyp. Epithelial infolding may result in what is termed  pseudoinvasion   that can lead to an incorrect diagnosis of \ncancer. Adenoma and cancer may occur in PJS polyps ( 186 ). Th  eir \nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1818f55-b1ab-4b0f-bbdd-1c5ea96c12ad": {"__data__": {"id_": "a1818f55-b1ab-4b0f-bbdd-1c5ea96c12ad", "embedding": null, "metadata": {"page_label": "243", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "24bc8201-f996-4f23-bb8a-2cd99fc637b9", "node_type": "4", "metadata": {"page_label": "243", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "5c2b860af435a8128af692471263c8b46cc167cd6e5dbab5fc6f74e5473ec3dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa75e4a2-58ab-4f47-8711-93fcf4007f00", "node_type": "1", "metadata": {"page_label": "242", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "afd03a0e05a1d3dc3e519bf9968e4f73946b4ecbed0bac3edcf6cfb2ef360d9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad9a7b5b-fdde-4e62-b968-b06043a692b6", "node_type": "1", "metadata": {"page_label": "243", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "a2b78a87beedb7d8684d0c39cf7f89f08d04feb335cbb412aff21f8a019d2fa1", "class_name": "RelatedNodeInfo"}}, "hash": "777d6de277a861817f7148c31b2d449ff2cb282d2ea6d0e6f346f27bd4e96eaf", "text": "Hereditary GI Cancer Syndromes\n\u00a9 2015 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY\n 243\n Table 10  .     Surveillance recommendations for hereditary gastrointestinal (GI) cancer syndromes \n  Site    Age to begin \nsurveillance (years)    Surveillance \ninterval (years)    Surveillance procedures and comments    References  \n  Lynch syndrome   \n  Colon  20\u201325 ( MLH1/\nMSH2   mutation) \n 25\u201330 ( MSH6/\nPMS2   mutation)  1\u20132  a    Colonoscopy  a    ( 24,29,47 ) \n  Endometrial and ovarian  30\u201335  1  No evidence of survival bene\ufb01  t of surveillance proven ( see   Table 8  ). Annual \npelvic exam; offer annual endometrial biopsy and transvaginal ultrasound to at-risk women. Consider total abdominal hysterectomy/bilateral salpingo-oophorectomy in women who have completed childbearing.  ( 24,58,60,359 ) \n  Pancreas    1\u20132  Consider magnetic resonance imaging (MRI) and/or endoscopic ultrasound \nin mismatch repair gene mutation carriers with pancreas cancer in a \ufb01  rst-degree relative  ( 73 ) \n  Urinary tract  25\u201330  1  Limited data exist to advocate urinary screening (NCCN recommends \nconsidering an annual urinalysis).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad9a7b5b-fdde-4e62-b968-b06043a692b6": {"__data__": {"id_": "ad9a7b5b-fdde-4e62-b968-b06043a692b6", "embedding": null, "metadata": {"page_label": "243", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "24bc8201-f996-4f23-bb8a-2cd99fc637b9", "node_type": "4", "metadata": {"page_label": "243", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "5c2b860af435a8128af692471263c8b46cc167cd6e5dbab5fc6f74e5473ec3dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1818f55-b1ab-4b0f-bbdd-1c5ea96c12ad", "node_type": "1", "metadata": {"page_label": "243", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "777d6de277a861817f7148c31b2d449ff2cb282d2ea6d0e6f346f27bd4e96eaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ff59e37-9e3b-450b-bbe9-7c9f50d94d83", "node_type": "1", "metadata": {"page_label": "243", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "48149e62ca68ad4b3079671de39a93e3cb8c8974285e5ad72fbdc0838ac17732", "class_name": "RelatedNodeInfo"}}, "hash": "a2b78a87beedb7d8684d0c39cf7f89f08d04feb335cbb412aff21f8a019d2fa1", "text": "( 24 ) \n  Small bowel and gastric  30\u201335  3\u20135  Consider esophagogastroduodenoscopy with extended duodenoscopy in \nselect individuals  ( 24 ) \n  Familial adenomatous polyposis (FAP)   \n  Colon  10\u201315  1\u20132  \nb    Flexible sigmoidoscopy or colonoscopy  b    ( 24,127 ) \n  Upper gastrointestinal  25\u201330  1\u20135  c    Esophagogastroduodenoscopy with a side-viewing instrument  ( 127 ) \n  Thyroid  Late teenage years  1  Annual thyroid examination; annual thyroid ultrasound  ( 24,171 ) \n  Intraabdominal desmoids    1  Annual abdominal palpation. (NCCN Guidelines: Consider abdominal \nMRI or computed tomography (CT) 1\u20133 years after colectomy then at 5\u201310-year intervals with family history of symptomatic desmoids or if suggestive abdominal symptoms occur).  ( 24 ) \n  Attenuated FAP   \n  Colon  18\u201320  1\u20132  \nb    Colonoscopy  ( 24,127 ) \n  Upper gastrointestinal  25\u201330  1\u20135  c    Esophagogastroduodenoscopy with a side-viewing instrument  ( 127 ) \n  Thyroid    1  Annual thyroid examination  ( 24 ) \n  MUTYH-associated polyposis   \n  Colon  25\u201330  1\u20132  b    Colonoscopy  ( 127 ) \n  Upper gastrointestinal  30\u201335  Baseline  c    Esophagogastroduodenoscopy with a side-viewing instrument  ( 24 ) \n  Peutz\u2013Jeghers syndrome   \n  Colon  8, 18  d    3  Colonoscopy  d    ( 182 ) \n  Stomach  8, 18  d    3  Esophagogastroduodenoscopy  d    ( 182 ) \n  Small bowel  8,", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ff59e37-9e3b-450b-bbe9-7c9f50d94d83": {"__data__": {"id_": "7ff59e37-9e3b-450b-bbe9-7c9f50d94d83", "embedding": null, "metadata": {"page_label": "243", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "24bc8201-f996-4f23-bb8a-2cd99fc637b9", "node_type": "4", "metadata": {"page_label": "243", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "5c2b860af435a8128af692471263c8b46cc167cd6e5dbab5fc6f74e5473ec3dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad9a7b5b-fdde-4e62-b968-b06043a692b6", "node_type": "1", "metadata": {"page_label": "243", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "a2b78a87beedb7d8684d0c39cf7f89f08d04feb335cbb412aff21f8a019d2fa1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37dff770-65ac-4ac7-ba1f-5f948bda8746", "node_type": "1", "metadata": {"page_label": "244", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "77fb6a1fe626119ce7a1f66cf7334e68d2a3a6d08620c269c99e0fe8c7ce18d3", "class_name": "RelatedNodeInfo"}}, "hash": "48149e62ca68ad4b3079671de39a93e3cb8c8974285e5ad72fbdc0838ac17732", "text": "18  d    3  Video capsule endoscopy  d    ( 182 ) \n  Pancreas  30  1\u20132  Magnetic resonance cholangiopancreatography or endoscopic ultrasound  ( 24,182,196 ) \n  Breast  25  1  Annual self-exam starting age 18, annual breast MRI, and/or mammogram \nstarting at age 25  ( 182,196,360 ) \n  Ovarian  25  1  Pelvic exam and pelvic or transvaginal ultrasound, CA-125 probably not \nhelpful  ( 182 ) \n  Endometrial  25  1  Pelvic exam and pelvic or transvaginal ultrasound  ( 182 ) \n   Cervix (adenoma \nmalignum)  25  1  Pap smear  ( 182,196 ) \n   SCTAT (sex cord tumor \nwith annular tubules)  25  1  Same as uterine and ovarian; almost all women develop SCTAT, but 20% \nbecome malignant  ( 182 ) \n   Testicular (Sertoli cell \ntumor)  Birth to teenage years  1  Testicular exam, ultrasound if abnormalities palpated or if feminization \noccurs; 10 to 20% of benign Sertoli cell tumors become malignant  ( 182 ) \n  Lung  \u2014  \u2014  Provide education about symptoms and smoking cessation  ( 24 ) \n  Juvenile polyposis syndrome   \n  Colon  12\u201315  1\u20133  Colonoscopy  e    ( 24,210 ) \nTable 10 continued on following page\nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37dff770-65ac-4ac7-ba1f-5f948bda8746": {"__data__": {"id_": "37dff770-65ac-4ac7-ba1f-5f948bda8746", "embedding": null, "metadata": {"page_label": "244", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1c1e7ff5-1978-471d-ba26-cb58841ff89a", "node_type": "4", "metadata": {"page_label": "244", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "a83008b4941f1a426519c2ae6ebf1aac94e3d8d4c0d5f4eeaf99b3b56bea05d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ff59e37-9e3b-450b-bbe9-7c9f50d94d83", "node_type": "1", "metadata": {"page_label": "243", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "48149e62ca68ad4b3079671de39a93e3cb8c8974285e5ad72fbdc0838ac17732", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83a8276b-53fa-47a4-a3d0-277dba6464ce", "node_type": "1", "metadata": {"page_label": "244", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "40cd5fc4b472fe7a1915baeaab21e94b57c0ad03b41dbba07759d5644791a6a4", "class_name": "RelatedNodeInfo"}}, "hash": "77fb6a1fe626119ce7a1f66cf7334e68d2a3a6d08620c269c99e0fe8c7ce18d3", "text": "Syngal  et al.  \nThe American Journal of GASTROENTEROLOGY VOLUME 110 | FEBRUARY 2015    www.amjgastro.com 244\nadenoma malignum ( 186 ). Nine percent of males develop large \ncell calcifying sertoli cell tumors of the testes, resembling sex cord tumors with annular tubules, that have a 10 to 20% chance of becoming malignant ( 199 ). Feminization may occur with the benign testicular tumors. Mainly because of cancer, the overall survival of PJS patients is signifi  cantly shorter than age- and \ngender-matched controls ( 200 ).\n  Surveillance guidelines for PJS are empiric and based on the risk \nfor GI complications and cancer. See  Table 10   for specifi  c recom-\nmendations. A consortium review group has recommended that upper GI endoscopy (EGD) and colonoscopy be done fi  rst at age \n8 years ( 182 ). If polyps are found, both examinations should be repeated every 3 years. If none are found, a second baseline exami-nation should be done at age 18 years and then every 3 years there-aft er. Similar surveillance is recommended for the small bowel, i.e., \nfi rst examine the small bowel by video capsule endoscopy at age \n8 years, but then repeat this surveillance every 3 years from that age. Modern CT enterography is accurate at detecting small bowel polyps, particularly those \u22651 cm in diameter, but repeated X-ray exposure is problematic. Table 10  .     Continued \n  Site    Age to begin \nsurveillance (years)    Surveillance \ninterval (years)    Surveillance procedures and comments    References  \n  Stomach  12\u201315  1\u20133  Esophagogastroduodenoscopy  e    ( 24,208 ) \n  Small Intestine  \u2014  \u2014  Rare, unde\ufb01  ned lifetime risk. Periodic enteroscopy, capsule endoscopy, \nand/or CT enterography  ( 24,208 ) \n  Pancreas  \u2014  \u2014  Rare, unde\ufb01  ned lifetime risk.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83a8276b-53fa-47a4-a3d0-277dba6464ce": {"__data__": {"id_": "83a8276b-53fa-47a4-a3d0-277dba6464ce", "embedding": null, "metadata": {"page_label": "244", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1c1e7ff5-1978-471d-ba26-cb58841ff89a", "node_type": "4", "metadata": {"page_label": "244", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "a83008b4941f1a426519c2ae6ebf1aac94e3d8d4c0d5f4eeaf99b3b56bea05d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37dff770-65ac-4ac7-ba1f-5f948bda8746", "node_type": "1", "metadata": {"page_label": "244", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "77fb6a1fe626119ce7a1f66cf7334e68d2a3a6d08620c269c99e0fe8c7ce18d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd3d098e-f384-4f1a-9448-ebcfa9e06062", "node_type": "1", "metadata": {"page_label": "244", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "408dd5d3a12d3aa357de1c995ee746d9da66ccd79d543ea04bf8980f2ce73055", "class_name": "RelatedNodeInfo"}}, "hash": "40cd5fc4b472fe7a1915baeaab21e94b57c0ad03b41dbba07759d5644791a6a4", "text": "No screening recommendations given  ( 24 ) \n   HHT (hereditary hemor-\nrhagic telangiectasia)  Within \ufb01  rst \n6 months of life  \u2014  Unde\ufb01  ned lifetime risk. In individuals with SMAD4 mutations, screen for \nvascular lesions associated with HHT  ( 24,361 ) \n  Cowden syndrome    f   \n  Colon  15  2  Colonoscopy, intervals may increase or decrease, depending on \ufb01  ndings  ( 183 ) \n   Upper GI tract and small \nbowel  15  2\u20133  Esophagogastroduodenoscopy. If duodenal polyposis is present, repeat \ndepending on number of polyps  ( 183 ) \n  Thyroid  Adolescence  1  Thyroid exam and baseline ultrasound  ( 183,347 ) \n  Breast  25 \n 30\u201335  Monthly \n 1  Self-breast exam \n Mammography and breast magnetic resonance imaging  ( 24 ) \n  Uterine  30\u201335  1  Annual endometrial sampling or vaginal ultrasound  ( 24 ) \n  Renal cell  18  1  Urine analysis with cytology and possibly renal ultrasound  ( 235 ) \n  Melanoma  By 18  1  Physical cutaneous examination  ( 235 ) \n  Serrated polyposis syndrome   \n  Colon  ?  1\u20133  Colonoscopy  g    ( 24 ) \n  Hereditary pancreatic cancer   \n  Pancreas  50  h    1  i    Endoscopic ultrasound and/or \n MRI/magnetic resonance cholangiopancreatography (MRCP)  i   \n Provide education about smoking cessation  ( 295,302 ) \n  Hereditary gastric cancer   \n  Stomach  5\u201310 Years before \nearliest cancer in \nfamily  0.5\u20131  Esophagogastroduodenoscopy; detailed 30-min exam with multiple random \nbiopsies  ( 313,314 ) \n  Breast  35  1  Breast exam, annual mammography \n Annual breast magnetic resonance imaging   \n  Colon  40  ?", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd3d098e-f384-4f1a-9448-ebcfa9e06062": {"__data__": {"id_": "bd3d098e-f384-4f1a-9448-ebcfa9e06062", "embedding": null, "metadata": {"page_label": "244", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1c1e7ff5-1978-471d-ba26-cb58841ff89a", "node_type": "4", "metadata": {"page_label": "244", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "a83008b4941f1a426519c2ae6ebf1aac94e3d8d4c0d5f4eeaf99b3b56bea05d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83a8276b-53fa-47a4-a3d0-277dba6464ce", "node_type": "1", "metadata": {"page_label": "244", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "40cd5fc4b472fe7a1915baeaab21e94b57c0ad03b41dbba07759d5644791a6a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b5c1ae8-394d-4313-a071-17824ded121d", "node_type": "1", "metadata": {"page_label": "245", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "9b4a6c9a2d2ad495a7604959b8e54e4aee7e9ab526babbcf51c272a797aa0ae8", "class_name": "RelatedNodeInfo"}}, "hash": "408dd5d3a12d3aa357de1c995ee746d9da66ccd79d543ea04bf8980f2ce73055", "text": "Colonoscopy  j     \n   a   Consider annual colonoscopy in con\ufb01  rmed mutation carriers.  \n   b   Annual colonoscopy if surgery is delayed for >1year after onset of colon polyps.  \n   c   Frequency depends on severity of duodenal polyposis.  \n   d   Start at age 8 years; if polyps present, repeat every 3 years; if no polyps, repeat at age 18, then every 3 years, or earlier i f symptoms occur.  \n   e   Start at age 12 years; if polyps present, repeat annually; if no polyps, repeat every 2\u20133 years.  \n   f   Baseline physical examination at diagnosis and annual targeted history and physical examination thereafter.( 235 )  \n   g   Colonoscopy with polypectomy until all polyps \u22655 mm are removed, then colonoscopy every 1\u20133 years.  \n   h   Or 10 years younger than the earliest age of pancreatic cancer in the family.  \n   i   MRI/MRCP. Frequency depends on severity of observed lesions and the need for pathologic examination.  \n   j   Consider in hereditary gastric cancer families with individuals affected by colon cancer.  \nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b5c1ae8-394d-4313-a071-17824ded121d": {"__data__": {"id_": "4b5c1ae8-394d-4313-a071-17824ded121d", "embedding": null, "metadata": {"page_label": "245", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "66757d82-468d-4e89-bfd6-e6516b4cb324", "node_type": "4", "metadata": {"page_label": "245", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "0293cc23b0c6be5117b8884e81ce8b865ab667f5b3d1dd893f3ed6fb055be6e2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd3d098e-f384-4f1a-9448-ebcfa9e06062", "node_type": "1", "metadata": {"page_label": "244", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "408dd5d3a12d3aa357de1c995ee746d9da66ccd79d543ea04bf8980f2ce73055", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c4c990c-c761-4531-beb2-7bb58b960c81", "node_type": "1", "metadata": {"page_label": "245", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "2fa286be9929ea8d845bc389cab8417809d49b94aec274b9ca68289c2f36dc48", "class_name": "RelatedNodeInfo"}}, "hash": "9b4a6c9a2d2ad495a7604959b8e54e4aee7e9ab526babbcf51c272a797aa0ae8", "text": "Hereditary GI Cancer Syndromes\n\u00a9 2015 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY\n 245\n  Treatment involves EGD and colonoscopic removal of polyps \n(probably all those >0.5 or 1 cm in diameter) ( 185 ). Clearing of all polyps is preferable but not always possible. Colectomy is some-times necessary to control colonic polyps and should be considered if colonoscopic management is diffi   cult and especially if neoplastic \nchange is found in colonic polyps. Intussusception is the primary complication of small bowel polyps, starting at a young age, and continuing throughout life ( 188 ). Surveillance and treatment of the small bowel are based in large part on prevention of this complica-\ntion. In the recent study by van Lier  et al.   ( 188 ), the initial episode \nof intussusception occurred at a median age of 16 years (range, 3\u201350 years), with 50% of fi  rst episodes presenting by age 20 years. \nOf all intussusceptions, 80% presented as an acute abdomen and the average polyp size causing this complication was 3.5 cm (range, 15\u201360 cm). When small bowel intussusceptions occur, surgery is oft  en necessary and should include careful examination of the \nentire small bowel to eliminate all signifi  cant polyps. Intraopera-\ntive endoscopy is oft  en a helpful adjunct to accomplish extensive \npolyp removal. Th  is is also an appropriate time to examine and \nremove gastric and duodenal polyps of signifi  cant size ( 201 ). Th  e \nadvent of video capsule endoscopy, double balloon enteroscopy, and CT enterography is changing diagnostic and management approaches to PJS by allowing earlier detection of polyps and non-operative removal in many cases ( 202\u2013205 ).\n     Prevention strategies\n  Chemoprevention approaches to decrease polyp burden in PJS are \nunder study but not yet a reality.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c4c990c-c761-4531-beb2-7bb58b960c81": {"__data__": {"id_": "3c4c990c-c761-4531-beb2-7bb58b960c81", "embedding": null, "metadata": {"page_label": "245", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "66757d82-468d-4e89-bfd6-e6516b4cb324", "node_type": "4", "metadata": {"page_label": "245", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "0293cc23b0c6be5117b8884e81ce8b865ab667f5b3d1dd893f3ed6fb055be6e2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b5c1ae8-394d-4313-a071-17824ded121d", "node_type": "1", "metadata": {"page_label": "245", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "9b4a6c9a2d2ad495a7604959b8e54e4aee7e9ab526babbcf51c272a797aa0ae8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b93cb61-6364-4deb-ad88-f63669693558", "node_type": "1", "metadata": {"page_label": "245", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "655417b7a12e4005e3603352d50bca9d19024a3332d55f5c80c884f4ce32ef6a", "class_name": "RelatedNodeInfo"}}, "hash": "2fa286be9929ea8d845bc389cab8417809d49b94aec274b9ca68289c2f36dc48", "text": "PJS polyps exhibit overexpres-\nsion of COX-2, suggesting that COX-2 inhibitors may be useful in reducing polyps ( 206 ). Hyperactivation of the mammalian target of rapamycin has been associated with PJS. In addition, inhibi-tion of mammalian target of rapamycin in a PJS mouse model has demonstrated decreased polyp burden ( 207 ). Everolimus, a mam-malian target of rapamycin inhibitor, is under study as a potential agent for treatment of PJS ( 182 ).\n    Juvenile polyposis syndrome\n   Indications for genetic testing   \n     Summary statement   \n\u2022       Individuals with fi  ve or more juvenile polyps in the colo-\nrectum or any juvenile polyps in other parts of the GI tract should undergo evaluation for JPS. \n     Summary of evidence  \n    JPS is an autosomal-dominantly inherited condition where mul-\ntiple juvenile polyps are found in the colorectum (98%), stomach \n(14%), jejunum and ileum (7%), and duodenum (7%) ( 183,208\u2013\n210 ). Th  e incidence of JPS is between 1 in 100,000 and 1 in 160,000 \nindividuals ( 210 ). Th  e polyps in JPS vary in size from small sessile \nnodules to pedunculated lesions that are \u22653 cm in diameter. Most large polyps are pedunculated, but small polyps, especially those in the stomach, are sessile. Grossly, most polyps exhibit a surface that is smooth, rounded, reddish colored, and without fi  ssures \nor lobulations; large polyps may appear to be multilobulated. A white exudate is oft  en seen on the polyp surface. On cut section, \nthere are cystic spaces fi  lled with mucin. Microscopically, there \nis abundant lamina propria with benign but oft  en elongated and \ncystically dilated glands and lack of a smooth muscle core. Excess chronic infl  ammatory cells are sometimes present.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b93cb61-6364-4deb-ad88-f63669693558": {"__data__": {"id_": "1b93cb61-6364-4deb-ad88-f63669693558", "embedding": null, "metadata": {"page_label": "245", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "66757d82-468d-4e89-bfd6-e6516b4cb324", "node_type": "4", "metadata": {"page_label": "245", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "0293cc23b0c6be5117b8884e81ce8b865ab667f5b3d1dd893f3ed6fb055be6e2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c4c990c-c761-4531-beb2-7bb58b960c81", "node_type": "1", "metadata": {"page_label": "245", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "2fa286be9929ea8d845bc389cab8417809d49b94aec274b9ca68289c2f36dc48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da1c4d03-5d64-4763-9dea-e7f397553b08", "node_type": "1", "metadata": {"page_label": "245", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "7d74039b27a74292728e411fe87c70961f672bde780dc197c8fa0c1ffab197b5", "class_name": "RelatedNodeInfo"}}, "hash": "655417b7a12e4005e3603352d50bca9d19024a3332d55f5c80c884f4ce32ef6a", "text": "Excess chronic infl  ammatory cells are sometimes present. Th  e epithelial \nlining of the surface and cysts is nondysplastic and refl  ects the \narea of the GI tract where the polyp is located. Polyps begin to appear in the fi  rst decade of life, and dozens to many hundreds of \npolyps are present in the fully developed syndrome. Most patients \ndevelop symptoms in the fi  rst two decades of life. Th  e average age \nat diagnosis is 18.5 years but may be later. Rectal bleeding with anemia is the most common presenting symptom, followed by abdominal pain, diarrhea, passage of tissue per rectum, and intus-susception ( 183,208 ). Th  e majority of colonic polyps, 70% in one \nstudy, occurred in the proximal colon ( 210 ).\n  Th e generally accepted clinical criteria for JPS include: (i) at least \nfi ve juvenile polyps in the colorectum; (ii) juvenile polyps in other \nparts of the GI tract; or (iii) any number of juvenile polyps in a person with a known family history of juvenile polyps ( 210 ).\n      Genetic etiology\n   Summary statement   \n\u2022       Genetic evaluation of a patient with possible JPS should \ninclude testing for  SMAD4   and  BMPR1A   mutations. \n     Summary of evidence   \n    Juvenile polyposis occurs as a result of mutations of the  SMAD4   \ngene (also called the  MADH4   gene) or the  BMPR1A   gene ( 210\u2013\n214 ). Up to 60% of individuals with clinically defi  ned JPS are \nnow found to exhibit mutations of the  SMAD4   or  BMPR1A   genes \n( 215 ). Approximately 25% of newly diagnosed cases are sporadic and thus represent new or  de novo   mutations, whereas 75% will \nhave a family history ( 183 ). Fourteen percent of mutations are large deletions and 10% are promoter mutations ( 215\u2013217 ). Both genes are tumor suppressor genes involved in the tumor growth factor- \u03b2  signaling family and directly or indirectly aff  ect cell \ngrowth inhibition and apoptosis.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da1c4d03-5d64-4763-9dea-e7f397553b08": {"__data__": {"id_": "da1c4d03-5d64-4763-9dea-e7f397553b08", "embedding": null, "metadata": {"page_label": "245", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "66757d82-468d-4e89-bfd6-e6516b4cb324", "node_type": "4", "metadata": {"page_label": "245", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "0293cc23b0c6be5117b8884e81ce8b865ab667f5b3d1dd893f3ed6fb055be6e2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b93cb61-6364-4deb-ad88-f63669693558", "node_type": "1", "metadata": {"page_label": "245", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "655417b7a12e4005e3603352d50bca9d19024a3332d55f5c80c884f4ce32ef6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb59f905-005a-4f1d-93b2-369f48816c7f", "node_type": "1", "metadata": {"page_label": "246", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "52a549a1ba38bb6222a1a9170403dc41d19cd760b7d4259eaa04f8703334910c", "class_name": "RelatedNodeInfo"}}, "hash": "7d74039b27a74292728e411fe87c70961f672bde780dc197c8fa0c1ffab197b5", "text": "Th  ere is evidence that normal \nbone morphogenetic protein signa ling also suppresses Wnt sign-\naling to ensure a balanced control of stem cell self-renewal ( 218 ). Biallelic gene inactivation has been noted in both stromal cells and epithelial cells of polyps ( 208,219 ).\n  Genetic testing is particularly important in JPS, both to con-\nfi rm the diagnosis in a proband and to test relatives. Testing is also \nimportant to separate JPS from other conditions in which juvenile \npolyps form, especially CS and Bannayan\u2013Riley\u2013Ruvalcaba syn-drome. Once a disease-causing mutation is identifi  ed in a patient \nwith JPS, other family members should undergo mutation-specifi  c \ntesting to determine whether the disease is present or absent so that appropriate surveillance can be undertaken.\n     Surveillance and management\n   Recommendations   \n    15.  Surveillance of the GI tract in aff  ected or at-risk JPS patients \nshould include screening for colon, stomach, and small bowel \nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb59f905-005a-4f1d-93b2-369f48816c7f": {"__data__": {"id_": "eb59f905-005a-4f1d-93b2-369f48816c7f", "embedding": null, "metadata": {"page_label": "246", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3ded5d19-ba3e-431c-8c91-8993af126911", "node_type": "4", "metadata": {"page_label": "246", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "e05e3ad270898a95c3dbf3d0d9c5120b675694ca63ff1d0d5371c72caffe2d26", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da1c4d03-5d64-4763-9dea-e7f397553b08", "node_type": "1", "metadata": {"page_label": "245", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "7d74039b27a74292728e411fe87c70961f672bde780dc197c8fa0c1ffab197b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c009e2aa-a2df-4fc2-97b3-8c5dc00559ea", "node_type": "1", "metadata": {"page_label": "246", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "6fda4d2ed804eb1a376979f04e5307c15b7fbe4fd2c73f5f9a45353908dfa6ed", "class_name": "RelatedNodeInfo"}}, "hash": "52a549a1ba38bb6222a1a9170403dc41d19cd760b7d4259eaa04f8703334910c", "text": "Syngal  et al.  \nThe American Journal of GASTROENTEROLOGY VOLUME 110 | FEBRUARY 2015    www.amjgastro.com 246\ncancers (strong recommendation, very low quality of evi-\ndence).\n  16.  Colectomy and IRA or proctocolectomy and IPAA is indicated \nfor polyp-related symptoms, or when the polyps cannot be managed endoscopically (strong recommendation, low quality \nof evidence).\n  17.  Cardiovascular examination for and evaluation for hereditary \nhemorrhagic telangiectasia should be considered for  SMAD4   \nmutation carriers (conditional recommendation, very low \nquality of evidence).\n    \nSummary of evidence   \n    JPS mutation carriers have a very high risk for colon cancer and \nan increased risk for gastric, duodenal, and pancreatic cancers ( Tables 5 and 7 ). Th e cancer risk in JPS is believed to arise from \nadenomatous tissue within the juvenile polyp, as up to 50% of ju-venile polyps in JPS contain areas of adenomatous change. Th  e \nrisk of colon cancer is 17\u201322% by age 35 years and approaches 68% by age 60 years ( 183,220 ). Th  e mean age of colon cancer is 34 \nyears, with a range of 15 to 68 years. Gastric cancer risk is 30% in those with  SMAD4   mutations ( 183,210 ). Th  e median age of upper \nGI carcinoma is 58 years, with a range of 21 to 73 years ( 221,222 ).\n  Surveillance guidelines for JPS are found in  Table 10  . Colo-\nnoscopy should be annual, beginning at age 12 years or earlier if symptoms occur, especially rectal bleeding. It should be repeated every 1 to 3 years depending on polyp burden and polyps \u22655 mm should be removed ( 210 ). Upper endoscopy is recommended \nevery 1 to 3 years beginning at age 12 years, or earlier for symp-\ntoms, and should be repeated every 1 to 3 years, depending on severity with removal of polyps \u22655 mm.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c009e2aa-a2df-4fc2-97b3-8c5dc00559ea": {"__data__": {"id_": "c009e2aa-a2df-4fc2-97b3-8c5dc00559ea", "embedding": null, "metadata": {"page_label": "246", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3ded5d19-ba3e-431c-8c91-8993af126911", "node_type": "4", "metadata": {"page_label": "246", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "e05e3ad270898a95c3dbf3d0d9c5120b675694ca63ff1d0d5371c72caffe2d26", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb59f905-005a-4f1d-93b2-369f48816c7f", "node_type": "1", "metadata": {"page_label": "246", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "52a549a1ba38bb6222a1a9170403dc41d19cd760b7d4259eaa04f8703334910c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a8a33dd-ac42-4f41-bc47-a86ee0506601", "node_type": "1", "metadata": {"page_label": "246", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "77316ed2255e4374ce1be32a1f6975411b6a599c0a776710916101d06099f2a5", "class_name": "RelatedNodeInfo"}}, "hash": "6fda4d2ed804eb1a376979f04e5307c15b7fbe4fd2c73f5f9a45353908dfa6ed", "text": "Th  e small bowel past \nthe duodenum should be periodically surveilled, depending on initial polyp fi  ndings, by enteroscopy, capsule endoscopy, and/or \nCT enterography if duodenal polyposis is present or if there is unexplained anemia, protein-losing en teropathy, or other small \nbowel symptoms. Patients with limited numbers of polyps in any area of the GI tract can usually be managed with endoscopic polypectomy. Colectomy with IRA is indicated if cancer, high-grade dysplasia, or polyposis cannot be adequately controlled endoscopically ( 183,208 ). Surveillance of the remaining rectum or pouch is necessary ( 223 ). Proctocolectomy with IPAA may be needed depending on the number of rectal polyps ( 223 ). Half of those with IRA will later need proctectomy because of polyp per-fusion. Complete or partial gastrectomy may also be necessary for patients with advanced dysplasia, gastric cancer, or even massive gastric polypsis that cannot be eff  ectively controlled endoscopi-\ncally ( 183,208 ). Other screening should include annual complete blood count, cardiovascular examination, and hereditary hemor-rhagic telangiectasia protocol evaluation if  SMAD4   mutation is \npresent ( 210 ).\n     Cowden syndrome (PTEN hamartoma tumor syndrome)\n   Summary statement   \n\u2022       Individuals with multiple GI hamartomas or ganglioneuro-\nmas should be evaluated for CS and related conditions.      Summary of evidence   \n    CS and its variants, including Bannayan\u2013Riley\u2013Ruvalcaba syn-\ndrome and PTEN hamartoma tumor syndrome (PHTS), have been associated with a broad range of clinical phenotypes. Colon-ic polyps are found in up to 95% of CS patients undergoing colo-noscopy ( 224,225 ). Polyps are few to numerous (even hundreds) and are distributed throughout the colon. Th  e natural history of \npolyps is not well characterized, although polyps may occur at a young age. Hamartomatous polyps are the most common histo-\nlogic type, occurring in up to 29% in one study ( 224 ).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a8a33dd-ac42-4f41-bc47-a86ee0506601": {"__data__": {"id_": "0a8a33dd-ac42-4f41-bc47-a86ee0506601", "embedding": null, "metadata": {"page_label": "246", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3ded5d19-ba3e-431c-8c91-8993af126911", "node_type": "4", "metadata": {"page_label": "246", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "e05e3ad270898a95c3dbf3d0d9c5120b675694ca63ff1d0d5371c72caffe2d26", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c009e2aa-a2df-4fc2-97b3-8c5dc00559ea", "node_type": "1", "metadata": {"page_label": "246", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "6fda4d2ed804eb1a376979f04e5307c15b7fbe4fd2c73f5f9a45353908dfa6ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "952253bb-36c9-4b13-9f68-7a3acc1b5148", "node_type": "1", "metadata": {"page_label": "246", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1ad66bdcaa7392671f9ef7914411a0d783746dc13c2caa5b4242885c07209293", "class_name": "RelatedNodeInfo"}}, "hash": "77316ed2255e4374ce1be32a1f6975411b6a599c0a776710916101d06099f2a5", "text": "Polyp types \ninclude juvenile polyps, ganglioneuromas, adenomas, and infl  am-\nmatory polyps ( 224,226,227 ), and less commonly leiomyomas, li-pomas, and lymphoid polyps ( 228 ). Hyperplastic polyps have also been reported as an association, but have not been observed in all studies ( 224,227 ). Th  e majority of CS patients have multiple \nsynchronous histologic types at colonoscopy.\n  A frequent fi  nding in the esophagus is diff  use glycogenic acan-\nthosis ( 228,229 ). One or several such lesions may occasionally be observed in patients undergoing EGD for various reasons, but diff  use, sometimes many hundreds of lesions are observed in \n\u226580% of those with PHTS ( 227 ). It has been suggested that diff  use \nesophageal glycogenic acanthosis combined with colonic polypo-sis should be considered pathognomonic for CS ( 228 ).\n  Several investigations report the frequent fi  nding of multiple \nhamartomatous polyps in the stomach, duodenum, and small bowel ( 183,224,229 ). Similar to the colon, histologies include hamartomas, hyperplastic polyps (diff  erent from colonic hyper-\nplastic polyps), ganglioneuromas, adenomas, and infl  ammatory \npolyps. An upper GI study of 10  phosphate and tensin homolog   \n( PTEN  ) mutation-positive patients found all 10 to have multiple \nhyperplastic gastric polyps and 3 to have multiple hamartomatous polyps in that location ( 227 ). One patient had a single hamartoma-tous polyp in the duodenum whereas three had adenomatous pol-yps. Th  ere are reports of gastric and colon cancers in CS patients \n( 183,230 ).\n  Specifi  c indications for evaluation for CS are delineated in \n Table 11  .\n     Genetic etiology\n   Summary statement   \n\u2022       Genetic evaluation of a patient with possible CS should \ninclude testing for  PTEN   mutations.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "952253bb-36c9-4b13-9f68-7a3acc1b5148": {"__data__": {"id_": "952253bb-36c9-4b13-9f68-7a3acc1b5148", "embedding": null, "metadata": {"page_label": "246", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3ded5d19-ba3e-431c-8c91-8993af126911", "node_type": "4", "metadata": {"page_label": "246", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "e05e3ad270898a95c3dbf3d0d9c5120b675694ca63ff1d0d5371c72caffe2d26", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a8a33dd-ac42-4f41-bc47-a86ee0506601", "node_type": "1", "metadata": {"page_label": "246", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "77316ed2255e4374ce1be32a1f6975411b6a599c0a776710916101d06099f2a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8369808-da1a-472f-864d-5e7c5a640d50", "node_type": "1", "metadata": {"page_label": "247", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "fe34727683d128d5a8a17dd71b6ea9602bda790254912fef380da8a96394be6c", "class_name": "RelatedNodeInfo"}}, "hash": "1ad66bdcaa7392671f9ef7914411a0d783746dc13c2caa5b4242885c07209293", "text": "Summary of evidence   \n    CS is caused by mutations in the  PTEN   gene ( 231\u2013234 ). Once \na disease-causing mutation is identifi  ed in a patient with CS or \nrelated conditions, other family members should undergo muta-\ntion-specifi  c testing to determine whether the disease is present \nor absent so that appropriate surveillance can be undertaken.\n     Surveillance and management\n   Recommendation   \n    18.  Surveillance in aff  ected or at-risk CS patients should include \nscreening for colon, stomach, small bowel, thyroid, breast, \nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8369808-da1a-472f-864d-5e7c5a640d50": {"__data__": {"id_": "a8369808-da1a-472f-864d-5e7c5a640d50", "embedding": null, "metadata": {"page_label": "247", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b26ba6c1-9ce5-4cc3-bb19-6fc5dea556b9", "node_type": "4", "metadata": {"page_label": "247", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "dd24205491eded8cfce2206895f91f225078b9b2e244c1e59f4780c560e9af43", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "952253bb-36c9-4b13-9f68-7a3acc1b5148", "node_type": "1", "metadata": {"page_label": "246", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1ad66bdcaa7392671f9ef7914411a0d783746dc13c2caa5b4242885c07209293", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f94fea48-051b-470a-a19a-0de86eff7b73", "node_type": "1", "metadata": {"page_label": "247", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "301a6ab691863db9d5fc997b92489cfb87db7221454dc67c8ef1c5526e079aef", "class_name": "RelatedNodeInfo"}}, "hash": "fe34727683d128d5a8a17dd71b6ea9602bda790254912fef380da8a96394be6c", "text": "Hereditary GI Cancer Syndromes\n\u00a9 2015 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY\n 247\n Table 11  .", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f94fea48-051b-470a-a19a-0de86eff7b73": {"__data__": {"id_": "f94fea48-051b-470a-a19a-0de86eff7b73", "embedding": null, "metadata": {"page_label": "247", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b26ba6c1-9ce5-4cc3-bb19-6fc5dea556b9", "node_type": "4", "metadata": {"page_label": "247", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "dd24205491eded8cfce2206895f91f225078b9b2e244c1e59f4780c560e9af43", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8369808-da1a-472f-864d-5e7c5a640d50", "node_type": "1", "metadata": {"page_label": "247", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "fe34727683d128d5a8a17dd71b6ea9602bda790254912fef380da8a96394be6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6449eaae-0e1c-4d1c-bd85-c83ed3c005e1", "node_type": "1", "metadata": {"page_label": "247", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "ac06434e41aa9f13e895ddb31ff3ee3261c2989dee7b945cfb2cbcea34f00622", "class_name": "RelatedNodeInfo"}}, "hash": "301a6ab691863db9d5fc997b92489cfb87db7221454dc67c8ef1c5526e079aef", "text": "Indications for genetic evaluation for Cowden syndrome (PTEN hamartoma tumor syndrome)  a   \n Individual from a family with a known  PTEN   mutation \n Individual meeting clinical diagnostic criteria for Cowden syndrome (CS) as outlined below \n Individual with a personal history of any of the following: \n  Bannayan\u2013Riley\u2013Ruvalcaba syndrome (BRRS) \n  Adult Lhermitte\u2013Duclos disease \n  Autism spectrum disorder and macrocephaly \n  Two or more biopsy-proven trichilemmomas \n  Two or more major criteria (one must be macrocephaly) \n  Three major criteria, without macrocephaly \n  One major and \u2265three minor criteria  b   \n  \u2265Four minor criteria \n At-risk individual with one major or two minor criteria and a relative with a clinical diagnosis of CS or BRRS for whom testing  has not been performed \n  Major criteria   \n  Breast cancer \n  Endometrial cancer \n  Follicular thyroid cancer \n  Multiple gastrointestinal hamartomas or ganglioneuromas \n  Macrocephaly (megalocephaly, \u226597th percentile) \n  Macular pigmentation of glans penis \n  Mucocutaneous lesions alone if: \n   One biopsy proven trichilemmoma, or \n   Multiple palmoplantar keratoses, or \n   Multifocal or extensive oral mucosal papillomatosis, or \n   Multiple cutaneous facial papules (often verrucous) \n  Minor criteria   \n  Autism spectrum disorder \n  Colon cancer \n  Esophageal glycogenic acanthosis (\u22653) \n  Lipomas \n  Mental retardation (i.e., IQ \u226475) \n  Papillary or follicular variant of papillary thyroid cancer \n  Thyroid structural lesions (e.g., adenoma, nodule(s), goiter) \n  Renal cell carcinoma \n  Single gastrointestinal hamartoma or ganglioneuroma \n  Testicular lipomatosis \n  Vascular anomalies (including multiple intracranial developmental venous anomalies) \n   a   Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk  Assessment: Breast and Ovarian \nV.4.2013.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6449eaae-0e1c-4d1c-bd85-c83ed3c005e1": {"__data__": {"id_": "6449eaae-0e1c-4d1c-bd85-c83ed3c005e1", "embedding": null, "metadata": {"page_label": "247", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b26ba6c1-9ce5-4cc3-bb19-6fc5dea556b9", "node_type": "4", "metadata": {"page_label": "247", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "dd24205491eded8cfce2206895f91f225078b9b2e244c1e59f4780c560e9af43", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f94fea48-051b-470a-a19a-0de86eff7b73", "node_type": "1", "metadata": {"page_label": "247", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "301a6ab691863db9d5fc997b92489cfb87db7221454dc67c8ef1c5526e079aef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4774f6eb-f32f-4b3a-9f1b-683869895af4", "node_type": "1", "metadata": {"page_label": "248", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "20d006b2219b4afa0044e94d0e2f1c4b24fbe90556d86028856710fd29b07f01", "class_name": "RelatedNodeInfo"}}, "hash": "ac06434e41aa9f13e895ddb31ff3ee3261c2989dee7b945cfb2cbcea34f00622", "text": "( 3 ) 2014 National Comprehensive Cancer Network. All rights reserved. The NCCN Guidelines and illustrations herein may not be repr oduced in any form for \nany purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidel ines, go online to NCCN.org. \nNATIONAL COMPREHENSIVE CANCER NETWORK, NCCN, NCCN GUIDELINES, and all other NCCN content are trademarks owned by the National C omprehensive \nCancer Network.  \n   b   If an individual has two or more major criteria, such as breast cancer and nonmedullary thyroid cancer, but does not have macro cephaly, one of the major criteria may \nbe included as one of the three minor criteria to meet testing criteria.  \nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4774f6eb-f32f-4b3a-9f1b-683869895af4": {"__data__": {"id_": "4774f6eb-f32f-4b3a-9f1b-683869895af4", "embedding": null, "metadata": {"page_label": "248", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "dd900cd0-597f-48ad-9805-a97dbcb03071", "node_type": "4", "metadata": {"page_label": "248", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "6074d7dbab4dea30b170838aa851a98797a99483d9c391730373bf5c6aeebf16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6449eaae-0e1c-4d1c-bd85-c83ed3c005e1", "node_type": "1", "metadata": {"page_label": "247", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "ac06434e41aa9f13e895ddb31ff3ee3261c2989dee7b945cfb2cbcea34f00622", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25c359c5-81b5-4928-80fb-6c47f4074a0c", "node_type": "1", "metadata": {"page_label": "248", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "4881d6e197ec92eb5b8cdb12948033773878307b7502338557388bb4dfef9278", "class_name": "RelatedNodeInfo"}}, "hash": "20d006b2219b4afa0044e94d0e2f1c4b24fbe90556d86028856710fd29b07f01", "text": "Syngal  et al.  \nThe American Journal of GASTROENTEROLOGY VOLUME 110 | FEBRUARY 2015    www.amjgastro.com 248\nuterine, kidney, and skin (melanoma) cancers (conditional \nrecommendation, low quality of evidence).\n    Summary of evidence   \n    Management of PHTS involves prevention and early detection of \nthe associated cancers through surveillance. Colon cancer has not been associated with CS historically ( 183 ), although recent stud-ies have indeed shown increased risk for this malignancy. One multicenter study found 13% of  PTEN   mutation carriers to have \ncolon cancer, all younger than 50 years of age ( 224 ). Investiga-\ntions have now indicated a 9 to 16% lifetime risk for large bowel cancer ( 225,235,236 ). It is uncertain whether colon malignancy arises from adenomatous and/or hamartomatous polyps in PHTS, although there is little doubt as to the increased risk and possibil-ity of young age onset.\n  Surveillance recommendations are provided in  Table 10  . Rec-\nommendations are all expert opinion based rather than evidence based, and derived from screening guidelines of the relevant cancers in other settings but adjusted for the malignancy risks observed in PHTS.\n   Hereditary mixed polyposis syndrome (HMPS)   is a condition \nthat was originally described in a large Ashkenazi Jewish fam-ily with multiple colorectal polyps and cancer. Aff  ected patients \nexhibited mixed juvenile\u2013adenomatous polyps and also adeno-matous, hyperplastic, serrated adenomas, and mixed hyper-plastic\u2013adenomatous polyps and adenocarcinomas. Mean age of polyp occurrence in one family was 28 years. HMPS may be \nmisdiagnosed as JPS or serrated polyposis syndrome (SPS) and \nvice versa.\n  Even though HMPS linked to a locus on chromosome 15q13.3\u2013\nq14 in a number of families, which includes the  CRAC1   gene, the \netiology remains elusive.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25c359c5-81b5-4928-80fb-6c47f4074a0c": {"__data__": {"id_": "25c359c5-81b5-4928-80fb-6c47f4074a0c", "embedding": null, "metadata": {"page_label": "248", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "dd900cd0-597f-48ad-9805-a97dbcb03071", "node_type": "4", "metadata": {"page_label": "248", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "6074d7dbab4dea30b170838aa851a98797a99483d9c391730373bf5c6aeebf16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4774f6eb-f32f-4b3a-9f1b-683869895af4", "node_type": "1", "metadata": {"page_label": "248", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "20d006b2219b4afa0044e94d0e2f1c4b24fbe90556d86028856710fd29b07f01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58cda90e-5c88-420f-8829-eb72ff79e9f6", "node_type": "1", "metadata": {"page_label": "248", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c9c0c89d504d13e1d1e9cf5a18e01a1280972d0bedfeb82179a4ee4738072dd4", "class_name": "RelatedNodeInfo"}}, "hash": "4881d6e197ec92eb5b8cdb12948033773878307b7502338557388bb4dfef9278", "text": "Recently, a duplication 40 kb upstream of the  GREM1   gene locus at chromosome 15 was found in two \nindividuals with HMPS. Th  e authors hypothesized that this dupli-\ncation interacts with the  GREM1   promoter causing increased \n GREM1   expression, resulting in a predisposition to multiple colo-\nrectal polyps.\n  Genetic testing for  GREM1   mutation and expression might \nbe considered in families with adenomatous and hamartoma-tous polyposis in which an etiology cannot be determined. Management from what is now known should probably be similar to that for FAP , depending on the polyp number, size, and histology.\n     Serrated polyposis syndrome\n   Clinical defi  nitions   \n     Summary statement   \n\u2022       Individuals who meet at least one of the following crite-\nria have the clinical diagnosis of SPS: (i) at least 5 serrated polyps proximal to the sigmoid colon with \u22652 of these being >10 mm; (ii) any number of serrated polyps proximal to the sigmoid colon in an individual who has a fi  rst-degree relative \nwith serrated polyposis; and (iii) >20 serrated polyps of any size, distributed throughout the large intestine.      Summary of evidence  \n    SPS, previously referred to as hyperplastic polyposis syndrome, \nis a rare condition currently defi  ned by clinical criteria and char-\nacterized by a predisposition to serrated polyps and an increased risk of CRC ( 237\u2013239 ). Originally, hyperplastic polyps were the only lesion included in the diagno stic criteria for hyperplastic \npolyposis ( 240 ). In addition to hyperplastic polyps, other serrated polyps including sessile serrated polyps and traditional serrated adenomas may also be found, and hence the preferred term ser-\nrated polyposis syndrome ( 241 ).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58cda90e-5c88-420f-8829-eb72ff79e9f6": {"__data__": {"id_": "58cda90e-5c88-420f-8829-eb72ff79e9f6", "embedding": null, "metadata": {"page_label": "248", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "dd900cd0-597f-48ad-9805-a97dbcb03071", "node_type": "4", "metadata": {"page_label": "248", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "6074d7dbab4dea30b170838aa851a98797a99483d9c391730373bf5c6aeebf16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25c359c5-81b5-4928-80fb-6c47f4074a0c", "node_type": "1", "metadata": {"page_label": "248", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "4881d6e197ec92eb5b8cdb12948033773878307b7502338557388bb4dfef9278", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4de6e89-0921-4f20-aa7e-d7270cb7ae35", "node_type": "1", "metadata": {"page_label": "248", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "cf8fac0fb6f4b0156c49bbe3a3bb777efce4c659f20758ec19826645bc85b55e", "class_name": "RelatedNodeInfo"}}, "hash": "c9c0c89d504d13e1d1e9cf5a18e01a1280972d0bedfeb82179a4ee4738072dd4", "text": "Th e updated World Health Organization (WHO) diagnostic \ncriteria for SPS include any one of the following: (i) at least fi  ve \nserrated polyps proximal to the sigmoid colon with two or more of them >10 mm in diameter, (ii) any number of serrated polyps proximal to the sigmoid colon in an individual who has a FDR with SPS, or (iii) >20 serrated polyps of any size, but distributed throughout the colon ( 242 ). Th  e true prevalence of SPS is not \nknown, but had been previously estimated to be 1:100,000 based on a large screening colonoscopy study of 50,148 participants in which 28 subjects (0.06%) were found to have the syndrome. ( 243 ). More recent studies have evaluated the prevalence of SPS based on the WHO criteria. Th  e National Health Service Bowel \nCancer Screening Programme (NHSBCSP) reviewed all pathology and colonoscopy records for guaiac fecal occult blood test-positive patients presenting for index screening colonoscopy ( 244 ). Out of 755 patients, 5 (0.66%) met SPS criteria 1 and/or 3 ( 244 ). Th  ere-\nfore, 1 in 151 patients in the NHSBCSP met SPS criteria during \ntheir index colonoscopy, a much higher rate than previous reports \nof SPS in the general population ( 244 ). In a study from Barcelona, the prevalence of SPS in patients undergoing colonoscopy aft  er a \npositive fecal immunochemical testing was 8 out of 2,355 (0.34%) ( 245 ).\n      Genetic etiology\n   Summary statement   \n\u2022      Indications for genetic testing  .     A clear genetic etiology has \nnot yet been defi  ned for SPS, and therefore genetic testing \nis currently not routinely recommended for SPS patients; testing for  MUTYH   mutations may be considered for SPS \npatients with concurrent adenomas and/or a family history of adenomas.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4de6e89-0921-4f20-aa7e-d7270cb7ae35": {"__data__": {"id_": "b4de6e89-0921-4f20-aa7e-d7270cb7ae35", "embedding": null, "metadata": {"page_label": "248", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "dd900cd0-597f-48ad-9805-a97dbcb03071", "node_type": "4", "metadata": {"page_label": "248", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "6074d7dbab4dea30b170838aa851a98797a99483d9c391730373bf5c6aeebf16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58cda90e-5c88-420f-8829-eb72ff79e9f6", "node_type": "1", "metadata": {"page_label": "248", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c9c0c89d504d13e1d1e9cf5a18e01a1280972d0bedfeb82179a4ee4738072dd4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9f87f9f-2d1c-4cc4-ba38-e9161447ff4f", "node_type": "1", "metadata": {"page_label": "249", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "cf002d95d5d2fe47e4be5026559094546c93418900531f06ecc5f628c625f1e9", "class_name": "RelatedNodeInfo"}}, "hash": "cf8fac0fb6f4b0156c49bbe3a3bb777efce4c659f20758ec19826645bc85b55e", "text": "Summary of evidence  \n    Although the genetic etiology of SPS remains unknown, 3 patients \nwere found to meet diagnostic criteria for SPS in a series of 17 biallelic  MUTYH   mutation carriers (18%) ( 136 ). Conversely, only \none biallelic  MUTYH   mutation carrier was observed in a study of \n126 patients with SPS (0.8%) ( 246 ). In both studies, the patients who met criteria for SPS also reported a history of adenomas. Th ese observations indicate some overlap in the presentation \n(and potentially the pathogenesis) of MAP and serrated polypo-sis. Although data are currently limited, it may be reasonable to consider genetic testing for  MUTYH   mutations in patients with \nSPS, particularly if adenomas are concurrently seen.\nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9f87f9f-2d1c-4cc4-ba38-e9161447ff4f": {"__data__": {"id_": "a9f87f9f-2d1c-4cc4-ba38-e9161447ff4f", "embedding": null, "metadata": {"page_label": "249", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4bc0fcc8-190d-4968-892c-df3ca7512fe8", "node_type": "4", "metadata": {"page_label": "249", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "43d39f88e4c8c91fbc0c5b9b682b5628016a9ed798efe34be95c4e9170cae3bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4de6e89-0921-4f20-aa7e-d7270cb7ae35", "node_type": "1", "metadata": {"page_label": "248", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "cf8fac0fb6f4b0156c49bbe3a3bb777efce4c659f20758ec19826645bc85b55e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22cc2716-bff3-4348-aee1-23518b0c00c1", "node_type": "1", "metadata": {"page_label": "249", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "013a4d2b66c1e0dd2d558630226b81cd5891613a61d3da1ee8e8d9bed40e1c94", "class_name": "RelatedNodeInfo"}}, "hash": "cf002d95d5d2fe47e4be5026559094546c93418900531f06ecc5f628c625f1e9", "text": "Hereditary GI Cancer Syndromes\n\u00a9 2015 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY\n 249\n\u22651 cm should be done when possible. Subsequent colonoscopy \nintervals should be determined by the number and size of pol-yps, as well as the number of concurrent adenomas, but generally should be performed every 1\u20133 years.\n    \nRecommendation   \n    20.  Indications for surgery for SPS include an inability to control \nthe growth of serrated polyps, or the development of cancer. Colectomy and IRA is a reasonable option given the risks of \nmetachronous neoplasia (conditional recommendation, low \nquality of evidence).\n    \nSummary of evidence   \n    Surgery is advised when polyps cannot be endoscopically con-\ntrolled ( 256 ). Prophylactic or therapeutic colectomy is indicated with an inability to control the growth of serrated polyps, the presence of high-grade dysplasia in a serrated polyp that cannot be removed in its entirety, or the development of cancer. Subtotal colectomy and IRA is a reasonable option given the risks of me-tachronous neoplasia.\n     Surveillance and management of extracolonic malignancies\n   Recommendation   \n    21.  Th  ere is no evidence to support extracolonic cancer surveil-\nlance for SPS at this time. Screening recommendations for family members are currently unclear pending further data and should be individualized based on results of baseline evaluations in family members (conditional recommendation, very low quality of evidence).\n    \nSummary of evidence   \n    Th e data on extracolonic cancers in SPS are insuffi   cient at this \ntime, although Win  et al.   ( 250 ) reported an increased risk of colo-\nrectal and pancreas cancer in relatives of patients with SPS. How-ever, PC was not found in any of the 115 patients with SPS in a study by Kalady  et al.   ( 249 ). In a larger study of 105 patients with \nSPS and 341 FDRs, no increased risk of extracolonic malignancies were seen in patients or their relatives ( 257 ).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22cc2716-bff3-4348-aee1-23518b0c00c1": {"__data__": {"id_": "22cc2716-bff3-4348-aee1-23518b0c00c1", "embedding": null, "metadata": {"page_label": "249", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4bc0fcc8-190d-4968-892c-df3ca7512fe8", "node_type": "4", "metadata": {"page_label": "249", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "43d39f88e4c8c91fbc0c5b9b682b5628016a9ed798efe34be95c4e9170cae3bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9f87f9f-2d1c-4cc4-ba38-e9161447ff4f", "node_type": "1", "metadata": {"page_label": "249", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "cf002d95d5d2fe47e4be5026559094546c93418900531f06ecc5f628c625f1e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e0166c7-fd61-47c7-a387-935f88dcbf45", "node_type": "1", "metadata": {"page_label": "249", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "880033c548fcb11263e9bbc46ea53c0998c8d9d508323fdd3037f61b982900ec", "class_name": "RelatedNodeInfo"}}, "hash": "013a4d2b66c1e0dd2d558630226b81cd5891613a61d3da1ee8e8d9bed40e1c94", "text": "Hazewinkel  et al.   \n( 257 ) concluded that extracolonic cancer in SPS and their FDRs is not increased compared with the general population.\n  Familial cases of SPS have been reported, although infrequently \nin most studies. However, a recent prospective study of 78 FDRs of patients with SPS found that the incidence of SPS was 32% ( 258 ). Only one of these relatives was diagnosed with CRC during screening colonoscopy ( 258 ). Other studies have reported a family history of CRCs in 50\u201359% of FDRs of patients with SPS ( 241,248 ). In one of these studies, only 2 (5%) of the 38 probands with SPS \nreported a family history of SPS ( 241 ). In a recent study, Boparai \n et al.   ( 259 ) FDRs of serrated polyposis patients had fi  ve times the \nincidence of CRC, suggestive of a hereditary disorder.\n  Surveillance recommendations fo r individuals with a family his-\ntory of serrated polyposis are currently unclear, pending further data. It is reasonable to screen FDRs at the youngest age of onset of serrated polyposis diagnosis (aft  er the exclusion of other genetic \ncauses), and subsequently per colonoscopic fi  ndings ( 248 ). Th  e   Although the mechanisms are not entirely clear, there seems to \nbe a strong association between smoking and SPS ( 247 ). In a small study of 32 SPS patients, the rate of current smoking was 47%, and this was signifi  cantly higher than the rate in colonoscopy controls \n(17%) and population controls (12%) ( 247 ). In another study of patients with multiple serrated polyps, many of whom met criteria for SPS, 51 of 88 (58%) were ever smokers ( 248 ). It is speculated that smoking, although not the cause of SPS, does intensify the phenotypic expression and therefore may be a modifi  able risk fac-\ntor for colorectal lesions( 247 ).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e0166c7-fd61-47c7-a387-935f88dcbf45": {"__data__": {"id_": "1e0166c7-fd61-47c7-a387-935f88dcbf45", "embedding": null, "metadata": {"page_label": "249", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4bc0fcc8-190d-4968-892c-df3ca7512fe8", "node_type": "4", "metadata": {"page_label": "249", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "43d39f88e4c8c91fbc0c5b9b682b5628016a9ed798efe34be95c4e9170cae3bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22cc2716-bff3-4348-aee1-23518b0c00c1", "node_type": "1", "metadata": {"page_label": "249", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "013a4d2b66c1e0dd2d558630226b81cd5891613a61d3da1ee8e8d9bed40e1c94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e30a455b-12ae-42a7-b392-71dc0b1d1d04", "node_type": "1", "metadata": {"page_label": "249", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "17702c550ebe3e1e1a8eb62a79e7270e5161b43eb8bcc15d004cf2f91b26cd0b", "class_name": "RelatedNodeInfo"}}, "hash": "880033c548fcb11263e9bbc46ea53c0998c8d9d508323fdd3037f61b982900ec", "text": "Various studies have shown that a family history of colorectal \nand other cancers is common and even increased in patients with SPS. Some have suggested that this supports a hereditary etiology to SPS ( 249,250 ). However, nongenetic causes, referral bias, and chance occurrence should not be overlooked as substantial factors in these studies ( 251 ).\n      Surveillance and management of CRC\n   Recommendation   \n    19.  Patients with serrated polyposis should undergo colonos-\ncopies every 1\u20133 years with attempted removal of all polyps >5 mm diameter (conditional recommendation, low quality of evidence).\n    \nSummary of evidence   \n    It is now well established that SPS is associated with an increased \nrisk for CRC ( 252 ). Th  e specifi  c lifetime risk of colorectal in SPS is \nnot well defi  ned as most study cohorts to date are relatively small, \nphenotypically diverse, and subject to referral bias. It has been es-timated that the lifetime CRC risk is >50%, although this is likely an overestimate ( 243 ). CRC was diagnosed in 5 of 77 (6.5%) SPS patients aft  er a median follow-up time of 1.3 years ( 253 ). Four \nout of fi  ve of these CRCs were found in serrated polyps <20 mm \n( 253 ). Boparai  et al.   ( 253 ) estimated that the 5-year risk of CRC \nunder surveillance was 7%. In two large descriptive studies of SPS patients, the majority of index cases displayed a pancolonic distri-bution of polyps (89\u201396%), the presence of adenomas (78\u201380%), a diagnosis of CRC (31\u201342%) ,and a mean age at diagnosis of 48 years ( 250,254 ). In a smaller prospective series of 13 hyperplas-tic polyposis syndrome patients, 5 (71%) of the 7 CRCs reported were located in the right colon ( 237 ). In another retrospective study of 77 patients with SPS, 22 (28.6%) were diagnosed with CRC at their baseline colonoscopy.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e30a455b-12ae-42a7-b392-71dc0b1d1d04": {"__data__": {"id_": "e30a455b-12ae-42a7-b392-71dc0b1d1d04", "embedding": null, "metadata": {"page_label": "249", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4bc0fcc8-190d-4968-892c-df3ca7512fe8", "node_type": "4", "metadata": {"page_label": "249", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "43d39f88e4c8c91fbc0c5b9b682b5628016a9ed798efe34be95c4e9170cae3bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e0166c7-fd61-47c7-a387-935f88dcbf45", "node_type": "1", "metadata": {"page_label": "249", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "880033c548fcb11263e9bbc46ea53c0998c8d9d508323fdd3037f61b982900ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "489753a0-dc7b-4f3f-b57a-229f5a66a947", "node_type": "1", "metadata": {"page_label": "250", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "fecedac661b53ad6d7b2b145450ab2e43634a01a3039a3a9ad6d9e237ffbd186", "class_name": "RelatedNodeInfo"}}, "hash": "17702c550ebe3e1e1a8eb62a79e7270e5161b43eb8bcc15d004cf2f91b26cd0b", "text": "Five (6.5%) more patients developed CRC while being followed for hyperplastic polyposis syndrome ( 253 ). Synchronous adenomas are found in the major-ity of patients with SPS ( 248,252 ). Conventional adenomas were more frequently found in patients with CRC than those without \n( 254 ). In a study of CRCs from SPS patients, 18 of 39 (46%) had \nthe  BRAF   V600E mutation, 2 of 40 (5.0%) had  KRAS   mutations, \nand 17 of 45 (38%) had loss of imm unohistochemistry expression \nof  MLH1   and  PMS2   ( 255 ).\n  Th ere are no available studies regarding the eff  ectiveness of sur-\nveillance in SPS. Based on the reported colon cancer risks, colo-noscopy and polypectomy is recommended for individuals who fulfi ll the WHO defi  nition of SPS. Complete clearance of all polyps \nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "489753a0-dc7b-4f3f-b57a-229f5a66a947": {"__data__": {"id_": "489753a0-dc7b-4f3f-b57a-229f5a66a947", "embedding": null, "metadata": {"page_label": "250", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "72a1c3c5-1335-4c75-b26b-1803c0d2eaff", "node_type": "4", "metadata": {"page_label": "250", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "915ef2e304b4334acffa952c75138b3a0b4422703c07a05c99764f3ea633684d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e30a455b-12ae-42a7-b392-71dc0b1d1d04", "node_type": "1", "metadata": {"page_label": "249", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "17702c550ebe3e1e1a8eb62a79e7270e5161b43eb8bcc15d004cf2f91b26cd0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca053614-ff23-4f9e-adcb-fe7da617b7b3", "node_type": "1", "metadata": {"page_label": "250", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "e0260eab0a4c32f77c4b7e54f9d30fb13e4d91ad12c1715cc383d44e9f2f525a", "class_name": "RelatedNodeInfo"}}, "hash": "fecedac661b53ad6d7b2b145450ab2e43634a01a3039a3a9ad6d9e237ffbd186", "text": "Syngal  et al.  \nThe American Journal of GASTROENTEROLOGY VOLUME 110 | FEBRUARY 2015    www.amjgastro.com 250\nfrequency and age of initiation of colonoscopic screening in at-risk \nfamily members of patients with SPS is less clear. Oquinena  et al.   \n( 258 ) recommended that colonoscopy in FDRs start at age 35 years (or 10 years before the youngest age of SPS onset in the family, whichever comes fi  rst) and then every 3\u20135 years if no polyps are \nfound. If the FDRs are found to meet SPS criteria 1 or 3, annual surveillance should be performed or every 2 years if only SPS cri-teria 2 is met ( 258 ). On the contrary, the National Comprehensive Cancer Network (NCCN) recommends that FDRs should have \ncolonoscopy at the earliest of the following: (i) age 40 years, (ii) \nsame age as the youngest SPS di agnosis in the family, and (iii) 10 \nyears before CRC in the family in a patient with SPS ( 260 ). Further work is ongoing to better defi  ne the cancer risks in probands and \ntheir relatives so that accurate risk stratifi  cation and risk recom-\nmendations can be made regarding SPS.\n     Prevention strategies\n   Summary of evidence   \n    Observational studies suggest a strong association between \nsmoking and SPS. Independent studies have reported signifi  cant \nsmoking history in patients with SPS, leading to the assumption that smoking may be a modifi  able risk factor in the pathogenic \npathway of colorectal lesions ( 248,250 ).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca053614-ff23-4f9e-adcb-fe7da617b7b3": {"__data__": {"id_": "ca053614-ff23-4f9e-adcb-fe7da617b7b3", "embedding": null, "metadata": {"page_label": "250", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "72a1c3c5-1335-4c75-b26b-1803c0d2eaff", "node_type": "4", "metadata": {"page_label": "250", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "915ef2e304b4334acffa952c75138b3a0b4422703c07a05c99764f3ea633684d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "489753a0-dc7b-4f3f-b57a-229f5a66a947", "node_type": "1", "metadata": {"page_label": "250", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "fecedac661b53ad6d7b2b145450ab2e43634a01a3039a3a9ad6d9e237ffbd186", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0af86f6f-684a-4de2-8456-18785313fd2c", "node_type": "1", "metadata": {"page_label": "250", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "a4e3634affa33d171c04be0dd00e1178d63d5c1cfdcf9ba11d220971df914f22", "class_name": "RelatedNodeInfo"}}, "hash": "e0260eab0a4c32f77c4b7e54f9d30fb13e4d91ad12c1715cc383d44e9f2f525a", "text": "Hereditary pancreatic cancer\n   Clinical defi  nitions   \n     Summary statement   \n\u2022       Individuals should be considered to be at risk for familial \npancreatic adenocarcinoma if they: (i) have a known genetic syndrome associated with pancreatic cancer, including hereditary breast\u2013ovarian cancer syndrome, familial atypical multiple melanoma and mole syndrome (FAMMM), PJS, LS, or other gene mutations associated with an increased risk of pancreatic adenocarcinoma; (ii) have two relatives with pancreatic adenocarcinoma, where one is a FDR; (iii) have \nthree or more relatives with pancreatic cancer; or (iv) have a history of hereditary pancreatitis. \n     Summary of evidence  \n    Th e known hereditary syndromes associated with an increased \nrisk for developing PC along with their relative risk for devel-oping PC are shown in  Table 12  . PC is one of the key cancers \nused in determining whether a patient\u2019s family history warrants \ngenetic risk evaluation for hereditary breast and ovarian cancer \nsyndrome according to the NCCN Guidelines for Genetic/Famil-ial High-Risk Assessment: Breast and Ovarian ( 3 ). Referral for genetic assessment for FAMMM syndrome should be considered in a PC patient with a personal or family history of melanoma or multiple dysplastic nevi ( 261 ). Patients who meet the afore-mentioned criteria for LS, PJS, or FAP may also be at increased risk for PC. Consideration for genetic counseling for testing for hereditary pancreatitis is based on expert opinion and warranted for PC patients with a personal history of at least 2 attacks of acute pancreatitis of unknown etiology, a family history of pancreatitis, or early-age onset chronic pancreatitis ( 262,263 ).\n  Th e risk for development of PC in those patients with an inher-\nited predisposition for PC development is shown in  Table 12  . \nTh e risk is highest in hereditary pancreatitis (53-fold risk) ( 264 ), \nPJS (132-fold risk) ( 197 ), and FAMMM families with a known  CDKN2A   mutation (13- to 39-fold risk) ( 265\u2013267 ).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0af86f6f-684a-4de2-8456-18785313fd2c": {"__data__": {"id_": "0af86f6f-684a-4de2-8456-18785313fd2c", "embedding": null, "metadata": {"page_label": "250", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "72a1c3c5-1335-4c75-b26b-1803c0d2eaff", "node_type": "4", "metadata": {"page_label": "250", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "915ef2e304b4334acffa952c75138b3a0b4422703c07a05c99764f3ea633684d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca053614-ff23-4f9e-adcb-fe7da617b7b3", "node_type": "1", "metadata": {"page_label": "250", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "e0260eab0a4c32f77c4b7e54f9d30fb13e4d91ad12c1715cc383d44e9f2f525a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc60bb06-4f3e-4669-8a1b-804761b19e9b", "node_type": "1", "metadata": {"page_label": "250", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "93d9a947ef2f35c2e4c9c9d431f91c1105251408f58978cc1919ebb4a86539e5", "class_name": "RelatedNodeInfo"}}, "hash": "a4e3634affa33d171c04be0dd00e1178d63d5c1cfdcf9ba11d220971df914f22", "text": "Th  e risk is not \nas great for  BRCA1   (~2-fold) ( 268 ),  BRCA2   (3- to 9-fold) ( 269,270 ), \nLS (9- to 11-fold) ( 71,271 ), and  ATM   (~3-fold) ( 272 ) mutation car-\nriers based on registry data. Th  ere are currently no data available \non the risk of developing PC in  PALB2   mutation carriers.\n  Familial pancreatic cancer (FPC) has been defi  ned by consen-\nsus opinion as families with \u22652 FDRs relatives who do not meet criteria for a known PC-associated hereditary syndrome ( 262 ). Case reports fi  rst demonstrated families with an excess number \nof PC cases. Best estimates from case\u2013control and cohort studies \n Table 12  .", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc60bb06-4f3e-4669-8a1b-804761b19e9b": {"__data__": {"id_": "bc60bb06-4f3e-4669-8a1b-804761b19e9b", "embedding": null, "metadata": {"page_label": "250", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "72a1c3c5-1335-4c75-b26b-1803c0d2eaff", "node_type": "4", "metadata": {"page_label": "250", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "915ef2e304b4334acffa952c75138b3a0b4422703c07a05c99764f3ea633684d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0af86f6f-684a-4de2-8456-18785313fd2c", "node_type": "1", "metadata": {"page_label": "250", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "a4e3634affa33d171c04be0dd00e1178d63d5c1cfdcf9ba11d220971df914f22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eaad1912-b8bb-435f-92e5-f19148d5e2ab", "node_type": "1", "metadata": {"page_label": "251", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "73d4dcdf342723800042acd704dc1edc490120269ffc73081017ad3279672a84", "class_name": "RelatedNodeInfo"}}, "hash": "93d9a947ef2f35c2e4c9c9d431f91c1105251408f58978cc1919ebb4a86539e5", "text": "Best estimates from case\u2013control and cohort studies \n Table 12  .     Syndromes associated with pancreatic adenocarcinoma and risk of developing pancreatic cancer \n  Syndrome    Relative risk of pancreatic cancer    Gene    References  \n Familial atypical multiple melanoma and mole (FAMMM)  13- to 39-fold   CDKN2A    ( 265\u2013267 ) \n Familial breast and ovarian  2-fold  3- to 9-fold   BRCA1     BRCA2    ( 268 )  ( 269,270 ) \n Fanconi anemia, breast CA  Unknown   PALB2     \n Familial adenomatous polyposis (FAP)  5-fold   APC   ( 334 ) \n Lynch  9- to 11-fold   MLH1, MSH2     MSH6, PMS2    ( 71,362 ) \n Peutz\u2013Jeghers syndrome  Up to 132-fold   STK11/LKB1    ( 197 ) \n Li\u2013Fraumeni  Unknown   p53    \n Hereditary pancreatitis  53-fold   PRSS1    ( 264 ) \n Ataxia\u2013telangiectasia  3-fold   ATM   ( 272 ) \n Familial pancreatic cancer:       \n  1 Or 2 \ufb01  rst-degree relatives  4- to 7-fold  See  Table 13    ( 276,277 ) \n  \u22653 First-degree relatives  17- to 32-fold  Majority unknown   \nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eaad1912-b8bb-435f-92e5-f19148d5e2ab": {"__data__": {"id_": "eaad1912-b8bb-435f-92e5-f19148d5e2ab", "embedding": null, "metadata": {"page_label": "251", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e652a10a-ba4e-43e4-9d91-6a2c478b54f3", "node_type": "4", "metadata": {"page_label": "251", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "2a1b17e6b4343230bc11c380e66698358fd48f324711f22c913da0a6e11df693", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc60bb06-4f3e-4669-8a1b-804761b19e9b", "node_type": "1", "metadata": {"page_label": "250", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "93d9a947ef2f35c2e4c9c9d431f91c1105251408f58978cc1919ebb4a86539e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cf3a57d-51db-49d4-92d0-a8b583d09504", "node_type": "1", "metadata": {"page_label": "251", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "a26c440a63f6a4e9188f4c6af34f6f94f85e18fa29a47a59799b64f92ee1d634", "class_name": "RelatedNodeInfo"}}, "hash": "73d4dcdf342723800042acd704dc1edc490120269ffc73081017ad3279672a84", "text": "Hereditary GI Cancer Syndromes\n\u00a9 2015 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY\n 251\nsuggest that up to 10% of PC patients will have a fi  rst- or second-\ndegree relative with PC ( 273,274 ). Th  e risk for developing PC in \nFPC kindreds is dependent on the number of FDRs as shown in  Table 12  . Segregation analysis of families with multiple PC cases \nhas shown an autosomal-dominant inheritance pattern and a 32% lifetime risk for PC development at age 85 years ( 275 ). Th  e \nprospective risk for PC development in individuals with FPC is related to the number of FDRs with PC in the kindred. Th  ose with \none or two PC-aff  ected FDRs had a risk ranging from 4- to 7-fold, \nalthough whereas those with \u22653 PC-aff  ected FDRs had a risk rang-\ning from 17 to 32-fold ( 262,276,277 ). Th  e complexity in cancer risk \nassessment has led to the development of a risk prediction model (PancPRO) to provide more detailed risk estimates for individuals from FPC kindreds that take into account the ages at diagnosis, family size, and the relationship between family members ( 278 ).\n      Genetic etiology\n   Summary statement   \n\u2022       Genetic testing of patients with suspected FPC should \ninclude analysis  of BRCA1/2  ,  CDKN2A  ,  PALB2  , and  ATM  . \nEvaluation for PJS, LS, and hereditary pancreatitis-associated genes should be considered if other component personal and/or family history criteria are met for the syndrome.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cf3a57d-51db-49d4-92d0-a8b583d09504": {"__data__": {"id_": "6cf3a57d-51db-49d4-92d0-a8b583d09504", "embedding": null, "metadata": {"page_label": "251", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e652a10a-ba4e-43e4-9d91-6a2c478b54f3", "node_type": "4", "metadata": {"page_label": "251", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "2a1b17e6b4343230bc11c380e66698358fd48f324711f22c913da0a6e11df693", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eaad1912-b8bb-435f-92e5-f19148d5e2ab", "node_type": "1", "metadata": {"page_label": "251", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "73d4dcdf342723800042acd704dc1edc490120269ffc73081017ad3279672a84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59d995b0-8ede-4b0f-9ad0-b3319356c9fd", "node_type": "1", "metadata": {"page_label": "251", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "df36eb7e59f99349d76df28b9e0722e6324c300a79ee9c20fdc80037003c3376", "class_name": "RelatedNodeInfo"}}, "hash": "a26c440a63f6a4e9188f4c6af34f6f94f85e18fa29a47a59799b64f92ee1d634", "text": "Summary of evidence   \n    In attempts to discover the cause of their PC susceptibility, studies \nhave been performed on familial FPC kindreds for known candi-\ndate genes that fall into two groups: (i) genes that cause inherited disorders that are associated with increased risk of PC develop-ment (e.g.,  BRCA1  ,  BRCA2  , and  CDKN2A  ) even in the absence \nof meeting criteria for these hereditary syndromes ( 279\u2013281 ) and (ii) recently described genes such as  palladin   ( PALLD  ) ( 282 ), \n ATM   ( 283 ), and  PALB2   ( 284,285 ) that were discovered by whole \ngenome sequencing or linkage analysis of FPC kindred(s). As shown in  Table 13  , results vary depending on the study popula-\ntion with mutations, for example, in  BRCA1   ranging from 0 to 6% ( 281,286 ),  BRCA2   ranging from 0 to 6% ( 281,287,288 ),  CDKN2A   \nranging from 0 to 20% ( 280,281,288 ), and  PALB2   ranging from \n0 to 5% ( 281,285,288 ).  PALLD   was found to be the susceptibility \nmutation in a large well-characterized family at the University of Washington ( 282 ); however, subsequent studies have not found this gene to be responsible for other FPC families ( 289,290 ). Re-sults from a recent study found  ATM   mutations in 2.4% of FPC \nfamilies ( 283 ). Known genetic mutations are responsible for ~20% of the familial clustering of pancreatic cancer. Th  us, in the major-\nity of cases, the responsible inherited factor(s) accounting for the \nincreased number of PC cases in these kindreds have not been identifi  ed.\n     Surveillance and management\n   Recommendations  \n    22.  Surveillance of individuals with a genetic predisposition for \npancreatic adenocarcinoma should ideally be performed in experienced centers utilizing a multidisciplinary approach and under research conditions.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59d995b0-8ede-4b0f-9ad0-b3319356c9fd": {"__data__": {"id_": "59d995b0-8ede-4b0f-9ad0-b3319356c9fd", "embedding": null, "metadata": {"page_label": "251", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e652a10a-ba4e-43e4-9d91-6a2c478b54f3", "node_type": "4", "metadata": {"page_label": "251", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "2a1b17e6b4343230bc11c380e66698358fd48f324711f22c913da0a6e11df693", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cf3a57d-51db-49d4-92d0-a8b583d09504", "node_type": "1", "metadata": {"page_label": "251", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "a26c440a63f6a4e9188f4c6af34f6f94f85e18fa29a47a59799b64f92ee1d634", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10d8a31a-564c-4924-91ee-30a43a1192aa", "node_type": "1", "metadata": {"page_label": "251", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "d510c481ad2ee547641af8bec04876b9f767597f1df833b139e95cc143d35fe3", "class_name": "RelatedNodeInfo"}}, "hash": "df36eb7e59f99349d76df28b9e0722e6324c300a79ee9c20fdc80037003c3376", "text": "Th  ese individuals should be \nknown mutation carriers from hereditary syndromes asso-ciated with increased risk of PC (Peutz\u2013Jeghers, hereditary pancreatitis, FAMMM) or members of FPC kindreds with a PC-aff  ected FDR. Because of a lower relative risk for pancre-\natic adenocarcinoma development in  BRCA1  ,  BRCA2  ,  PALB2  , \n ATM  , and LS families, surveillance should be limited to mu-\ntation carriers with a fi  rst- or second-degree relative aff  ected \nwith PC (conditional recommendation; very low quality of \nevidence).\n  23.  Surveillance for PC should be with endoscopic ultrasound and/\nor MRI of the pancreas annually starting at age 50 years, or 10 years younger than the earliest age of PC in the family. Patients with PJS should start surveillance at age 35 years (conditional recommendation, very low quality of evidence).\n    \nSummary of evidence   \n    It is not feasible to screen for PC because of its low incidence in \nthe general population with an estimated lifetime risk in the Unit-ed States of 1.4% in 2013 ( 291 ). Expert opinion has recommended that individuals with a relative risk of more than fi  vefold when \ncompared with the general population warrant consideration for PC surveillance ( 73,262,292 ), with the aim to detect early pan-creatic lesions that can be intervened upon. Two such precursor lesions of PC include intraductal papillary mucinous neoplasms and pancreatic intraepithelial neoplasia ( 293 ).\n  Based on this degree of risk, candidates for PC surveillance \nare limited at this time to unaff  ected individuals from pancreatic \ncancer-prone families who are candidates for pancreatic surgery. \nUnlike colon cancer, in which colonoscopy has been proven to be \nan eff  ective screening tool to reduce colon cancer-related mortality, \nthere is no proven strategy for PC ( 294 ). As stated in a recent Inter-national Cancer of the Pancreas Screening Consortium summit ( 73 ), recommendations for screening patients with a family history of PC \u201care primarily based on evidence of increased risk, rather than a proven effi   cacy of screening.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10d8a31a-564c-4924-91ee-30a43a1192aa": {"__data__": {"id_": "10d8a31a-564c-4924-91ee-30a43a1192aa", "embedding": null, "metadata": {"page_label": "251", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e652a10a-ba4e-43e4-9d91-6a2c478b54f3", "node_type": "4", "metadata": {"page_label": "251", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "2a1b17e6b4343230bc11c380e66698358fd48f324711f22c913da0a6e11df693", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59d995b0-8ede-4b0f-9ad0-b3319356c9fd", "node_type": "1", "metadata": {"page_label": "251", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "df36eb7e59f99349d76df28b9e0722e6324c300a79ee9c20fdc80037003c3376", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c4a741f-f118-440b-9c73-4bd61d421d1c", "node_type": "1", "metadata": {"page_label": "252", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "4e8d8db51bd09a57fadafa13924d5c443861d3efb939500fb21e981557cfc543", "class_name": "RelatedNodeInfo"}}, "hash": "d510c481ad2ee547641af8bec04876b9f767597f1df833b139e95cc143d35fe3", "text": "\u201d In light of these acknowledged \nlimitations in PC screening, expert opinion has repeatedly empha- Table 13  .     Yield for germline mutations in familial pancreatic \ncancer (FPC) kindreds without criteria for known genetic syndromes  \na   \n  Mutation    Yield of testing    References  \n  BRCA1    0 to 6%  ( 281,286 ) \n  BRCA2    0 to 6%  ( 281,287,288 ) \n  CDKN2A    0 to 20%  ( 280,281,288 ) \n  PALB2    0 to 5%  ( 281,285,288 ) \n  ATM   2.4%  ( 283 ) \n  STK11    0%  ( 288 ) \n  PALLD    0%  ( 289,363 ) \n   a   Unknown for Lynch syndrome, familial adenomatous polyposis (FAP), and \nLi\u2013Fraumeni syndrome.  \nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c4a741f-f118-440b-9c73-4bd61d421d1c": {"__data__": {"id_": "9c4a741f-f118-440b-9c73-4bd61d421d1c", "embedding": null, "metadata": {"page_label": "252", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1bc37f17-7742-409c-8d61-1d45f5c3b01a", "node_type": "4", "metadata": {"page_label": "252", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "3b686bd0124c74ab80589d77158eae16b55b8b96ea732cb94f26063c89f5c5bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10d8a31a-564c-4924-91ee-30a43a1192aa", "node_type": "1", "metadata": {"page_label": "251", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "d510c481ad2ee547641af8bec04876b9f767597f1df833b139e95cc143d35fe3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1792aa38-bf95-4e63-b115-b8ce074da9e2", "node_type": "1", "metadata": {"page_label": "252", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "2b30a93fd7e8c36bf61e5c58ec3c832cd4c38088a13b66b6b979b2968ea4ceba", "class_name": "RelatedNodeInfo"}}, "hash": "4e8d8db51bd09a57fadafa13924d5c443861d3efb939500fb21e981557cfc543", "text": "Syngal  et al.  \nThe American Journal of GASTROENTEROLOGY VOLUME 110 | FEBRUARY 2015    www.amjgastro.com 252\n     Hereditary gastric cancer\n   Hereditary diff  use gastric cancer   \n     Clinical defi  nitions  \n     Summary statement \n\u2022     Individuals with (i) \u22652 cases of diff  use gastric cancer, with at \nleast one diagnosed at <50 years, (ii) \u22653 cases of documented diff use cancer in fi  rst- or second-degree relatives independ-\nent of age of onset; (iii) diff  use gastric cancer diagnosed at \n<40 years; and (iv) a personal or family history of diff  use \ngastric cancer and lobular breast cancer with one diagnosed \nat <50 years should be evaluated for hereditary diff  use gastric \ncancer. \n    \nSummary of evidence  \n  It is estimated that there were \u223c 21,600 new cases of gastric can-\ncer in the United States in 2013 ( 303 ). Th  e lifetime risk for gastric \ncancer is \u223c 0.9% ( 303 ). Th  e majority of gastric cancer cases are spo-\nradic, but familial clustering is present in \u223c 10% of cases. Th  ere are \ntwo main types of gastric cancer: diff  use and intestinal. Intestinal-\ntype gastric cancer is a component tumor in LS, familial adeno-matous polyposis, and PJS. Th  ese syndromes have already been \ndescribed previously in this guideline, including the risks for gas-tric cancer, surveillance guidelines fo r gastric cancer, and genetic \ntesting recommendations, and therefore intestinal forms of gastric cancer will not be discussed in this section.\n  Th e only hereditary cancer susceptibility syndrome known to \ncause diff  use gastric cancer is hereditary diff  use gastric cancer \n(HDGC). Th  is condition was originally described in three Maori \nfamilies with autosomal-dominant diff  use gastric cancer in New \nZealand in 1964 ( 304 ). Approximately 1\u20133% of diff  use gastric \ncancers are attributable to HDGC.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1792aa38-bf95-4e63-b115-b8ce074da9e2": {"__data__": {"id_": "1792aa38-bf95-4e63-b115-b8ce074da9e2", "embedding": null, "metadata": {"page_label": "252", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1bc37f17-7742-409c-8d61-1d45f5c3b01a", "node_type": "4", "metadata": {"page_label": "252", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "3b686bd0124c74ab80589d77158eae16b55b8b96ea732cb94f26063c89f5c5bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c4a741f-f118-440b-9c73-4bd61d421d1c", "node_type": "1", "metadata": {"page_label": "252", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "4e8d8db51bd09a57fadafa13924d5c443861d3efb939500fb21e981557cfc543", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ac72ee7-ee20-44c9-8618-7c5a11f4d99e", "node_type": "1", "metadata": {"page_label": "252", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "4c2d5d64e27e54e349055b8e445a694e410570df40e79abb8b9f3ee56f7add80", "class_name": "RelatedNodeInfo"}}, "hash": "2b30a93fd7e8c36bf61e5c58ec3c832cd4c38088a13b66b6b979b2968ea4ceba", "text": "A genetic evaluation for HDGC is indicated for families having individuals with (i) \u22652 cases of diff use gastric cancer, with at least one diagnosed at <50 years, \n(ii) \u22653 cases of documented diff  use cancer in fi  rst- or second-\ndegree relatives independent of age of onset; (iii) diff  use gastric \ncancer diagnosed at <40 years; and (iv) a personal or family history of diff  use gastric cancer and lobular breast cancer with one diag-\nnosed at <50 years ( 305 ).\n      Genetic etiology\n   Summary statement   \n\u2022       Genetic testing of individuals who fulfi  ll HDGC clinical \ncriteria should include analysis of  CDH1   mutations. \n     Summary of the evidence   \n    Mutations in the E-cadherin gene ( CDH1  ) were found to be the \ncause of HDGC in 1998 through linkage analysis ( 306 ). Th  e  CDH1   \ngene encodes for the cell-to-cell adhesion protein E-cadherin. \nTh is initial fi  nding led to subsequent studies confi  rming the \npresence of  CDH1   mutations in other gastric cancer families \n( 307\u2013309 ). Genetic testing for the  CDH1   gene is indicated for \nindividuals from families who meet HDGC criteria and should be initiated in an aff  ected individual if at all possible.  CDH1   test-\ning should include sequencing analysis (3\u201350% of mutations are sequence changes) and deletion/duplication analysis (4% of sized the importance of performing PC surveillance in the setting of active peer-reviewed research protocols by experienced centers utilizing a multidisciplinary team approach ( 73,262,292 ).\n  Attempts at a unifi  ed recommendation for age to commence \nscreening have been unsuccessful with no clear consensus achieved despite being addressed at two international meetings ( 73,262 ). Two recently reported surveillance studies have shown that the majority of signifi  cant lesions have been found in older patients \n( 295,296 ). Canto  et al.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ac72ee7-ee20-44c9-8618-7c5a11f4d99e": {"__data__": {"id_": "2ac72ee7-ee20-44c9-8618-7c5a11f4d99e", "embedding": null, "metadata": {"page_label": "252", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1bc37f17-7742-409c-8d61-1d45f5c3b01a", "node_type": "4", "metadata": {"page_label": "252", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "3b686bd0124c74ab80589d77158eae16b55b8b96ea732cb94f26063c89f5c5bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1792aa38-bf95-4e63-b115-b8ce074da9e2", "node_type": "1", "metadata": {"page_label": "252", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "2b30a93fd7e8c36bf61e5c58ec3c832cd4c38088a13b66b6b979b2968ea4ceba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0b63f00-acb3-4148-8865-2ac10f9a491f", "node_type": "1", "metadata": {"page_label": "252", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c19e10cd8f5fe33e686c3a746c51cc30e4691ba1933a98a52d5e680846121d40", "class_name": "RelatedNodeInfo"}}, "hash": "4c2d5d64e27e54e349055b8e445a694e410570df40e79abb8b9f3ee56f7add80", "text": "Canto  et al.   ( 295 ) reported in their large multicenter \nsurveillance study of high-risk individuals that the prevalence \nof pancreatic lesions was age related with a signifi  cant diff  erence \nfound in the number of lesions detected between patients <50 years old when compared with patients \u226550 years old. Furthermore, all pancreatic lesions with high-grade dysplasia were in patients >65 years of age. Ludwig  et al.   ( 296 ) also reported diff  erences in fi  nd-\ning a signifi  cant abnormality based on age, with a yield of 35% in \nthose >65 years old as compared with only 3% in those \u226465 years \nold. Several studies in both the hereditary and sporadic setting have found that smokers have an earlier age of PC diagnosis as compared with nonsmokers ( 297\u2013299 ), but no data exist regarding whether smoking status should aff  ect surveillance strategy.\n  Endoscopic ultrasound and MRI/magnetic resonance cholangi-\nopancreatography are the preferred imaging modalities for surveil-lance as they do not involve the use of radiation like CT scanning and are signifi  cantly more accurate in fi  nding pancreatic lesions, \nparticularly small cystic lesions, based on data from CAPS3 study ( 295 ).\n    \nRecommendation   \n    24.  Because of the increased risk for PC development when com-\npared with a pancreatic cyst in the sporadic setting, cystic lesion(s) of the pancreas detected during surveillance of a hereditary pancreatic cancer-prone family member requires evaluation by centers experienced in the care of these high-risk individuals. Determining when surgery is required for pancreatic lesions is diffi   cult and is best individualized aft  er \nmultidisciplinary assessment (conditional recommendation, low quality of evidence).\n    \nSummary of evidence   \n    Th e most common fi  ndings in surveillance studies are cystic le-\nsions in the pancreas ( 295,300 ). Management of these cysts is un-clear as similar to cysts in a nonhereditary setting, most are benign or just have low-grade dysplasia ( 73,292 ).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0b63f00-acb3-4148-8865-2ac10f9a491f": {"__data__": {"id_": "e0b63f00-acb3-4148-8865-2ac10f9a491f", "embedding": null, "metadata": {"page_label": "252", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1bc37f17-7742-409c-8d61-1d45f5c3b01a", "node_type": "4", "metadata": {"page_label": "252", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "3b686bd0124c74ab80589d77158eae16b55b8b96ea732cb94f26063c89f5c5bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ac72ee7-ee20-44c9-8618-7c5a11f4d99e", "node_type": "1", "metadata": {"page_label": "252", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "4c2d5d64e27e54e349055b8e445a694e410570df40e79abb8b9f3ee56f7add80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9012f71b-4b25-460c-a8c5-8a7911d01f9a", "node_type": "1", "metadata": {"page_label": "253", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "b9060e85cbf6261baa0992166c95e30fcaac47904cd43a86ff39e22dee86adb0", "class_name": "RelatedNodeInfo"}}, "hash": "c19e10cd8f5fe33e686c3a746c51cc30e4691ba1933a98a52d5e680846121d40", "text": "Recent consensus rec-ommendations propose that these patients be followed according to international consensus guidelines for sporadic branch duct in-traductal papillary mucinous neoplasms ( 301 ), although the ma-\njority agreed that surgery should be considered for those branch \nduct intraductal papillary mucinous neoplasms \u22652 cm in size ( 73 ).\n    Prevention strategies   .     As smoking has been shown to be an inde-\npendent risk factor for PC in families with FPC, all high-risk indi-viduals should be counseled against smoking ( 302 ). In individuals with hereditary pancreatitis, in addition to smoking cessation, a low-fat diet should also be recommended.\nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9012f71b-4b25-460c-a8c5-8a7911d01f9a": {"__data__": {"id_": "9012f71b-4b25-460c-a8c5-8a7911d01f9a", "embedding": null, "metadata": {"page_label": "253", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "40fa6b97-cac6-4995-9694-37d6f39324b1", "node_type": "4", "metadata": {"page_label": "253", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "befe8a31855448908c12fea1e2b778c3903f5b719a050bc0d5d6432e6a184e80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0b63f00-acb3-4148-8865-2ac10f9a491f", "node_type": "1", "metadata": {"page_label": "252", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c19e10cd8f5fe33e686c3a746c51cc30e4691ba1933a98a52d5e680846121d40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8aec57d1-ac7c-4edd-8c17-8148492378cd", "node_type": "1", "metadata": {"page_label": "253", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "8580fe1fe6cbc8a7244e29f91475b304595fbbceda8dc3f4fd38aeba2c2ff02c", "class_name": "RelatedNodeInfo"}}, "hash": "b9060e85cbf6261baa0992166c95e30fcaac47904cd43a86ff39e22dee86adb0", "text": "Hereditary GI Cancer Syndromes\n\u00a9 2015 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY\n 253\nmutations are large rearrangements) ( 305 ). Between 10.5 and 47% \nof individuals meeting these criteria will be found to have a  CDH1   \nmutation ( 305 ). Once a mutation has been identifi  ed in a family, \nall at-risk individuals should be tested beginning at age 16 years, given the early ages of gastric cancer diagnosis in some families ( 310 ).\n     Surveillance and management\n   Recommendation  \n    25.  Management for patients with HDGC should include (i) pro-\nphylactic gastrectomy aft  er age 20 years (>80% risk by age 80 \nyears); (ii) breast cancer surveillance in women beginning at age 35 years with annual mammography and breast MRI and clinical breast examination every 6 months, and (iii) co-lonoscopy beginning at age 40 years for families that include colon cancer (conditional recommendation, low quality of evidence).\n    \nSummary of the evidence  \n    An international consortium study of 11 families with at least \n3 cases of diff  use gastric cancer who had tested positive for a  CDH1   \ngene mutation found that the lifetime risk of developing gastric cancer was 67% for males and 83% for females, with a mean age at diagnosis of 38\u201340 years of age (range, 14\u201385) ( 311 ). Females also had an increased risk of lobular breast cancer with a lifetime risk of 39% ( 311 ). A recent analysis by an international consortium suggests that the risk of gastric cancer is 80% for both men and \nwomen, and that the risk of lobular breast cancer is 60% in women \n( 312 ). Th  ere is some evidence that individuals with HDGC are \nalso at increased risk for signet ring cell colon cancer, although \nexact risk estimates are not known ( 313 ). Th  ere is a high rate of \ngastric cancer detection at the time of prophylactic gastrectomy.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8aec57d1-ac7c-4edd-8c17-8148492378cd": {"__data__": {"id_": "8aec57d1-ac7c-4edd-8c17-8148492378cd", "embedding": null, "metadata": {"page_label": "253", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "40fa6b97-cac6-4995-9694-37d6f39324b1", "node_type": "4", "metadata": {"page_label": "253", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "befe8a31855448908c12fea1e2b778c3903f5b719a050bc0d5d6432e6a184e80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9012f71b-4b25-460c-a8c5-8a7911d01f9a", "node_type": "1", "metadata": {"page_label": "253", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "b9060e85cbf6261baa0992166c95e30fcaac47904cd43a86ff39e22dee86adb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02dee197-b316-4cae-9083-0eca374863b4", "node_type": "1", "metadata": {"page_label": "253", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "70d8e22c0b0a83cbeb1a849d7584d6d5a7343971e58437f13dd4103ff20295e0", "class_name": "RelatedNodeInfo"}}, "hash": "8580fe1fe6cbc8a7244e29f91475b304595fbbceda8dc3f4fd38aeba2c2ff02c", "text": "A recent systematic review ( 305 ) found that of 220 previously re-\nported patients who tested positive for  CDH1   mutations, 76.8% \nunderwent a prophylactic gastrectomy whereas 23.2% declined to undergo prophylactic surgery. Among the 169 patients who underwent surgery, 62.7% had negative preoperative endoscopic biopsies and 12.4% (21) tested positive for cancer in their preop-erative screening. No information was available on 42 patients. Following gastrectomy, 87% (147) patients had positive histopa-thology results (including early lesions such as foci of signet ring \ncells to advanced lesions such as linitis plastica). Only 10% (17 \npatients) had negative fi  nal pathology and it was not reported in \n5 patients. It is important to identify both the esophageal and duodenal mucosa at the ends of the surgical specimen because there has been a report of gastric cancer aft  er prophylactic \ngastrectomy ( 314 ).\n  Gastric cancer surveillance may be used before prophylactic \ngastrectomy and for patients who decline gastrectomy, but the effi   -\ncacy is uncertain and should be used with caution. Given the pen-etrance of this condition, it is recommended that these individuals undergo screening every 6\u201312 months beginning 5\u201310 years before the earliest cancer diagnosis in the family ( 313,314 ). It is recom-mended that this is a detailed 30-min endoscopic examination of the gastric mucosa with multiple random biopsies ( 313,314 ). Some studies have shown an improved detection rate of early gastric can-cer with indigo-carmine staining or a pH-sensitive congo red dye followed by pentagastrin stimulation ( 315 )\n  Because of limited data, the breast cancer surveillance guidelines \nare based on those for women with a  BRCA1   or  BRCA2   mutation. \nGiven that lobular breast cancers can be diffi   cult to diagnose by \nclinical examination and mammography, annual MRI is recom-mended as part of the surveillance regimen. Th  e colonoscopy \nguidelines are also based on limited evidence at present.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02dee197-b316-4cae-9083-0eca374863b4": {"__data__": {"id_": "02dee197-b316-4cae-9083-0eca374863b4", "embedding": null, "metadata": {"page_label": "253", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "40fa6b97-cac6-4995-9694-37d6f39324b1", "node_type": "4", "metadata": {"page_label": "253", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "befe8a31855448908c12fea1e2b778c3903f5b719a050bc0d5d6432e6a184e80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8aec57d1-ac7c-4edd-8c17-8148492378cd", "node_type": "1", "metadata": {"page_label": "253", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "8580fe1fe6cbc8a7244e29f91475b304595fbbceda8dc3f4fd38aeba2c2ff02c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd4ded46-0595-4ae8-8643-bc0af6019a4a", "node_type": "1", "metadata": {"page_label": "254", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "01167692e0f299a8abedf8361f2eb2a9c80fb6c5483e3b6ffa4132302ac1ba1e", "class_name": "RelatedNodeInfo"}}, "hash": "70d8e22c0b0a83cbeb1a849d7584d6d5a7343971e58437f13dd4103ff20295e0", "text": "Th  e colonoscopy \nguidelines are also based on limited evidence at present.\n Table 14  .     Standards for informed consent for genetic testing in gastrointestinal (GI) practice ( 364 ) \n Components of a proper informed consent for cancer genetic testing should include: \n   1. Information on the speci\ufb01  c genetic mutation(s) or genomic variant(s) being tested, including whether or not the range of ri sk associated with the variant \nwill affect medical care. \n  2. Implications of positive and negative results. \n  3. Possibility that the test will not be informative. \n  4. Options for risk estimation without genetic or genomic testing. \n  5. Risk of passing a genetic variant to children. \n  6. Technical accuracy of the test, including, where required by law, licensure of the testing laboratory \n  7. Fees involved in testing and counseling and, for direct to consumer testing, whether the counselor is employed by the testi ng company. \n  8. Psychological implications of test results (bene\ufb01  ts and risks). \n  9. Risks and protections against genetic discrimination by employers or insurers. \n  10. Con\ufb01  dentiality issues, including, for direct-to-consumer testing companies, polices related to privacy and data security.  \n  11. Possible use of DNA testing samples in future research. \n  12. Options and limitations of medical surveillance and strategies for prevention after genetic or genomic testing. \n  13. Importance of sharing genetic and genomic test results with at-risk relatives so that they may bene\ufb01  t from this informati on. \n  14. Plans for follow-up after testing. \nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd4ded46-0595-4ae8-8643-bc0af6019a4a": {"__data__": {"id_": "bd4ded46-0595-4ae8-8643-bc0af6019a4a", "embedding": null, "metadata": {"page_label": "254", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8d66af4c-ecef-466f-8a33-3db59aff07e8", "node_type": "4", "metadata": {"page_label": "254", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "6196dca0aa62f998c37ce13dc801a74a5788e38987fdf2147b3a396e42564479", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02dee197-b316-4cae-9083-0eca374863b4", "node_type": "1", "metadata": {"page_label": "253", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "70d8e22c0b0a83cbeb1a849d7584d6d5a7343971e58437f13dd4103ff20295e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b66cf91-a05a-41fc-a86a-e9c836adee2a", "node_type": "1", "metadata": {"page_label": "254", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1339535489e12dbd79a2d341a04966f0d231ae642586c8ae0f662bbf06d0902f", "class_name": "RelatedNodeInfo"}}, "hash": "01167692e0f299a8abedf8361f2eb2a9c80fb6c5483e3b6ffa4132302ac1ba1e", "text": "Syngal  et al.  \nThe American Journal of GASTROENTEROLOGY VOLUME 110 | FEBRUARY 2015    www.amjgastro.com 254\n     Informed consent\n  Genetic testing should only be done in the setting of pre- and \nposttest genetic counseling. Full informed consent should always be part of the process of cancer genetic counseling. Nongenet-ics professionals should consider off  ering cancer genetic testing \nonly if they are able to provide or make available adequate genetic education and counseling as well as access to preventive and surveillance options. Otherwise they should consider referring the patient and family for these services. Standards for informed \nconsent that should be adopted in gastroenterology practices are \noutlined in  Table 14  .\n    Emergence of new genetic testing technologies\n  Th e advent and commercial availability of next-generation \nsequencing panels have increased both the complexity and the ease of cancer genetic testing signifi  cantly in the past few years. Next-\ngeneration sequencing allows for analysis of multiple genes at one time for a lower cost than traditional Sanger sequencing. Th  ere \nare multiple cancer gene panels including anywhere from 6 to 52 genes now off  ered at a variety of diagnostic laboratories. Some \nlimitations of the new technology include the longer turnaround time (results can take up to 3 months instead of 2\u20133 weeks) and a higher chance of fi  nding uncertain results (known as variants of \nuncertain signifi  cance) given the large number of genes included. \nIn addition, there are some genes on these panels for which there are very little data available about the associated cancer risks or appropriate management and others for which the cancer risks are so low that the family would be managed based on the can-cer history and not the mutation result. In these cases, the results are not useful clinically and can cause confusion for the patient. However, gene panels also may streamline testing for individuals at increased risk for a cancer susceptibility syndrome and reduce greatly the need for sequential tests where multiple diagnoses are under consideration.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b66cf91-a05a-41fc-a86a-e9c836adee2a": {"__data__": {"id_": "1b66cf91-a05a-41fc-a86a-e9c836adee2a", "embedding": null, "metadata": {"page_label": "254", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8d66af4c-ecef-466f-8a33-3db59aff07e8", "node_type": "4", "metadata": {"page_label": "254", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "6196dca0aa62f998c37ce13dc801a74a5788e38987fdf2147b3a396e42564479", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd4ded46-0595-4ae8-8643-bc0af6019a4a", "node_type": "1", "metadata": {"page_label": "254", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "01167692e0f299a8abedf8361f2eb2a9c80fb6c5483e3b6ffa4132302ac1ba1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7520d7c5-f166-4c97-8b41-58e19ff2289b", "node_type": "1", "metadata": {"page_label": "254", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "ce3c862927ee022010d862731d2a744aa4398b99b1a6dd0258642c09aa8808e6", "class_name": "RelatedNodeInfo"}}, "hash": "1339535489e12dbd79a2d341a04966f0d231ae642586c8ae0f662bbf06d0902f", "text": "In general, genetics professionals are using the next-generation sequencing panels for patients with a long list of diff  erential diagnoses (e.g., if testing for >1 possible genetic \nsyndrome) because the panels are much more cost eff  ective and \ncan shorten the diagnostic journey. It is conceivable that gene pan-els may in a short period of time replace in large part individual genetic tests and that testing for all the syndromes discussed in this guideline will soon be done simultaneously for at-risk patients.\n     CONCLUSION\n  Several well-established heredi tary cancer syndromes now exist, \neach with implications for specifi  c cancer risks in GI and other \norgan systems. Th  e assessment for cancer susceptibility should be \na standard part of patient evaluations in gastroenterology offi   ce \nand endoscopy practices. A systematic and focused family his-tory of cancer and premalignant conditions is the fi  rst step and \nsuffi  cient to screen for \u223c 10\u201315% of patients who may need more \ndetailed risk assessment by more extensive family history assess-ment, genetic counseling, and genetic testing. Th  e underlying \ngenetic etiologies for sev eral syndromes are now well established, \nand the array of cancer susceptibility genes is continually expand-ing. Genetic testing is widely available and should be part of \nstandard of care of patients at increased risk for a hereditary can-cer syndrome. Mutation carriers and at-risk individuals require intensive surveillance, possibly prophylactic surgery, and family counseling, and management needs to be individualized based on the syndrome under consideration, as well as the specifi  cs of the \nfamily history at hand. Th  ere is a dire need of organized collabo-\nrative international eff  orts to study benefi  ts of surveillance and \nsurgical strategies in patients with these relatively rare syndromes \nin order to be able to off  er truly evidence-based management \nrecommendations.\n     ACKNOWLEDGMENTS \n  Th is guideline was produced in collaboration with the Practice \nParameters Committee of the American College of Gastroentero-logy. Th  e Committee gives special thanks to Christine Y . Hachem, \nMD, FACG, who served as guideline monitor for this document.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7520d7c5-f166-4c97-8b41-58e19ff2289b": {"__data__": {"id_": "7520d7c5-f166-4c97-8b41-58e19ff2289b", "embedding": null, "metadata": {"page_label": "254", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8d66af4c-ecef-466f-8a33-3db59aff07e8", "node_type": "4", "metadata": {"page_label": "254", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "6196dca0aa62f998c37ce13dc801a74a5788e38987fdf2147b3a396e42564479", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b66cf91-a05a-41fc-a86a-e9c836adee2a", "node_type": "1", "metadata": {"page_label": "254", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1339535489e12dbd79a2d341a04966f0d231ae642586c8ae0f662bbf06d0902f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c18d9974-38e4-4edc-bb6e-3ac01e767c4b", "node_type": "1", "metadata": {"page_label": "254", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1ba63711f65ad6f4dd6b7b6019a4fb63593aa379658dba81da8631d9e03e8727", "class_name": "RelatedNodeInfo"}}, "hash": "ce3c862927ee022010d862731d2a744aa4398b99b1a6dd0258642c09aa8808e6", "text": "Hachem, \nMD, FACG, who served as guideline monitor for this document. We are grateful to Christine Hachem, Lauren Gerson, and Maria Susano for assistance with guideline development, to Paul Moayyedi for reviewing and grading recommendations, and to Chinedu Ukaegbu for help with draft  ing of the manuscript tables and \nassembling reference libraries.\n    CONFLICT OF INTEREST \n  Guarantor of the article  : Sapna Syngal, MD, MPH, FACG.\n   Specifi  c author contributions:   Each of the authors (Syngal, Hampel, \nBurt, Brand, Giardiello, and Church) played a role in writing \nportions of the manuscript. Dr Syngal assimilated the sections into \nthe comprehensive document and each co-author subsequently provided feedback in conference calls and written form on subsequent revisions.   Financial support  : Th is study was supported by the National Cancer \nInstitute K24-11311 (to S.S.).   Potential competing interests  : Dr Syngal has served as a consult-\nant to EXACT Sciences and Merck. She is an unpaid collaborator/advisor to Myriad Genetics. One of her mentees receives research grant support from Myriad Genetics. Dr Syngal does not receive sal-ary support from this grant, but is a collaborator on the project. Dr Brand has served as a consult to Myriad Genetics and is a Scientifi  c \nAdvisory Board Member for Asuragen. Ms Hampel has received honoraria from Quest Diagnost ics and InVitae Laboratory for \neducational talks in the past year. In addition, she receives research genetic testing support from Myriad Genetics. Dr Burt consults for Myriad Genetics. Th  e authors have no relationships with the funding \nsources specifi  ed.\n    REFERENCES \n1 .      G u y a t t      G H    ,     O x m a n      A D    ,     V i s t      G E     et al.       GRADE: an emerging consensus \non rating quality of evidence and strength of recommendations  .   BMJ     2008  ;  336  :  924  .  \n2 .", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c18d9974-38e4-4edc-bb6e-3ac01e767c4b": {"__data__": {"id_": "c18d9974-38e4-4edc-bb6e-3ac01e767c4b", "embedding": null, "metadata": {"page_label": "254", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8d66af4c-ecef-466f-8a33-3db59aff07e8", "node_type": "4", "metadata": {"page_label": "254", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "6196dca0aa62f998c37ce13dc801a74a5788e38987fdf2147b3a396e42564479", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7520d7c5-f166-4c97-8b41-58e19ff2289b", "node_type": "1", "metadata": {"page_label": "254", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "ce3c862927ee022010d862731d2a744aa4398b99b1a6dd0258642c09aa8808e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d52c2ab9-dd69-40ba-9edc-36359b6dcafd", "node_type": "1", "metadata": {"page_label": "1043", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "44b103d62c54b79254979b32bf0599749053564427903971d62d07e5d35d8d8b", "class_name": "RelatedNodeInfo"}}, "hash": "1ba63711f65ad6f4dd6b7b6019a4fb63593aa379658dba81da8631d9e03e8727", "text": "2 .       L u      K H    ,     W o o d      M E    ,     D a n i e l s      M     et al.       American Society of Clinical Oncology \nExpert Statement: collection and use of a cancer family history for oncology providers  .   J Clin Oncol     2014  ;  32  :  833  \u2013  40 .   \n3.     Referenced with permission from the NCCN Clinical Practice Guidelines \nin Oncology (NCCN Guidelines\u00ae) for Genetic/Familial High-Risk Assess-ment: Breast and Ovarian. Version 4.2013. \u00a9 National Comprehensive \nDownloaded from http://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWn\nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 04/10/2023", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d52c2ab9-dd69-40ba-9edc-36359b6dcafd": {"__data__": {"id_": "d52c2ab9-dd69-40ba-9edc-36359b6dcafd", "embedding": null, "metadata": {"page_label": "1043", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1dbe19fa-7132-4758-92a4-06c10cebc198", "node_type": "4", "metadata": {"page_label": "1043", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "385f7fc5008847b81fd1ed932c3dd0b15223bd39b90c4d9851b8d2ca63a9b630", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c18d9974-38e4-4edc-bb6e-3ac01e767c4b", "node_type": "1", "metadata": {"page_label": "254", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1ba63711f65ad6f4dd6b7b6019a4fb63593aa379658dba81da8631d9e03e8727", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef65e270-2fbf-48cc-8d14-ec74b2b05f67", "node_type": "1", "metadata": {"page_label": "1043", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "423650cfce17122ebea8e5143a9bf84082d2ba82bc3dbc1ad179692109f56cba", "class_name": "RelatedNodeInfo"}}, "hash": "44b103d62c54b79254979b32bf0599749053564427903971d62d07e5d35d8d8b", "text": "CLINICAL PRACTICE UPDATE\nAGA Clinical Practice Update on Endoscopic Surveillance and\nManagement of Colorectal Dysplasia in In \ufb02ammatory Bowel\nDiseases: Expert Review\nSanjay K. Murthy,1Joseph D. Feuerstein,2Geoffrey C. Nguyen,3and Fernando S. Velayos4\n1The Ottawa Hospital In \ufb02ammatory Bowel Disease Centre, Department of Medicine, University of Ottawa, Ottawa Hospital\nResearch Institute, Ottawa, Ontario, Canada;2Center for In \ufb02ammatory Bowel Disease Beth Israel Medical Center, Harvard\nMedical School, Boston, Massachusetts;3Mount Sinai Hospital Centre for In \ufb02ammatory Bowel Disease, University of Toronto,\nToronto, Ontario, Canada; and4Division of Gastroenterology and Hepatology, The Permanente Medical Group, San\nFrancisco, California\nImprovements in disease management, as well as endo-\nscopic technology and quality, have dramatically changed\nthe way in which we conceptualize and manage in \ufb02am-\nmatory bowel disease \u2013related dysplasia over the past 20\nyears. Based on evolving literature, we propose a concep-\ntual model and best practice advice statements for the\nprevention, detection, and management of colorectaldysplasia in people with in \ufb02ammatory bowel disease. This\nexpert review was commissioned and approved by the\nAmerican Gastroenterological Association Institute Clinical\nPractice Updates Committee and the American Gastroen-terological Association Governing Board to provide timely\nguidance on a topic of high clinical importance to the\nAmerican Gastroenterological Association membership. Itunderwent internal peer review by the Clinical Practice\nUpdates Committee and external peer review through\nstandard procedures of Gastroenterology .\nKeywords: In\ufb02ammatory Bowel Disease; Colorectal Cancer\nScreening; Chromoendoscopy; Colonoscopy.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef65e270-2fbf-48cc-8d14-ec74b2b05f67": {"__data__": {"id_": "ef65e270-2fbf-48cc-8d14-ec74b2b05f67", "embedding": null, "metadata": {"page_label": "1043", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1dbe19fa-7132-4758-92a4-06c10cebc198", "node_type": "4", "metadata": {"page_label": "1043", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "385f7fc5008847b81fd1ed932c3dd0b15223bd39b90c4d9851b8d2ca63a9b630", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d52c2ab9-dd69-40ba-9edc-36359b6dcafd", "node_type": "1", "metadata": {"page_label": "1043", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "44b103d62c54b79254979b32bf0599749053564427903971d62d07e5d35d8d8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6c765ba-91bb-4829-b068-8968f3411279", "node_type": "1", "metadata": {"page_label": "1043", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "6083d84f17f08bdfdf9e07b668d1daef7773c06f576de263ab500feea1b1ef6e", "class_name": "RelatedNodeInfo"}}, "hash": "423650cfce17122ebea8e5143a9bf84082d2ba82bc3dbc1ad179692109f56cba", "text": "Since its \ufb01rst description in 1925, colorectal cancer\n(CRC) has been one of the most feared complications\nof in\ufb02ammatory bowel diseases (IBDs).1Not long ago, no-\ntions of imperceptible CRC development and urgent need\nfor colectomy in the face of dysplasia dominated IBD prac-\ntice. However, improvements in disease management, aswell as endoscopic technology and quality, have dramati-cally changed the way in which we conceptualize andmanage IBD-related dysplasia over the past 20 years. Theproposed conceptual model and best practice advice state-ments in this review are best used in conjunction withevolving literature and existing societal guidelines as part ofa shared decision-making process.\nA summary of the Best Practice Advice statements is\nprovided in Table 1 .\nNomenclature and Reporting\nBest Practice Advice 1: Precancerous colorectal le-\nsions in in \ufb02ammatory bowel disease should be\ndescribed as either polypoid ( \u20212.5 mm tall), non-\npolypoid ( <2.5 mm), or invisible (detected onnontargeted biopsy), using a modi \ufb01ed Paris Classi \ufb01ca-\ntion. The older terms dysplasia-associated lesion or\nmass ,adenoma-like mass , and \ufb02at dysplasia (when\nreferring to dysplasia detected in nontargeted biopsies)should be abandoned.\nPrecancerous colorectal lesions affecting people with\ncolonic IBD (cIBD) have been described previously usingterms such as adenomatous polyp ,adenoma-like mass (ALM),\ndysplasia-associated lesion or mass (DALM), and \ufb02at dysplasia\n(Figure 1 A).\n2In 2015, the international Surveillance for\nColorectal Endoscopic Neoplasia Detection and Managementin In\ufb02ammatory Bowel Disease Patients consortium recom-\nmended modifying the vocabulary using an adaptation of the\nParis Classi \ufb01cation to closely match what is used for pre-\ncancerous lesions in people without IBD,\n3thereby recog-\nnizing the inherent similarity of visible lesions in IBD andnon-IBD colons.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6c765ba-91bb-4829-b068-8968f3411279": {"__data__": {"id_": "a6c765ba-91bb-4829-b068-8968f3411279", "embedding": null, "metadata": {"page_label": "1043", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1dbe19fa-7132-4758-92a4-06c10cebc198", "node_type": "4", "metadata": {"page_label": "1043", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "385f7fc5008847b81fd1ed932c3dd0b15223bd39b90c4d9851b8d2ca63a9b630", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef65e270-2fbf-48cc-8d14-ec74b2b05f67", "node_type": "1", "metadata": {"page_label": "1043", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "423650cfce17122ebea8e5143a9bf84082d2ba82bc3dbc1ad179692109f56cba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89e7509d-e2b7-4d9a-8ae8-b832c8da1b32", "node_type": "1", "metadata": {"page_label": "1044", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "e61a993bf88a999195c4983eb86a2579fcdccceda0eacee863969a8d6bb9c941", "class_name": "RelatedNodeInfo"}}, "hash": "6083d84f17f08bdfdf9e07b668d1daef7773c06f576de263ab500feea1b1ef6e", "text": "4In this system, lesions that protrude /C212.5\nmm above the mucosa should be described as polypoid(pedunculated or sessile), and lesions that protrude <2.5 mm\nabove the mucosa should be described as nonpolypoid ( \ufb02at\nelevated, \ufb02at, or \ufb02at depressed) ( Figure 1 B). Unique to IBD,\ndysplastic histology detected from nontargeted (random)biopsies should be described as \u201cinvisible \u201ddysplasia and no\nlonger described as \ufb02at dysplasia. The terms DALM andALM\nshould no longer used.\nBest Practice Advice 2: Visible precancerous lesions\nshould be described based on size, morphology, clarityof borders, presence of ulceration, location, presencewithin an area of past or current colitis, perceivedcompleteness of resection, and whether any specialtechniques were used for visualization.\nReducing variation in reporting is important for facili-\ntating lesion identi \ufb01cation during follow-up colonoscopy,\nguiding subsequent management (resection vs surgery), and\nAbbreviations used in this paper: ALM, adenoma-like mass; cIBD, colonic\nIBD; CRC, colorectal cancer; DALM, dysplasia-associated lesion or mass;\nDCE, dye spray chromoendoscopy; HD, high de \ufb01nition; IBD, in \ufb02ammatory\nbowel disease; NBI, narrow band imaging; PSC, primary sclerosing\ncholangitis; UC, ulcerative colitis; VCE, virtual chromoendoscopy; WLE,\nwhite light endoscopy.\nMost current article\n\u00a9 2021 by the AGA Institute\n0016-5085/$36.00\nhttps://doi.org/10.1053/j.gastro.2021.05.063Gastroenterology 2021;161:1043 \u20131051\nCLINICAL PRACTICE UPDATE", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89e7509d-e2b7-4d9a-8ae8-b832c8da1b32": {"__data__": {"id_": "89e7509d-e2b7-4d9a-8ae8-b832c8da1b32", "embedding": null, "metadata": {"page_label": "1044", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "105d7069-5266-4bf2-a3fa-a3b49898b22e", "node_type": "4", "metadata": {"page_label": "1044", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "e60037440ec945a2c50fdf1804c721a13e226b221ddeb6dd16c9345c6a5a3157", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6c765ba-91bb-4829-b068-8968f3411279", "node_type": "1", "metadata": {"page_label": "1043", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "6083d84f17f08bdfdf9e07b668d1daef7773c06f576de263ab500feea1b1ef6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcdfdf5e-02f4-49eb-842b-629498b0a089", "node_type": "1", "metadata": {"page_label": "1044", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "ba58754a2b7a1a6f50d2e38cacf228b852192566d25c99039c99a2b7f1e4d4dc", "class_name": "RelatedNodeInfo"}}, "hash": "e61a993bf88a999195c4983eb86a2579fcdccceda0eacee863969a8d6bb9c941", "text": "Table 1. Best Practice Advice Regarding Endoscopic Surveillance and Management of Colorectal Dysplasia in In \ufb02ammatory\nBowel Diseases\nBest Practice Advice Statement\n1 Precancerous colorectal lesions in in \ufb02ammatory bowel disease should be described as either polypoid ( /C212.5\nmm tall), nonpolypoid ( <2.5 mm), or invisible (detected on nontargeted biopsy), using a modi \ufb01ed Paris\nClassi \ufb01cation. The older terms dysplasia-associated lesion or mass ,adenoma-like mass , and \ufb02at dysplasia\n(when referring to dysplasia detected in nontargeted biopsies) should be abandoned\n2 Visible precancerous lesions should be described based on size, morphology, clarity of borders, presence of\nulceration, location, presence within an area of past or current colitis, perceived completeness ofresection, and whether any special techniques were used for visualization.\n3 Initial colonoscopy screening for dysplasia should be performed at 8 \u201310 years after disease diagnosis in all\npeople with colonic in \ufb02ammatory bowel disease, and immediately on diagnosis of primary sclerosing\ncholangitis. Staging biopsies should be taken from multiple colonic segments to assess histologic diseaseactivity and extent and to help guide future surveillance intervals.\n4 Conditions and practices for dysplasia detection should be optimized, including control of in \ufb02ammation, use\nof high-de \ufb01nition endoscopes, bowel preparation, careful washing and inspection of all colorectal mucosa,\nand targeted sampling of any suspicious mucosal irregularities.\n5 Targeted biopsies should be performed where mucosal \ufb01ndings are suspicious for dysplasia or are inexplicably\ndifferent from the surrounding mucosa. Endoscopic resection is preferred to biopsies when lesions are\nclearly demarcated without stigmata of invasive cancer or submucosal \ufb01brosis. Mucosal biopsies\nsurrounding a resected lesion are not required unless there are concerns about resection completeness.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcdfdf5e-02f4-49eb-842b-629498b0a089": {"__data__": {"id_": "dcdfdf5e-02f4-49eb-842b-629498b0a089", "embedding": null, "metadata": {"page_label": "1044", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "105d7069-5266-4bf2-a3fa-a3b49898b22e", "node_type": "4", "metadata": {"page_label": "1044", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "e60037440ec945a2c50fdf1804c721a13e226b221ddeb6dd16c9345c6a5a3157", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89e7509d-e2b7-4d9a-8ae8-b832c8da1b32", "node_type": "1", "metadata": {"page_label": "1044", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "e61a993bf88a999195c4983eb86a2579fcdccceda0eacee863969a8d6bb9c941", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f467e84-1f34-48e4-a634-821228999c5c", "node_type": "1", "metadata": {"page_label": "1044", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "8940c1e02296316349f059c952c492c269287bc3663f3956986ccd1cc7629400", "class_name": "RelatedNodeInfo"}}, "hash": "ba58754a2b7a1a6f50d2e38cacf228b852192566d25c99039c99a2b7f1e4d4dc", "text": "6 Dye spray chromoendoscopy, performed by appropriately trained endoscopists, should be considered in all\npersons with colonic in \ufb02ammatory bowel disease undergoing surveillance colonoscopy, particularly if a\nstandard de \ufb01nition endoscope is used or if there is a history of dysplasia\n7 Virtual chromoendoscopy is a suitable alternative to dye spray chromoendoscopy for dysplasia detection in\npersons with colonic in \ufb02ammatory bowel disease when using high-de \ufb01nition endoscopy.\n8 Extensive nontargeted biopsies (roughly 4 adequately spaced biopsies every 10 cm) should be taken from \ufb02at\ncolorectal mucosa in areas previously affected by colitis when white light endoscopy is used without dyespray chromoendoscopy or virtual chromoendoscopy. Additional biopsies should be taken from areas of\nprior dysplasia or poor mucosal visibility. Nontargeted biopsies are not routinely required if dye spray\nchromoendoscopy or virtual chromoendoscopyis performed using a high-de \ufb01ntion endoscope, but should\nbe considered if there is a history of dysplasia or primary sclerosing cholangitis.\n9 All clearly delineated dysplastic-appearing lesions without stigmata of invasive cancer or signi \ufb01cant\nsubmucosal \ufb01brosis should be considered for endoscopic resection. If the resectability of a lesion is in\nquestion, referral to a specialized endoscopist or in \ufb02ammatory bowel disease center is suggested.\n10 A \ufb01nding of invisible dysplasia should prompt repeat examination by an experienced endoscopist using high-\nde\ufb01nition dye spray chromoendoscopy under optimized viewing conditions, with extensive nontargeted\nbiopsies in the area of prior dysplasia if no lesion is seen. A \ufb01nding of unresectable visible dysplasia or of\ninvisible multifocal or high-grade dysplasia on histology should prompt colectomy.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f467e84-1f34-48e4-a634-821228999c5c": {"__data__": {"id_": "5f467e84-1f34-48e4-a634-821228999c5c", "embedding": null, "metadata": {"page_label": "1044", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "105d7069-5266-4bf2-a3fa-a3b49898b22e", "node_type": "4", "metadata": {"page_label": "1044", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "e60037440ec945a2c50fdf1804c721a13e226b221ddeb6dd16c9345c6a5a3157", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcdfdf5e-02f4-49eb-842b-629498b0a089", "node_type": "1", "metadata": {"page_label": "1044", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "ba58754a2b7a1a6f50d2e38cacf228b852192566d25c99039c99a2b7f1e4d4dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "586fe2c3-c535-472f-9189-452f66d382a1", "node_type": "1", "metadata": {"page_label": "1045", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "c35a7fffb058c8b1ffdbb6c26908078c2db41e064d7420531d9d24870b3dfd7c", "class_name": "RelatedNodeInfo"}}, "hash": "8940c1e02296316349f059c952c492c269287bc3663f3956986ccd1cc7629400", "text": "For visible lesions thatcan be resected or if histologic dysplasia is not con \ufb01rmed on a high-quality dye spray chromoendoscopy\nexamination, continued endoscopic surveillance at frequent intervals is appropriate.\n11 After a negative screening colonoscopy, surveillance colonoscopy should be performed every 1 \u20135 years\nbased on risk factors for colorectal cancer, considering current and prior burden of colonic in \ufb02ammation,\nfamily history of colorectal cancer, primary sclerosing cholangitis, history of colorectal dysplasia, andfrequency and quality of prior surveillance examinations.\n12 Pouch surveillance should be performed at least annually in those at high risk for developing colorectal\ndysplasia (prior colorectal cancer or dysplasia, primary sclerosing cholangitis), as well as in those with\npersistent moderate to severe pouchitis and/or pre-pouch ileitis (to assess for treatment response).Surveillance intervals in those at lower risk should be individualized.\n13 Targeted biopsies of representative or concerning pseudopolyps is appropriate during colonoscopy. Removal\nand sampling of all lesions is neither required nor practical. Surgery should be a last resort to manage\ncolorectal cancer risk in the setting of severe pseudopolyposis. Dye spray chromoendoscopy should notbe used to detect \ufb02at or subtle lesions within a \ufb01eld of pseudopolyps.\n14 Optimal disease control with medical therapy is imperative to minimizing an individual \u2019s lifetime risk of\ndeveloping colorectal cancer. There is uncertainty regarding the independent chemotherapeutic bene \ufb01to f\nmesalamine therapy in people with colonic in \ufb02ammatory bowel disease.1044 Murthy et al Gastroenterology Vol. 161, No. 3\nCLINICAL PRACTICE UPDATE", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "586fe2c3-c535-472f-9189-452f66d382a1": {"__data__": {"id_": "586fe2c3-c535-472f-9189-452f66d382a1", "embedding": null, "metadata": {"page_label": "1045", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e4ce00ce-7ddd-4459-9e54-1411121bbf37", "node_type": "4", "metadata": {"page_label": "1045", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "2fb3b575050b65497048a34f46286333a3aad3570c418fc42fc8648ff5ce4015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f467e84-1f34-48e4-a634-821228999c5c", "node_type": "1", "metadata": {"page_label": "1044", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "8940c1e02296316349f059c952c492c269287bc3663f3956986ccd1cc7629400", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e358d092-6ea3-4da1-9b0f-86634fe3b3af", "node_type": "1", "metadata": {"page_label": "1045", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "c7200dc9d8f4bb1bbd4cbfc62cd1f11da2bf6514f4d2450dd17cebe85088b455", "class_name": "RelatedNodeInfo"}}, "hash": "c35a7fffb058c8b1ffdbb6c26908078c2db41e064d7420531d9d24870b3dfd7c", "text": "providing suf \ufb01cient information for high-quality second-\nopinion consultations. Several international consortia haveendorsed a standardized approach to reporting key pre-,intra-, and postprocedural quality elements, including bowelpreparation; photodocumentation; extent and activity ofin\ufb02ammation; technique of visualization; and resection.\n3,5\u20137\nThe \u201c\ufb01ve S \u201dfeatures have been proposed to describe colonic\nlesions (shape, size, site, surface [Kudo pit pattern], andsurrounding [mucosal activity and other lesions]).\n7\nIn\ufb02ammatory Bowel Disease Dysplasia\nDetection\nWhen to Start Screening for Dysplasia\nBest Practice Advice 3: Initial colonoscopy screening\nfor dysplasia should be performed at 8 \u201310 years after\ndisease diagnosis in all people with colonic in \ufb02amma-\ntory bowel disease, and immediately on diagnosis ofprimary sclerosing cholangitis. Staging biopsies shouldbe taken from multiple colonic segments to assess his-tologic disease activity and extent and to help guidefuture surveillance intervals.\nEpidemiologic studies have demonstrated that CRC risk\nbegins to rise at 8 \u201310 years after diagnosis of cIBD.\n8\u201310The\n\ufb01rst screening examination performed at this interval pre-\nsents an opportunity to restage macroscopic and micro-scopic disease activity and extent, which can be used to helpguide future surveillance intervals. When performing bi-opsies in a segment with in \ufb02ammation, targeting the most\nseverely affected area, speci \ufb01cally at the edges of ulcers, if\npresent, can be helpful.\n11Screening should begin immedi-\nately after a diagnosis of primary sclerosing cholangitis(PSC), given the well-recognized subclinical colitis that canbe present for years before diagnosis.\n12\u201314\nFoundations of Dysplasia Detection\nBest Practice Advice 4: Conditions and practices for\ndysplasia detection should be optimized, includingcontrol of in \ufb02ammation, use of high-de \ufb01nition endo-\nscopes, bowel preparation, careful washing and in-spection of all colorectal mucosa, and targeted samplingof any suspicious mucosal irregularities.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e358d092-6ea3-4da1-9b0f-86634fe3b3af": {"__data__": {"id_": "e358d092-6ea3-4da1-9b0f-86634fe3b3af", "embedding": null, "metadata": {"page_label": "1045", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e4ce00ce-7ddd-4459-9e54-1411121bbf37", "node_type": "4", "metadata": {"page_label": "1045", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "2fb3b575050b65497048a34f46286333a3aad3570c418fc42fc8648ff5ce4015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "586fe2c3-c535-472f-9189-452f66d382a1", "node_type": "1", "metadata": {"page_label": "1045", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "c35a7fffb058c8b1ffdbb6c26908078c2db41e064d7420531d9d24870b3dfd7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2910286-7626-47e1-a289-9ee294e2236e", "node_type": "1", "metadata": {"page_label": "1045", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "536837ec667d5862cc838b64681a7077f93777008e7152bd7767c688d4c8962e", "class_name": "RelatedNodeInfo"}}, "hash": "c7200dc9d8f4bb1bbd4cbfc62cd1f11da2bf6514f4d2450dd17cebe85088b455", "text": "Colorectal dysplasia surveillance should be ideally per-\nformed when all in \ufb02ammatory disease has been well\ncontrolled, as subtle precancerous \ufb01ndings can be obscured\nby in\ufb02ammation and in \ufb02ammation can lead to false-positive\npathology \ufb01ndings of dysplasia.\n15Meta-analyses of studies\nin patients with IBD have further shown that use of high-de\ufb01nition (HD) endoscopes, with or without dye spray\nchromoendoscopy (DCE), have improved the visibility ofdysplasia, such that 90% of dysplastic lesions are nowvisible compared with 80% with standard-de \ufb01nition endo-\nscopes.\n3Most centers in North America now use HD endo-\nscopes. Excellent bowel preparation, careful inspection of\nthe mucosal surface, and targeted sampling of suspicious\nmucosal irregularities also increase dysplasia yield.3,16\u201320\nBest Practice Advice 5: Targeted biopsies should be\nperformed where mucosal \ufb01ndings are suspicious fordysplasia or are inexplicably different from the sur-\nrounding mucosa. Endoscopic resection is preferred tobiopsies when lesions are clearly demarcated withoutstigmata of invasive cancer or submucosal \ufb01brosis.\nMucosal biopsies surrounding a resected lesion are notrequired unless there are concerns about resection\ncompleteness.\nBiopsies performed during colonoscopy in patients with\nIBD can be categorized as targeted, nontargeted, or staging(Figure 1 F). Targeted sampling should be performed for\nsuspicious-appearing polypoid or \ufb02at mucosal abnormal-\nities that are either mass-like or not clearly delineated, orfor any inexplicable mucosal irregularities that mightrepresent atypical signs of dysplasia, including changes inmucosal color or vascularity, nodularity, elevation, or ul-ceration.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2910286-7626-47e1-a289-9ee294e2236e": {"__data__": {"id_": "d2910286-7626-47e1-a289-9ee294e2236e", "embedding": null, "metadata": {"page_label": "1045", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e4ce00ce-7ddd-4459-9e54-1411121bbf37", "node_type": "4", "metadata": {"page_label": "1045", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "2fb3b575050b65497048a34f46286333a3aad3570c418fc42fc8648ff5ce4015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e358d092-6ea3-4da1-9b0f-86634fe3b3af", "node_type": "1", "metadata": {"page_label": "1045", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "c7200dc9d8f4bb1bbd4cbfc62cd1f11da2bf6514f4d2450dd17cebe85088b455", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e0fe710-2980-4b8f-9586-d2fed5ba51c0", "node_type": "1", "metadata": {"page_label": "1045", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "fcd336470faccbfa46af4395df2af45b72d46065c0f49333be0ea4dbd71fc57a", "class_name": "RelatedNodeInfo"}}, "hash": "536837ec667d5862cc838b64681a7077f93777008e7152bd7767c688d4c8962e", "text": "21,22Endoscopic resection has been shown to be\nsafe and preferred to targeted biopsies for clearly delin-\neated lesions without stigmata of invasive cancer or sub-\nmucosal \ufb01brosis.23\u201329Given the immense improvements in\nvisibility with modern-day HD endoscopes, unless concernsarise regarding a lesion \u2019s borders and completeness of\nresection, routine biopsies of the \ufb02at mucosa surrounding a\nresected lesion are not needed, as they rarely demonstrateresidual dysplasia.\n30\u201332\nAdjuncts to Enhance Dysplasia Detection\nBest Practice Advice 6: Dye spray chromoendoscopy,\nperformed by appropriately trained endoscopists,should be considered in all persons with colonic in-\ufb02ammatory bowel disease undergoing surveillance co-\nlonoscopy, particularly if a standard-de \ufb01nition\nendoscope is used or if there is a history of dysplasia.\nIn dye spray chromoendoscopy (DCE), dilute contrast\n(ie, indigo carmine 0.03% \u20130.1%) or absorptive (ie, meth-\ny l e n eb l u e0 . 0 4 % \u20130.1%) dyes are liberally applied over\nthe entire colonic mucosal surface during withdrawal ofthe colonoscope using a spray catheter or waterjet to\n\u201cunmask \u201ddysplastic lesions by highlighting the borders\nand surface architecture of poorly delineated lesions.\n3,33,34\nOnce a suspicious lesion is identi \ufb01ed, some experts\nrecommend spraying a more concentrated dye (indigocarmine 0.13% or methylene blue 0.2%) to further de \ufb01ne\nlesion border and topography.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e0fe710-2980-4b8f-9586-d2fed5ba51c0": {"__data__": {"id_": "4e0fe710-2980-4b8f-9586-d2fed5ba51c0", "embedding": null, "metadata": {"page_label": "1045", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e4ce00ce-7ddd-4459-9e54-1411121bbf37", "node_type": "4", "metadata": {"page_label": "1045", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "2fb3b575050b65497048a34f46286333a3aad3570c418fc42fc8648ff5ce4015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2910286-7626-47e1-a289-9ee294e2236e", "node_type": "1", "metadata": {"page_label": "1045", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "536837ec667d5862cc838b64681a7077f93777008e7152bd7767c688d4c8962e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9dab2bc6-d7d9-4b2b-bdbe-f5860e3a7b39", "node_type": "1", "metadata": {"page_label": "1046", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "a5928918e6766b98051261a8c0628e5669a5a5904d87252a9b165c70abe714e0", "class_name": "RelatedNodeInfo"}}, "hash": "fcd336470faccbfa46af4395df2af45b72d46065c0f49333be0ea4dbd71fc57a", "text": "3Optimal criteria for DCE\nhave been reported.34Studies have demonstrated a\nroughly 2-fold greater dysplasia yield with DCE overstandard-de \ufb01nition white light endoscopy (WLE),\n3,18,19\nand a meta-analysis of 4 randomized controlled trials\n(RCTs) reported a 1.6-fold greater dysplasia yield with\nDCE compared with HD-WLE.19Studies have not evaluated\nthe impact of DCE on the long-term risks of CRC or CRC-related death.\nBest Practice Advice 7: Virtual chromoendoscopy is a\nsuitable alternative to dye spray chromoendoscopy for\ndysplasia detection in persons with colonic in \ufb02ammatory\nbowel disease when using high-de \ufb01nition endoscopy.\nVirtual chromoendoscopy (VCE) modalities, such as\nnarrow band imaging (NBI) (Olympus; Tokyo, Japan), i-scan\n(Pentax; Tokyo, Japan), and Fuji intelligent colorSeptember 2021 Surveillance and Management of Colorectal Dysplasia in IBDs 1045\nCLINICAL PRACTICE UPDATE", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9dab2bc6-d7d9-4b2b-bdbe-f5860e3a7b39": {"__data__": {"id_": "9dab2bc6-d7d9-4b2b-bdbe-f5860e3a7b39", "embedding": null, "metadata": {"page_label": "1046", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5063b093-a32d-4dd1-bec8-c39a3f8c618b", "node_type": "4", "metadata": {"page_label": "1046", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "622d022e3074203fcd5c6c688167f62359a9f476f42afd471819ae6ae6b1b417", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e0fe710-2980-4b8f-9586-d2fed5ba51c0", "node_type": "1", "metadata": {"page_label": "1045", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "fcd336470faccbfa46af4395df2af45b72d46065c0f49333be0ea4dbd71fc57a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "658136fc-110c-423b-a2e2-673d30cab125", "node_type": "1", "metadata": {"page_label": "1047", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "76251ce4c914951c37f8192a38805ee4a74fb6e55e18bd62ed78b1300a6d4dec", "class_name": "RelatedNodeInfo"}}, "hash": "a5928918e6766b98051261a8c0628e5669a5a5904d87252a9b165c70abe714e0", "text": "Figure 1. Principles of CRC screening in IBD.1046 Murthy et al Gastroenterology Vol. 161, No. 3\nCLINICAL PRACTICE UPDATE", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "658136fc-110c-423b-a2e2-673d30cab125": {"__data__": {"id_": "658136fc-110c-423b-a2e2-673d30cab125", "embedding": null, "metadata": {"page_label": "1047", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ad7d0a21-3e29-4e0a-af01-2382c406de2a", "node_type": "4", "metadata": {"page_label": "1047", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "b30421c075af65b0e3a401c065316cf5b4f924341a8db249fa320d979591202d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9dab2bc6-d7d9-4b2b-bdbe-f5860e3a7b39", "node_type": "1", "metadata": {"page_label": "1046", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "a5928918e6766b98051261a8c0628e5669a5a5904d87252a9b165c70abe714e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49d83f81-a8c4-47ee-836f-82ceabc06c60", "node_type": "1", "metadata": {"page_label": "1047", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "2e914907f779271acdb5a727681f8bae2c94f527269ae90e1056b988f524d13c", "class_name": "RelatedNodeInfo"}}, "hash": "76251ce4c914951c37f8192a38805ee4a74fb6e55e18bd62ed78b1300a6d4dec", "text": "enhancement (Fujinon, Fuji \ufb01lm; Tokyo, Japan) apply narrow\nwavelength spectrums of light to illuminate mucosal tissueusing either selective light \ufb01lters (NBI) or post-image pro-\ncessing techniques ( i-scan and Fuji intelligent color\nenhancement), which enhance the vascular and surface ar-chitecture of mucosal lesions without the need for dye.\n35\nEarly studies generally failed to show a bene \ufb01t of VCE\ntechnologies for dysplasia detection with either standard-de\ufb01nition or HD endoscopes in patients with cIBD.\n36\u201341\nHowever, several recent studies have shown similar\ndysplasia detection rates when comparing HD NBI withDCE\n39,42,43or HD iscan with DCE,36,39with shorter with-\ndrawal times favoring VCE methods. A recent meta-analysisof 11 RCTs con \ufb01rmed that VCE performed similarly to DCE\nand HD-WLE with respect to dysplasia detection on a per-patient basis.\n39\nBest Practice Advice 8: Extensive nontargeted bi-\nopsies (roughly 4 adequately spaced biopsies every 10\ncm) should be taken from \ufb02at colorectal mucosa in\nareas previously affected by colitis when white lightendoscopy is used without dye spray chromoendoscopyor virtual chromoendoscopy. Additional biopsies shouldbe taken from areas of prior dysplasia or poor mucosalvisibility. Nontargeted biopsies are not routinelyrequired if dye spray chromoendoscopy or virtualchromoendoscopyis performed using a high-de \ufb01ntion\nendoscope, but should be considered if there is a his-tory of dysplasia or primary sclerosing cholangitis.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49d83f81-a8c4-47ee-836f-82ceabc06c60": {"__data__": {"id_": "49d83f81-a8c4-47ee-836f-82ceabc06c60", "embedding": null, "metadata": {"page_label": "1047", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ad7d0a21-3e29-4e0a-af01-2382c406de2a", "node_type": "4", "metadata": {"page_label": "1047", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "b30421c075af65b0e3a401c065316cf5b4f924341a8db249fa320d979591202d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "658136fc-110c-423b-a2e2-673d30cab125", "node_type": "1", "metadata": {"page_label": "1047", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "76251ce4c914951c37f8192a38805ee4a74fb6e55e18bd62ed78b1300a6d4dec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39c7ddb0-fce0-4e67-aea5-69aa567901de", "node_type": "1", "metadata": {"page_label": "1047", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "e788a0076d4317772a75ea0852b942594b67e5690267f68e954bf10008699055", "class_name": "RelatedNodeInfo"}}, "hash": "2e914907f779271acdb5a727681f8bae2c94f527269ae90e1056b988f524d13c", "text": "The practice of taking nontargeted (random) biopsies for\ndysplasia surveillance in cIBD gained popularity during the1980s and 1990s for several reasons: concerns for misseddysplastic lesions, driven by fears of multifocal and accel-erated tumorigenesis due to widespread genetic aberrationswithin colitic mucosa ( \u201c\ufb01eld carcinogenesis \u201d),\n44\u201346reports\nof high rates of synchronous and metachronous cancerswithin \ufb01elds of invisible dysplasia,\n47\u201351and early recogni-\ntion of unconventional growth patterns of dysplasia thatmirrored in \ufb02ammatory changes (ie, nodular, strictured, or\nulcerated).\n21,22,52Mathematical modeling in 1 study\ndemonstrated that 33 or more nontargeted jumbo forceps\nbiopsies could detect dysplasia with 90% con \ufb01dence,44\nleading to current recommendations.2,33,53\nThis practice was founded during a period in which\nvisibility of the mucosa differs from today, due to use ofstandard-de \ufb01nition (or even optical) endoscopes, less\neffective bowel preparation solutions and regimens, andless effective medical therapies for IBD.\n47,49\u201351,54\u201358\nThe notion of whether any dysplastic lesion is truly\ninvisible (as opposed to just subtle) is being increasinglychallenged, as is the practice of taking truly randombiopsies.\n3,16\u201320,28,59,60Notably, a small RCT from Japan\nfailed to show a bene \ufb01t of nontargeted biopsies in patients\nwith ulcerative colitis (UC).61Conversely, pooled estimates\nindicate that 1% \u20131.5% of patients with IBD undergoing\nsurveillance with HD-WLE would not have dysplasiadetected if nontargeted biopsies were eliminated.\n3Recent\nlarge series further report that up to 20% of dysplasticlesions are detected with nontargeted biopsies alone,\n62,63\nleading to concerns about eliminating this practice if DCEor VCE is not used.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39c7ddb0-fce0-4e67-aea5-69aa567901de": {"__data__": {"id_": "39c7ddb0-fce0-4e67-aea5-69aa567901de", "embedding": null, "metadata": {"page_label": "1047", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ad7d0a21-3e29-4e0a-af01-2382c406de2a", "node_type": "4", "metadata": {"page_label": "1047", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "b30421c075af65b0e3a401c065316cf5b4f924341a8db249fa320d979591202d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49d83f81-a8c4-47ee-836f-82ceabc06c60", "node_type": "1", "metadata": {"page_label": "1047", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "2e914907f779271acdb5a727681f8bae2c94f527269ae90e1056b988f524d13c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adb69bec-50f8-44d8-8af5-416182d544ba", "node_type": "1", "metadata": {"page_label": "1047", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "b4dfd35e25701b9141767c33b37873b73ad2b7ff08ced267ae2725cabd611bbf", "class_name": "RelatedNodeInfo"}}, "hash": "e788a0076d4317772a75ea0852b942594b67e5690267f68e954bf10008699055", "text": "A recent study noted additional\ndysplasia cases detected using nontargeted biopsies, evenwhen DCE was performed, particularly in those with ahistory of dysplasia, concomitant PSC, or a tubular colon.\n62\nApplying Adjunctive Modalities in Routine\nSurveillance\nThe literature on enhanced dysplasia detection tech-\nniques is large and growing, but heterogeneous. Severalgastroenterological societies recommend HD-DCE with tar-geted biopsies of suspicious lesions by appropriately trained\nendoscopists.\n59,64\u201370The American College of Gastroenter-\nology and European Society of Gastrointestinal Endoscopynow endorse virtual chromoendoscopy as an alternative toDCE.\n70Most societies no longer recommend taking non-\ntargeted biopsies for dysplasia detection if DCE isperformed.\n33,62,67,70There is greater trepidation among\nexperts of abandoning nontargeted biopsies if DCE is notperformed.\n3,71The American Society of Gastrointestinal\nEndoscopy endorses nontargeted biopsies as an alternativeto DCE if this expertise is unavailable or if the mucosa ispoorly visualized, such as in areas of signi \ufb01cant underlying\nin\ufb02ammation, signi \ufb01cant pseudopolyposis, or poor bowel\npreparation.\n32A Canadian multicenter RCT aims to shed\nfurther light on the utility of nontargeted biopsies fordysplasia surveillance in persons with cIBD ( ClinicalTrials.\ngovidenti \ufb01er NCT04067778).\nMore recent network meta-analyses of RCTs have not\nshown any single technique to be statistically superior fordetecting dysplasia (HD-WLE [with nontargeted biopsies],DCE, or NBI) although there is a trend favoring DCE.\n72,73\nSome studies have shown a very low incidence of\nadvanced colorectal neoplasia in follow-up examinations\nwhen dysplasia is not identi \ufb01ed with DCE or on consecutive\nnegative examinations,74\u201376questioning the necessity to\nroutinely perform frequent DCE after multiple negativehigh-quality examinations.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adb69bec-50f8-44d8-8af5-416182d544ba": {"__data__": {"id_": "adb69bec-50f8-44d8-8af5-416182d544ba", "embedding": null, "metadata": {"page_label": "1047", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ad7d0a21-3e29-4e0a-af01-2382c406de2a", "node_type": "4", "metadata": {"page_label": "1047", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "b30421c075af65b0e3a401c065316cf5b4f924341a8db249fa320d979591202d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39c7ddb0-fce0-4e67-aea5-69aa567901de", "node_type": "1", "metadata": {"page_label": "1047", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "e788a0076d4317772a75ea0852b942594b67e5690267f68e954bf10008699055", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c229caf-7c30-47d6-8a0a-2a2d3c5514ee", "node_type": "1", "metadata": {"page_label": "1048", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "c9a2c1da3f738793866b1918d676286d3bf80337e60cbc2bc897a00ebddd9466", "class_name": "RelatedNodeInfo"}}, "hash": "b4dfd35e25701b9141767c33b37873b73ad2b7ff08ced267ae2725cabd611bbf", "text": "Surveys in both Japan and theUnited States report that most gastroenterologists continueto use HD-WLE with targeted biopsies for surveillance,reserving DCE for higher-risk situations (eg, PSC and historyof dysplasia).\n77,78This current document endorses HD-DCE\nwith targeted biopsies, but acknowledges that this is anevolving area, with more recent data suggesting HD-VCEwith targeted biopsies or careful HD-WLE with targeted\nand nontargeted biopsies also appear appropriate.\nIn\ufb02ammatory Bowel Disease Dysplasia\nSurveillance and Management\nVisible Dysplasia\nBest Practice Advice 9: All clearly delineated\ndysplastic-appearing lesions without stigmata of inva-sive cancer or signi \ufb01cant submucosal \ufb01brosis should be\nconsidered for endoscopic resection. If the resectabilityof a lesion is in question, referral to a specializedendoscopist or in \ufb02ammatory bowel disease center is\nsuggested.September 2021 Surveillance and Management of Colorectal Dysplasia in IBDs 1047\nCLINICAL PRACTICE UPDATE", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c229caf-7c30-47d6-8a0a-2a2d3c5514ee": {"__data__": {"id_": "1c229caf-7c30-47d6-8a0a-2a2d3c5514ee", "embedding": null, "metadata": {"page_label": "1048", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9902a8c2-5457-4a78-82c1-b431991caf64", "node_type": "4", "metadata": {"page_label": "1048", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "3805a81ff7eb5a605f7b5633cb4f3b72c1c7bcf507f8ff5689d5c2fd6ac69818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adb69bec-50f8-44d8-8af5-416182d544ba", "node_type": "1", "metadata": {"page_label": "1047", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "b4dfd35e25701b9141767c33b37873b73ad2b7ff08ced267ae2725cabd611bbf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c42581a4-29c6-4310-903e-8a9dc1dbab99", "node_type": "1", "metadata": {"page_label": "1048", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "abd23ce2bb211c2726cb11d2c14b4007c5210f6a3c9b6d9f79aca2a1c7d29310", "class_name": "RelatedNodeInfo"}}, "hash": "c9a2c1da3f738793866b1918d676286d3bf80337e60cbc2bc897a00ebddd9466", "text": "Available data and guidelines support endoscopic\nresection of clearly delineated lesions, especially <2 cm,\nthat do not harbor features of invasive cancer or submu-cosal \ufb01brosis (such as mucosal depression, irregular surface\narchitecture, radiating folds, or failure to symmetrically liftwith submucosal saline injection), irrespective of lesion\nmorphology.\n3,5,28,33,79Although more data are needed to\nde\ufb01ne long-term outcomes with endoscopic resection of\nlarge (>2 cm) and/or complex dysplastic colorectal lesions,\nit is reasonable to consider endoscopic resection dependingon lesion characteristics, local expertise, as well as currentand past disease activity ( Figure 2 A). If there is uncertainty\nabout the most appropriate management strategy, casediscussion in multidisciplinary rounds or referral to aspecialized IBD center for a comprehensive evaluationshould be sought.\nStandard polypectomy techniques should generally suf-\n\ufb01ce for simpler lesions. For large and highly irregular le-\nsions, resection using advanced polypectomy techniques,including endoscopic mucosal resection or endoscopicsubmucosal dissection, can be considered.\n80Excessive or\ndeep biopsies or attempts to raise a lesion without resectionshould be avoided in this setting, as should unsuccessfulattempts to resect a complex lesion by less experiencedendoscopists, so as to limit submucosal scarring that willmake the lesion more dif \ufb01cult to resect endoscopically in\nthe future. When there is submucosal invasion or scarring,partial or total colectomy might ultimately be required to\ncompletely remove a lesion.\n81,82Good photodocumentation\nand an India Ink stain placed at least 3 cm distal to a lesion(for larger or more complex lesions) are helpful adjuncts.After endoscopic resection of a visible dysplastic lesion, thenext surveillance examination should occur at 3 \u20136 months\nfor the highest-risk lesions and no more than 24 monthsafter for the lowest risk,\n3,33,64,67with the latter group\nincluding simple sub-centimeter sessile or pedunculatedlow-grade adenomas ( Figure 2 A).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c42581a4-29c6-4310-903e-8a9dc1dbab99": {"__data__": {"id_": "c42581a4-29c6-4310-903e-8a9dc1dbab99", "embedding": null, "metadata": {"page_label": "1048", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9902a8c2-5457-4a78-82c1-b431991caf64", "node_type": "4", "metadata": {"page_label": "1048", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "3805a81ff7eb5a605f7b5633cb4f3b72c1c7bcf507f8ff5689d5c2fd6ac69818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c229caf-7c30-47d6-8a0a-2a2d3c5514ee", "node_type": "1", "metadata": {"page_label": "1048", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "c9a2c1da3f738793866b1918d676286d3bf80337e60cbc2bc897a00ebddd9466", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d33e945-d4c0-4691-8ed3-407e23aeb35e", "node_type": "1", "metadata": {"page_label": "1048", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "a8dfebfa8172b5e487567bb77e3ece13f4fea8ff48dbeb11b7ea882294612342", "class_name": "RelatedNodeInfo"}}, "hash": "abd23ce2bb211c2726cb11d2c14b4007c5210f6a3c9b6d9f79aca2a1c7d29310", "text": "24\u201326,29,83\nInvisible Dysplasia\nBest Practice Advice 10: A \ufb01nding of invisible\ndysplasia should prompt repeat examination by anexperienced endoscopist using high-de \ufb01nition dye\nspray chromoendoscopy under optimized viewing con-ditions, with extensive nontargeted biopsies in the areaof prior dysplasia if no lesion is seen. A \ufb01nding of\nunresectable visible dysplasia or of invisible multifocalor high-grade dysplasia on histology should promptcolectomy. For visible lesions that can be resected or if\nhistologic dysplasia is not con \ufb01rmed on a high-quality\ndye spray chromoendoscopy examination, continuedendoscopic surveillance at frequent intervals isappropriate.\nA\ufb01nding of invisible dysplasia (inde \ufb01nite, de \ufb01nite low-\ngrade, or high-grade) from nontargeted biopsies,con\ufb01rmed by a second expert pathologist, should prompt a\nrepeat colonoscopy with DCE using an HD endoscope by anexperienced endoscopist with the goal of unmasking invis-ible/subtle lesions for targeted resection ( Figure 2 B).\n3,33,70If there was active colonic in \ufb02ammation during the\noriginal examination, which can sometimes lead to misdi-agnosis of reactive atypia as dysplasia, measures should betaken to control the in \ufb02ammation before DCE. Extensive\nbiopsies should also be taken from the areas containingdysplasia in the original examination. If conditions for\nmucosal visualization are suboptimal, the DCE examination\nshould be repeated after optimization of viewing conditions.\nModern data suggest that the risk of future CRC in the\nsetting of unifocal low-grade dysplasia is considerably lowerthan in previous reports.\n84,85This is likely because of\nimproved endoscopic visualization of early dysplastic le-sions due to better in \ufb02ammatory control, improved endo-\nscope resolution, improved bowel preparation, and betteroverall endoscopy quality.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d33e945-d4c0-4691-8ed3-407e23aeb35e": {"__data__": {"id_": "6d33e945-d4c0-4691-8ed3-407e23aeb35e", "embedding": null, "metadata": {"page_label": "1048", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9902a8c2-5457-4a78-82c1-b431991caf64", "node_type": "4", "metadata": {"page_label": "1048", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "3805a81ff7eb5a605f7b5633cb4f3b72c1c7bcf507f8ff5689d5c2fd6ac69818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c42581a4-29c6-4310-903e-8a9dc1dbab99", "node_type": "1", "metadata": {"page_label": "1048", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "abd23ce2bb211c2726cb11d2c14b4007c5210f6a3c9b6d9f79aca2a1c7d29310", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae989339-631d-4def-935c-d770077c2933", "node_type": "1", "metadata": {"page_label": "1048", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "8368a7e4b8667c80ecece4e915cd22015556a8263939d0293a8373638ad2e9dd", "class_name": "RelatedNodeInfo"}}, "hash": "a8dfebfa8172b5e487567bb77e3ece13f4fea8ff48dbeb11b7ea882294612342", "text": "3,16\u201320CRC rates among IBD pa-\ntients have also declined substantially over time,approaching those of the non-IBD population in some cen-\nters.\n9,86,87Although the current document endorses inten-\nsive surveillance if unifocal invisible dysplasia or nodysplasia is found on extensive nontargeted biopsies in thearea of prior dysplasia during a high-quality DCE, data onlong-term outcomes are sparse. A risk \u2013bene\ufb01t discussion\nwith patients, which includes assessment of disease control,as well as short- and long-term cancer risk factors, isappropriate. Discussion in multidisciplinary rounds orreferral to a center with expertise in IBD care may behelpful if there is uncertainty about the most appropriatemanagement strategy.\nNo Dysplasia\nBest Practice Advice 11: After a negative screening\ncolonoscopy, surveillance colonoscopy should be per-formed every 1 \u20135 years based on risk factors for colo-\nrectal cancer, considering current and prior burden ofcolonic in \ufb02ammation, family history of colorectal can-\ncer, primary sclerosing cholangitis, history of colorectaldysplasia, and frequency and quality of prior surveil-\nlance examinations.\nAlthough no RCTs have evaluated the ef \ufb01cacy of\ndysplasia surveillance in IBD, observational studies havesuggested an earlier cancer stage at diagnosis and improvedCRC-related survival.\n88\u201392Once initiated, dysplasia surveil-\nlance should be performed at intervals guided by estab-lished CRC risk factors, including current and historicalin\ufb02ammatory burden (considering endoscopic and histo-\nlogic extent\n9,93,94and severity95\u201398), colitis duration,8,9,99\nfamily history of CRC,100,101PSC,12\u201314history of colorectal\ndysplasia,29,84frequency and quality of prior surveillance\nexaminations, as well as factors that may obscure subtle\ndysplasia, such as chronic changes associated with severecolitis (moderate to severe post-in \ufb02ammatory polyposis or\nextensive mucosal scarring) ( Figure 2 C).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae989339-631d-4def-935c-d770077c2933": {"__data__": {"id_": "ae989339-631d-4def-935c-d770077c2933", "embedding": null, "metadata": {"page_label": "1048", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9902a8c2-5457-4a78-82c1-b431991caf64", "node_type": "4", "metadata": {"page_label": "1048", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "3805a81ff7eb5a605f7b5633cb4f3b72c1c7bcf507f8ff5689d5c2fd6ac69818", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d33e945-d4c0-4691-8ed3-407e23aeb35e", "node_type": "1", "metadata": {"page_label": "1048", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "a8dfebfa8172b5e487567bb77e3ece13f4fea8ff48dbeb11b7ea882294612342", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8aa07ea-9972-479e-a448-8334e662da33", "node_type": "1", "metadata": {"page_label": "1049", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "2d6aa0c5247b83431b2c6d1b4049ff74e4f57ba2cf2c5f9cbb769741f564b2bb", "class_name": "RelatedNodeInfo"}}, "hash": "8368a7e4b8667c80ecece4e915cd22015556a8263939d0293a8373638ad2e9dd", "text": "Intervals have traditionally ranged between 1 and 3\nyears among US societies\n2,33,70and between 1 and 5 years\namong European societies.64,67For most patients in remis-\nsion, a 2- or 3-year interval is appropriate unless additionalhigh-risk factors are present, in which case a 1-year follow-up should be performed ( Figure 2 C). Improvements in1048 Murthy et al Gastroenterology Vol. 161, No. 3\nCLINICAL PRACTICE UPDATE", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8aa07ea-9972-479e-a448-8334e662da33": {"__data__": {"id_": "d8aa07ea-9972-479e-a448-8334e662da33", "embedding": null, "metadata": {"page_label": "1049", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "883fdb2b-3ab4-4258-9211-abfc1afbb23c", "node_type": "4", "metadata": {"page_label": "1049", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "19d474463413c19f685e3544557f32aa85737bb8aa88df7990390569d46bc639", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae989339-631d-4def-935c-d770077c2933", "node_type": "1", "metadata": {"page_label": "1048", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "8368a7e4b8667c80ecece4e915cd22015556a8263939d0293a8373638ad2e9dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "792ab654-96af-43dc-b817-0b3dfc8f9faf", "node_type": "1", "metadata": {"page_label": "1050", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "0cf915c2afe8163331429cd5bf2209363c8deeb28383771a9e0eb08631fa475e", "class_name": "RelatedNodeInfo"}}, "hash": "2d6aa0c5247b83431b2c6d1b4049ff74e4f57ba2cf2c5f9cbb769741f564b2bb", "text": "Figure 2. Principles of dysplasia management and surveillance intervals in IBD.September 2021 Surveillance and Management of Colorectal Dysplasia in IBDs 1049\nCLINICAL PRACTICE UPDATE", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "792ab654-96af-43dc-b817-0b3dfc8f9faf": {"__data__": {"id_": "792ab654-96af-43dc-b817-0b3dfc8f9faf", "embedding": null, "metadata": {"page_label": "1050", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "db333755-7304-4d6b-9ea7-6a8a3e1e075f", "node_type": "4", "metadata": {"page_label": "1050", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "8cf81c0e4f90f6e06c8f9e549d1b2295bcf48317970a398d012a97b8b55a76c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8aa07ea-9972-479e-a448-8334e662da33", "node_type": "1", "metadata": {"page_label": "1049", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "2d6aa0c5247b83431b2c6d1b4049ff74e4f57ba2cf2c5f9cbb769741f564b2bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00a41ff1-4456-45ed-927b-2805c2579936", "node_type": "1", "metadata": {"page_label": "1050", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "16b85419499d6189f727ae6600ac66a02b9ab37415fe9fbd2b8cf41e6742b51c", "class_name": "RelatedNodeInfo"}}, "hash": "0cf915c2afe8163331429cd5bf2209363c8deeb28383771a9e0eb08631fa475e", "text": "disease control, dysplasia detection capabilities over time,\nand general reduction in CRC risk in society suggest thatextending surveillance intervals to every 5 years in thelowest-risk patients is reasonable.\n64,67,76These patients\ninclude those with historically well-controlled disease be-tween consecutive colonoscopies with either short-segment\ncolonic disease (eg, isolated proctitis in UC or less than one-\nthird of colon in Crohn \u2019s disease),\n93,94,102,103or who have\nhad repeated examinations without dysplasia and withmucosal healing, in the absence of other inherent CRC riskfactors ( Figure 2 C).\n33,76Clinicians should, however, err on\nthe side of sooner surveillance (2 \u20133 years) in this group if\nuncertainty exists regarding disease control or dysplasiarisk, such as in those undergoing their \ufb01rst dysplasia sur-\nveillance examination ever or after many years. Patientswith Crohn \u2019s disease isolated to the small bowel do not\nappear to harbor a greater risk of CRC than comparable non-\nIBD patients,\n104thus average-risk CRC surveillance recom-\nmendations appear appropriate.105\nSpecial Topics\nSurveillance of Ileoanal Pouch\nBest Practice Advice 12: Pouch surveillance should\nbe performed at least annually in those at high risk fordeveloping colorectal dysplasia (prior colorectal canceror dysplasia, primary sclerosing cholangitis), as well asin those with persistent moderate to severe pouchitisand/or pre-pouch ileitis (to assess for treatmentresponse). Surveillance intervals in those at lower riskshould be individualized.\nA meta-analysis showed that IBD patients with prior\ncolorectal dysplasia or CRC had 4.4- and 15.0-fold increasedrisks of pouch cancer, respectively.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00a41ff1-4456-45ed-927b-2805c2579936": {"__data__": {"id_": "00a41ff1-4456-45ed-927b-2805c2579936", "embedding": null, "metadata": {"page_label": "1050", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "db333755-7304-4d6b-9ea7-6a8a3e1e075f", "node_type": "4", "metadata": {"page_label": "1050", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "8cf81c0e4f90f6e06c8f9e549d1b2295bcf48317970a398d012a97b8b55a76c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "792ab654-96af-43dc-b817-0b3dfc8f9faf", "node_type": "1", "metadata": {"page_label": "1050", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "0cf915c2afe8163331429cd5bf2209363c8deeb28383771a9e0eb08631fa475e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7cccca3-14f9-4572-a46a-e5909620b90e", "node_type": "1", "metadata": {"page_label": "1050", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "fae47570f0ddb40bba292e21d29d5fc8d49cd2148f1d0ddb8c981d81c2506176", "class_name": "RelatedNodeInfo"}}, "hash": "16b85419499d6189f727ae6600ac66a02b9ab37415fe9fbd2b8cf41e6742b51c", "text": "106Conversely, the cu-\nmulative incidence of cancers of the pouch and cuff (3.4% at25 years\n106) in those without risk factors remains lower\nthan the lifetime CRC risk in the general population.American Society of Gastrointestinal Endoscopy,\n59British\nSociety of Gastroenterology,64and European Crohn \u2019s and\nColitis Organisation107recommend annual surveillance for\nthose at high risk of dysplasia (prior colorectal dysplasia orcancer, PSC) and those with persistent pouchitis or type C\n(atrophic and in \ufb02amed) mucosa. The British Society of\nGastroenterology further recommends surveillance every 5years for those without risk factors.\nPseudopolyps\nBest Practice Advice 13: Targeted biopsies of\nrepresentative or concerning pseudopolyps is appro-priate during colonoscopy. Removal and sampling of alllesions is neither required nor practical. Surgery shouldbe a last resort to manage colorectal cancer risk in thesetting of severe pseudopolyposis. Dye spray chro-moendoscopy should not be used to detect \ufb02at or subtle\nlesions within a \ufb01eld of pseudopolyps.\nAcute pseudopolyps (normal mucosa within areas of\nulceration, giving the impression of a polyp) and chronicpost-in \ufb02ammatory polyps ( \ufb01nger-like or sessile projectionsof submucosa with surface architecture similar to the\nsurrounding mucosa on all sides) can sometimes mimicadenomas and make surveillance colonoscopy challenging,especially if present in high numbers. As these lesions arenot considered precancerous,\n108their removal is not\nrequired; however, targeted sampling of representative or\nsuspicious lesions is appropriate. Careful inspection of the\n\ufb02at mucosa between pseudopolyps, with or without non-\ntargeted biopsies, might be required to identify \ufb02at or subtle\nlesions. Colectomy to mitigate cancer risk in the setting ofextensive pseudopolyposis is rarely performed, but may beappropriate in select cases.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7cccca3-14f9-4572-a46a-e5909620b90e": {"__data__": {"id_": "d7cccca3-14f9-4572-a46a-e5909620b90e", "embedding": null, "metadata": {"page_label": "1050", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "db333755-7304-4d6b-9ea7-6a8a3e1e075f", "node_type": "4", "metadata": {"page_label": "1050", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "8cf81c0e4f90f6e06c8f9e549d1b2295bcf48317970a398d012a97b8b55a76c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00a41ff1-4456-45ed-927b-2805c2579936", "node_type": "1", "metadata": {"page_label": "1050", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "16b85419499d6189f727ae6600ac66a02b9ab37415fe9fbd2b8cf41e6742b51c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e0a450e-6dc4-42d6-b7b2-6de749c52350", "node_type": "1", "metadata": {"page_label": "1050", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "b0f3df20cf6a2faef2deaf5d523fe7d402bc54b4e49953ee7e4967f034e1bd6f", "class_name": "RelatedNodeInfo"}}, "hash": "fae47570f0ddb40bba292e21d29d5fc8d49cd2148f1d0ddb8c981d81c2506176", "text": "Chemoprevention\nBest Practice Advice 14: Optimal disease control\nwith medical therapy is imperative to minimizing an\nindividual \u2019s lifetime risk of developing colorectal can-\ncer. There is uncertainty regarding the independentchemotherapeutic bene \ufb01t of mesalamine therapy in\npeople with colonic in \ufb02ammatory bowel disease.\nBecause CRC risk in IBD is primarily driven by in \ufb02am-\nmation\n97and available data do not demonstrate a clear in-\ndependent chemopreventive effect of available agents, thefocus of chemoprevention in IBD should be control ofin\ufb02ammation. Although mesalamine has been linked to\nmultiple pathways involved in oncogenesis,\n109meta-\nanalyses of population-based studies have yielded con \ufb02ict-\ning results regarding the chemopreventive effect of mesal-amine therapy.\n110 \u2013114\nConclusions\nImprovements in disease management, as well as\nendoscopic technology and quality, have dramaticallychanged the way in which we think about IBD-relateddysplasia, aligning closely with how we conceptualizedysplasia in the non-IBD population. The practices of takingnontargeted biopsies and of referring patients for colectomy\nin the setting of low-grade or invisible dysplasia are being\nincreasingly challenged in favor of \u201csmart \u201dapproaches that\nemphasize careful inspection and targeted sampling ofvisible and subtle lesions using newer technologies(including HD-WLE and DCE), as well as endoscopic man-agement of most lesions that appear endoscopicallyresectable. Indeed, surgery is being increasingly reservedfor lesions harboring strong risk factors for invasive canceror when endoscopic clearance is not possible. More data arerequired to clarify the role of nontargeted biopsies whenperforming an examination using HD scopes, the long-termsafety of endoscopic management of large and complex\ndysplastic lesions, and the optimal surveillance intervals\nthat consider an individual \u2019s lifetime in \ufb02ammatory burden\nand other CRC risk factors.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e0a450e-6dc4-42d6-b7b2-6de749c52350": {"__data__": {"id_": "5e0a450e-6dc4-42d6-b7b2-6de749c52350", "embedding": null, "metadata": {"page_label": "1050", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "db333755-7304-4d6b-9ea7-6a8a3e1e075f", "node_type": "4", "metadata": {"page_label": "1050", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "8cf81c0e4f90f6e06c8f9e549d1b2295bcf48317970a398d012a97b8b55a76c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7cccca3-14f9-4572-a46a-e5909620b90e", "node_type": "1", "metadata": {"page_label": "1050", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "fae47570f0ddb40bba292e21d29d5fc8d49cd2148f1d0ddb8c981d81c2506176", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7e13590-8791-4629-b2c5-e1d24c641aaf", "node_type": "1", "metadata": {"page_label": "137", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "e75b20cb33cf50527f6a413ce1e764946c1fec14a37a3e1e827fb9ed5e098b6b", "class_name": "RelatedNodeInfo"}}, "hash": "b0f3df20cf6a2faef2deaf5d523fe7d402bc54b4e49953ee7e4967f034e1bd6f", "text": "We look forward to a day when asingle guideline can potentially address dysplasia surveil-lance and management in IBD and non-IBD patients alike.Until then, this document serves to summarize updatedunderstanding and best practice advice for dysplasia man-agement in IBD.1050 Murthy et al Gastroenterology Vol. 161, No. 3\nCLINICAL PRACTICE UPDATE", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7e13590-8791-4629-b2c5-e1d24c641aaf": {"__data__": {"id_": "b7e13590-8791-4629-b2c5-e1d24c641aaf", "embedding": null, "metadata": {"page_label": "137", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "27e7fbff-4a42-4e21-9625-d7726ea2e19f", "node_type": "4", "metadata": {"page_label": "137", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "4329452a47547d2a7e919f34fefc0b483046bf926d77903c4b86acb930865a21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e0a450e-6dc4-42d6-b7b2-6de749c52350", "node_type": "1", "metadata": {"page_label": "1050", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "b0f3df20cf6a2faef2deaf5d523fe7d402bc54b4e49953ee7e4967f034e1bd6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d5176e3-dbdd-4c66-8ca8-e5874094ee02", "node_type": "1", "metadata": {"page_label": "137", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "53e4db5c1e6341452b0f129bfc0af1d33fcfa3d40234f7436754dc979ef0244f", "class_name": "RelatedNodeInfo"}}, "hash": "e75b20cb33cf50527f6a413ce1e764946c1fec14a37a3e1e827fb9ed5e098b6b", "text": "Copyright \u00a9 The American Society of Colon & Rectal Surgeons, Inc. Unauthorized reproduction of this article is prohibited.137 Diseases of the Colon & ReCtum Volume  60: 2 (2017) the american s ociety of Colon and Rectal s urgeons \nis dedicated to ensuring high-quality patient care \nby advancing the science, prevention, and manage-\nment of disorders and diseases of the colon, rectum, and \nanus. t he Clinical Practice Guidelines Committee is com-\nposed of s ociety members who are chosen because they \nhave demonstrated expertise in the specialty of colon and rectal surgery. t his Committee was created to lead interna-\ntional efforts in defining quality care for conditions related \nto the colon, rectum, and anus. t his is accompanied by \ndeveloping Clinical Practice Guidelines based on the best available evidence. t hese guidelines are inclusive and not \nprescriptive. t heir purpose is to provide information on \nwhich decisions can be made, rather than to dictate a spe-cific form of treatment. t hese guidelines are intended for \nthe use of all practitioners, healthcare workers, and patients who desire information about the management of the con-ditions addressed by the topics covered in these guidelines.\nit should be recognized that these guidelines should \nnot be deemed inclusive of all proper methods of care or exclusive of methods of care reasonably directed to ob-taining the same results. t he ultimate judgment regarding \nthe propriety of any specific procedure must be made by the physician in light of all of the circumstances presented by the individual patient.\nSTATEMENT OF THE PROBLEM\nthe american society of Colon and Rectal surgeons par -\nticipated in development of the 2014 us m ulti-s ociety \ntask force on Colorectal Cancer Guidelines1 for l ynch \nsyndrome, which provide a colorectal cancer risk-assess-ment tool to screen individuals in the office or endos-copy setting and a strategy for universal screening for lynch syndrome by tumor testing of patients diagnosed \nwith colorectal cancer, algorithms for genetic evaluation of affected and at-risk family members of pedigrees with \nlynch syndrome, and guidelines for screening at-risk and \naffected persons with l ynch syndrome.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d5176e3-dbdd-4c66-8ca8-e5874094ee02": {"__data__": {"id_": "1d5176e3-dbdd-4c66-8ca8-e5874094ee02", "embedding": null, "metadata": {"page_label": "137", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "27e7fbff-4a42-4e21-9625-d7726ea2e19f", "node_type": "4", "metadata": {"page_label": "137", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "4329452a47547d2a7e919f34fefc0b483046bf926d77903c4b86acb930865a21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7e13590-8791-4629-b2c5-e1d24c641aaf", "node_type": "1", "metadata": {"page_label": "137", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "e75b20cb33cf50527f6a413ce1e764946c1fec14a37a3e1e827fb9ed5e098b6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41ff8c99-fa75-489b-9740-41bd06363d24", "node_type": "1", "metadata": {"page_label": "137", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "44576ac7dc7915d974a3e419af5822f430c7f2e8ace62a4d323519397d1a1a78", "class_name": "RelatedNodeInfo"}}, "hash": "53e4db5c1e6341452b0f129bfc0af1d33fcfa3d40234f7436754dc979ef0244f", "text": "t hese guidelines \nare summarized in t able 1, and the reader is encouraged \nto refer to them directly for supplementary content. ad-\nditional guidance is given here more specifically for the surgical management of patients with l ynch syndrome.\nColorectal cancer is the third most common cancer in \nmen and women in the u nited states and the second lead-\ning cause of cancer deaths.\n2 approximately 20% to 30% of \ncolorectal cancer cases are associated with a family history of colorectal polyps or cancer, and \u2248 3% to 5% of cases are associ-\nated with an identifiable inherited colorectal cancer syndrome. the most common of these is l ynch syndrome, characterized \nby a mutation in one of the Dna mismatch repair genes.\nthe diagnosis of l ynch syndrome was initially based \non a set of clinical criteria known as the amsterdam cri-\nteria ( table 2).\n3,4 as the molecular understanding of the \nsyndrome improved, microsatellite testing has been used as a screening test for patients with l ynch syndrome. t he \nBethesda criteria, first published in 1997 and updated in 2004 ( table 3),\n5,6 were initially intended to define who \nshould be tested for microsatellite instability and not meant as a way to diagnose l ynch syndrome. With the \nidentification of the specific genes involved, additional screening methods were developed, including immuno-histochemical staining of the proteins produced by the genes and germline testing. Germline sequencing of the mismatch repair genes remains the gold standard for con-firming the causative gene mutation for l ynch syndrome. \nan estimated 40% of patients meet amsterdam criteria \nbut have no mutation identified; because l ynch syndrome \nis now defined by its genetic basis, this clinical condition, termed familial colorectal cancer type X, is now considered \nseparately from l ynch syndrome.\n7\nMETHODOLOGY\nthese guidelines are built on the last set of the american \nsociety of Colon and Rectal s urgeons Practice Parameters Clinical Practice Guidelines for the Surgical \nTreatment of Patients With Lynch Syndrome\nDaniel O. Herzig, M.D. \u2022 W. Donald Buie, M.D. \u2022 Martin R. Weiser, M.D.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41ff8c99-fa75-489b-9740-41bd06363d24": {"__data__": {"id_": "41ff8c99-fa75-489b-9740-41bd06363d24", "embedding": null, "metadata": {"page_label": "137", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "27e7fbff-4a42-4e21-9625-d7726ea2e19f", "node_type": "4", "metadata": {"page_label": "137", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "4329452a47547d2a7e919f34fefc0b483046bf926d77903c4b86acb930865a21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d5176e3-dbdd-4c66-8ca8-e5874094ee02", "node_type": "1", "metadata": {"page_label": "137", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "53e4db5c1e6341452b0f129bfc0af1d33fcfa3d40234f7436754dc979ef0244f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de658d79-ea8d-478f-8692-88cbe424fd65", "node_type": "1", "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "4caec64a7f514bc83e4c2680710b61e5c271038daeafc43bcd26e7e6fc637c1b", "class_name": "RelatedNodeInfo"}}, "hash": "44576ac7dc7915d974a3e419af5822f430c7f2e8ace62a4d323519397d1a1a78", "text": "\u2022 Martin R. Weiser, M.D.  \nY. Nancy Y ou, M.D. \u2022 Janice F. Rafferty, M.D. \u2022 Daniel Feingold, M.D.  scott R. steele, m.D.\nPrepared on Behalf of the Clinical Practice Guidelines Committee of the american s ociety of Colon and Rectal s urgeons\nDis Colon Rectum 2017; 60: 137\u2013143\nDoi: 10.1097/DCR.0000000000000785\n\u00a9 the asCRs 2016CLiNiCAL  PRACTiCE GUiDELiNES", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de658d79-ea8d-478f-8692-88cbe424fd65": {"__data__": {"id_": "de658d79-ea8d-478f-8692-88cbe424fd65", "embedding": null, "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b8663f18-a984-4313-98e9-31be402eb51a", "node_type": "4", "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "11b56bac22e7701235a5d4c6007315560d4acc95c97a68aba18a709450cfac15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41ff8c99-fa75-489b-9740-41bd06363d24", "node_type": "1", "metadata": {"page_label": "137", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "44576ac7dc7915d974a3e419af5822f430c7f2e8ace62a4d323519397d1a1a78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80f75769-d5b7-4bd1-8f58-1e7325f29b6a", "node_type": "1", "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "27f24bc35144541b28c6e40bca8afa07aab3d5ad5a06ae9e18d23a1630cb8200", "class_name": "RelatedNodeInfo"}}, "hash": "4caec64a7f514bc83e4c2680710b61e5c271038daeafc43bcd26e7e6fc637c1b", "text": "Copyright \u00a9 The American Society of Colon & Rectal Surgeons, Inc. Unauthorized reproduction of this article is prohibited.Herzig  et al: Surgical  treatment  of lyncH  Syndrome 138\nfor the Identification and Testing of Patients At Risk for \nDominantly Inherited Colorectal Cancer published in 2003.8 \nan organized search of meDline (o vid meDline and \novid olDmeDline), Pubm ed, and Cochrane Database of systematic Reviews was performed through april 2016. \nKeyword combinations, including colorectal neoplasm \n(limited to genetics subheading and limited to clinical study, clinical trial, comparative study, guideline, journal TABLE 1.   Summary of Multi-Society Task Force guidelines\nVariable Recommendation\nScreening/testing  \n Genetic testing Universal testing (tumor testing)\n\u2022\u2002Testing\u2002for\u2002MMR\u2002deficiency\u2002of\u2002newly\u2002diagnosed\u2002CRC\u2002should\u2002be\u2002performed\u2022\u2002This\u2002can\u2002be\u2002done\u2002for\u2002all\u2002CRCs\u2002or\u2002CRC\u2002diagnosed\u2002at\u2002age\u2002\u226470\u2002y\u2002and\u2002in\u2002individuals\u2002>70\u2002y\u2002who\u2002have\u2002a\u2002family\u2002\nhistory\u2002concerning\u2002for\u2002LS\n\u2022\u2002 Analysis\u2002can\u2002be\u2002done\u2002by\u2002IHC\u2002testing\u2002for\u2002the\u2002MLH1/MSH2/MSH6/PMS2\u2002proteins\u2002and/or\u2002testing\u2002for\u2002MSI\u2022\u2002Tumors\u2002that\u2002demonstrate\u2002loss\u2002of\u2002MLH1\u2002should\u2002undergo\u2002BRAF\u2002testing\u2002or\u2002analysis\u2002of\u2002MLH1\u2002promoter\u2002\nhypermethylation\n\u2022\u2002\u2002To\u2002facilitate\u2002surgical\u2002planning,", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80f75769-d5b7-4bd1-8f58-1e7325f29b6a": {"__data__": {"id_": "80f75769-d5b7-4bd1-8f58-1e7325f29b6a", "embedding": null, "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b8663f18-a984-4313-98e9-31be402eb51a", "node_type": "4", "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "11b56bac22e7701235a5d4c6007315560d4acc95c97a68aba18a709450cfac15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de658d79-ea8d-478f-8692-88cbe424fd65", "node_type": "1", "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "4caec64a7f514bc83e4c2680710b61e5c271038daeafc43bcd26e7e6fc637c1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd440220-dccc-4636-98d4-8b2ec3565af7", "node_type": "1", "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "29839c6da8bc683e8909c263e7f7c0f0088723c62206ffe5be74190d8779af6e", "class_name": "RelatedNodeInfo"}}, "hash": "27f24bc35144541b28c6e40bca8afa07aab3d5ad5a06ae9e18d23a1630cb8200", "text": "tumor\u2002testing\u2002on\u2002suspected\u2002CRC\u2002should\u2002be\u2002performed\u2002on\u2002preoperative\u2002\nbiopsy\u2002specimens,\u2002if\u2002possible\nTraditional testing (germline testing)\n\u2022\u2002 Individuals\u2002who\u2002have\u2002a\u2002personal\u2002history\u2002of\u2002a\u2002Lynch\u2002syndrome\u2013related\u2002tumor\u2002showing\u2002evidence\u2002of\u2002MMR\u2002\ndeficiency\u2002(without\u2002evidence\u2002of\u2002MLH1\u2002promoter\u2002methylation)\n\u2022\u2002 Personal\u2002history\u2002of\u2002uterine\u2002cancer\u2002diagnosed\u2002at\u2002age\u2002<50\u2002y\u2022\u2002 A\u2002known\u2002family\u2002MMR\u2002gene\u2002mutation\u2022\u2002 Fulfill\u2002Amsterdam\u2002criteria\u2002or\u2002revised\u2002Bethesda\u2002guidelines\u2022\u2002 Have\u2002a\u2002personal\u2002risk\u2002of\u2002\u22655%\u2002chance\u2002of\u2002LS\u2002based\u2002on\u2002prediction\u2002models\n\u2002LS\u2002management \u2022\u2002 Screening\u2002for\u2002CRC\u2002by\u2002colonoscopy\u2002is\u2002recommended\u2002in\u2002persons\u2002at\u2002risk\u2002(first-degree\u2002relatives\u2002of\u2002known\u2002MMR\u2002\ngene\u2002mutation\u2002carriers\u2002who\u2002have\u2002not\u2002had\u2002genetic\u2002testing)\u2002or\u2002affected\u2002with\u2002LS\u2002every\u20021\u2002to\u20022\u2002y,", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd440220-dccc-4636-98d4-8b2ec3565af7": {"__data__": {"id_": "cd440220-dccc-4636-98d4-8b2ec3565af7", "embedding": null, "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b8663f18-a984-4313-98e9-31be402eb51a", "node_type": "4", "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "11b56bac22e7701235a5d4c6007315560d4acc95c97a68aba18a709450cfac15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80f75769-d5b7-4bd1-8f58-1e7325f29b6a", "node_type": "1", "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "27f24bc35144541b28c6e40bca8afa07aab3d5ad5a06ae9e18d23a1630cb8200", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca0da5a0-5b58-487b-be61-1cfddb8488df", "node_type": "1", "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1fd963dcca355c200d21bfec3f2fcf35f739327d5c27154249b63782f15c1b10", "class_name": "RelatedNodeInfo"}}, "hash": "29839c6da8bc683e8909c263e7f7c0f0088723c62206ffe5be74190d8779af6e", "text": "beginning\u2002between\u2002ages\u200220\u2002and\u200225\u2002y\u2002or\u20022\u2002to\u20025\u2002y\u2002before\u2002the\u2002youngest\u2002age\u2002of\u2002diagnosis\u2002of\u2002CRC\u2002in\u2002the\u2002family\u2002if\u2002diagnosed\u2002before\u2002age\u200225\u2002y\n\u2022\u2002 For\u2002MMR\u2002germline\u2002mutation\u2013positive\u2002patients,\u2002consideration\u2002should\u2002be\u2002given\u2002to\u2002annual\u2002colonoscopy\u2022\u2002 In\u2002carriers\u2002of\u2002deleterious\u2002MSH6\u2002and\u2002PMS2\u2002mutations,\u2002the\u2002risk\u2002of\u2002CRC\u2002is\u2002lower\u2002and\u2002age\u2002at\u2002diagnosis\u2002later\u2002than\u2002\nin\u2002patients\u2002with\u2002MLH1\u2002and\u2002MSH2\u2002mutations;\u2002consideration\u2002could\u2002be\u2002given\u2002to\u2002starting\u2002screening\u2002at\u2002age\u200230\u2002y\u2002in\u2002MSH6\u2002and\u200235\u2002y\u2002in\u2002PMS2\u2002carriers,", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca0da5a0-5b58-487b-be61-1cfddb8488df": {"__data__": {"id_": "ca0da5a0-5b58-487b-be61-1cfddb8488df", "embedding": null, "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b8663f18-a984-4313-98e9-31be402eb51a", "node_type": "4", "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "11b56bac22e7701235a5d4c6007315560d4acc95c97a68aba18a709450cfac15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd440220-dccc-4636-98d4-8b2ec3565af7", "node_type": "1", "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "29839c6da8bc683e8909c263e7f7c0f0088723c62206ffe5be74190d8779af6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "892ba7b3-421f-4771-ae77-73466e2bcfa7", "node_type": "1", "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "fb3376c1b6f6a3ac06a73ee955b6627a2f7a24279ee4a660cab4c83bb74fe818", "class_name": "RelatedNodeInfo"}}, "hash": "1fd963dcca355c200d21bfec3f2fcf35f739327d5c27154249b63782f15c1b10", "text": "unless\u2002an\u2002early\u2002onset\u2002cancer\u2002exists\u2002in\u2002a\u2002given\u2002family\n Endometrial cancer \u2022\u2002 Screening\u2002should\u2002be\u2002offered\u2002to\u2002women\u2002at\u2002risk\u2002for\u2002or\u2002affected\u2002with\u2002LS\u2002by\u2002pelvic\u2002examination\u2002and\u2002\nendometrial\u2002sampling\u2002annually\u2002starting\u2002at\u2002age\u200230\u201335\u2002y\n Ovarian cancer \u2022\u2002 Screening\u2002should\u2002be\u2002offered\u2002to\u2002women\u2002at\u2002risk\u2002for\u2002or\u2002affected\u2002with\u2002LS\u2002by\u2002transvaginal\u2002ultrasound\u2002annually\u2002\nstarting\u2002at\u2002age\u200230\u201335\u2002y\n\u2002Prophylactic\u2002hysterectomy\u2002and\u2002oophorectomy\u2022\u2002 Hysterectomy\u2002and\u2002bilateral\u2002salpingo-oophorectomy\u2002should\u2002be\u2002recommended\u2002to\u2002women\u2002with\u2002LS\u2002who\u2002have\u2002\nfinished\u2002childbearing\u2002or\u2002at\u2002age\u200240\u2002y\n\u2022\u2002 Patient\u2002considerations\u2002in\u2002this\u2002decision\u2002could\u2002include\u2002differences\u2002in\u2002uterine\u2002cancer\u2002risk,\u2002depending\u2002on\u2002MMR\u2002\ngene\u2002mutation;\u2002morbidity\u2002of\u2002surgery;\u2002and\u2002the\u2002risk\u2002of\u2002menopausal\u2002symptoms,\u2002osteoporosis,", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "892ba7b3-421f-4771-ae77-73466e2bcfa7": {"__data__": {"id_": "892ba7b3-421f-4771-ae77-73466e2bcfa7", "embedding": null, "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b8663f18-a984-4313-98e9-31be402eb51a", "node_type": "4", "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "11b56bac22e7701235a5d4c6007315560d4acc95c97a68aba18a709450cfac15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca0da5a0-5b58-487b-be61-1cfddb8488df", "node_type": "1", "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "1fd963dcca355c200d21bfec3f2fcf35f739327d5c27154249b63782f15c1b10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "635a6896-84aa-4c99-9f94-0d498af2f29c", "node_type": "1", "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "9d96e5114bda6443270fa05860fe706b78db963f1da0d8e15fc409feb68bb123", "class_name": "RelatedNodeInfo"}}, "hash": "fb3376c1b6f6a3ac06a73ee955b6627a2f7a24279ee4a660cab4c83bb74fe818", "text": "osteoporosis,\u2002and\u2002cardiac\u2002disease\u2002if\u2002hormone\u2002replacement\u2002therapy\u2002is\u2002not\u2002given\n Gastric cancer \u2022\u2002 Screening\u2002should\u2002be\u2002considered\u2002in\u2002persons\u2002at\u2002risk\u2002for\u2002or\u2002affected\u2002with\u2002LS\u2002by\u2002esophagogastroduodenoscopy\u2002\nwith\u2002gastric\u2002biopsy\u2002of\u2002the\u2002antrum\u2002at\u2002age\u200230\u201335\u2002y\n\u2022\u2002Treatment\u2002of\u2002Helicobacter pylori\u2002infection\u2002should\u2002be\u2002administered\u2002when\u2002found\u2022\u2002 Subsequent,\u2002surveillance\u2002every\u20022\u20133\u2002y\u2002can\u2002be\u2002considered\u2002based\u2002on\u2002individual\u2002patient\u2002risk\u2002factors\n Small intestinal cancer \u2022\u2002 Routine\u2002screening\u2002of\u2002the\u2002small\u2002intestine\u2002is\u2002not\u2002recommended\n\u2002Cancers\u2002of\u2002urinary\u2002tract \u2022\u2002 Screening\u2002should\u2002be\u2002considered\u2002for\u2002persons\u2002at\u2002risk\u2002for\u2002or\u2002affected\u2002with\u2002LS,\u2002with\u2002urinalysis\u2002annually\u2002starting\u2002\nat\u2002age\u200230\u201335\u2002y\n\u2002Pancreatic\u2002cancer \u2022\u2002 Routine\u2002screening\u2002of\u2002the\u2002pancreas\u2002is\u2002not\u2002recommended;", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "635a6896-84aa-4c99-9f94-0d498af2f29c": {"__data__": {"id_": "635a6896-84aa-4c99-9f94-0d498af2f29c", "embedding": null, "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b8663f18-a984-4313-98e9-31be402eb51a", "node_type": "4", "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "11b56bac22e7701235a5d4c6007315560d4acc95c97a68aba18a709450cfac15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "892ba7b3-421f-4771-ae77-73466e2bcfa7", "node_type": "1", "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "fb3376c1b6f6a3ac06a73ee955b6627a2f7a24279ee4a660cab4c83bb74fe818", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c72ad10-f9b4-464e-9195-3bc59dcf1af9", "node_type": "1", "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "3e7d4b1ff8e1a3268130139ba3c6e964e922fe0cb82bb73ed7de8be364279b1a", "class_name": "RelatedNodeInfo"}}, "hash": "9d96e5114bda6443270fa05860fe706b78db963f1da0d8e15fc409feb68bb123", "text": "the\u2002benefit\u2002of\u2002screening\u2002for\u2002pancreatic\u2002cancer\u2002with\u2002\nthis\u2002magnitude\u2002of\u2002risk\u2002is\u2002not\u2002established\n\u2002Breast\u2002and\u2002prostate\u2002cancer \u2022\u2002 Routine\u2002screening\u2002of\u2002the\u2002prostate\u2002and\u2002breast\u2002cancer\u2002is\u2002not\u2002recommended\u2002beyond\u2002what\u2002is\u2002advised\u2002for\u2002the\u2002\ngeneral\u2002population.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c72ad10-f9b4-464e-9195-3bc59dcf1af9": {"__data__": {"id_": "9c72ad10-f9b4-464e-9195-3bc59dcf1af9", "embedding": null, "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b8663f18-a984-4313-98e9-31be402eb51a", "node_type": "4", "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "11b56bac22e7701235a5d4c6007315560d4acc95c97a68aba18a709450cfac15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "635a6896-84aa-4c99-9f94-0d498af2f29c", "node_type": "1", "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "9d96e5114bda6443270fa05860fe706b78db963f1da0d8e15fc409feb68bb123", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6dcb522b-391f-4d43-a61b-0a0984ab010d", "node_type": "1", "metadata": {"page_label": "139", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "ff751f95464ffb7c99c0728182cc68a3bd75dec235ca6e74bb44b965dad42d6c", "class_name": "RelatedNodeInfo"}}, "hash": "3e7d4b1ff8e1a3268130139ba3c6e964e922fe0cb82bb73ed7de8be364279b1a", "text": "Treatment/prevention  \n\u2002Colectomy \u2022\u2002 Colectomy\u2002with\u2002ileorectal\u2002anastomosis\u2002is\u2002the\u2002primary\u2002treatment\u2002of\u2002patients\u2002affected\u2002with\u2002LS\u2002with\u2002colon\u2002\ncancer\u2002or\u2002colon\u2002neoplasia\u2002not\u2002removable\u2002by\u2002endoscopy\n\u2022\u2002 Consideration\u2002for\u2002less-extensive\u2002surgery\u2002should\u2002be\u2002given\u2002in\u2002patients\u2002>60\u201365\u2002y\u2002and\u2002those\u2002with\u2002underlying\u2002\nsphincter\u2002dysfunction\n\u2002Aspirin \u2022\u2002 Growing\u2002but\u2002not\u2002conclusive\u2002evidence\u2002exists\u2002that\u2002use\u2002of\u2002aspirin\u2002is\u2002beneficial\u2002in\u2002preventing\u2002cancer\u2002in\u2002patients\u2002\nwith\u2002LS\u2002\n\u2022\u2002Treatment\u2002of\u2002an\u2002individual\u2002patient\u2002with\u2002aspirin\u2002is\u2002a\u2002consideration\u2002after\u2002discussion\u2002of\u2002patient-specific\u2002risks,\u2002\nbenefits,\u2002and\u2002uncertainties\u2002of\u2002treatment\u2002is\u2002conducted\nMSI\u2002=\u2002microsatellite\u2002instability;\u2002MMR\u2002=\u2002mismatch\u2002repair;\u2002CRC\u2002=\u2002colorectal\u2002cancer;\u2002LS\u2002=\u2002Lynch\u2002syndrome;\u2002IHC\u2002=\u2002immunohistochemistry.\nTable\u2002was\u2002adapted\u2002from\u2002Giardiello\u2002et\u2002al.1", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6dcb522b-391f-4d43-a61b-0a0984ab010d": {"__data__": {"id_": "6dcb522b-391f-4d43-a61b-0a0984ab010d", "embedding": null, "metadata": {"page_label": "139", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fead70f1-cc0a-4faa-a49f-b49c6202bad4", "node_type": "4", "metadata": {"page_label": "139", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "9548bfec64abc72c38c1a056ebb5b2607ff2311b998a44d9a24fab9179aca097", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c72ad10-f9b4-464e-9195-3bc59dcf1af9", "node_type": "1", "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "3e7d4b1ff8e1a3268130139ba3c6e964e922fe0cb82bb73ed7de8be364279b1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7dec904-665d-4332-a297-7797d199e171", "node_type": "1", "metadata": {"page_label": "139", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "34b3a27c64c57889747baf935f798267cc84932f7110ac03d4d7bd3800b593a4", "class_name": "RelatedNodeInfo"}}, "hash": "ff751f95464ffb7c99c0728182cc68a3bd75dec235ca6e74bb44b965dad42d6c", "text": "Copyright \u00a9 The American Society of Colon & Rectal Surgeons, Inc. Unauthorized reproduction of this article is prohibited.Diseases of the Colon & ReCtum  Volume  60: 2 (2017) 139\narticle, meta-analysis, multicenter study, or observational \nstudy; 546 references); hereditary nonpolyposis colon cancer \nor Lynch syndrome (which mapped to the subject heading \ncolon neoplasms, hereditary nonpolyposis, 3344 referenc-es); genetic counseling and colon; and genetic screening and \ncolon (14 references) were included. t itles were screened \nand 1688 selected abstract were reviewed, yielding 229 \nreferences selected for additional review. after review, 60 \nreferences were considered for grading. Directed searches \nof the embedded references from the primary articles were also performed in selected circumstances. t he final grade \nof recommendation was performed using the Grades of \nRecommendation, assessment, Development, and evalu-\nation system ( table 4).\n9\nMANAGEMENT\n1. For individuals with Lynch syndrome who develop a co-\nlon cancer, a total colectomy is preferred for cancer risk \nreduction. Strong recommendation based on moderate-\nquality evidence. 1Bin contrast to sporadic colon cancer, 3 issues must be evalu-\nated when considering the appropriate surgical treatment \nfor colon cancer in the setting of l ynch syndrome: 1) appro-\npriate treatment of the primary tumor, 2) consideration of risk reduction with prophylactic removal of nonneoplastic colon, and 3) morbidity and quality of life after colectomy. there is no prospective randomized trial comparing extend-\ned resection with a limited resection. t hree retrospective \nstudies have examined the degree of metachronous cancer risk reduction. Kalady et al\n10 examined a cohort of patients \nmeeting amsterdam criteria with colon cancer. of the co-\nhort of 296 patients, segmental colectomy was performed \nin 253 patients (85%) and total colectomy in the remaining \n43. t here was superior risk reduction in the total colectomy \ngroup, with second primary cancers occurring in 25% of the segmental colectomy group versus 8% of the total colectomy group.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7dec904-665d-4332-a297-7797d199e171": {"__data__": {"id_": "d7dec904-665d-4332-a297-7797d199e171", "embedding": null, "metadata": {"page_label": "139", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fead70f1-cc0a-4faa-a49f-b49c6202bad4", "node_type": "4", "metadata": {"page_label": "139", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "9548bfec64abc72c38c1a056ebb5b2607ff2311b998a44d9a24fab9179aca097", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6dcb522b-391f-4d43-a61b-0a0984ab010d", "node_type": "1", "metadata": {"page_label": "139", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "ff751f95464ffb7c99c0728182cc68a3bd75dec235ca6e74bb44b965dad42d6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "369f5fbe-afa3-4572-96ac-19776ef25b93", "node_type": "1", "metadata": {"page_label": "139", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "11ed3aec4f366073b7466a59d445ce0201423f2f4fe247b28f92877c574f9edc", "class_name": "RelatedNodeInfo"}}, "hash": "34b3a27c64c57889747baf935f798267cc84932f7110ac03d4d7bd3800b593a4", "text": "t he difference was seen despite annual endoscopic \nsurveillance in 88% of patients; median follow-up was 104 months. n early identical findings were noted from a case\u2013\ncontrol study of 37 patients with l ynch syndrome who were \ntreated with either segmental or prophylactic total colecto-\nmy compared with 69 matched control subjects. t he study \nshowed a significant decrease in metachronous cancer with a \ntotal abdominal colectomy compared with segmental resec-\ntions of cancers (6% vs 26%).\n11 the largest cohort analysis to \ndate from the Colon Cancer f amily Registry examined 382 \npatients with colon cancer and mismatch repair gene muta-tions.\n12 most patients (332/382 (87%)) underwent segmen-\ntal resection. m etachronous cancer occurred in 74 (22%) of \n332 patients who had segmental colectomy versus 0 (0%) of \n50 patients who had total colectomy. Both groups under -\nwent appropriate endoscopic surveillance, with an average of 1 examination every 20 months in the segmental group and 1 examination every 16 months in the total colectomy group. \nthe cumulative risk of metachronous colorectal cancer in \npatients in the segmental group was 16% at 10 years, 41% \nat 20 years, and 62% at 30 years. t his rate is at least as high, \nor higher, than the anticipated risk of a patient with l ynch \nsyndrome developing colorectal cancer without ever having a segmental colectomy, suggesting that there is no risk reduc-tion against metachronous cancer when patients undergo segmental resection. t hey noted that the risk of metachro-\nnous colorectal cancer was reduced by 31% for every 10 cm \nof bowel removed.\nas noted in t able 1, the us m ulti-s ociety t ask f orce on \nColorectal Cancer recommends total colectomy with ileo-rectal anastomosis for the treatment of colon cancer in the setting of l ynch syndrome.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "369f5fbe-afa3-4572-96ac-19776ef25b93": {"__data__": {"id_": "369f5fbe-afa3-4572-96ac-19776ef25b93", "embedding": null, "metadata": {"page_label": "139", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fead70f1-cc0a-4faa-a49f-b49c6202bad4", "node_type": "4", "metadata": {"page_label": "139", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "9548bfec64abc72c38c1a056ebb5b2607ff2311b998a44d9a24fab9179aca097", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7dec904-665d-4332-a297-7797d199e171", "node_type": "1", "metadata": {"page_label": "139", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "34b3a27c64c57889747baf935f798267cc84932f7110ac03d4d7bd3800b593a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d92516a-c9e8-4eec-8f3a-aa390d1cd2ac", "node_type": "1", "metadata": {"page_label": "139", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "a01cc48b1267c7461cbdf6645b1fb5597b360d1a753439dab7f0b77d9248a1a5", "class_name": "RelatedNodeInfo"}}, "hash": "11ed3aec4f366073b7466a59d445ce0201423f2f4fe247b28f92877c574f9edc", "text": "1 the 2013 m allorca guidelines, \ncomposed of expert opinion from the m allorca group, rec-\nommend that \u201cthe option of subtotal colectomy including \nits pros and cons should be discussed with all l ynch syn-\ndrome patients with CRC, especially younger patients.\u201d13\nit should be noted that before available data regard-\ning the benefit of metachronous cancer risk reduction TABLE 2.\u2002 \u2002\u2002Amsterdam\u2002II\u2002criteria3,4\n\u2002 \u20021.\u2002\u2002Three\u2002or\u2002more\u2002relatives\u2002with\u2002an\u2002associated\u2002cancer\u2002(colorectal \u2002\ncancer\u2002or\u2002cancer\u2002of\u2002the\u2002endometrium,\u2002small\u2002 intestine,\u2002ureter,\u2002or \u2002\nrenal\u2002pelvis);\u20021\u2002should\u2002be\u2002a\u2002first-degree\u2002relative\u2002of\u2002the\u2002other\u20022\n\u2002 \u20022.\u2002Two\u2002or\u2002more\u2002successive\u2002generations\u2002affected\n\u2002 \u20023.\u2002One\u2002or\u2002more\u2002relatives\u2002diagnosed\u2002before\u2002the\u2002age\u2002of\u200250\u2002y\nFamilial\u2002adenomatous\u2002polyposis\u2002should\u2002be\u2002excluded\u2002in\u2002cases\u2002of\u2002\ncolorectal carcinoma\nTumors\u2002should\u2002be\u2002verified\u2002by\u2002pathologic\u2002examination\u2002whenever\u2002\npossible\nTABLE 3.\u2002 \u2002\u2002Revised\u2002Bethesda\u2002criteria6\nTumors\u2002from\u2002individuals\u2002should\u2002be\u2002tested\u2002for\u2002MSI\u2002in\u2002the\u2002following\u2002\nsituations:\n1.\u2002Colorectal\u2002cancer\u2002diagnosed\u2002in\u2002a\u2002patient\u2002who\u2002is\u2002<50\u2002y\u2002of\u2002age\n2.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d92516a-c9e8-4eec-8f3a-aa390d1cd2ac": {"__data__": {"id_": "6d92516a-c9e8-4eec-8f3a-aa390d1cd2ac", "embedding": null, "metadata": {"page_label": "139", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fead70f1-cc0a-4faa-a49f-b49c6202bad4", "node_type": "4", "metadata": {"page_label": "139", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "9548bfec64abc72c38c1a056ebb5b2607ff2311b998a44d9a24fab9179aca097", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "369f5fbe-afa3-4572-96ac-19776ef25b93", "node_type": "1", "metadata": {"page_label": "139", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "11ed3aec4f366073b7466a59d445ce0201423f2f4fe247b28f92877c574f9edc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c78b5db-df48-4670-b09b-9167269fa92c", "node_type": "1", "metadata": {"page_label": "139", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "2ff90a58a3f1e7c05bff229fc0344871c4b699436e08c835302ba00afb2adf7b", "class_name": "RelatedNodeInfo"}}, "hash": "a01cc48b1267c7461cbdf6645b1fb5597b360d1a753439dab7f0b77d9248a1a5", "text": "Presence\u2002of\u2002synchronous,\u2002metachronous\u2002colorectal,\u2002or\u2002other\u2002\nHNPCC-associated\u2002tumors,\u2002regardless\u2002of\u2002agea\n3.\u2002Colorectal\u2002cancer\u2002with\u2002the\u2002MSI-Hb\u2002histologyc diagnosed in a \npatient\u2002who\u2002is\u2002<60\u2002y\u2002of\u2002aged\n4.\u2002Colorectal\u2002cancer\u2002diagnosed\u2002in\u20021\u2002or\u2002more\u2002first-degree\u2002relatives\u2002\nwith\u2002an\u2002HNPCC-related\u2002tumor,\u2002with\u20021\u2002of\u2002the\u2002cancers\u2002being\u2002diagnosed\u2002under\u2002age\u200250\u2002y\n5.\u2002Colorectal\u2002cancer\u2002diagnosed\u2002in\u20022\u2002or\u2002more\u2002first-\u2002or\u2002second-\ndegree\u2002relatives\u2002with\u2002HNPCC-related\u2002tumors,\u2002regardless\u2002of\u2002age\naHereditary\u2002nonpolyposis\u2002colorectal\u2002cancer\u2002(HNPCC)\u2002\u2013related\u2002tumors\u2002include\u2002\ncolorectal,\u2002endometrial,\u2002stomach,\u2002ovarian,\u2002pancreas,\u2002ureter\u2002and\u2002renal\u2002pelvis,\u2002biliary\u2002\ntract,\u2002and\u2002brain\u2002(usually\u2002glioblastoma\u2002as\u2002seen\u2002in\u2002 Turcot\u2002syndrome)\u2002tumors;\u2002seba-\nceous\u2002gland\u2002adenomas;\u2002and\u2002keratoacanthomas\u2002in\u2002Muir\u2013Torre\u2002syndrome,\u2002as\u2002well\u2002as\u2002carcinoma\u2002of\u2002the\u2002small\u2002bowel.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c78b5db-df48-4670-b09b-9167269fa92c": {"__data__": {"id_": "8c78b5db-df48-4670-b09b-9167269fa92c", "embedding": null, "metadata": {"page_label": "139", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fead70f1-cc0a-4faa-a49f-b49c6202bad4", "node_type": "4", "metadata": {"page_label": "139", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "9548bfec64abc72c38c1a056ebb5b2607ff2311b998a44d9a24fab9179aca097", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d92516a-c9e8-4eec-8f3a-aa390d1cd2ac", "node_type": "1", "metadata": {"page_label": "139", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "a01cc48b1267c7461cbdf6645b1fb5597b360d1a753439dab7f0b77d9248a1a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "908eac1d-4018-4261-bfc4-8277c30745e2", "node_type": "1", "metadata": {"page_label": "140", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "90b0266a7c848c8612cd4723c9dbd3866cbf3157b9329ab635624b1d2ab97a47", "class_name": "RelatedNodeInfo"}}, "hash": "2ff90a58a3f1e7c05bff229fc0344871c4b699436e08c835302ba00afb2adf7b", "text": "bMicrosatellite\u2002instability\u2013high\u2002(MSI-H)\u2002in\u2002tumors\u2002refers\u2002to\u2002changes\u2002in\u20022\u2002or\u2002more\u2002of\u2002\nthe\u20025\u2002National\u2002Cancer\u2002Institute\u2013recommended\u2002panels\u2002of\u2002microsatellite\u2002markers.\ncData\u2002include\u2002the\u2002presence\u2002of\u2002tumor-infiltrating\u2002lymphocytes,\u2002Crohn\u2019s-like\u2002lympho -\ncytic\u2002reaction,\u2002mucinous/signet-ring\u2002differentiation,\u2002or\u2002medullary\u2002growth\u2002pattern.\ndThere\u2002was\u2002no\u2002consensus\u2002among\u2002the\u2002workshop\u2002participants\u2002on\u2002whether\u2002to\u2002include\u2002\nthe\u2002age\u2002criteria\u2002in\u2002guideline\u20023\u2002above;\u2002participants\u2002voted\u2002to\u2002keep\u2002<60\u2002y\u2002of\u2002age\u2002in\u2002the\u2002guidelines.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "908eac1d-4018-4261-bfc4-8277c30745e2": {"__data__": {"id_": "908eac1d-4018-4261-bfc4-8277c30745e2", "embedding": null, "metadata": {"page_label": "140", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c63ea98e-a01c-44b8-9f33-adf025ad6602", "node_type": "4", "metadata": {"page_label": "140", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "53355ab52766aff02059c346db85193929297c1dbce915b47af5437f85aee8b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c78b5db-df48-4670-b09b-9167269fa92c", "node_type": "1", "metadata": {"page_label": "139", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "2ff90a58a3f1e7c05bff229fc0344871c4b699436e08c835302ba00afb2adf7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1248f89d-a96c-4f17-aec9-4e52135023e1", "node_type": "1", "metadata": {"page_label": "140", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "798e53cb45c187431660b854bdb39be90cd4a5782ca50f5f57684b7fc3ec558b", "class_name": "RelatedNodeInfo"}}, "hash": "90b0266a7c848c8612cd4723c9dbd3866cbf3157b9329ab635624b1d2ab97a47", "text": "Copyright \u00a9 The American Society of Colon & Rectal Surgeons, Inc. Unauthorized reproduction of this article is prohibited.Herzig  et al: Surgical  treatment  of lyncH  Syndrome 140\nwas defined, segmental resection was widely preferred \nand performed (\u2248 85%\u201387% of the time, as shown \nabove). i n part, this may be secondary to functional is-\nsues of a total versus segmental colectomy (see below), \nalthough oncologically segmental colectomy does not \naddress the risk of metachronous cancer. t his practice \nmay be slow to change given the recent nature of the cited literature. h owever, based on currently available \nevidence, there is superior cancer risk reduction with total colectomy for the treatment of colon cancer in the setting of l ynch syndrome, and total abdominal colec-\ntomy with ileorectal anastomosis is the preferred treat-ment for most patients. t his may not be applicable to \nall patients because of the morbidity of the operation or quality-of-life issues.\n2. Patients with Lynch syndrome who develop a colon \ncancer may consider segmental colectomy despite the \ninferior cancer risk reduction because of differences \nin bowel function between segmental and total colec-\ntomy. Weak recommendation based on low-quality evi-\ndence. 2C\nDespite the benefits of cancer risk reduction from a more \nextensive colectomy, some patients may still consider segmental resection. t wo retrospective surveys have ex-amined functional results and quality of life after more \nextensive resections.\n14,15 although not limited to patients \nwith l ynch syndrome, Y ou et al15 examined 201 patients \nwith total colectomy and 321 patients who had a segmen-\ntal colectomy using the i rritable Bowel s yndrome-Quality \nof life instrument.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1248f89d-a96c-4f17-aec9-4e52135023e1": {"__data__": {"id_": "1248f89d-a96c-4f17-aec9-4e52135023e1", "embedding": null, "metadata": {"page_label": "140", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c63ea98e-a01c-44b8-9f33-adf025ad6602", "node_type": "4", "metadata": {"page_label": "140", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "53355ab52766aff02059c346db85193929297c1dbce915b47af5437f85aee8b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "908eac1d-4018-4261-bfc4-8277c30745e2", "node_type": "1", "metadata": {"page_label": "140", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "90b0266a7c848c8612cd4723c9dbd3866cbf3157b9329ab635624b1d2ab97a47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3ebdabd-f2a1-47af-9ed7-e92ea87fc650", "node_type": "1", "metadata": {"page_label": "140", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "55986c071e339e53b8cb2cbfed95b36dfc1904d8cb3c5a97c05c5332719560c4", "class_name": "RelatedNodeInfo"}}, "hash": "798e53cb45c187431660b854bdb39be90cd4a5782ca50f5f57684b7fc3ec558b", "text": "o verall, quality of life scores after seg-\nmental resection and ileorectal anastomosis were 98.5 and 91.2. h aanstra et al\n14 surveyed patients with l ynch syn-\ndrome who had surgical treatment of a colorectal cancer and compared quality-of-life outcomes in 51 patients who had a partial colectomy with 53 patients who had a total \ncolectomy with 3 validated instruments. after total colec-\ntomy, there was a detrimental effect on stool frequency, \nsocial impact, and problems with defecation. h owever, \nnone of the 3 instruments demonstrated a negative im-pact on overall quality of life. i n light of these 2 reports, \npatients should be informed of the functional differences \nbut similar overall quality of life between the 2 operations. \nunfortunately, there are no studies that can provide guid-\nance regarding who might be at higher-than-average risk for functional impairment after total colectomy. as noted \nabove, in the absence of data regarding a benefit of reduc-tion of risk for metachronous cancer, segmental resection is widely preferred to total colectomy. t herefore, some pa-\ntients may choose segmental colectomy for its positive dif-TABLE 4.\u2002 \u2002\u2002The\u2002GRADE\u2002system:\u2002grading\u2002recommendations\nNumber Description Benefit vs risk and burdensMethodologic quality of  \nsupporting evidence Implications\n1A Strong\u2002recommendation,\u2002\nHigh-quality\u2002evidenceBenefits\u2002clearly\u2002outweigh\u2002risk\u2002\nand\u2002burdens\u2002or\u2002vice\u2002versaRCTs\u2002without\u2002important\u2002limitations\u2002\nor\u2002overwhelming\u2002evidence\u2002from\u2002\nobservational\u2002studiesStrong\u2002recommendation,\u2002can\u2002\napply\u2002to\u2002most\u2002patients\u2002in\u2002most\u2002circumstances\u2002without\u2002reservation\n1B Strong\u2002recommendation,", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3ebdabd-f2a1-47af-9ed7-e92ea87fc650": {"__data__": {"id_": "e3ebdabd-f2a1-47af-9ed7-e92ea87fc650", "embedding": null, "metadata": {"page_label": "140", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c63ea98e-a01c-44b8-9f33-adf025ad6602", "node_type": "4", "metadata": {"page_label": "140", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "53355ab52766aff02059c346db85193929297c1dbce915b47af5437f85aee8b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1248f89d-a96c-4f17-aec9-4e52135023e1", "node_type": "1", "metadata": {"page_label": "140", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "798e53cb45c187431660b854bdb39be90cd4a5782ca50f5f57684b7fc3ec558b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4c100e9-544b-4032-9c7c-a6e44c0128f4", "node_type": "1", "metadata": {"page_label": "140", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "7c0963c716798bca62791cb0372ddc8e3a71415cb6fe26fdf02d6e7b4cc3c175", "class_name": "RelatedNodeInfo"}}, "hash": "55986c071e339e53b8cb2cbfed95b36dfc1904d8cb3c5a97c05c5332719560c4", "text": "moderate-quality\u2002evidenceBenefits\u2002clearly\u2002outweigh\u2002risk\u2002\nand\u2002burdens\u2002or\u2002vice\u2002versaRCTs\u2002with\u2002important\u2002limitations\u2002\n(inconsistent\u2002 results,\u2002methodologic\u2002\nflaws,\u2002indirect,\u2002or\u2002imprecise)\u2002or\u2002exceptionally\u2002strong\u2002evidence\u2002from\u2002observational\u2002studiesStrong\u2002recommendation,\u2002can\u2002\napply\u2002to\u2002most\u2002patients\u2002in\u2002most\u2002circumstances\u2002without\u2002reservation\n1C Strong\u2002recommendation,\u2002\nLow-\u2002or\u2002very\u2002low\u2013\u2002quality\u2002evidenceBenefits\u2002clearly\u2002outweigh\u2002risk\u2002\nand\u2002burdens\u2002or\u2002vice\u2002versaObservational\u2002studies\u2002or\u2002case\u2002series Strong\u2002recommendation\u2002but\u2002\nmay\u2002change\u2002when\u2002higher- quality\u2002evidence\u2002becomes\u2002available\n2A Weak\u2002recommendation,\u2002\nhigh-quality\u2002evidenceBenefits\u2002closely\u2002balanced\u2002with\u2002\nrisks\u2002and\u2002burdensRCTs\u2002without\u2002important\u2002limitations\u2002\nor\u2002overwhelming\u2002evidence\u2002from\u2002observational\u2002studiesWeak\u2002recommendation,\u2002best\u2002\naction\u2002may\u2002differ\u2002depending\u2002on\u2002circumstances\u2002or\u2002patient\u2002or societal values\n2B Weak\u2002recommendation,\u2002\nmoderate-quality\u2002evidenceBenefits\u2002closely\u2002balanced\u2002with\u2002\nrisks\u2002and\u2002burdensRCTs\u2002with\u2002important\u2002limitations\u2002\n(inconsistent\u2002 results,\u2002methodologic\u2002\nflaws,\u2002indirect,", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4c100e9-544b-4032-9c7c-a6e44c0128f4": {"__data__": {"id_": "b4c100e9-544b-4032-9c7c-a6e44c0128f4", "embedding": null, "metadata": {"page_label": "140", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c63ea98e-a01c-44b8-9f33-adf025ad6602", "node_type": "4", "metadata": {"page_label": "140", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "53355ab52766aff02059c346db85193929297c1dbce915b47af5437f85aee8b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3ebdabd-f2a1-47af-9ed7-e92ea87fc650", "node_type": "1", "metadata": {"page_label": "140", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "55986c071e339e53b8cb2cbfed95b36dfc1904d8cb3c5a97c05c5332719560c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c82ed093-b94f-4309-aa65-eb4686cd5c0f", "node_type": "1", "metadata": {"page_label": "141", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "0a7542ef30faa1c6e2f2b42d1f04b8b355e26407a0be4bfcac3b31d73e9bdb5a", "class_name": "RelatedNodeInfo"}}, "hash": "7c0963c716798bca62791cb0372ddc8e3a71415cb6fe26fdf02d6e7b4cc3c175", "text": "methodologic\u2002\nflaws,\u2002indirect,\u2002or\u2002imprecise)\u2002or\u2002exceptionally\u2002strong\u2002evidence\u2002from\u2002observational\u2002studiesWeak\u2002recommendation,\u2002best\u2002\naction\u2002may\u2002differ\u2002depending\u2002on\u2002circumstances\u2002or\u2002patient\u2002or societal values\n2C Weak\u2002recommendation,\u2002\nLow-\u2002or\u2002very\u2002low\u2013\u2002quality\u2002evidenceUncertainty\u2002in\u2002the\u2002estimates\u2002of\u2002\nbenefits,\u2002risks,\u2002and\u2002burden;\u2002benefits,\u2002risk,\u2002and\u2002burden\u2002may\u2002be\u2002closely\u2002balancedObservational\u2002studies\u2002or\u2002case\u2002series Very\u2002weak\u2002recommendations,\u2002\nother\u2002alternatives\u2002may\u2002be\u2002equally\u2002reasonable\nTable\u2002was\u2002adapted\u2002from\u2002Guyatt\u2002et\u2002al.1\u2002Grading\u2002strength\u2002of\u2002recommendations\u2002and\u2002quality\u2002of\u2002evidence\u2002in\u2002clinical\u2002guidelines\u2002are\u2002found\u2002in\u2002a\u2002report\u2002from\u2002the\u2002American\u2002College\u2002of\u2002\nChest\u2002Physicians\u2002 Task\u2002Force.\nRCT\u2002=\u2002randomized\u2002controlled\u2002trial.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c82ed093-b94f-4309-aa65-eb4686cd5c0f": {"__data__": {"id_": "c82ed093-b94f-4309-aa65-eb4686cd5c0f", "embedding": null, "metadata": {"page_label": "141", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "00f89055-c291-4589-9e59-c47474e50130", "node_type": "4", "metadata": {"page_label": "141", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "cc5b4b748d7c3aefdd3dcb3aa476e928cd3c04d23eeb316a9a209bb77a750da0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4c100e9-544b-4032-9c7c-a6e44c0128f4", "node_type": "1", "metadata": {"page_label": "140", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "7c0963c716798bca62791cb0372ddc8e3a71415cb6fe26fdf02d6e7b4cc3c175", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9929b247-1a5f-4541-9eb8-e3a1d4e2a7d5", "node_type": "1", "metadata": {"page_label": "141", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "3dbf480e67074133706901ac71e75f3cc46698d23fc1ecd010b4e9835739516d", "class_name": "RelatedNodeInfo"}}, "hash": "0a7542ef30faa1c6e2f2b42d1f04b8b355e26407a0be4bfcac3b31d73e9bdb5a", "text": "Copyright \u00a9 The American Society of Colon & Rectal Surgeons, Inc. Unauthorized reproduction of this article is prohibited.Diseases of the Colon & ReCtum  Volume  60: 2 (2017) 141\nference in bowel function despite the superior cancer risk \nreduction with a total abdominal colectomy.\n3. Annual colonoscopy should be performed after seg-\nmental resection of colon cancer in patients with Lynch \nsyndrome. Strong recommendation based on moderate-\nquality evidence. 1B\nConsiderable data exist regarding the screening interval for \nlynch syndrome before a diagnosis of cancer. a systematic \nreview of the literature from lindor et al16 concluded that \nendoscopic surveillance should occur every 1 to 2 years starting at age 20 to 25 or 10 years younger than the young-est age of colon cancer in a family member. a recent meta-\nanalysis suggests that the balance of benefits of screening may not outweigh the risks until age 30 years.\n17 Conven -\ntional colonoscopy at yearly intervals may detect polyps, but there is a high rate of interval cancers even with appropriate screening.\n18,19 enhanced detection techniques, such as chro-\nmoendoscopy, prolonged withdrawal time, and narrow-band imaging, may improve the detection of flat lesions.\n20\u201322 \nit is not clear how much of the data from screening done \nbefore a diagnosis of cancer are applicable to determining the endoscopy interval after segmental resection.\ntwo of the retrospective reviews of segmental versus \ntotal colectomy (described earlier) have addressed the ef-fectiveness of postoperative endoscopic surveillance. Ka-lady et al\n10 reported results of endoscopic surveillance \nin their 253 segmental colectomy patients, 221 (88%) of whom had postoperative surveillance at a medial interval of 25 months between endoscopies. i n 74 patients (33%), \n256 adenomas were detected, and 55 patients (25%) devel-oped a second colorectal cancer despite surveillance. only \n16 of these 55 cancers were stage i at diagnosis, demon-\nstrating the difficulty in preventing advanced-stage cancer with endoscopic surveillance after segmental colectomy.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9929b247-1a5f-4541-9eb8-e3a1d4e2a7d5": {"__data__": {"id_": "9929b247-1a5f-4541-9eb8-e3a1d4e2a7d5", "embedding": null, "metadata": {"page_label": "141", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "00f89055-c291-4589-9e59-c47474e50130", "node_type": "4", "metadata": {"page_label": "141", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "cc5b4b748d7c3aefdd3dcb3aa476e928cd3c04d23eeb316a9a209bb77a750da0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c82ed093-b94f-4309-aa65-eb4686cd5c0f", "node_type": "1", "metadata": {"page_label": "141", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "0a7542ef30faa1c6e2f2b42d1f04b8b355e26407a0be4bfcac3b31d73e9bdb5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22f2515c-4e63-4f88-a6de-43c34a996cbc", "node_type": "1", "metadata": {"page_label": "141", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "f392cc942547a6acf60d2a7187914bf45269553e449c0945856137dd6800cea0", "class_name": "RelatedNodeInfo"}}, "hash": "3dbf480e67074133706901ac71e75f3cc46698d23fc1ecd010b4e9835739516d", "text": "Parry et al\n12 reported the cumulative risk of colon cancer \nafter segmental resection to be 16% after 10 years, and this was despite an average of 1 colonoscopy every 20 months. in those developing a metachronous cancer after total col-\nectomy, 47% were diagnosed as stage i, in contrast to the study by Kalady et al,\n10 which showed a higher proportion \nof advanced-stage disease. only 1 retrospective review has separately described the risk of rectal neoplasia after resec-tion of a colon cancer in the setting of l ynch syndrome.\n23 \nthere are inadequate data to clearly define the role of an-\nnual surveillance of the rectum after total colectomy, but an annual examination is recommended, because there is clearly a risk of metachronous rectal cancer.\n24\n4. For patients with Lynch syndrome and rectal cancer, the \nrectal cancer should be treated based on standard onco-\nlogic principles, as in sporadic rectal cancer. The deci-sion for concomitant colectomy may be considered on a selective basis. Weak recommendation based on poor-\nquality evidence. 2CPatient-specific variables need to be considered in devel-\noping a treatment plan for patients with a rectal cancer in \nthe setting of l ynch syndrome. although proctocolectomy \nwith or without iP aa would possibly provide absolute risk \nreduction, specific concerns about bowel function, uro-genital function, and the need for pelvic radiation must be \nconsidered. i n 2012, Kalady et al\n25 reported outcomes of \na cohort of 50 patients meeting amsterdam criteria with \nrectal cancer treated with proctectomy. of the 33 patients \nwith long-term follow-up, 5 (15%) developed a meta-chronous colon cancer after a median of 6 years, only 2 of which were early stage. Despite endoscopic surveillance, 17 (33%) of the cohort developed an advanced adenoma or cancer in the remaining colon. Win et al\n26 reported a ret -\nrospective review of 79 patients with l ynch syndrome and \nrectal cancer who were treated with proctectomy. With a median follow-up of 9 years, 27% developed colon cancer.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22f2515c-4e63-4f88-a6de-43c34a996cbc": {"__data__": {"id_": "22f2515c-4e63-4f88-a6de-43c34a996cbc", "embedding": null, "metadata": {"page_label": "141", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "00f89055-c291-4589-9e59-c47474e50130", "node_type": "4", "metadata": {"page_label": "141", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "cc5b4b748d7c3aefdd3dcb3aa476e928cd3c04d23eeb316a9a209bb77a750da0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9929b247-1a5f-4541-9eb8-e3a1d4e2a7d5", "node_type": "1", "metadata": {"page_label": "141", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "3dbf480e67074133706901ac71e75f3cc46698d23fc1ecd010b4e9835739516d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc56a0bb-204c-4b36-89e4-276e8254e7a0", "node_type": "1", "metadata": {"page_label": "142", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "fe3d42702c1d2372ff79ce34ac937778aedb215ebb4c97fdca0a7319e5570460", "class_name": "RelatedNodeInfo"}}, "hash": "f392cc942547a6acf60d2a7187914bf45269553e449c0945856137dd6800cea0", "text": "With a median follow-up of 9 years, 27% developed colon cancer. endoscopic surveillance in this study was more frequent than other reports, with an average of 1 colonoscopy every 1.2 years.\nthe evidence base of 2 small retrospective cohort \nstudies suggests that the high risk of neoplasia in the re-maining colon justifies consideration of proctocolectomy for risk reduction. h owever, the functional differences \nfrom a proctocolectomy compared with a more limited resection would be expected to be more pronounced. individual characteristics, such as tumor location, need \nfor pelvic radiation, preoperative functional status, and \nthe possibility of sphincter salvage, create a much differ -\nent set of variables when considering the appropriateness \nof risk reduction through more extensive resection. t he \nquality-of-life data reviewed in recommendation 2 sug-gest that, in many cases, the oncologic benefit of a more extensive resection is justified. i n most cases, treatment of \nthe rectal cancer should follow standard oncologic prin-ciples. t he decision to remove the rest of the colon may \nbe performed on an individual basis after discussion with \nthe patient.\n5. Hysterectomy and bilateral salpingo-oophorectomy \nshould be offered to women with Lynch syndrome un-\ndergoing colectomy, particularly if they have finished childbearing. Strong recommendation based on moder -\nate-quality evidence. 1B\nthe 2014 l ynch syndrome guidelines by the us m ulti-\nsociety t ask force on Colorectal Cancer, which were \nreviewed by the american s ociety of Colon and Rectal s ur-\ngeons, recommended hysterectomy and bilateral salpingo-\noophorectomy in all women over age 40 years or who \nhave finished childbearing.1 the evidence base for this is 1 \ncase\u2013control study of 315 women, all of whom had l ynch \nsyndrome. s ixty-one women who underwent prophylac-\ntic hysterectomy and 47 women who underwent bilateral \nsalpingo-oophorectomy were matched with women who", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc56a0bb-204c-4b36-89e4-276e8254e7a0": {"__data__": {"id_": "fc56a0bb-204c-4b36-89e4-276e8254e7a0", "embedding": null, "metadata": {"page_label": "142", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b0e52743-911b-4a5f-a6c4-f12d9edb9289", "node_type": "4", "metadata": {"page_label": "142", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c09304188d7c7ff929eb7d361a7b1a03f3a8d89c89494cddc9ceaf0aa0c32643", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22f2515c-4e63-4f88-a6de-43c34a996cbc", "node_type": "1", "metadata": {"page_label": "141", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "f392cc942547a6acf60d2a7187914bf45269553e449c0945856137dd6800cea0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea6a11d5-11e5-4731-9903-f2f31fc797e0", "node_type": "1", "metadata": {"page_label": "142", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "f6c1669b44e57b3c2c8a673d0231245a50b4847b44f814df54aec276b5bd7d26", "class_name": "RelatedNodeInfo"}}, "hash": "fe3d42702c1d2372ff79ce34ac937778aedb215ebb4c97fdca0a7319e5570460", "text": "Copyright \u00a9 The American Society of Colon & Rectal Surgeons, Inc. Unauthorized reproduction of this article is prohibited.Herzig  et al: Surgical  treatment  of lyncH  Syndrome 142\nhad not had the procedures.27 the risk reduction was dra-\nmatic, preventing 100% of endometrial and 100% of ovar -\nian cancers. f or endometrial cancer, there were no cancers \nin the prophylactic surgery group versus 69 (33%) of 210 \nin the control group, and for ovarian cancer there were no \ncancers in the prophylactic surgery group versus 12 (5%) \nof 223 in the control group. t he basis for recommending \nthe procedures in women over age 40 years is from 1 cost-effectiveness analysis, which suggested that prophylactic \nsurgery at age 40 years is the optimal strategy.\n28 however, \nthere are major limitations in the assumptions made, and \nthe decision about the proper strategy must also take into \naccount other factors than cost-effectiveness, most nota-\nbly patient preference. n o clear specific age recommenda-\ntion can be made based on the evidence. Because of the \nclear benefit of prophylactic surgery independent of col-\nectomy, it is reasonable to offer hysterectomy and bilateral salpingo-oophorectomy to all women who are having a \ncolon resection for l ynch syndrome.\nREFERENCES\n 1. Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genet-\nic evaluation and management of lynch syndrome: a consen-\nsus statement by the us m ulti-s ociety t ask f orce on Colorectal \nCancer. Dis Colon Rectum. 2014;57:1025\u20131048.\n 2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statis-tics, 2009. CA Cancer J Clin. 2009;59:225\u2013249.\n 3. Vasen HF, Mecklin JP , Khan PM, Lynch HT. The International Collaborative Group on h ereditary n on-Polyposis Colorectal \nCancer (iCG-hnPCC).", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea6a11d5-11e5-4731-9903-f2f31fc797e0": {"__data__": {"id_": "ea6a11d5-11e5-4731-9903-f2f31fc797e0", "embedding": null, "metadata": {"page_label": "142", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b0e52743-911b-4a5f-a6c4-f12d9edb9289", "node_type": "4", "metadata": {"page_label": "142", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c09304188d7c7ff929eb7d361a7b1a03f3a8d89c89494cddc9ceaf0aa0c32643", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc56a0bb-204c-4b36-89e4-276e8254e7a0", "node_type": "1", "metadata": {"page_label": "142", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "fe3d42702c1d2372ff79ce34ac937778aedb215ebb4c97fdca0a7319e5570460", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca57c163-69d1-4092-819c-1f383c7e114e", "node_type": "1", "metadata": {"page_label": "142", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "4615af224f5a3f274fc651bfc7bd30886b90a1a6b02de4a9f3c843c10712fb08", "class_name": "RelatedNodeInfo"}}, "hash": "f6c1669b44e57b3c2c8a673d0231245a50b4847b44f814df54aec276b5bd7d26", "text": "Dis Colon Rectum. 1991;34:424\u2013425.\n 4. Vasen HF, Watson P , Mecklin JP , Lynch HT. New clinical criteria \nfor hereditary nonpolyposis colorectal cancer (hnPCC, l ynch \nsyndrome) proposed by the i nternational Collaborative group \non hnPCC. Gastroenterology. 1999;116:1453\u20131456.\n 5. Rodriguez-Bigas ma, Boland CR, h amilton sR, et al. a \nnational Cancer i nstitute workshop on hereditary nonpol-\nyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst. 1997;89:1758\u20131762.\n 6. Umar A, Boland CR, T erdiman JP , et al. Revised Bethesda \nGuidelines for hereditary nonpolyposis colorectal cancer \n(lynch syndrome) and microsatellite instability. J Natl Cancer \nInst. 2004;96:261\u2013268.\n 7. lindor nm, Rabe K, Petersen Gm, et al. l ower cancer inci-\ndence in amsterdam-i criteria families without mismatch \nrepair deficiency: familial colorectal cancer type X. JAMA. \n2005;293:1979\u20131985.\n 8. Church J, Simmang C; Standards Task Force; American Society of Colon and Rectal s urgeons; Collaborative Group of the \namericas on i nherited Colorectal Cancer and the standards \nCommittee of t he american s ociety of Colon and Rectal \nsurgeons. Practice parameters for the treatment of patients \nwith dominantly inherited colorectal cancer (familial adeno-\nmatous polyposis and hereditary nonpolyposis colorectal can-\ncer). Dis Colon Rectum. 2003;46:1001\u20131012.\n 9. Guyatt G, Gutterman D, Baumann mh, et al. Grading strength \nof recommendations and quality of evidence in clinical guide-lines: report from an american College of Chest Physicians \ntask f orce. Chest.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca57c163-69d1-4092-819c-1f383c7e114e": {"__data__": {"id_": "ca57c163-69d1-4092-819c-1f383c7e114e", "embedding": null, "metadata": {"page_label": "142", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b0e52743-911b-4a5f-a6c4-f12d9edb9289", "node_type": "4", "metadata": {"page_label": "142", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c09304188d7c7ff929eb7d361a7b1a03f3a8d89c89494cddc9ceaf0aa0c32643", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea6a11d5-11e5-4731-9903-f2f31fc797e0", "node_type": "1", "metadata": {"page_label": "142", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "f6c1669b44e57b3c2c8a673d0231245a50b4847b44f814df54aec276b5bd7d26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b4b8088-844b-43ac-b5c2-f7d46de7710f", "node_type": "1", "metadata": {"page_label": "142", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c5f202560c198865c3358e6fcdee593da20455444d0af3e6b9c82b4926a119e5", "class_name": "RelatedNodeInfo"}}, "hash": "4615af224f5a3f274fc651bfc7bd30886b90a1a6b02de4a9f3c843c10712fb08", "text": "Chest. 2006;129:174\u2013181.\n 10. Kalady MF, McGannon E, Vogel JD, Manilich E, Fazio VW, \nChurch JM. Risk of colorectal adenoma and carcinoma after colectomy for colorectal cancer in patients meeting amsterdam \ncriteria. Ann Surg. 2010;252:507\u2013511.\n 11. natarajan n, Watson P , s ilva-l opez e, l ynch ht . Comparison \nof extended colectomy and limited resection in patients with \nlynch syndrome. Dis Colon Rectum. 2010;53:77\u201382.\n 12. Parry s, Win aK, Parry B, et al. metachronous colorectal cancer \nrisk for mismatch repair gene mutation carriers: the advantage \nof more extensive colon surgery. Gut . 2011;60:950\u2013957.\n 13. Vasen hf , Blanco i, aktan-Collan K, et al.; m allorca group. \nRevised guidelines for the clinical management of l ynch syn-\ndrome (hnPCC): recommendations by a group of e uropean \nexperts. Gut . 2013;62:812\u2013823.\n 14. Haanstra JF, de Vos T ot Nederveen Cappel WH, Gopie JP , et al. Quality of life after surgery for colon cancer in patients with \nlynch syndrome: partial versus subtotal colectomy. Dis Colon \nRectum. 2012;55:653\u2013659.\n 15. Y ou Yn, Chua hK, n elson h, h assan i, Barnes sa, h arrington \nJ. Segmental vs. extended colectomy: measurable differences \nin morbidity, function, and quality of life. Dis Colon Rectum. 2008;51:1036\u20131043.\n 16. lindor nm, Petersen Gm, h adley DW, et al. Recommendations \nfor the care of individuals with an inherited predispo-sition to l ynch syndrome: a systematic review. JAMA. \n2006;296:1507\u20131517.\n 17.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b4b8088-844b-43ac-b5c2-f7d46de7710f": {"__data__": {"id_": "5b4b8088-844b-43ac-b5c2-f7d46de7710f", "embedding": null, "metadata": {"page_label": "142", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b0e52743-911b-4a5f-a6c4-f12d9edb9289", "node_type": "4", "metadata": {"page_label": "142", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c09304188d7c7ff929eb7d361a7b1a03f3a8d89c89494cddc9ceaf0aa0c32643", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca57c163-69d1-4092-819c-1f383c7e114e", "node_type": "1", "metadata": {"page_label": "142", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "4615af224f5a3f274fc651bfc7bd30886b90a1a6b02de4a9f3c843c10712fb08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8f86ef4-8f55-4156-80f5-e20b78d58995", "node_type": "1", "metadata": {"page_label": "142", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "5629e41427630f2f7e00ffcbc81033c9b307ed2cc7b4df8227f9881dca875b3b", "class_name": "RelatedNodeInfo"}}, "hash": "c5f202560c198865c3358e6fcdee593da20455444d0af3e6b9c82b4926a119e5", "text": "JAMA. \n2006;296:1507\u20131517.\n 17. Jenkins MA, Dowty JG, Ait Ouakrim D, et al. Short-term risk of colorectal cancer in individuals with lynch syndrome: a meta-analysis. J Clin Oncol. 2015;33:326\u2013331.\n 18. engel C, Rahner n, schulmann K, et al.; German hnPCC \nConsortium. efficacy of annual colonoscopic surveillance in \nindividuals with hereditary nonpolyposis colorectal cancer. \nClin Gastroenterol Hepatol. 2010;8:174\u2013182.\n 19. stoffel em, t urgeon DK, stockwell Dh, et al.; Great lakes-n ew \nengland Clinical e pidemiology and Validation Center of the \nearly Detection Research n etwork. m issed adenomas during \ncolonoscopic surveillance in individuals with lynch syndrome \n(hereditary nonpolyposis colorectal cancer). Cancer Prev Res (Phila). 2008;1:470\u2013475.\n 20. h\u00fcneburg R, lammert f, Rabe C, et al. Chromocolonoscopy \ndetects more adenomas than white light colonoscopy or nar -\nrow band imaging colonoscopy in hereditary nonpolyposis \ncolorectal cancer screening. Endoscopy. 2009;41:316\u2013322.\n 21. lecomte t , Cellier C, m eatchi t , et al. Chromoendoscopic \ncolonoscopy for detecting preneoplastic lesions in hereditary nonpolyposis colorectal cancer syndrome. Clin Gastroenterol \nHepatol . 2005;3:897\u2013902.\n 22. East JE, Suzuki N, Stavrinidis M, Guenther T, Thomas HJ, \nsaunders BP . n arrow band imaging for colonoscopic sur -\nveillance in hereditary non-polyposis colorectal cancer. Gut . \n2008;57:65\u201370.\n 23. de Vos tot n ederveen Cappel Wh, n agengast fm, Griffioen G, et al.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8f86ef4-8f55-4156-80f5-e20b78d58995": {"__data__": {"id_": "b8f86ef4-8f55-4156-80f5-e20b78d58995", "embedding": null, "metadata": {"page_label": "142", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b0e52743-911b-4a5f-a6c4-f12d9edb9289", "node_type": "4", "metadata": {"page_label": "142", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c09304188d7c7ff929eb7d361a7b1a03f3a8d89c89494cddc9ceaf0aa0c32643", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b4b8088-844b-43ac-b5c2-f7d46de7710f", "node_type": "1", "metadata": {"page_label": "142", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "c5f202560c198865c3358e6fcdee593da20455444d0af3e6b9c82b4926a119e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f51c627f-6fcd-4938-933d-15664f6a9564", "node_type": "1", "metadata": {"page_label": "1", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "b5f3e91d8f4e6e3b149dfe4a9abc915ed8c212dbeff218f0c17f408cad762fa7", "class_name": "RelatedNodeInfo"}}, "hash": "5629e41427630f2f7e00ffcbc81033c9b307ed2cc7b4df8227f9881dca875b3b", "text": "surveillance for hereditary nonpolyposis colorectal cancer: a long-\nterm study on 114 families. Dis Colon Rectum. 2002;45:1588\u20131594.\n 24. Cirillo l, u rso eD, Parrinello G, et al. h igh risk of rectal cancer \nand of metachronous colorectal cancer in probands of families fulfilling the amsterdam criteria. Ann Surg. 2013;257:900\u2013904.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f51c627f-6fcd-4938-933d-15664f6a9564": {"__data__": {"id_": "f51c627f-6fcd-4938-933d-15664f6a9564", "embedding": null, "metadata": {"page_label": "1", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c22672c7-9436-4df9-9531-b81e104aedca", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "f5d368c3ef90e06994288a0a7753ad949cb5674feca83d6ee56a46b467d0bdf7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8f86ef4-8f55-4156-80f5-e20b78d58995", "node_type": "1", "metadata": {"page_label": "142", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}, "hash": "5629e41427630f2f7e00ffcbc81033c9b307ed2cc7b4df8227f9881dca875b3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73e47913-5174-471f-9672-74b4474e3612", "node_type": "1", "metadata": {"page_label": "1", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "2e53eee5c548ae2d3a020a08630418e0e2e35f4e55591f0ff72479db2c4b025d", "class_name": "RelatedNodeInfo"}}, "hash": "b5f3e91d8f4e6e3b149dfe4a9abc915ed8c212dbeff218f0c17f408cad762fa7", "text": "Colorectal Cancer Screening: Recommendations for Physicians\nand Patients From the U.S. Multi-Society Task Force on\nColorectal Cancer\nDouglas K. Rex,1C. Richard Boland,2Jason A. Dominitz,3Francis M. Giardiello,4\nDavid A. Johnson,5Tonya Kaltenbach,6Theodore R. Levin,7David Lieberman,8and\nDouglas J. Robertson9\n1Indiana University School of Medicine, Indianapolis, Indiana;2University of California San Diego, San Diego, California;\n3VA Puget Sound Health Care System, University of Washington, Seattle, Washington;4Johns Hopkins University School of\nMedicine, Baltimore, Maryland;5Eastern Virginia Medical School, Norfolk, Virginia;6San Francisco Veterans Affairs Medical\nCenter, San Francisco, California;7Kaiser Permanente Medical Center, Walnut Creek, California;8Oregon Health and Science\nUniversity, Portland, Oregon;9VA Medical Center, White River Junction, Vermont, and Geisel School of Medicine at Dartmouth,\nHanover, New Hampshire\nThis document updates the colorectal cancer (CRC)\nscreening recommendations of the U.S. Multi-Society Task\nForce of Colorectal Cancer (MSTF), which represents theAmerican College of Gastroenterology, the American\nGastroenterological Association, and The American Society\nfor Gastrointestinal Endoscopy. CRC screening tests areranked in 3 tiers based on performance features, costs, and\npractical considerations. The \ufb01rst-tier tests are colonoscopy\nevery 10 years and annual fecal immunochemical test (FIT).Colonoscopy and FIT are recommended as the cornerstonesof screening regardless of how screening is offered. Thus, in\na sequential approach based on colonoscopy offered \ufb01rst,\nFIT should be offered to patients who decline colonoscopy.Colonoscopy and FIT are recommended as tests of choice\nwhen multiple options are presented as alternatives. A risk-\nstrati \ufb01ed approach is also appropriate, with FIT screening\nin populations with an estimated low prevalence of\nadvanced neoplasia and colonoscopy screening in high\nprevalence populations.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73e47913-5174-471f-9672-74b4474e3612": {"__data__": {"id_": "73e47913-5174-471f-9672-74b4474e3612", "embedding": null, "metadata": {"page_label": "1", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c22672c7-9436-4df9-9531-b81e104aedca", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "f5d368c3ef90e06994288a0a7753ad949cb5674feca83d6ee56a46b467d0bdf7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f51c627f-6fcd-4938-933d-15664f6a9564", "node_type": "1", "metadata": {"page_label": "1", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "b5f3e91d8f4e6e3b149dfe4a9abc915ed8c212dbeff218f0c17f408cad762fa7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45ef922d-5078-4ed3-a2c2-bb6b07933eac", "node_type": "1", "metadata": {"page_label": "1", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "cd3b0507d57b4351304a20bab095345a3b4a8e8a9e6da96047808dfba33f53d0", "class_name": "RelatedNodeInfo"}}, "hash": "2e53eee5c548ae2d3a020a08630418e0e2e35f4e55591f0ff72479db2c4b025d", "text": "The second-tier tests include CTcolonography every 5 years, the FIT \u2013fecal DNA test every 3\nyears, and \ufb02exible sigmoidoscopy every 5 to 10 years. These\ntests are appropriate screening tests, but each has disad-\nvantages relative to the tier 1 tests. Because of limited evi-dence and current obstacles to use, capsule colonoscopy\nevery 5 years is a third-tier test. We suggest that the Septin9\nserum assay (Epigenomics, Seattle, Wash) not be used forscreening. Screening should begin at age 50 years in\naverage-risk persons, except in African Americans in whom\nlimited evidence supports screening at 45 years. CRC inci-dence is rising in persons under age 50, and thorough\ndiagnostic evaluation of young persons with suspected\ncolorectal bleeding is recommended. Discontinuation ofscreening should be considered when persons up to datewith screening, who have prior negative screening (partic-\nularly colonoscopy), reach age 75 or have <10 years of life\nexpectancy. Persons without prior screening should beconsidered for screening up to age 85, depending on age and\ncomorbidities. Persons with a family history of CRC or a\ndocumented advanced adenoma in a \ufb01rst-degree relative\nage<60 years or 2 \ufb01rst-degree relatives with these \ufb01ndings\nat any age are recommended to undergo screening by colo-\nnoscopy every 5 years, beginning 10 years before the age atdiagnosis of the youngest affected relative or age 40,\nwhichever is earlier. Persons with a single \ufb01rst-degree\nrelative diagnosed at \u202160 years with CRC or an advanced\nadenoma can be offered average-risk screening optionsbeginning at age 40 years.\nColorectal cancer (CRC) screening is the process\nof detecting early-stage CRCs and precancerous\nlesions in asymptomatic people with no prior history of\ncancer or precancerous lesions. The U.S.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45ef922d-5078-4ed3-a2c2-bb6b07933eac": {"__data__": {"id_": "45ef922d-5078-4ed3-a2c2-bb6b07933eac", "embedding": null, "metadata": {"page_label": "1", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c22672c7-9436-4df9-9531-b81e104aedca", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "f5d368c3ef90e06994288a0a7753ad949cb5674feca83d6ee56a46b467d0bdf7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73e47913-5174-471f-9672-74b4474e3612", "node_type": "1", "metadata": {"page_label": "1", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "2e53eee5c548ae2d3a020a08630418e0e2e35f4e55591f0ff72479db2c4b025d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7461657-d4cb-4018-9124-570a03386644", "node_type": "1", "metadata": {"page_label": "2", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "2fcf655b08592b802f0f970bb8858d28bc7b4a1108f81f95c39a4e57d4b87e89", "class_name": "RelatedNodeInfo"}}, "hash": "cd3b0507d57b4351304a20bab095345a3b4a8e8a9e6da96047808dfba33f53d0", "text": "The U.S. Multi-Society TaskForce of Colorectal Cancer (MSTF) is a panel of expertgastroenterologists representing the American College ofGastroenterology, the American Gastroenterological Associ-ation, and the American Society for GastrointestinalEndoscopy. The MSTF, like others, has long endorsed sys-tematic offers of CRC screening to average-risk persons(persons without a high-risk family history of colorectalneoplasia) beginning at age 50 years, with general evidencesupporting screening reviewed in previous publications.\n1\nThis publication updates the screening recommendationsof the MSTF for screening in average-risk persons.\n1\nScreening differs from surveillance. Surveillance refers\nto the interval use of colonoscopy in patients with previ-ously detected CRC or precancerous lesions and intervalcolonoscopy in patients performed to detect dysplasia inpersons with in \ufb02ammatory bowel disease affecting the co-\nlon. Surveillance recommendations from the MSTF on sur-veillance after cancer\n2and removal of precancerous lesions3\nare available in other documents. Screening is also distinctfrom diagnostic examinations, which refer to the\nAbbreviations used in this paper: CRC, colorectal cancer; FIT, fecal\nimmunochemical test; MSTF, U.S. Multi-Society Task Force on Colorectal\nCancer; SSP, sessile serrated polyp.\n\u00a9 2017 by the AGA Institute, American College of Gastroenterology, and\nthe American Society for Gastrointestinal Endoscopy.\nThis article is being published jointly in Gastroenterology, American\nJournal of Gastroenterology, and Gastrointestinal Endoscopy.\n0016-5085/$36.00\nhttp://dx.doi.org/10.1053/j.gastro.2017.05.013Gastroenterology 2017; -:1\u201317\nAGA SECTION", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7461657-d4cb-4018-9124-570a03386644": {"__data__": {"id_": "e7461657-d4cb-4018-9124-570a03386644", "embedding": null, "metadata": {"page_label": "2", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7a475de4-81c7-44f5-8826-c442acb7a396", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "69513df4475d20f9626e11fde7c63fa5d5fc96e54d6da40e2b31980b22bfcb0d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45ef922d-5078-4ed3-a2c2-bb6b07933eac", "node_type": "1", "metadata": {"page_label": "1", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "cd3b0507d57b4351304a20bab095345a3b4a8e8a9e6da96047808dfba33f53d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b39189a5-845b-4ce4-9a78-19955830569a", "node_type": "1", "metadata": {"page_label": "2", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "66dec63fd03c5b0ff46fd320375d46ad72a6236758a2b2819dc0a10ce35abd04", "class_name": "RelatedNodeInfo"}}, "hash": "2fcf655b08592b802f0f970bb8858d28bc7b4a1108f81f95c39a4e57d4b87e89", "text": "investigation of patients with symptoms or positive\nscreening tests other than colonoscopy. Colonoscopy isgenerally the test of choice for diagnostic examinations.\nMethods\nLiterature Review\nThe English language medical literature using MEDLINE\n(2005 to August 1, 2016), EMBASE (2005 to third quarter 2016\nupdate), the Database of Abstracts of Reviews and Effects\n(2005 to third quarter 2016 update), and the Cochrane Data-base of Systematic Reviews (2005 to third quarter 2014 up-\ndate) was searched. In MEDLINE, subject headings for\ncolorectal cancer screening were combined with headings forfecal occult blood test, fecal immunochemical test, colonoscopy,\nsigmoidoscopy, CT colonoscopy, fecal DNA, serum testing, cost-\neffectiveness, and quality. Similar searches were performed inEMBASE, the Database of Abstracts of Reviews and Effects, and\nthe Cochrane Database of Systematic Reviews. Case reports and\nstudies performed in patients with in \ufb02ammatory bowel disease,\nprior CRC or polyps, or hereditary CRC syndromes wereexcluded. Review papers, meta-analyses, gastroenterology\ntextbooks, and editorials were searched manually for additional\npertinent references. The review includes studies publishedsince 2008 but also incorporates older evidence used to draft\nthe 2008 recommendations.\n1Evidence-based weighted rec-\nommendations are provided with supporting discussion to helpguide clinicians in the management of these patients.\nProcess and Levels of Evidence\nGuidance statements were developed by consensus ob-\ntained through joint teleconferences. The completed article was\nreviewed and approved by all 3 gastroenterology societies.\nThe use of GRADE for MSTF guidance papers has been\noutlined in detail elsewhere.2GRADE involves comprehensive\nliterature search and summary (often through meta-analysis)\nand then a separate review of literature quality and develop-ment of recommendations. The MSTF uses a modi \ufb01ed qualita-\ntive approach based on literature review (as described above\nfor this article) but without formal meta-analysis. GRADEallows for a separate assessment of the quality of the evidenceand strength of recommendation.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b39189a5-845b-4ce4-9a78-19955830569a": {"__data__": {"id_": "b39189a5-845b-4ce4-9a78-19955830569a", "embedding": null, "metadata": {"page_label": "2", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7a475de4-81c7-44f5-8826-c442acb7a396", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "69513df4475d20f9626e11fde7c63fa5d5fc96e54d6da40e2b31980b22bfcb0d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7461657-d4cb-4018-9124-570a03386644", "node_type": "1", "metadata": {"page_label": "2", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "2fcf655b08592b802f0f970bb8858d28bc7b4a1108f81f95c39a4e57d4b87e89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ce181c2-d05f-4ef2-8249-9a5662f38dfd", "node_type": "1", "metadata": {"page_label": "2", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "a837ec27688351a8a3f587d35243277166da71814457c2f7ed6cdbc37300ce85", "class_name": "RelatedNodeInfo"}}, "hash": "66dec63fd03c5b0ff46fd320375d46ad72a6236758a2b2819dc0a10ce35abd04", "text": "GRADEallows for a separate assessment of the quality of the evidenceand strength of recommendation. This approach explicitly\nrecognizes the importance of literature in informing clinical\nrecommendations but allows latitude because recommenda-tions may be in \ufb02uenced by other factors, such as patient\npreference, cost, and expert consensus. \u201cStrong recommenda-\ntions \u201dare those that would be chosen by most informed pa-\ntients. \u201cWeak recommendations \u201dare those where patient\nvalues and preferences might play a larger role than the qualityof evidence. Within the document we preface strong recom-\nmendations with phrases such as \u201cwe recommend \u201dand weak\nrecommendations with \u201cwe suggest. \u201d\nApproaches to Screening\nIn the United States CRC screening usually results from\nan of \ufb01ce-based interaction between a healthcare provider\nand patient. Screening in this setting is termedopportunistic.\n4\nProgrammatic screening (sometimes called organized\nscreening) refers to a system-wide, organized approach tooffering screening to a population or members of a health-care plan.\n4Programmatic screening has potential advan-\ntages over opportunistic screening, including systematic\noffers of screening, reduction of overscreening, superiormonitoring of quality, and systematic follow-up of testing.National CRC screening programs in Europe\n5and Australia6\nuse fecal occult blood testing and include screening colo-noscopy in Germany and Poland.\n5The United States has no\nnational program for CRC screening, although several largehealthcare plans offer programmatic screening, typicallywith a fecal immunochemical test (FIT).\n7Despite the po-\ntential advantages of programmatic screening, the UnitedStates has achieved the world \u2019s highest rates of CRC\nscreening compliance at 60% and the greatest CRC inci-\ndence and mortality reduction, using an almost entirelyopportunistic approach.\n8\u201312Incidence reductions in the\nUnited States were 3% to 4% per year and 30% overall inthe\ufb01rst decade of this century.\n11,12High rates of screening\nin the United States may re \ufb02ect widespread awareness of\nCRC and insurance coverage of screening. The MSTF antic-ipates growth of programmatic screening within healthcaresystems but expects at least short-term continued relianceon opportunistic screening in the United States.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ce181c2-d05f-4ef2-8249-9a5662f38dfd": {"__data__": {"id_": "9ce181c2-d05f-4ef2-8249-9a5662f38dfd", "embedding": null, "metadata": {"page_label": "2", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7a475de4-81c7-44f5-8826-c442acb7a396", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "69513df4475d20f9626e11fde7c63fa5d5fc96e54d6da40e2b31980b22bfcb0d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b39189a5-845b-4ce4-9a78-19955830569a", "node_type": "1", "metadata": {"page_label": "2", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "66dec63fd03c5b0ff46fd320375d46ad72a6236758a2b2819dc0a10ce35abd04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3002bd0-f7f9-48b1-857e-6a29bbee824f", "node_type": "1", "metadata": {"page_label": "3", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "70fa667ce23274b356dfbf5f8125ec2486b559c5b3194acc94ea9830a8d11592", "class_name": "RelatedNodeInfo"}}, "hash": "a837ec27688351a8a3f587d35243277166da71814457c2f7ed6cdbc37300ce85", "text": "Reliance onopportunistic screening can affect the preference for CRC\nscreening, because achieving compliance with tests that\nshould be repeated at short intervals is more challenging inthe opportunistic setting.\n13\nIn the setting of opportunistic screening, healthcare\nproviders can use several broad strategies to offer screeningto patients. One approach is multiple options , in which the\nbene\ufb01ts, risks, and costs of 2 or more tests are discussed\nand offered to patients ( Table 1 ).\n14Some evidence suggests\nthat when patients are offered both colonoscopy and fecaloccult blood testing, more patients undergo screening.\n15\nOther data suggest no bene \ufb01t in overall compliance when\nmultiple options are offered.16\u201318In 1 study, offering pa-\ntients 5 options did not enhance compliance over 2\nTable 1. Approaches to Offering Screening in the Opportunistic Setting\nApproach Description\nMultiple options The relative bene \ufb01ts, risks, and costs of 2 or more options are presented\nSequential testing A preferred test is offered \ufb01rst. If the patients decline another option(s) is offered\nRisk strati \ufb01ed approach Colonoscopy is offered to patients predicted to have a high prevalence of advanced pre-cancerous\nlesions; other tests are offered to patients predicted at low risk2 Rex et al Gastroenterology Vol. -, No.-\nAGA SECTION", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3002bd0-f7f9-48b1-857e-6a29bbee824f": {"__data__": {"id_": "b3002bd0-f7f9-48b1-857e-6a29bbee824f", "embedding": null, "metadata": {"page_label": "3", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e5f12b3b-6830-4f35-913b-592305c682be", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "d3343257d73ec9ae7462b9f973b88651c33d0e6a602343f573bc2fbd9f21cca0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ce181c2-d05f-4ef2-8249-9a5662f38dfd", "node_type": "1", "metadata": {"page_label": "2", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "a837ec27688351a8a3f587d35243277166da71814457c2f7ed6cdbc37300ce85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6df321de-b7ec-4532-8aea-a104a0f4c01a", "node_type": "1", "metadata": {"page_label": "3", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "16a37c6679c217ca5511697afa9b87ac5d32b75d60f75fe7ea6595a300ccfb1d", "class_name": "RelatedNodeInfo"}}, "hash": "70fa667ce23274b356dfbf5f8125ec2486b559c5b3194acc94ea9830a8d11592", "text": "options.19In this regard, at least 9 different screening tests\n(colonoscopy, FIT, guaiac-based fecal occult blood test, FIT \u2013\nfecal DNA, sigmoidoscopy, sigmoidoscopy plus fecal occultblood test, CT colonography, barium enema, and the Septin9serum assay [Epigenomics, Seattle, Wash]) are endorsed ordiscussed in recent major screening guidelines.\n14,20Thus,\nthe multiple options discussion may best be limited to 2 or 3\npreferred options. If patients decline all the offered options,1 or more of the other options can be offered.\nThe sequential approach to screening involves an offer of\na\ufb01rst test that is usually the provider \u2019s preferred screening\noption; if the patient declines the \ufb01rst option, a second test\nis offered, and so on. In the United States the sequentialapproach often involves an offer of colonoscopy, followed byFIT if colonoscopy is declined, or another screening test.\n9\nSeparate guidelines from the American College of Gastro-enterology\n21and the American Society for Gastrointestinal\nEndoscopy22recommend a sequential approach with colo-\nnoscopy offered \ufb01rst. Sequential testing can maximize\ncompliance overall as well as with the test recommended\ufb01rst.\n23\u201325Clinicians using the colonoscopy- \ufb01rst sequential\napproach place emphasis on the high ef \ufb01cacy of colonoscopy\nin preventing CRC and less emphasis on the risks of colo-noscopy. Indeed, high-quality colonoscopy has both highersingle-time testing ef \ufb01cacy and greater risks than any other\nscreening tests but with absolute risk rates that are stillvery low when performed by skilled operators.\n26A variant\nof sequential testing often used in the programmatic setting\nis to offer patients FIT as the initial or preferred test and\nhave other options such as colonoscopy available to patientswho express interest in alternatives.\n4\nA third approach to offering screening to average-risk\npersons is a risk-strati \ufb01edapproach. Risk strati \ufb01cation\nuses evidence that the \u201caverage-risk \u201dpopulation actually\nrepresents a wide range of risk that can be estimated basedon demographic and other risk factors.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6df321de-b7ec-4532-8aea-a104a0f4c01a": {"__data__": {"id_": "6df321de-b7ec-4532-8aea-a104a0f4c01a", "embedding": null, "metadata": {"page_label": "3", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e5f12b3b-6830-4f35-913b-592305c682be", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "d3343257d73ec9ae7462b9f973b88651c33d0e6a602343f573bc2fbd9f21cca0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3002bd0-f7f9-48b1-857e-6a29bbee824f", "node_type": "1", "metadata": {"page_label": "3", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "70fa667ce23274b356dfbf5f8125ec2486b559c5b3194acc94ea9830a8d11592", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "031e7b18-e8e3-477d-9849-b5775667473e", "node_type": "1", "metadata": {"page_label": "3", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "f477137b00578b25e44bb670fecba7924f91ea2c15e35c82cd24d6bfffef8363", "class_name": "RelatedNodeInfo"}}, "hash": "16a37c6679c217ca5511697afa9b87ac5d32b75d60f75fe7ea6595a300ccfb1d", "text": "For example, olderage, male gender, obesity, diabetes, and cigarette smokingare all associated with colorectal adenomas and cancer andtherefore might be used in stratifying risk within the\naverage-risk population.\n21The goal is to predict subgroups\nof patients with a high prevalence of important precancer-ous lesions bene \ufb01ting most from referral directly to colo-\nnoscopy, whereas the subgroups with a predicted lower risk(prevalence) of important precancerous lesions are referredfor screening tests with less risk and cost than colonoscopy.Risk strati \ufb01cation has been poorly accepted because of\nlimited accuracy in discriminating high- and low-prevalencesubgroups.\n27However, recent validated models appear to\nbe simple to apply and had substantial accuracy in de \ufb01ning\nhigh- and low-risk groups for advanced adenomas.28,29\nThere are no clinical trials comparing compliance or other\noutcomes using a risk-strati \ufb01ed approach to the multiple\noptions or sequential approaches. Few data are currentlyavailable regarding ease of application of a risk-strati \ufb01ed\napproach in clinical practice.\nThe MSTF considers that each of the approaches out-\nlined above is reasonable when offering screening in theopportunistic setting. There is insuf \ufb01cient evidence to\nidentify one approach as superior. Patients undergoingscreening tests other than colonoscopy should understand\nthat colonoscopy is used to evaluate these tests when pos-itive. In some instances insurance coverage of colonoscopyperformed to evaluate other positive screening tests may beless than coverage of primary screening colonoscopy.Awareness of the different approaches may assist clinicians\nin understanding screening literature and in selecting an\napproach to offering screening that seems to be optimal fortheir practice or for an individual patient.\nRecommendations\n1. We recommend that clinicians offer CRC screening\nbeginning at age 50 (strong recommendation, high-quality evidence). (See below for adjustments in recom-mended age for onset of screening based on race andfamily history.)\n2. We suggest that sequential offers of screening tests, of-\nfering multiple screening options, and risk-strati \ufb01ed\nscreening are all reasonable approaches to offering\nscreening (weak recommendation, low-quality evidence).\nScreening Targets\nThe object of screening is to reduce CRC incidence and\nmortality.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "031e7b18-e8e3-477d-9849-b5775667473e": {"__data__": {"id_": "031e7b18-e8e3-477d-9849-b5775667473e", "embedding": null, "metadata": {"page_label": "3", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e5f12b3b-6830-4f35-913b-592305c682be", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "d3343257d73ec9ae7462b9f973b88651c33d0e6a602343f573bc2fbd9f21cca0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6df321de-b7ec-4532-8aea-a104a0f4c01a", "node_type": "1", "metadata": {"page_label": "3", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "16a37c6679c217ca5511697afa9b87ac5d32b75d60f75fe7ea6595a300ccfb1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e82bcb0-f426-432f-88a7-3ab60aaeeb7e", "node_type": "1", "metadata": {"page_label": "4", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "a0763d678e63126a9aa9a3fa89497f848d2676688845fda7d2af3778583e331d", "class_name": "RelatedNodeInfo"}}, "hash": "f477137b00578b25e44bb670fecba7924f91ea2c15e35c82cd24d6bfffef8363", "text": "Screening Targets\nThe object of screening is to reduce CRC incidence and\nmortality. To accomplish both aims, tests need to detectearly-stage (ie, curable) CRCs and high-risk precancerouslesions.\n1,21Detection and removal of precancerous lesions\nprevents CRC.30,31The 2 main classes of precancerous le-\nsions in the colon are conventional adenomas and serratedclass lesions ( Table 2 ). These 2 classes of precancerous le-\nsions have distinct endoscopic features and histology anddifferent (though overlapping) distributions within the col-orectum. Speci \ufb01c screening tests sometimes have particular\nstrengths or weaknesses detecting 1 or the other class ofprecancerous lesions, particularly the serrated class.\nTherefore, we review here the main clinical features of the 2\nclasses of precancerous lesions.\nAdenomas, also known as conventional adenomas, are\nthe precursors of perhaps 70% of all CRCs.\n32,33The ade-\nnoma \u2013carcinoma sequence is believed to typically take\nTable 2. Histologic Classi \ufb01cation of the Two Major Classes of\nColorectal Polyps\nI. Conventional adenomas\na. Dysplasia grade\ni. High grade\nii. Low grade\nb. Villousity\ni. Tubular\nii. Tubulovillous\niii. Villous\nII. Serrated lesions\na. Hyperplastic polyps (not considered precancerous)\nb. Sessile serrated polyp\ni. Without cytologic dysplasia\nii. With cytologic dysplasia\nc. Traditional serrated adenoma-2017 MSTF Recommendations for CRC Screening 3\nAGA SECTION", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e82bcb0-f426-432f-88a7-3ab60aaeeb7e": {"__data__": {"id_": "6e82bcb0-f426-432f-88a7-3ab60aaeeb7e", "embedding": null, "metadata": {"page_label": "4", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "51b691a2-5a4b-4e7c-a60b-bbc029ff72d9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "90831515b7b3072814190223edbcacfbf1f5b7b8bccb6c688da954ec646d2200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "031e7b18-e8e3-477d-9849-b5775667473e", "node_type": "1", "metadata": {"page_label": "3", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "f477137b00578b25e44bb670fecba7924f91ea2c15e35c82cd24d6bfffef8363", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f6fd072-eea0-447c-b81c-da513e2f27d4", "node_type": "1", "metadata": {"page_label": "4", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "8ead42f54aa7c7e253d12d2a9ba4bff8aab5aacf9bd9466949c23f5eb7b79f1e", "class_name": "RelatedNodeInfo"}}, "hash": "a0763d678e63126a9aa9a3fa89497f848d2676688845fda7d2af3778583e331d", "text": "more than 10 years to complete in sporadic cancers,\nwhereas much shorter intervals occur in Lynch syndrome.34\nCorrespondingly, colonoscopy is recommended at 10-yearintervals in average-risk persons and at 1- to 2-year in-tervals in those with Lynch syndrome.\n1,34The distribution\nof adenomas is relatively even throughout the colon,\nalthough adenomas with a \ufb02at or depressed morphology are\ndistributed more to the proximal colon and pedunculatedlesions more to the distal colon.\n35Adenomas are by de \ufb01-\nnition dysplastic, with the overwhelming majority being lowgrade. The presence of high-grade dysplasia in an adenomashould be noted by a pathologist. Adenomas can also becharacterized by tubular versus villous histology, with theoverwhelming majority tubular. Lesions with >25% villous\nelements are termed tubulovillous and those with >75%\nvillous elements villous . Villous elements and invasive can-\ncer are associated with increasing size of adenomas. Inva-\nsive cancer in adenomas /C205 mm in size is extremely rare,\nand the prevalence remains well below 1% in adenomas 6to 9 mm in size.\n36Recent colonoscopic studies have iden-\nti\ufb01ed lower prevalence rates of cancer in polyps <1c mi n\nsize compared with early studies, probably because im-provements in colonoscope technology and performancehave led to routine detection of an array of small, \ufb02at, low-\nvolume adenomas.\n36Interobserver agreement in differen-\ntiation of high- versus low-grade dysplasia by pathologistsand tubular versus tubulovillous histology is poor tomoderate, particularly in adenomas <1 cm in size.\n37\nConversely, interobserver agreement between pathologists\nis good to excellent in placing lesions within the conven-tional adenomas versus serrated polyps and in identifyinginvasive cancer.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f6fd072-eea0-447c-b81c-da513e2f27d4": {"__data__": {"id_": "8f6fd072-eea0-447c-b81c-da513e2f27d4", "embedding": null, "metadata": {"page_label": "4", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "51b691a2-5a4b-4e7c-a60b-bbc029ff72d9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "90831515b7b3072814190223edbcacfbf1f5b7b8bccb6c688da954ec646d2200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e82bcb0-f426-432f-88a7-3ab60aaeeb7e", "node_type": "1", "metadata": {"page_label": "4", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "a0763d678e63126a9aa9a3fa89497f848d2676688845fda7d2af3778583e331d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7838844-e90c-4d4a-928c-594b5bfdf4d8", "node_type": "1", "metadata": {"page_label": "4", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "4125b9419732d455682db29dcfafe9e49a700f96a56a872be43d99c7a95ccd36", "class_name": "RelatedNodeInfo"}}, "hash": "8ead42f54aa7c7e253d12d2a9ba4bff8aab5aacf9bd9466949c23f5eb7b79f1e", "text": "38\nAn important clinical concept is the \u201cadvanced \u201dade-\nnoma, de \ufb01ned as a lesion /C211 cm in size or having high-grade\ndysplasia or villous elements.3Because nonadvanced ade-\nnomas have a very low prevalence of cancer and a longadenoma \u2013cancer sequence, screening tests can remain\nuseful if they target cancer and advanced adenomas and notsmall adenomas. Further, the prevalence of nonadvancedadenomas is so high in modern colonoscopy studies thatdetection of such lesions by noncolonoscopic screening testsleads to unacceptably low speci \ufb01city. Colonoscopy has an\nimportant bene \ufb01t over other screening methods because of\nits ability to detect and remove both advanced and non-\nadvanced adenomas. Although nonadvanced adenomas have\nlimited clinical importance and are not the target of non-colonoscopic screening methods, colonoscopists strive toidentify and remove nonadvanced adenomas. Thus, resect-ing lesions with any precancerous potential during colo-noscopy is safe, seems to be better accepted by patients inthe United States, and removes them as a clinical concern.\nSerrated colorectal lesions ( Figure 1 ) represent an\nemerging area in the \ufb01eld of precancerous colorectal lesions.\nThe serrated class of precursor lesions accounts for up to\nFigure 1. Endoscopic photographs of conventional adenomas and sessile serrated polyps. ( A), Small (8-mm diameter) con-\nventional adenoma. The red lines are surface blood vessels. ( B), A portion of a 40-mm advanced conventional adenoma; one\nof the targets of all screening tests. The prominent blood vessel pattern is again visible. ( C), A conventional adenoma with a\nfocus of invasive cancer. The prominent blood vessel pattern of a conventional adenoma visible over the lesion except in theulcerated area. The cancer is located at the ulcer (arrows) (D), A sessile serrated polyp without cytologic dysplasia. Note the\nabsence of blood vessels on the surface. ( E), A sessile serrated polyp (visualized in narrow-band imaging) with multiple foci of\ncytologic dysplasia (yellow arrows) .", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7838844-e90c-4d4a-928c-594b5bfdf4d8": {"__data__": {"id_": "b7838844-e90c-4d4a-928c-594b5bfdf4d8", "embedding": null, "metadata": {"page_label": "4", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "51b691a2-5a4b-4e7c-a60b-bbc029ff72d9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "90831515b7b3072814190223edbcacfbf1f5b7b8bccb6c688da954ec646d2200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f6fd072-eea0-447c-b81c-da513e2f27d4", "node_type": "1", "metadata": {"page_label": "4", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "8ead42f54aa7c7e253d12d2a9ba4bff8aab5aacf9bd9466949c23f5eb7b79f1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5070772-fd4d-450b-9098-4c60f7b0b404", "node_type": "1", "metadata": {"page_label": "5", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "04f63fb1a2b25a7e412890dc51077c616ec7e093ec845bcb2b6afba3cb1e5c64", "class_name": "RelatedNodeInfo"}}, "hash": "4125b9419732d455682db29dcfafe9e49a700f96a56a872be43d99c7a95ccd36", "text": "The dysplastic areas have the blood vessel pattern (and the histologic features) of an\nadenoma. The white arrows point to non-dysplastic portions of this sessile serrated polyp. ( F), A sessile serrated polyp with\ninvasive cancer; white arrows designate the residual sessile serrated polyp, whereas yellow arrows indicate the ulcerated\nmalignant portion of the lesion.4 Rex et al Gastroenterology Vol.\n-, No.-\nAGA SECTION", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5070772-fd4d-450b-9098-4c60f7b0b404": {"__data__": {"id_": "d5070772-fd4d-450b-9098-4c60f7b0b404", "embedding": null, "metadata": {"page_label": "5", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ab015375-8dec-405f-9b23-1e921ebe6904", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "000f0c89cffd12e8275cb565b0339d81ced77fc1853b55de1f46a9c7d097b636", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7838844-e90c-4d4a-928c-594b5bfdf4d8", "node_type": "1", "metadata": {"page_label": "4", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "4125b9419732d455682db29dcfafe9e49a700f96a56a872be43d99c7a95ccd36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62d5ae79-716e-4eea-910e-46fb2db0a78d", "node_type": "1", "metadata": {"page_label": "5", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "6f3c3aebc392cf6bc8ab3383e797fb16f634d5f1ed4caa9c94c2b11c8d6f154a", "class_name": "RelatedNodeInfo"}}, "hash": "04f63fb1a2b25a7e412890dc51077c616ec7e093ec845bcb2b6afba3cb1e5c64", "text": "30% of CRCs.33Within the serrated class, hyperplastic\npolyps are not currently considered precancerous, whereassessile serrated polyps (SSPs; also known as sessile serratedadenoma) and traditional serrated adenomas are consid-ered precancerous ( Table 2 ).\n33Hyperplastic polyps are\nusually small lesions and are distributed toward the distal\ncolon.39SSPs are common (found in 8%-9% of screening\ncolonoscopies performed by expert detectors)40,41and are\ndistributed toward the proximal colon compared with con-ventional adenomas. SSPs are typically \ufb02at or sessile in\nshape, have few or no surface blood vessels (conventionaladenomas by comparison have many surface vessels), andare more dif \ufb01cult to detect at colonoscopy than conven-\ntional adenomas.\n33,42,43Because of their prevalence and\nprecancerous potential, SSPs are the major precancerousserrated lesion. There is poor interobserver agreement be-tween pathologists in the differentiation of hyperplastic\npolyps from SSPs.\n44Consequently, clinicians can see widely\nvarying rates of SSPs in pathology reports, depending on thepathologist or even the center in which they practice.\n45Most\nSSPs are not dysplastic, and the lesions should consistentlybe designated as \u201cSSP without cytologic dysplasia \u201dor\u201cSSP\nwith cytologic dysplasia. \u201d\n46When a dysplastic component is\npresent, it is often evident endoscopically ( Figure 1 ) and\nhistologically is a region of conventional adenoma within anotherwise serrated lesion.\n47Microdissection studies indi-\ncate that the dysplastic area often has microsatellite insta-bility.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62d5ae79-716e-4eea-910e-46fb2db0a78d": {"__data__": {"id_": "62d5ae79-716e-4eea-910e-46fb2db0a78d", "embedding": null, "metadata": {"page_label": "5", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ab015375-8dec-405f-9b23-1e921ebe6904", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "000f0c89cffd12e8275cb565b0339d81ced77fc1853b55de1f46a9c7d097b636", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5070772-fd4d-450b-9098-4c60f7b0b404", "node_type": "1", "metadata": {"page_label": "5", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "04f63fb1a2b25a7e412890dc51077c616ec7e093ec845bcb2b6afba3cb1e5c64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d2acda1-7717-47b4-b288-302caf732c6d", "node_type": "1", "metadata": {"page_label": "5", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "1c0a5bd3722775110b04a838887f5640faee0620c47e9b13491d2a7879edb84a", "class_name": "RelatedNodeInfo"}}, "hash": "6f3c3aebc392cf6bc8ab3383e797fb16f634d5f1ed4caa9c94c2b11c8d6f154a", "text": "48The SSP with cytologic dysplasia is considered a\nmore advanced lesion in the polyp cancer sequence than\nSSP without cytologic dysplasia.3,33,49,50\nThe traditional serrated adenoma is a rare lesion, often in\nthe left colon, sessile, and uniformly dysplastic.33,46Because\ntraditional serrated adenoma is rare, dysplastic, and has avillous-like growth pattern histologically, it is often mis-interpreted as a tubulovillous conventional adenoma.\n33\nThe features of these 2 classes of precancerous lesions\nare relevant to the available screening tests. Colonoscopy isthe criterion standard for the detection of all precancerouscolorectal lesions. Colonoscopy achieves its greatest supe-\nriority relative to other screening tests in the detection of\nconventional adenomas <1 cm in size and serrated class\nlesions. Detection of SSPs is a major de \ufb01ciency of \ufb02exible\nsigmoidoscopy because SSPs are predominantly in theproximal colon,\n51of CT colonography because the lesions\ntend to be \ufb02at,52and of FIT53probably because SSPs have\nno or few surface blood vessels with less tendency to bleedthan conventional adenomas. The combined FIT \u2013fecal DNA\ntest achieves its greatest relative performance comparedwith FIT alone in the detection of serrated class lesions,related to the poor sensitivity of FIT for these lesions andthe inclusion of hypermethylation markers in the DNA\npanel.\n53Hypermethylation is a feature of serrated lesions.33\nSpeci \ufb01c Screening Tests\nColonoscopy\nThe advantages of colonoscopy include high sensitivity\nfor cancer and all classes of precancerous lesions,single-session diagnosis and treatment, and long intervals\nbetween examinations (10 years) in subjects with normalexaminations. One or 2 negative examinations may signallifetime protection against CRC.\n54Patients who value the\nhighest level of sensitivity in detection of precancerous le-sions and are willing to undergo invasive screening should\nconsider choosing colonoscopy.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d2acda1-7717-47b4-b288-302caf732c6d": {"__data__": {"id_": "2d2acda1-7717-47b4-b288-302caf732c6d", "embedding": null, "metadata": {"page_label": "5", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ab015375-8dec-405f-9b23-1e921ebe6904", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "000f0c89cffd12e8275cb565b0339d81ced77fc1853b55de1f46a9c7d097b636", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62d5ae79-716e-4eea-910e-46fb2db0a78d", "node_type": "1", "metadata": {"page_label": "5", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "6f3c3aebc392cf6bc8ab3383e797fb16f634d5f1ed4caa9c94c2b11c8d6f154a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2703592c-c6ac-4f31-8389-0dee55c47a73", "node_type": "1", "metadata": {"page_label": "5", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "6471d737c7537ebf15ca97cebfb643d6251bf383a9b5524475256fe1579a2bc8", "class_name": "RelatedNodeInfo"}}, "hash": "1c0a5bd3722775110b04a838887f5640faee0620c47e9b13491d2a7879edb84a", "text": "Although no randomized\ntrials of colonoscopy for screening have been completed,extensive evidence from adenoma cohorts,\n30,31cohort\nstudies on incidence and mortality,55,56and case-control\nstudies57\u201364support the ef \ufb01cacy of colonoscopy in pre-\nventing incident CRC and cancer deaths. One cohort study56\nand 3 case-control studies58,59,64were performed in\nscreening populations. Reductions in incidence and mor-tality are approximately 80% in the distal colon and 40% to60% in the proximal colon, at least in the United States andGermany.\n57,59,61,62,64Furthermore, indirect evidence from\nrandomized trials of fecal occult blood testing65and\nsigmoidoscopy,66as well as studies showing highly variable\ncancer protection provided by different colonoscopists,67,68\nalso supports a protective effect of colonoscopy against CRC.These \ufb01ndings are consistent with the observed population\ntrends in the United States.\n11,12\nDisadvantages of colonoscopy include the need for\nthorough bowel cleansing, a higher risk of perforationrelative to the other screening tests, higher risk of aspirationpneumonitis (particularly when the procedure is performedwith deep sedation),\n69a small risk of splenic injury\nrequiring splenectomy, and a greater risk of postprocedural\nbleeding compared with other screening tests. A meta-analysis of population-based studies found risks of perfo-ration, bleeding, and death of .5 per 1000, 2.6 per 1000, and2.9 per 100,000, respectively.\n70Bleeding after colonoscopy\nis almost entirely related to polypectomy. When electro-cautery is used for resection of all colorectal polyps, mostbleeds occur after resection of small lesions. This relatesentirely to the high prevalence of these lesions becauseincreasing polyp size and proximal colon location are themajor risk factors for bleeding per individual resected\npolyp.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2703592c-c6ac-4f31-8389-0dee55c47a73": {"__data__": {"id_": "2703592c-c6ac-4f31-8389-0dee55c47a73", "embedding": null, "metadata": {"page_label": "5", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ab015375-8dec-405f-9b23-1e921ebe6904", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "000f0c89cffd12e8275cb565b0339d81ced77fc1853b55de1f46a9c7d097b636", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d2acda1-7717-47b4-b288-302caf732c6d", "node_type": "1", "metadata": {"page_label": "5", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "1c0a5bd3722775110b04a838887f5640faee0620c47e9b13491d2a7879edb84a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db9ca3e5-ad8b-4927-a2b9-ad2c67bbab11", "node_type": "1", "metadata": {"page_label": "6", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "e1eb7ae83ffa431289a3aff5dd639d8660f6f5bc51df4d8d64e2ef1435ccbc5b", "class_name": "RelatedNodeInfo"}}, "hash": "6471d737c7537ebf15ca97cebfb643d6251bf383a9b5524475256fe1579a2bc8", "text": "71Cold resection techniques are effective and nearly\ndevoid of clinically signi \ufb01cant bleeding risk and can be\ngenerally advised for nonpedunculated lesions <1c mi n\nsize.72Despite these risks, colonoscopy is the preferred\napproach to management of any benign colorectal polypregardless of size or location because the alternative ofsurgical resection has higher mortality and cost comparedwith colonoscopy.\n73,74To the extent that other screening\ntests effectively identify large lesions, they result in colo-noscopy and do not prevent adverse events related tocolonoscopic resection of large lesions.\nA major disadvantage of colonoscopy is operator\ndependence in performance. Operator dependence affects\ndetection of cancer,\n67,68,75adenomas,76,77and serrated le-\nsions40,41,78; selection of appropriate screening and sur-\nveillance intervals after colonoscopy79; and effective\nresection of colorectal polyps.80In general, gastroenterolo-\ngists performing colonoscopy are more effective than non-gastroenterologists in prevention of cancer\n62,81 \u201383and\ndetection of precancerous polyps.84However, substantial-2017 MSTF Recommendations for CRC Screening 5\nAGA SECTION", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db9ca3e5-ad8b-4927-a2b9-ad2c67bbab11": {"__data__": {"id_": "db9ca3e5-ad8b-4927-a2b9-ad2c67bbab11", "embedding": null, "metadata": {"page_label": "6", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d3e15656-ac50-4c58-86f8-bb385546b9d2", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "2477f11d5e59af76b338263ac5a41270edf9d12df305c3cf48893a11d4022e82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2703592c-c6ac-4f31-8389-0dee55c47a73", "node_type": "1", "metadata": {"page_label": "5", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "6471d737c7537ebf15ca97cebfb643d6251bf383a9b5524475256fe1579a2bc8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "399c07c0-cd2f-4101-bb7c-e4dc9586421e", "node_type": "1", "metadata": {"page_label": "6", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "459d19a68a926734785afa0311bdd653118b455f643ab718bedaeb01e1a482d7", "class_name": "RelatedNodeInfo"}}, "hash": "e1eb7ae83ffa431289a3aff5dd639d8660f6f5bc51df4d8d64e2ef1435ccbc5b", "text": "operator dependence within gastroenterologists is consis-\ntently observed,42,43,76 \u201378so that selection of a colono-\nscopist by specialty is not adequate protection againstsuboptimal operator performance. Table 3 shows a list of\nquestions that patients can ask potential colonoscopists tojudge whether performance is likely to be at a high level.Afterward, the colonoscopy report should contain the itemsinTable 3 as an additional check on the adequacy of the\nprocedure.\nFecal Immunochemical Test\nAdvantages of FIT include its noninvasive nature, 1-time\nsensitivity for cancer of 79% in 1 meta-analysis,85fair\nsensitivity for advanced adenomas (approximately 30%),and low 1-time cost (approximately $20). FIT is recom-mended annually in the United States. The MSTF has\nrecently issued detailed recommendations on the technical\nperformance of FIT\n86and considers FIT an essential\nelement of the CRC screening armamentarium for all prac-titioners. FIT is commonly the test of choice in program-matic screening, an excellent second choice for practitionersusing sequential testing who offer colonoscopy \ufb01rst, and\nshould likely always be one of the tests included in amultiple-options approach. Disadvantages of FIT include theneed for repeated testing, which can be problematic in thenonprogrammatic (opportunistic) setting,\n13and poor or no\nsensitivity for serrated class precursor lesions.53However,\nthere is no evidence that cancers arising through serrated\nclass lesions are less likely to bleed than those arising viaadenomas.\nFIT\u2013Fecal DNA Test\nThe U.S. Food and Drug Administration (FDA) approved\na CRC screening test that is a combination of a FIT andmarkers for abnormal DNA\n53(Cologuard; Exact Sciences;\nBoston, Mass). The Center for Medicaid & Medicare Servicesapproved the test for reimbursement and recommendsperformance at 3-year intervals. In a large screening colo-noscopy study, patients underwent FIT, the combined FIT \u2013\nfecal DNA test, and colonoscopy. The FIT \u2013fecal DNA test had\na 1-time sensitivity for CRC of 92%.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "399c07c0-cd2f-4101-bb7c-e4dc9586421e": {"__data__": {"id_": "399c07c0-cd2f-4101-bb7c-e4dc9586421e", "embedding": null, "metadata": {"page_label": "6", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d3e15656-ac50-4c58-86f8-bb385546b9d2", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "2477f11d5e59af76b338263ac5a41270edf9d12df305c3cf48893a11d4022e82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db9ca3e5-ad8b-4927-a2b9-ad2c67bbab11", "node_type": "1", "metadata": {"page_label": "6", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "e1eb7ae83ffa431289a3aff5dd639d8660f6f5bc51df4d8d64e2ef1435ccbc5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c027a6f-f532-4c5f-a73a-957e5859a3ae", "node_type": "1", "metadata": {"page_label": "6", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "566ce365b5bdbe9c4551b76783781a02f50da0bde91e623583979299e2366f93", "class_name": "RelatedNodeInfo"}}, "hash": "459d19a68a926734785afa0311bdd653118b455f643ab718bedaeb01e1a482d7", "text": "The FIT assay tested in\nthe study had 73.8% sensitivity for cancer, suggesting that\nmost cancer sensitivity of the FIT \u2013fecal DNA test can be\nachieved without addition of DNA markers. Advantages ofthe FIT \u2013fecal DNA test include the highest single-timetesting sensitivity for cancer of any noninvasive, non-\nimaging CRC screening test. Also, the study demonstrated\n40% sensitivity for SSPs >1 cm in size. The sensitivity of FIT\nfor SSPs was equal to the false-positive rate, indicating nosensitivity.\nThe major disadvantages of the FIT \u2013fecal DNA test are a\nsubstantial decrease in speci \ufb01city (86.6% in persons with\nnormal colonoscopy or nonadvanced lesions and 89.8% inthose with normal colonoscopy), compared with 96% forthe FIT test alone, and high cost relative to FIT. Speci \ufb01city\ndecreased with increasing age and was only 83% in personsaged>65 years. The cost of the FIT \u2013fecal DNA test is\napproximately $600 for privately insured patients and\nabout $500 for Medicare patients, about 10 times the directcosts of annual FIT. Moreover, there is a further increase inrelative costs related to higher numbers of colonoscopiesper test. However, speci \ufb01city of every 3-year testing with\nthe FIT \u2013fecal DNA test may be approximately equal to the\nanticipated speci \ufb01city over 3 years of annual FIT testing.\nThere is currently no information regarding the program-matic sensitivity of the FIT \u2013fecal DNA test.\nAnnual FIT is more effective and less costly than FIT \u2013\nfecal DNA every 3 years,\n87so the FIT \u2013fecal DNA test is\nunlikely to replace FIT in large organized screening pro-\ngrams. The FIT \u2013fecal DNA test could be particularly\nappropriate for patients in the 50- to 65-year age group whoseek a noninvasive test with very high sensitivity for cancer,because the test has better speci \ufb01city in this age group.\nAvailable evidence suggests that asymptomatic patientswith a positive FIT \u2013fecal DNA test and a negative high-\nquality colonoscopy do not need the colonoscopy repeatedor evaluation of the remainder of the GI tract.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c027a6f-f532-4c5f-a73a-957e5859a3ae": {"__data__": {"id_": "2c027a6f-f532-4c5f-a73a-957e5859a3ae", "embedding": null, "metadata": {"page_label": "6", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d3e15656-ac50-4c58-86f8-bb385546b9d2", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "2477f11d5e59af76b338263ac5a41270edf9d12df305c3cf48893a11d4022e82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "399c07c0-cd2f-4101-bb7c-e4dc9586421e", "node_type": "1", "metadata": {"page_label": "6", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "459d19a68a926734785afa0311bdd653118b455f643ab718bedaeb01e1a482d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4abc5c52-20c6-4150-bc64-a4f9f4d08cc5", "node_type": "1", "metadata": {"page_label": "7", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "949298ea0be1e5d457bf34f7f61ad5b3a92195edabe8f95eeb1023704c1bac42", "class_name": "RelatedNodeInfo"}}, "hash": "566ce365b5bdbe9c4551b76783781a02f50da0bde91e623583979299e2366f93", "text": "CT Colonography\nCT colonography has replaced double-contrast barium\nenema as the test of choice for colorectal imaging for nearlyall indications. CT colonography is more effective thanbarium enema and better tolerated.\n88,89\nAdvantages of CT colonography include a lower risk of\nperforation compared with colonoscopy and sensitivity of82% to 92% for adenomas /C211 cm in size.\n88\u201391Disadvan-\ntages of CT colonography include the use of bowel prepa-\nration in most centers in the United States. CT colonography\ncan be performed with laxative-free protocols, but this re-sults in clear reductions in sensitivity relative to colonos-copy,\n91including for large polyps. The sensitivity of CTTable 3. Tools for Patients to Enhance Colonoscopy Quality\nQuestions for patients to ask prospective colonoscopists to help ensure a high-quality examination\n1. What is your adenoma detection rate? (should be /C2125% overall or /C2130% for male patients and /C2120% for female patients)\n2. What is your cecal intubation rate (should be /C2195% for screening colonoscopies and /C2190% overall)\n3. Do you use split-dosing of bowel preparations? (effective bowel preparation requires that at least half the preparation be ingested on the\nday of the colonoscopy)\nChecks of the endoscopy report after the procedure\n1. Does the report include photographs of the end of the colon, including the appendiceal ori \ufb01ce and ileocecal valve/terminal ileum?\n(this demonstrates that the full extent of the colon was examined)\n2. Is the bowel preparation quality described? (the preparation must be adequate to ensure effective examination)6 Rex et al Gastroenterology Vol. -, No.-\nAGA SECTION", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4abc5c52-20c6-4150-bc64-a4f9f4d08cc5": {"__data__": {"id_": "4abc5c52-20c6-4150-bc64-a4f9f4d08cc5", "embedding": null, "metadata": {"page_label": "7", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "084919ce-227a-4a3e-8f93-78f25e33d762", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "c672a4d871227784c198fdfc32a7794d24ac956ef4217e5c41d5aeba93289760", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c027a6f-f532-4c5f-a73a-957e5859a3ae", "node_type": "1", "metadata": {"page_label": "6", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "566ce365b5bdbe9c4551b76783781a02f50da0bde91e623583979299e2366f93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8aae1fee-40b5-41a6-b65c-b5550a6ed1fa", "node_type": "1", "metadata": {"page_label": "7", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "4f1e4c2e14ab8117f6da26f6c4152ffd03bd81dab910b0376a80b83fc0d53a80", "class_name": "RelatedNodeInfo"}}, "hash": "949298ea0be1e5d457bf34f7f61ad5b3a92195edabe8f95eeb1023704c1bac42", "text": "colonography for polyps <1 cm is less than colonoscopy,88\u201391\nand detection of \ufb02at92and serrated lesions93are major\nde\ufb01ciencies of CT colonography. Detection of extracolonic\n\ufb01ndings by CT colonography is common, and these \ufb01ndings\nhave been classi \ufb01ed by the American College of Radiology\naccording to their clinical relevance.94Radiation exposure is\ngenerally viewed as a disadvantage of CT colonography.14\nEvidence that CT colonography reduces CRC incidence or\nmortality is lacking.\nEven in centers where CT colonography has long been\navailable, the impact of CT colonography is limited. At oneuniversity, after full development of a CT colonographyprogram, CT colonography accounted for about 10% ofcolorectal imaging studies, even with the availability of in-surance coverage.\n95,96Primary care physicians view the\nneed for frequent follow-up colonoscopy examinations andmanagement of incidental extracolonic \ufb01ndings as major\nfactors limiting the utility of CT colonography.\n96In general,\ndespite an extensive literature investigating the perfor-mance of CT colonography, the test has limited impact onCRC screening compliance.\n95However, CT colonography\nappeals to a niche of patients who are willing to undergobowel preparation and are concerned about the risks ofcolonoscopy. When used, the recommended interval is 5years in patients with normal CT colonography. We continueto recommend that patients with polyps /C216 mm in size at\nCT colonography undergo colonoscopy.\n1\nFlexible Sigmoidoscopy\nRandomized controlled trials con \ufb01rm reductions in\ndistal colon or rectosigmoid cancer incidence and/or mor-tality of 29% to 76% with \ufb02exible sigmoidoscopy.\n66,97 \u201399\nFlexible sigmoidoscopy can prevent a small fraction (14%)\nof proximal colon cancers, if liberal criteria are used toindicate colonoscopy based on \ufb02exible sigmoidoscopy \ufb01nd-\nings.\n66Advantages of \ufb02exible sigmoidoscopy include\ndisproportionately lower cost and risk compared with co-lonoscopy, a more limited bowel preparation, and no needfor sedation.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8aae1fee-40b5-41a6-b65c-b5550a6ed1fa": {"__data__": {"id_": "8aae1fee-40b5-41a6-b65c-b5550a6ed1fa", "embedding": null, "metadata": {"page_label": "7", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "084919ce-227a-4a3e-8f93-78f25e33d762", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "c672a4d871227784c198fdfc32a7794d24ac956ef4217e5c41d5aeba93289760", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4abc5c52-20c6-4150-bc64-a4f9f4d08cc5", "node_type": "1", "metadata": {"page_label": "7", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "949298ea0be1e5d457bf34f7f61ad5b3a92195edabe8f95eeb1023704c1bac42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e786b3d0-bd54-4db9-adf6-2f5d4c8b5d97", "node_type": "1", "metadata": {"page_label": "7", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "23a7050f57ef5221ff392a2a317c7ee8636edcb6c254ade1e02bd46b6b28fe0e", "class_name": "RelatedNodeInfo"}}, "hash": "4f1e4c2e14ab8117f6da26f6c4152ffd03bd81dab910b0376a80b83fc0d53a80", "text": "Disadvantages of \ufb02exible sigmoidoscopy\ninclude a lower bene \ufb01t in protection against right-sided\ncolon cancer compared with the level of protection ach-ieved in case-control and cohort studies using colonoscopy.Also, the absence of sedation leads to a low satisfaction\nexperience for patients, such that they are less willing to\nrepeat the examination compared with colonoscopy.\n100\nFurther, the concept of examining only part of the colonhas been unpopular in the United States, so that screeningby\ufb02exible sigmoidoscopy has almost disappeared from\nopportunistic screening settings.\n9Some groups have\nendorsed the combination of \ufb02exible sigmoidoscopy plus\nFIT for screening,14but compliance challenges associated\nwith completing 2 screening tests and the dramatic declinein screening \ufb02exible sigmoidoscopy make signi \ufb01cant uptake\nof this combination unlikely.\nFlexible sigmoidoscopy when used is often recom-\nmended at 5-year intervals. However, endoscopic screeningin general is more effective in the left than the right side ofthe colon, and there is no clear reason why \ufb02exiblesigmoidoscopy should not be recommended at 10-year in-\ntervals, similar to the recommendation for colonoscopy. TheMSTF considers that either 5- or 10-year intervals areacceptable but favors 10-year intervals.\nCapsule Colonoscopy\nCapsule colonoscopy has been approved by the FDA for\nimaging the proximal colon in patients with previousincomplete colonoscopies and more recently for patientswho need colorectal imaging but who are not candidates forcolonoscopy or sedation. Capsule colonoscopy is notapproved by the FDA for screening average-risk persons.Advantages of capsule colonoscopy are the achievement ofendoscopic imaging without an invasive procedure and\navoiding the risks of colonoscopy. Disadvantages are that\nthe bowel preparation is more extensive than that for co-lonoscopy.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e786b3d0-bd54-4db9-adf6-2f5d4c8b5d97": {"__data__": {"id_": "e786b3d0-bd54-4db9-adf6-2f5d4c8b5d97", "embedding": null, "metadata": {"page_label": "7", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "084919ce-227a-4a3e-8f93-78f25e33d762", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "c672a4d871227784c198fdfc32a7794d24ac956ef4217e5c41d5aeba93289760", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8aae1fee-40b5-41a6-b65c-b5550a6ed1fa", "node_type": "1", "metadata": {"page_label": "7", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "4f1e4c2e14ab8117f6da26f6c4152ffd03bd81dab910b0376a80b83fc0d53a80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d93f28e-aafe-4c1c-9b30-754af8e7dc61", "node_type": "1", "metadata": {"page_label": "8", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "c1d34ee26abb2bd110b14f3bef93d4ef31a415c17114cb0c458ba71bc115670f", "class_name": "RelatedNodeInfo"}}, "hash": "23a7050f57ef5221ff392a2a317c7ee8636edcb6c254ade1e02bd46b6b28fe0e", "text": "Also, because the logistics of performing same-day colonoscopy on patients with positive capsule studiesare quite dif \ufb01cult, most patients with positive studies will\nrequire re-preparation and colonoscopy on a separate day.In a large screening trial in 884 patients, capsule colonos-copy had 88% sensitivity for detecting patients with aconventional adenoma /C216 mm in size but was ineffective for\nthe detection of serrated lesions, and 9% of patients hadtechnically failed examinations for inadequate cleansing or\nrapid transit of the capsule.\n101\nOverall, the burden associated with bowel preparation\nand the relative superiority of colonoscopy are such thatcapsule colonoscopy would be expected to appeal to a nichepopulation concerned about the risks of colonoscopy, in afashion similar to CT colonography. Currently, lack of FDAapproval for screening and lack of reimbursement are majorobstacles to its use.\nSeptin9 Assay\nThe\ufb01rst FDA-approved serum test for CRC screening is\nthe Septin9 assay (Epigenomics, Seattle, Wash). In a largescreening colonoscopy study, this test had a sensitivity of48% for detection of CRC and no sensitivity for detection ofprecancerous polyps.\n102The test is expensive relative to\nFIT.\nThe advantage of the Septin9 test is that it is a serum\nassay and is at least potentially more convenient for pa-\ntients. Some patients who refused colonoscopy preferred\nthis test over FIT.103\nDisadvantages of the Septin9 assay are markedly inferior\nperformance characteristics compared with FIT, includinglower sensitivity for cancer, inability to detect advancedadenomas,\n104and low cost-effectiveness relative to other\nscreening tests.105The test appears to have higher sensi-\ntivity for late-stage compared with early-stage cancer.102\nThe willingness of patients with positive Septin9 tests toundergo colonoscopy remains uncertain. The uncertaintiesregarding the true clinical utility of Septin 9 makes shared\ndecision-making dif \ufb01cult. Clinicians should inform patients\nof the uncertain bene \ufb01ts of this test on CRC mortality, the\ninability of the assay to detect polyps, and the array of su-perior alternatives. The best frequency for performing the-2017 MSTF Recommendations for CRC Screening 7\nAGA SECTION", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d93f28e-aafe-4c1c-9b30-754af8e7dc61": {"__data__": {"id_": "1d93f28e-aafe-4c1c-9b30-754af8e7dc61", "embedding": null, "metadata": {"page_label": "8", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e50b7613-6371-427b-8eef-f34555dd6a3f", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "da82ca0a1dc06ab748b81d2ca4208ef8c6160a448431d8ea1f1c69ceb709b694", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e786b3d0-bd54-4db9-adf6-2f5d4c8b5d97", "node_type": "1", "metadata": {"page_label": "7", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "23a7050f57ef5221ff392a2a317c7ee8636edcb6c254ade1e02bd46b6b28fe0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9f562b5-380b-4440-b17d-a77160c751cc", "node_type": "1", "metadata": {"page_label": "8", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "e977523b27c71b067195228585906723737911e6b7bb9326e01459f11bc1dade", "class_name": "RelatedNodeInfo"}}, "hash": "c1d34ee26abb2bd110b14f3bef93d4ef31a415c17114cb0c458ba71bc115670f", "text": "test is uncertain. Given these limitations, the MSTF suggests\nthat Septin9 not be used for screening.\nCost Issues\nA consistent \ufb01nding is that CRC screening by any avail-\nable modality is cost-effective compared with noscreening,\n106,107and in some models screening results in\ncost savings. This \ufb01nding relates in part to the high costs of\nCRC treatment. Numerous modeling studies have addressedthe relative cost-effectiveness of 2 or more screening tests.The conclusions of the models frequently vary, likelydepending in part on the assumptions of the respectivemodels. For example, different models comparing colonos-\ncopy and CT colonography have had variable conclusions.\n108\nConsistent trends reveal that FIT performs well compared\nwith other screening tests.106,107,109Colonoscopy also per-\nforms well in most models,106 \u2013108,110and, in general, the\ntraditional tests are more cost-effective than the newermodalities, including CT colonography, FIT \u2013fecal DNA,\ncapsule colonoscopy, and the Septin9 assay.\n105 \u2013107,111 \u2013113\nNewer tests could reach cost-effectiveness by substantially\nincreasing compliance,112,113but evidence of improved\ncompliance is lacking. Some models support the cost-effectiveness of risk-strati \ufb01ed approaches to screening.\n114\nScreening remains cost-effective in patients into their mid-\n80s if they have few comorbidities and limited priorscreening.\n115,116\nQuality of Screening\nVariable performance of screening tests affects at least\ncolonoscopy, sigmoidoscopy, CT colonography, and FIT.\nOptimal results in CRC screening cannot be achieved\nwithout optimizing the technical performance and reportingof tests and ensuring that patients undergo appropriatefollow-up after testing.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9f562b5-380b-4440-b17d-a77160c751cc": {"__data__": {"id_": "d9f562b5-380b-4440-b17d-a77160c751cc", "embedding": null, "metadata": {"page_label": "8", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e50b7613-6371-427b-8eef-f34555dd6a3f", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "da82ca0a1dc06ab748b81d2ca4208ef8c6160a448431d8ea1f1c69ceb709b694", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d93f28e-aafe-4c1c-9b30-754af8e7dc61", "node_type": "1", "metadata": {"page_label": "8", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "c1d34ee26abb2bd110b14f3bef93d4ef31a415c17114cb0c458ba71bc115670f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f253ac9b-bb44-42bf-836b-065957a1bf34", "node_type": "1", "metadata": {"page_label": "8", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "377e6b6c0f8e87c3256c055ff05b1c1de61cfffc5a5f3a2f1dc0549409d05aed", "class_name": "RelatedNodeInfo"}}, "hash": "e977523b27c71b067195228585906723737911e6b7bb9326e01459f11bc1dade", "text": "The MSTF has made detailed rec-ommendations regarding the technical performance of FIT\n86\nand has previously issued quality recommendationsregarding the technical performance of sigmoidoscopy\n117\nand colonoscopy.118The recommendations of the MSTF\nregarding quality in the technical performance of colonos-copy\n118were largely incorporated in quality recommenda-\ntions from a combined American College of\nGastroenterology \u2013American Society for Gastrointestinal\nEndoscopy Task Force on quality in 2006119and 2015,120\nand the MSTF endorses the American College of Gastro-enterology \u2013American Society for Gastrointestinal Endos-\ncopy Task Force recommendations.\nThe burden of performing high-quality FIT falls largely\non primary care physicians and/or the healthcare systemsin which they work. In the opportunistic setting there maynot be resources allocated to systematically ensure that FIT-positive patients are referred for colonoscopy and that FIT-negative patients are offered repeat testing or to monitor\nwhether compliance with quality targets is adequate.\n13\nInability to allocate resources to monitor the quality of\nFIT testing is a factor favoring reliance on sequential testingwith colonoscopy the \ufb01rst test offered.Unlike primary care physicians, the main role of gas-\ntroenterologists in the screening process is to perform co-lonoscopy on patients referred for primary colonoscopyscreening or for colonoscopy to evaluate other positivescreening tests. As such, a primary task of gastroenterolo-gists is to perform high-quality colonoscopy and cost-\neffective follow-up. The adenoma detection rate, originally\nproposed by the MSTF in 2002,\n118has emerged as the most\nimportant and highly variable measure of the quality ofmucosal inspection during colonoscopy. Two large studieshave validated the adenoma detection rate as a predictor ofcancer prevention by colonoscopy.\n67,68Measurement of the\nadenoma detection rate is mandatory to appreciatingwhether a colonoscopist should be performing screeningcolonoscopy. Patients should expect a prospective colono-scopist to provide his or her adenoma detection rate, whichshould meet or exceed recommended minimum thresholds\n(Table 3 ).\nPractical Considerations\nNo published randomized trials have directly compared\nand reported the relative effects of different tests on CRC\nincidence or mortality.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f253ac9b-bb44-42bf-836b-065957a1bf34": {"__data__": {"id_": "f253ac9b-bb44-42bf-836b-065957a1bf34", "embedding": null, "metadata": {"page_label": "8", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e50b7613-6371-427b-8eef-f34555dd6a3f", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "da82ca0a1dc06ab748b81d2ca4208ef8c6160a448431d8ea1f1c69ceb709b694", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9f562b5-380b-4440-b17d-a77160c751cc", "node_type": "1", "metadata": {"page_label": "8", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "e977523b27c71b067195228585906723737911e6b7bb9326e01459f11bc1dade", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16d5f712-9c20-4c83-ab32-b03c35af0ffe", "node_type": "1", "metadata": {"page_label": "9", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "cb6b9da0fa6e64bafeb2c034c0c41ea1aa2a73ed2ebcf65c88da3e4aeb8d21a4", "class_name": "RelatedNodeInfo"}}, "hash": "377e6b6c0f8e87c3256c055ff05b1c1de61cfffc5a5f3a2f1dc0549409d05aed", "text": "Several trials are ongoing, but resultsare not yet available. When compared using simulationmodels that are dependent on assumptions about naturalhistory of disease, patient acceptance of screening, and testperformance, several tests appear to be similarly effec-tive.\n121Therefore, practical considerations are important for\ninforming our recommendations.\nA common statement made with regard to CRC\nscreening is that \u201cthe best test is the one that gets done. \u201d\nThe MSTF endorses this concept because it is generally\nbetter for any person who is eligible to be screened to un-\ndergo some screening test rather than not be screened at all.On the other hand, the core concept underlying sequentialtesting is that offering the \u201cbest \u201dtest(s) \ufb01rst optimizes the\nsensitivity and/or cost-effectiveness of screening and stillleaves the opportunity to offer other tests when patientsdecline. As an extreme example, the MSTF considers thatequating the Septin9 assay with colonoscopy would be adisservice to patients, because the sensitivity of colonoscopyfor cancer and advanced lesions exceeds that of Septin9 by avery large margin. Given these disparities in the perfor-\nmance of individual tests, the MSTF groups the available\ntests into 3 tiers based on various performance features andcosts ( Table 4 ).\nThe tier 1 tests representing the cornerstone of CRC\nscreening are colonoscopy every 10 years and annual FIT(Table 4 ). The use of these 2 tests as the primary screening\nmeasures provides a framework for screening that is simpleand accommodates almost every screening setting. Inorganized programmatic screening FIT will often be offeredas the primary screen, but colonoscopy can be considered asan alternative for patients and physicians who prefer or\nrequest it. In the opportunistic setting, colonoscopy will\noften be preferred when the infrastructure to ensure annualperformance of FIT is not available. As noted above, 1 of themost challenging aspects of FIT screening in the8 Rex et al Gastroenterology Vol. -, No.-\nAGA SECTION", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16d5f712-9c20-4c83-ab32-b03c35af0ffe": {"__data__": {"id_": "16d5f712-9c20-4c83-ab32-b03c35af0ffe", "embedding": null, "metadata": {"page_label": "9", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e3cd3045-eee6-4846-b02c-478a6e9e8e27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "bdf557c7b4a5bbe1ca571bea48ad6c0c0194232cefa9510974064353c7ed56f7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f253ac9b-bb44-42bf-836b-065957a1bf34", "node_type": "1", "metadata": {"page_label": "8", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "377e6b6c0f8e87c3256c055ff05b1c1de61cfffc5a5f3a2f1dc0549409d05aed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d072b2f-7bf5-4e10-bfde-93f0436daf4f", "node_type": "1", "metadata": {"page_label": "9", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "ff95034dd4aec88a8ed9a43dab63531bed36cc0c0e81fda95944373b0bf41e43", "class_name": "RelatedNodeInfo"}}, "hash": "cb6b9da0fa6e64bafeb2c034c0c41ea1aa2a73ed2ebcf65c88da3e4aeb8d21a4", "text": "opportunistic setting is ensuring repeated annual perfor-\nmance. Using a tier 1 approach that focuses on 2 tests makesthe discussion of CRC screening tests between physician andpatient manageable and feasible, and, as noted above,expanding the number of options in the initial discussionbeyond 2 did not increase screening rates.\n19Colonoscopy\nand FIT can be adapted readily to either the sequential offer\nof screening (colonoscopy is offered \ufb01rst with FIT reserved\nfor those who decline colonoscopy), the multiple-optionsapproach (colonoscopy and FIT are each discussed withpatients, and if both are declined the discussion movessequentially to tier 2 tests), and the risk-strati \ufb01ed approach\n(eg, colonoscopy is offered \ufb01rst to men age >60 and women\nage>65 with no prior screening, and FIT is offered to\npersons under these ages and persons with negative priorcolonoscopy). Risk strati \ufb01cation may also take into account\nfactors such as cigarette smoking, diabetes, and obesity.\nThe rationale for placing tests in the tier 2 and 3 cate-\ngories follows from the discussion above of individual tests.The ranking implies equivalence for tests within eachcategory, but this is not the intent of the MSTF. For example,\ufb02exible sigmoidoscopy screening has strong evidence to\nsupport its use. However, the steady decline in the use of\ufb02exible sigmoidoscopy in the United States\n9,10suggests that\nany strong endorsement of \ufb02exible sigmoidoscopy is not\nconsistent with the reality of the test \u2019s lack of popularity\namong patients and poor reimbursement for physicians. Thestrong evidence base supporting \ufb02exible sigmoidoscopy\nleads us to place the test in the tier 2 category, although we\nexpect that most practitioners using a sequential approachwould move to CT colonography or FIT \u2013fecal DNA in pa-\ntients who decline colonoscopy and FIT, because these testsare less invasive and survey the entire colon.\nPerformance characteristics alone would place capsule\ncolonoscopy in tier 2.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d072b2f-7bf5-4e10-bfde-93f0436daf4f": {"__data__": {"id_": "0d072b2f-7bf5-4e10-bfde-93f0436daf4f", "embedding": null, "metadata": {"page_label": "9", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e3cd3045-eee6-4846-b02c-478a6e9e8e27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "bdf557c7b4a5bbe1ca571bea48ad6c0c0194232cefa9510974064353c7ed56f7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16d5f712-9c20-4c83-ab32-b03c35af0ffe", "node_type": "1", "metadata": {"page_label": "9", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "cb6b9da0fa6e64bafeb2c034c0c41ea1aa2a73ed2ebcf65c88da3e4aeb8d21a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d914c8a2-7c2c-440a-92eb-5735fd5a2862", "node_type": "1", "metadata": {"page_label": "9", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "33b78dafabacb3620c4cd3e97d18fad8d4b8f7ce4f2256b57e112ead77711a56", "class_name": "RelatedNodeInfo"}}, "hash": "ff95034dd4aec88a8ed9a43dab63531bed36cc0c0e81fda95944373b0bf41e43", "text": "Performance characteristics alone would place capsule\ncolonoscopy in tier 2. However, offering capsule colonos-copy as a tier 2 test in a sequential methodology currentlywould often lead to frustration because reimbursement forscreening capsule colonoscopy is seldom available at thistime, and the test itself is frequently not available. Theonerous bowel preparation and the lack of systems to\naccomplish same-day colonoscopy in most patients with a\npositive capsule colonoscopy are additional factors placingcapsule colonoscopy in the tier 3 category at this time.In summary, we suggest that the tiered system ( Table 4 )\nhas numerous advantages. Predominant reliance on tier 1tests offers modalities with optimal effectiveness, cost-effectiveness, complete colon screening, proven popularitywith patients, and a simpli \ufb01ed discussion (compared with\noffering 5-7 different tests) and still leaves room to offer\nother tests in a sequential fashion. If patients decline colo-\nnoscopy and FIT, all tests in tier 2 are acceptable CRCscreening tests, but each has de \ufb01ciencies relative to the\ntier 1 tests.\nRecommendations\n1. We recommend colonoscopy every 10 years or annual\nFIT as \ufb01rst-tier options for screening the average-risk\npersons for colorectal neoplasia (strong recommenda-tion; moderate-quality evidence).\n2. We recommend that physicians performing screening\ncolonoscopy measure quality, including the adenomadetection rate (strong recommendation, high-qualityevidence).\n3. We recommend that physicians performing FIT monitor\nquality (strong recommendation, low-quality evidence).The recommended quality measurements for FIT pro-grams are detailed in a prior publication.\n86\n4. We recommend CT colonography every 5 years or FIT \u2013\nfecal DNA every 3 years (strong recommendation, low-quality evidence) or \ufb02exible sigmoidoscopy every 5 to\n10 years (strong recommendation, high-qualityevidence) in patients who refuse colonoscopy and FIT.\n5. We suggest that capsule colonoscopy (if available) is an\nappropriate screening test when patients decline colo-noscopy, FIT, FIT \u2013fecal DNA, CT colonography, and \ufb02ex-\nible sigmoidoscopy (weak recommendation, low-qualityevidence).\n6.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d914c8a2-7c2c-440a-92eb-5735fd5a2862": {"__data__": {"id_": "d914c8a2-7c2c-440a-92eb-5735fd5a2862", "embedding": null, "metadata": {"page_label": "9", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e3cd3045-eee6-4846-b02c-478a6e9e8e27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "bdf557c7b4a5bbe1ca571bea48ad6c0c0194232cefa9510974064353c7ed56f7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d072b2f-7bf5-4e10-bfde-93f0436daf4f", "node_type": "1", "metadata": {"page_label": "9", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "ff95034dd4aec88a8ed9a43dab63531bed36cc0c0e81fda95944373b0bf41e43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a2e717f-8e4b-41ca-9ac5-3ed519fe5e2f", "node_type": "1", "metadata": {"page_label": "10", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "3655a731e6568f88c3e129631757c5fe06d51f15c4e263633cf57c212f15dad5", "class_name": "RelatedNodeInfo"}}, "hash": "33b78dafabacb3620c4cd3e97d18fad8d4b8f7ce4f2256b57e112ead77711a56", "text": "6. We suggest against Septin9 for CRC screening (weak\nrecommendation, low-quality evidence).\nFamily History of CRC and Polyps\nWe recommend that screening in most average-risk\npersons be initiated at age 50 years. A family history of\nCRC or certain polyps can modify the recommended startingage and the frequency of screening. The MSTF has previ-ously issued recommendations for screening in personswith Lynch syndrome,\n34which is a genetically de \ufb01ned\ninherited syndrome caused by mutations in 1 or moremismatch repair genes. Patients in families that meet theclinical criteria for hereditary nonpolyposis CRC but havemicrosatellite-stable CRCs have family colon cancer syn-drome X, which has not been genetically de \ufb01ned.\n122Persons\nin families with syndrome X should undergo colonoscopy at\nleast every 3 to 5 years, beginning 10 years before the age at\ndiagnosis of the youngest affected relative.\nA family history of CRC in a \ufb01rst-degree relative in-\ncreases the risk of CRC regardless of the age at diagnosis ofTable 4. Multi-Society Task Force Ranking of Current\nColorectal Cancer Screening Tests\nTier 1\nColonoscopy every 10 years\nAnnual fecal immunochemical test\nTier 2\nCT colonography every 5 years\nFIT\u2013fecal DNA every 3 years\nFlexible sigmoidoscopy every 10 years (or every 5 years)\nTier 3\nCapsule colonoscopy every 5 years\nAvailable tests not currently recommended\nSeptin 9-2017 MSTF Recommendations for CRC Screening 9\nAGA SECTION", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a2e717f-8e4b-41ca-9ac5-3ed519fe5e2f": {"__data__": {"id_": "7a2e717f-8e4b-41ca-9ac5-3ed519fe5e2f", "embedding": null, "metadata": {"page_label": "10", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4aabf2c9-5a8a-4a57-869f-e3668a4ce6e1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "2d2d92fb7a0916c84ff7e2f65076f7c0ff0eca59d05ff4bf4b31d132470edd81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d914c8a2-7c2c-440a-92eb-5735fd5a2862", "node_type": "1", "metadata": {"page_label": "9", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "33b78dafabacb3620c4cd3e97d18fad8d4b8f7ce4f2256b57e112ead77711a56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c16f0fce-7bce-478e-bad9-63bc2cf3a153", "node_type": "1", "metadata": {"page_label": "10", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "9e85d8db2a6823b757fe3662fa0270a6ae9a6dd3cc6fb7d532dcb77aee822733", "class_name": "RelatedNodeInfo"}}, "hash": "3655a731e6568f88c3e129631757c5fe06d51f15c4e263633cf57c212f15dad5", "text": "the affected relative.123 \u2013125There is a gradient of risk such\nthat the younger the age of the affected relative, the greaterthe risk.\n123 \u2013125The MSTF has previously used age 60 as a\nthreshold of risk elevation, so that a single \ufb01rst-degree\nrelative diagnosed with CRC at age <60 years warrants\nboth earlier screening and at more-frequent intervals.1\nRecent population-based studies123,124and reviews of risk\nassociated with a positive family history125support using\nage at diagnosis of CRC above or below 60 years in theaffected \ufb01rst-degree relative as a risk strati \ufb01er. We continue\nto recommend that persons with a family history of CRC in a\ufb01rst-degree relative diagnosed at <60 years undergo colo-\nnoscopy every 5 years beginning at age 40 years or 10 yearsbefore the age the relative was diagnosed, whichever comes\ufb01rst (Table 5 ). In a randomized controlled trial, there was a\nnonsigni \ufb01cant trend toward detection of more advanced\nneoplasia in subjects with a positive family history who\nunderwent colonoscopy compared with FIT.\n126Thus, pa-\ntients with a positive family history who decline colonos-copy should be offered FIT screening.\n126\nThe greatest relative risk of CRC appears to be in\npersons <50 years who have a \ufb01rst-degree relative with\nCRC diagnosed at <50 years.123-125Compliance in young\npersons with a family history of CRC is suboptimal, andclinicians should make special efforts to ensure thatscreening occurs. Recent evidence suggests if persons with asingle \ufb01rst-degree relative with a family history of CRC\nreach the age of approximately 60 years without manifest-\ning signi \ufb01cant colorectal neoplasia,\n127then they are unlikely\nto be at increased risk of CRC and can be offered the optionof expanding the interval between examinations.\nWhen \ufb01rst-degree relatives have documented advanced\nserrated lesions (SSPs /C2110 mm in size, or an SSP with cyto-\nlogic dysplasia, or a traditional serrated adenoma /C2110 mm in\nsize), there is no clear evidence as to how to proceed, unlessthe relative meets criteria for serrated polyposis.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c16f0fce-7bce-478e-bad9-63bc2cf3a153": {"__data__": {"id_": "c16f0fce-7bce-478e-bad9-63bc2cf3a153", "embedding": null, "metadata": {"page_label": "10", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4aabf2c9-5a8a-4a57-869f-e3668a4ce6e1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "2d2d92fb7a0916c84ff7e2f65076f7c0ff0eca59d05ff4bf4b31d132470edd81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a2e717f-8e4b-41ca-9ac5-3ed519fe5e2f", "node_type": "1", "metadata": {"page_label": "10", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "3655a731e6568f88c3e129631757c5fe06d51f15c4e263633cf57c212f15dad5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22c7b819-396e-4d24-999f-0dfb570ce7e6", "node_type": "1", "metadata": {"page_label": "10", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "25520556547731beb9199fc28db154dfe5173ed1cdcdb0d0f3d31c2e4a8c7bce", "class_name": "RelatedNodeInfo"}}, "hash": "9e85d8db2a6823b757fe3662fa0270a6ae9a6dd3cc6fb7d532dcb77aee822733", "text": "46Currently,\nwe recommend that screening for \ufb01rst-degree relatives of\npersons with advanced serrated lesions should be similar tothe screening of \ufb01rst-degree relatives of persons with\nadvanced conventional adenomas.\nPersons with a single \ufb01rst-degree relative with CRC who\nwas diagnosed at age /C2160 years are recommended to beginscreening at 40 years.\n128However, the tests and intervals\nfor testing are the same as the average-risk screening rec-ommendations ( Tables 5 and4).\nWe no longer recommend that persons with a family\nhistory of adenomas in a \ufb01rst-degree relative undergo early\nscreening, unless there is clear documentation of an\nadvanced adenoma in a \ufb01rst-degree relative. In most cases\nthe patient has no information regarding whether the familymember \u2019s adenoma was advanced, and in this case we\nrecommend that it be assumed the adenomas or polypswere not advanced. If a colonoscopy and/or pathology re-port(s) is available for a family member that documents anadvanced adenoma or there is a report of a polyp requiringsurgical resection, an advanced adenoma in a family mem-ber is considered established. These considerationsregarding adequate documentation of advanced precancer-\nous neoplasms in \ufb01rst-degree relatives before intensifying\nscreening apply to documentation of both advanced ade-nomas and advanced serrated lesions. First-degree relativeswith advanced adenomas are recommended to be weightedthe same as \ufb01rst-degree relatives with CRC ( Table 5 ). The\nyield of colonoscopic screening in \ufb01rst-degree relatives of\npersons with advanced adenomas is substantiallyincreased.\n129 \u2013131\nRecommendations\n1. We suggest that persons with 1 \ufb01rst-degree relative with\nCRC or a documented advanced adenoma diagnosed atage<60 years or with 2 \ufb01rst-degree relatives with CRC\nand/or documented advanced adenomas undergo colo-noscopy every 5 years beginning 10 years younger thanthe age at which the youngest \ufb01rst-degree relative was\ndiagnosed or age 40, whichever is earlier (weak recom-\nmendation, low-quality evidence).\n2.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22c7b819-396e-4d24-999f-0dfb570ce7e6": {"__data__": {"id_": "22c7b819-396e-4d24-999f-0dfb570ce7e6", "embedding": null, "metadata": {"page_label": "10", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4aabf2c9-5a8a-4a57-869f-e3668a4ce6e1", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "2d2d92fb7a0916c84ff7e2f65076f7c0ff0eca59d05ff4bf4b31d132470edd81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c16f0fce-7bce-478e-bad9-63bc2cf3a153", "node_type": "1", "metadata": {"page_label": "10", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "9e85d8db2a6823b757fe3662fa0270a6ae9a6dd3cc6fb7d532dcb77aee822733", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa7041af-3aac-456d-b0a1-8a0d827fc4dc", "node_type": "1", "metadata": {"page_label": "11", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "22150bf93e9c2853839e5754bb788ef601bd7af717c5312bf3a125bdd4be2116", "class_name": "RelatedNodeInfo"}}, "hash": "25520556547731beb9199fc28db154dfe5173ed1cdcdb0d0f3d31c2e4a8c7bce", "text": "2. We suggest that persons with 1 \ufb01rst-degree relative\ndiagnosed with CRC or a documented advanced adenoma\nat age/C2160 years begin screening at age 40. The options\nfor screening and the recommended intervals are thesame as those for average-risk persons (weak recom-mendation, very-low-quality evidence).Table 5. MSTF Recommendations for Persons With High-Risk Family Histories Not Associated With Polyp Syndromes\nFamily history Recommended screening\nLynch Syndrome See reference 34\nFamily Colon Cancer Syndrome X Colonoscopy every 3-5 years beginning 10 years before the age at\ndiagnosis of the youngest affected relative\nColorectal cancer or an advanced adenoma in two\n\ufb01rst-degree relatives diagnosed at any age\nOR colorectal cancer or an advanced adenomain a single \ufb01rst-degree relative at age <60 yearsColonoscopy every 5 years beginning 10 years before the age\nat diagnosis of the youngest affect interval or age 40,whichever is earlier; for those with a single \ufb01rst-degree\nrelative with colorectal cancer in whom no signi \ufb01cant\nneoplasia appears by age 60 years, physicians can offer\nexpanding the interval between colonoscopies\nColorectal cancer or an advanced adenoma in a\nsingle \ufb01rst-degree relative diagnosed at\nage/C2160 yearsBegin screening at age 40 years; tests and intervals are as\nper the average-risk screening recommendations ( Table 4 )10 Rex et al Gastroenterology Vol. -, No.-\nAGA SECTION", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa7041af-3aac-456d-b0a1-8a0d827fc4dc": {"__data__": {"id_": "aa7041af-3aac-456d-b0a1-8a0d827fc4dc", "embedding": null, "metadata": {"page_label": "11", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fc4497c2-ec0a-4405-b523-9c6e940267ae", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "54b7a57130e591a0e34f6981e72466184006d3e65f6591f3871029f9485b7190", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22c7b819-396e-4d24-999f-0dfb570ce7e6", "node_type": "1", "metadata": {"page_label": "10", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "25520556547731beb9199fc28db154dfe5173ed1cdcdb0d0f3d31c2e4a8c7bce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "826083a6-bb32-458d-ae5c-04a0dbab7a1a", "node_type": "1", "metadata": {"page_label": "11", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "270941fa34efc09521b0b2294a484b33f387878a61b78d48822bacf4e17b6325", "class_name": "RelatedNodeInfo"}}, "hash": "22150bf93e9c2853839e5754bb788ef601bd7af717c5312bf3a125bdd4be2116", "text": "3. We suggest that persons with 1 or more \ufb01rst-degree\nrelatives with a documented advanced serrated lesion(SSP or traditional serrated adenoma /C2110 mm in size or\nan SSP with cytologic dysplasia) should be screened ac-cording to above recommendations for persons with afamily history of a documented advanced adenoma\n(weak recommendation, very-low-quality evidence).\n4. We recommend that persons with 1 or more \ufb01rst-degree\nrelatives with CRC or documented advanced adenomas,\nfor whom we recommend colonoscopy, should be offered\nannual FIT if they decline colonoscopy (strong recom-mendation, moderate-quality evidence).\nConsiderations Regarding Age\nand CRC Risk\nCRC screening is recommended to begin at age 50 years\nin most average-risk persons, including in prior recom-mendations from the MSTF.\n1Recent modeling supports this\nrecommendation.121Several issues related to age and CRC\nrisk warrant speci \ufb01c discussion.\nThe incidence of CRC is strongly age related and con-\ntinues to rise with increasing age. Partly because of wide-spread screening in the United States, the incidence of CRCin falling by 3% to 4% per year in persons age /C2150 years.\n12\nThe incidence of CRC in persons under age 50 is increasing\nin the United States.132,133Although the reasons for this\nrising incidence remain unclear and the relative incidence inpersons under age 50 remains low, the increasing incidenceof CRC in young people is a major public health concern.\nThe best course of action with regard to the rising\nincidence of CRC in young people is currently not certain.When a young person develops fatal CRC, the loss of lifeyears is great. The \ufb01rst step in reducing CRC morbidity and\nmortality in persons age <50 years is aggressive evaluation\n(usually colonoscopy) of patients with colorectal symptoms,\nspeci \ufb01cally those with bleeding symptoms: hematochezia,\niron de \ufb01ciency anemia, and/or melena with a negative\nupper endoscopy. Persons with bleeding symptoms evalu-ated with tests other than colonoscopy (eg, sigmoidoscopy)should have a bleeding source identi \ufb01ed and treated,\nand the patient should be followed to resolution of thesymptom.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "826083a6-bb32-458d-ae5c-04a0dbab7a1a": {"__data__": {"id_": "826083a6-bb32-458d-ae5c-04a0dbab7a1a", "embedding": null, "metadata": {"page_label": "11", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fc4497c2-ec0a-4405-b523-9c6e940267ae", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "54b7a57130e591a0e34f6981e72466184006d3e65f6591f3871029f9485b7190", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa7041af-3aac-456d-b0a1-8a0d827fc4dc", "node_type": "1", "metadata": {"page_label": "11", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "22150bf93e9c2853839e5754bb788ef601bd7af717c5312bf3a125bdd4be2116", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29cd5b70-adf1-4496-a82a-6c6233cd1143", "node_type": "1", "metadata": {"page_label": "11", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "fce709067b0a52aaa139cedc831f81892c9f75c5be4ac896e94bb3540fec83d5", "class_name": "RelatedNodeInfo"}}, "hash": "270941fa34efc09521b0b2294a484b33f387878a61b78d48822bacf4e17b6325", "text": "Patients who have nonbleeding symptoms (eg,abnormal bowel habit, change in bowel habit or shape, orabdominal pain) and who have no evidence of bleeding donot have an increased risk of CRC when they undergocolonoscopy.\n134,135\nThere is currently insuf \ufb01cient evidence to recommend\nsystematic screening in asymptomatic persons <50 years\nold who lack speci \ufb01c risk factors related to family history or\nLynch syndrome. The yield of screening colonoscopy in thisage group is low in available studies,\n136and the biologic\nreasons for the increasing incidence of CRC in persons un-der age 50 years are uncertain. Additional study of thebene\ufb01ts and harms of screening in persons <50 years is\nwarranted, perhaps particularly in persons with knowncolorectal risk factors such as cigarette smoking, diabetesmellitus, and obesity.\n137-139Relative to other races, African Americans have lower\nscreening rates for CRC, higher incidence rates, earlier meanage at onset, worse survival and late-stage presentation, anda higher proportion of cancers before age 50.\n140 \u2013143These\nvarious effects result from both socioeconomic and biologicfactors.\n144Two of the member organizations of the MSTF\nendorsed beginning average-risk screening in African\nAmericans at age 45,22,145and the American College of\nPhysicians recommended beginning at age 40.146The sci-\nenti\ufb01c rationale for beginning screening earlier includes the\nhigher overall incidence rates and younger mean age atonset of CRC in African Americans.\n140 \u2013143A recent joinpoint\nregression analysis147and a MISCAN-Colon microsimulation\nmodel148both supported screening African Americans\napproximately 5 years earlier compared with whites. Thereare few data on the yield of screening in African Americansbefore age 50 or whether earlier screening improves out-\ncomes. In persons over age 50, some reports have identi \ufb01ed\na higher risk of advanced polyps in African Americans.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29cd5b70-adf1-4496-a82a-6c6233cd1143": {"__data__": {"id_": "29cd5b70-adf1-4496-a82a-6c6233cd1143", "embedding": null, "metadata": {"page_label": "11", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fc4497c2-ec0a-4405-b523-9c6e940267ae", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "54b7a57130e591a0e34f6981e72466184006d3e65f6591f3871029f9485b7190", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "826083a6-bb32-458d-ae5c-04a0dbab7a1a", "node_type": "1", "metadata": {"page_label": "11", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "270941fa34efc09521b0b2294a484b33f387878a61b78d48822bacf4e17b6325", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d828df3-1379-40e1-8a5a-a28967484883", "node_type": "1", "metadata": {"page_label": "12", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "3b425542b0fb07d0bd96d651d9c6649a7e099ff49865de64d5867ae5e5483565", "class_name": "RelatedNodeInfo"}}, "hash": "fce709067b0a52aaa139cedc831f81892c9f75c5be4ac896e94bb3540fec83d5", "text": "149\nThe recommendations to begin screening earlier haveserved an important role in stimulating discussion of andresearch on CRC in African Americans, increasing awarenessin physicians of an important public health problem andracial disparity in health outcomes in the United States, andincreasing awareness of CRC in African Americans.Increasing screening rates in African Americans generally isan area of obvious importance. Provider recommendation iskey,\n150and navigation can improve compliance to colonos-\ncopy screening.151Additional study of the yield of screening\nin persons under age 50 is needed, particularly in AfricanAmericans.\nThe age to stop screening can be individualized.\nScreening is potentially bene \ufb01cial in persons up to age 86 if\nthere has not been previous screening\n116but should be\nconsidered in the context of comorbidities and life expec-tancy. Persons with previously negative screening tests,particularly negative screening colonoscopy, could considerstopping at age 75 years.\n14In a variation of this recom-\nmendation, the MSTF has recommended that persons with\nprevious negative screening stop when their life expectancy\nis less than 10 years.1Thus, the recommendation to stop\nscreening can be reasonably based on patient age andcomorbidities.\nThe wishes of the patient should be considered in un-\ncertain cases. These considerations do not necessarily applyin the surveillance setting, where patients with advancedneoplasia may bene \ufb01t from surveillance colonoscopy even\nat an advanced age, depending on comorbidities and thecon\ufb01dence in neoplasia clearing at colonoscopy.\nRecommendations\n1. We recommend that screening begin in non \u2013African\nAmerican average-risk persons at age 50 years (strongrecommendation; moderate-quality evidence).\n2. We suggest that screening begin in African Americans at\nage 45 years (weak recommendation, very-low-qualityevidence).-2017 MSTF Recommendations for CRC Screening 11\nAGA SECTION", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d828df3-1379-40e1-8a5a-a28967484883": {"__data__": {"id_": "1d828df3-1379-40e1-8a5a-a28967484883", "embedding": null, "metadata": {"page_label": "12", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "aaa3ae17-2f8e-4799-9eca-0349973ab0cf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "dc57c404022a755930ad0c2bc1914054abb6d2ad0b783abb7e4d9e7b3d5e3dc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29cd5b70-adf1-4496-a82a-6c6233cd1143", "node_type": "1", "metadata": {"page_label": "11", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "fce709067b0a52aaa139cedc831f81892c9f75c5be4ac896e94bb3540fec83d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9694ecf0-5498-4905-a78a-344dc77f2a05", "node_type": "1", "metadata": {"page_label": "12", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "ec71ab6ac6c60f23e8aa485f5751f0e3ec59c63e82918d12c246330d7dcf3f8c", "class_name": "RelatedNodeInfo"}}, "hash": "3b425542b0fb07d0bd96d651d9c6649a7e099ff49865de64d5867ae5e5483565", "text": "3. We recommend that adults age <50 years with colo-\nrectal bleeding symptoms (hematochezia, unexplainediron de \ufb01ciency anemia, melena with a negative upper\nendoscopy) undergo colonoscopy or an evaluation suf \ufb01-\ncient to determine a bleeding cause, initiate treatment,and complete follow-up to determine resolution of\nbleeding (strong recommendation, moderate-quality\nevidence).\n4. We suggest that persons who are up to date with\nscreening and have negative prior screening tests,\nparticularly colonoscopy, consider stopping screening atage 75 years or when life expectancy is less than 10years (weak recommendation, low-quality evidence).\n5. We suggest that persons without prior screening should\nbe considered for screening up to age 85, depending onconsideration of their age and comorbidities (weakrecommendation, low-quality evidence).\nSummary\nCRC screening should begin at age 50 years in asymp-\ntomatic persons. Colonoscopy every 10 years and annualFIT are currently the \ufb01rst considerations for screening.\nColonoscopy every 10 years has advantages in the oppor-tunistic screening setting. Annual FIT is likely to bepreferred in organized screening programs. Positioning ofthe 2 tests can be reasonably based on a sequential offer(colonoscopy \ufb01rst with FIT offered to patients who decline\ncolonoscopy, followed by second-tier tests for patients whodecline FIT), a multiple-options approach where both testsare discussed with patients (followed by a sequential offer\nof second-tier tests to patients who decline both colonos-\ncopy and FIT), or a risk-strati \ufb01ed approach (colonoscopy is\noffered to patients with a higher pretest probability ofneoplasia, and FIT is used in persons with a lower pretestprobability of neoplasia).\nPersons with a history of CRC or a documented\nadvanced adenoma in a \ufb01rst-degree relative age <60 years\nor 2\ufb01rst-degree relatives with these \ufb01ndings at any age are\nrecommended to undergo screening by colonoscopy every5 years, beginning 10 years before the age at diagnosis ofthe youngest affected relative, or at age 40, whichever is\nearlier.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9694ecf0-5498-4905-a78a-344dc77f2a05": {"__data__": {"id_": "9694ecf0-5498-4905-a78a-344dc77f2a05", "embedding": null, "metadata": {"page_label": "12", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "aaa3ae17-2f8e-4799-9eca-0349973ab0cf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "dc57c404022a755930ad0c2bc1914054abb6d2ad0b783abb7e4d9e7b3d5e3dc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d828df3-1379-40e1-8a5a-a28967484883", "node_type": "1", "metadata": {"page_label": "12", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "3b425542b0fb07d0bd96d651d9c6649a7e099ff49865de64d5867ae5e5483565", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f375cf8f-8eea-4f94-b959-9b217d2ceb36", "node_type": "1", "metadata": {"page_label": "12", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "f016016310a884f5c896744f3a328bb381a1262c5367fd352c4f931966c4309a", "class_name": "RelatedNodeInfo"}}, "hash": "ec71ab6ac6c60f23e8aa485f5751f0e3ec59c63e82918d12c246330d7dcf3f8c", "text": "Persons with a single \ufb01rst-degree relative diag-\nnosed at /C2160 years with CRC or an advanced adenoma can\nbe offered average-risk screening options beginning at age40 years.\nThe incidence of CRC is rising in persons under age 50.\nPatients under age 50 with bleeding symptoms consistentwith a colorectal source should be aggressively evaluatedand treated. We suggest that screening begin at age 45 inAfrican Americans. Discontinuation of screening should beconsidered when patients who are up to date with screeningand have had negative screening tests, particularly colo-\nnoscopy, reach age 75 years or when life expectancy is <10\nyears. Persons without prior screening should be consid-ered for screening up to age 85 years, depending on co-morbid conditions and life expectancy.References\n1.Levin B, Lieberman DA, McFarland B, et al. Screening\nand surveillance for the early detection of colorectal\ncancer and adenomatous polyps. Gastroenterology2008;134:1570 \u20131595 .\n2.Kahi CJ, Boland CR, Dominitz JA, et al. Colonoscopy\nsurveillance after colorectal cancer resection: recom-\nmendations of the US multi-society task force on colo-\nrectal cancer. Gastrointest Endosc 2016;83:489 \u2013498.\n3.Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for\ncolonoscopy surveillance after screening and poly-pectomy. Gastroenterology 2012;143:844 \u2013857.\n4.Levin TR, Jamieson L, Burley DA, et al. Organized colo-\nrectal cancer screening in integrated health care sys-\ntems. Epidemiol Rev 2011;33:101 \u2013110.\n5.Zavoral M, Suchanek S, Zavada F, et al. Colorectal\ncancer screening in Europe. World J Gastroenterol 2009;15:5907 \u20135915 .\n6.Cenin DR, St John DJB, Ledger MJN, et al. Optimizing\nthe expansion of the National Bowel Cancer Screening\nProgram. Med J Aust 2014;201:456 \u2013461.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f375cf8f-8eea-4f94-b959-9b217d2ceb36": {"__data__": {"id_": "f375cf8f-8eea-4f94-b959-9b217d2ceb36", "embedding": null, "metadata": {"page_label": "12", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "aaa3ae17-2f8e-4799-9eca-0349973ab0cf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "dc57c404022a755930ad0c2bc1914054abb6d2ad0b783abb7e4d9e7b3d5e3dc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9694ecf0-5498-4905-a78a-344dc77f2a05", "node_type": "1", "metadata": {"page_label": "12", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "ec71ab6ac6c60f23e8aa485f5751f0e3ec59c63e82918d12c246330d7dcf3f8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c53e7cb0-f9f0-4060-81ee-860fceb3d712", "node_type": "1", "metadata": {"page_label": "12", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "e22c84e403d9235a1f1e00df8223314a61c9c3cb4aa3f5e3071fe9b814bc63ac", "class_name": "RelatedNodeInfo"}}, "hash": "f016016310a884f5c896744f3a328bb381a1262c5367fd352c4f931966c4309a", "text": "Med J Aust 2014;201:456 \u2013461.\n7.Jensen CD, Corley DA, Quinn VP, et al. Fecal immuno-\nchemical test program over 4 rounds of annualscreening: a retrospective study. Ann Intern Med 2016;\n164:456 \u2013463.\n8.Siegel RL, Ward EM, Jemal A. Trends in colorectal can-\ncer incidence rates in the United States by tumor locationand stage, 1992-2008. Cancer Epidemiol Biomarkers\nPrev 2012;21:411 \u2013416.\n9.Klabunde CN, Joseph DA, King JB, et al. Vital signs:\ncolorectal cancer screening test use \u2014United States,\n2012. MMWR 2013;62:881 \u2013888.\n10.Sabatino SS, White MC, Thompson TT, et al. Cancer\nscreening test use \u2014United States, 2013. MMWR 2015;\n64:464 \u2013468.\n11.Siegel R, Desantis C, Jemal A. Colorectal cancer statis-\ntics, 2014. CA Cancer J Clin 2014;64:104 \u2013117.\n12.Edwards BK, Noone AM, Mariotto AB, et al. Annual\nreport to the nation on the status of cancer, 1975-2010,featuring prevalence of comorbidity and impact on sur-vival among persons with lung, colorectal, breast, or\nprostate cancer. Cancer 2014;120:1290 \u20131314 .\n13.Liang PS, Wheat CL, Abhat A, et al. Adherence to\ncompeting strategies for colorectal cancer screeningover 3 years. Am J Gastroenterol 2016;111:105 \u2013114.\n14.US Preventive Services Task Force, Bibbins-Domingo K,\nGrossman DC, Curry SJ, et al. Screening for colorectal\ncancer: US Preventive Services Task Force recommen-\ndation statement. JAMA 2016;315:2564 \u20132575 .\n15.\nInadomi JM, Vijan S, Janz NK, et al. Adherence to\ncolorectal cancer screening: a randomized clinical trial of\ncompeting strategies.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c53e7cb0-f9f0-4060-81ee-860fceb3d712": {"__data__": {"id_": "c53e7cb0-f9f0-4060-81ee-860fceb3d712", "embedding": null, "metadata": {"page_label": "12", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "aaa3ae17-2f8e-4799-9eca-0349973ab0cf", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "dc57c404022a755930ad0c2bc1914054abb6d2ad0b783abb7e4d9e7b3d5e3dc7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f375cf8f-8eea-4f94-b959-9b217d2ceb36", "node_type": "1", "metadata": {"page_label": "12", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}, "hash": "f016016310a884f5c896744f3a328bb381a1262c5367fd352c4f931966c4309a", "class_name": "RelatedNodeInfo"}}, "hash": "e22c84e403d9235a1f1e00df8223314a61c9c3cb4aa3f5e3071fe9b814bc63ac", "text": "Arch Intern Med 2012;172:\n575\u2013582.\n16.Segnan N, Senore C, Andreoni B, et al. Randomized trial\nof different screening strategies for colorectal cancer:patient response and detection rates. J Natl Cancer Inst\n2005;97:147 \u2013157.\n17.Multicentre Australian Colorectal-neoplasia Screening\n(MACS) Group. A comparison of colorectal neoplasia12 Rex et al Gastroenterology Vol.\n-, No.-\nAGA SECTION", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/ref_doc_info": {"fed750a1-344b-4cc1-a9e3-43aa3e2a9dc8": {"node_ids": ["cb06e274-8f84-4c07-9959-21d8a2b43e39", "2955d200-3d69-4c09-98e8-670107036db7", "4474d413-46ca-44b4-9c40-f05b8cc604be", "d57064e5-bb9f-4b7e-a278-8da8bcb5f388"], "metadata": {"page_label": "223", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "d03c26b4-5937-40d1-a094-9520d1ab61a8": {"node_ids": ["d1ebd309-4ec7-4ba8-bdba-a489ece0dae1", "6c12dc3d-c112-4002-bd73-d1565c54fece", "854b4134-fa1e-4e23-9fbd-11ff8ae104ca", "87a6f675-a8d6-432a-a4b6-88658a2391f2"], "metadata": {"page_label": "224", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "2fa71731-7e72-4fac-af86-8692b3ae2854": {"node_ids": ["cc477908-57ae-495f-bd09-079fe77a6b72", "63a265be-89a6-469f-af2c-54d215aa08fb", "de8f7c17-8877-4658-a464-bd0838881033", "fdf19d33-e750-4aa6-9e49-0069d820ec64"], "metadata": {"page_label": "225", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "f97a245a-22f1-48a5-8820-a409dcc5d14a": {"node_ids": ["05d70c96-e99a-49a7-8c15-cd4f4ce6f6b7", "bdaafdfd-7e6b-4488-93eb-894a0f7b7a57", "d6f1e6f7-5dc7-4653-a92a-ad0ac99f6431", "3395afff-957c-47f1-9f7b-12039009ba12"], "metadata": {"page_label": "226", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "febe9185-c2fa-4b8e-95c6-c8a33f8ce111": {"node_ids": ["07abcf04-c899-41b8-9bec-abe37e501058", "d82365eb-6434-41f1-87ab-a32788a8a18a", "55824f6b-09db-4aa6-9a22-ea52f55843a1", "c5fbf8c2-3522-4942-974b-d2b2e5043896"], "metadata": {"page_label": "227", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "c6a21ca2-90e1-4c65-bdff-b803654ec46f": {"node_ids": ["4bd15618-7230-4774-8b05-cad67a4861e2", "8597bfbe-72e4-4d0c-80b0-ea9c53f07f8c", "c66dd567-cce5-4bd8-a6af-6889c238978a", "4d90953d-8363-4f31-a021-82049fc4b9cc"], "metadata": {"page_label": "228", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "6ebbc63c-01f4-4e3e-b230-558532555d08": {"node_ids": ["d58abcdd-60d5-4e33-b098-c0d33480cce9", "620f4262-e455-4c54-8d98-30b7839bf517", "041848d4-e1e1-4d6f-b15d-6580c31c7ea2"], "metadata": {"page_label": "229", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "fe5bec53-1f2b-4c3c-829c-8495787e9122": {"node_ids": ["6dcf6419-715b-4a0e-851d-53b3954ad845", "cd92a56f-d2d6-42f2-859a-b5ecdab1521b", "c09b5ca2-f7f4-4baa-8cb6-cc280465f100", "802d5db0-e454-406b-bac6-6546cb040436"], "metadata": {"page_label": "230", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "487f0446-65f4-4882-ab3e-bed2586a8214": {"node_ids": ["2ec04b63-1847-481f-b2be-0982f04d6e0e", "9c71a7b5-0e2f-4924-b857-0bfebc4c6fec", "0c1011a6-d692-4e0b-b417-76e94f50be55", "fc56f9ed-1fc1-45e9-a954-56dbe740f786"], "metadata": {"page_label": "231", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "1dfd9907-68af-43c3-b265-7f4569dd82a8": {"node_ids": ["f463496b-27cc-4727-ba1e-786e7aeddbc8", "141b9542-6952-46d6-8405-bf80bc361419", "4d6ed2bb-755a-41c9-bb05-b466c2676786", "f9a8ad4b-4793-40e6-9d04-18e7afa681c5"], "metadata": {"page_label": "232", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "671cda4e-8944-448f-8054-6c718ccd0db3": {"node_ids": ["de2eebaa-da1a-4d63-bc17-3faf7f0291ff", "e4ac0b38-79c2-4ebb-8ce4-26f3ded5092b", "ff31a775-0515-49df-a20e-07f9aa15f925"], "metadata": {"page_label": "233", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "a81e88e8-aa74-4a71-82ae-177cdcfcf648": {"node_ids": ["4c01f901-fcef-4551-9052-b1b98f364fc9", "56c8371c-0e48-4e67-8af5-74f3d90f822f", "f4f71330-654b-4a21-a5ae-7faab9cdd2f1"], "metadata": {"page_label": "234", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "06ea3c36-f840-4e59-b835-99394dbf217e": {"node_ids": ["b9ac43ff-a56a-49ae-8e24-54eb1b4c7409", "e1f26ad7-da83-482e-8443-f5bac68bec65", "48f93b99-d093-4b32-9f6c-a5367ff12847", "eafe4a13-9bed-40bc-b8a4-751a7724b3a3"], "metadata": {"page_label": "235", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "d01648cf-3d66-490f-a813-395c0a26c02d": {"node_ids": ["476dc7cf-48eb-42f4-ba53-de43ad766c9e", "c968e55d-c2fa-485e-8999-c7081f68652e", "22d59266-a885-46e5-a73d-35b3c1781020", "7cb7d23e-c478-4dcd-ba8b-dce5cab26a19"], "metadata": {"page_label": "236", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "90a489b0-c353-465c-8d7d-6417983ac5ab": {"node_ids": ["e8e8c46d-dd70-4e40-a9b7-e1bdb1591c3a", "ebcbf99d-187e-4cd3-b16e-08da3f4349c8", "a953f635-57e9-4769-87ed-42498732ead0", "ccf1017f-6468-4128-b21b-e83bf9c9e9c9"], "metadata": {"page_label": "237", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "d6049be2-6741-4b9a-962b-62d6b721da5e": {"node_ids": ["cde14d95-96fd-4412-9428-83d1e6099c75", "f49add44-9e6f-4958-9ffa-7f2e1824d60c", "3ee8fc74-4fad-4193-aa12-5b53ca22fbef", "963b95c8-00f9-4576-a88d-382fef51ce00"], "metadata": {"page_label": "238", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "78617b07-b153-4000-9df0-5f080884cea0": {"node_ids": ["3725859c-104c-4065-ab66-186b172b7a06", "f8a053e7-f657-4e43-af93-4e2d05bd3915", "40e38f1f-79db-4e41-92c0-2443ac6a0220", "b355d4a5-913e-4c83-98e7-d9f2db353259"], "metadata": {"page_label": "239", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "997b874e-d73a-4f57-a490-73f63810361c": {"node_ids": ["d4117715-e302-48f9-b207-05a4488f6893", "8eed13dc-c2ce-4f73-b415-a0e666fd4528", "1eca0253-e991-45ab-80e3-a72c880b2edd", "6bca38d1-1786-47de-aa73-096e654656ce"], "metadata": {"page_label": "240", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "6f57cb37-f096-446b-8a86-6ad463f80904": {"node_ids": ["1d047ad8-e150-41c6-a26f-08da210c40b2", "7ae82f89-dd88-48e9-855f-a46e5d60769f", "0ae9e58f-ac3a-4c28-b1b0-a229da57fbc8", "c7287a59-a6af-411e-b079-a77191b4a239"], "metadata": {"page_label": "241", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "d096f65b-91df-4cab-9a1a-6a2c13173042": {"node_ids": ["c5fc137e-6b97-4966-adc3-10aff0b6b23c", "340de4aa-0fe2-4627-a123-4f5f617bb42e", "6d50ab8a-5677-4ffd-a5e6-6fb2f805f095", "fa75e4a2-58ab-4f47-8711-93fcf4007f00"], "metadata": {"page_label": "242", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "24bc8201-f996-4f23-bb8a-2cd99fc637b9": {"node_ids": ["a1818f55-b1ab-4b0f-bbdd-1c5ea96c12ad", "ad9a7b5b-fdde-4e62-b968-b06043a692b6", "7ff59e37-9e3b-450b-bbe9-7c9f50d94d83"], "metadata": {"page_label": "243", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "1c1e7ff5-1978-471d-ba26-cb58841ff89a": {"node_ids": ["37dff770-65ac-4ac7-ba1f-5f948bda8746", "83a8276b-53fa-47a4-a3d0-277dba6464ce", "bd3d098e-f384-4f1a-9448-ebcfa9e06062"], "metadata": {"page_label": "244", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "66757d82-468d-4e89-bfd6-e6516b4cb324": {"node_ids": ["4b5c1ae8-394d-4313-a071-17824ded121d", "3c4c990c-c761-4531-beb2-7bb58b960c81", "1b93cb61-6364-4deb-ad88-f63669693558", "da1c4d03-5d64-4763-9dea-e7f397553b08"], "metadata": {"page_label": "245", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "3ded5d19-ba3e-431c-8c91-8993af126911": {"node_ids": ["eb59f905-005a-4f1d-93b2-369f48816c7f", "c009e2aa-a2df-4fc2-97b3-8c5dc00559ea", "0a8a33dd-ac42-4f41-bc47-a86ee0506601", "952253bb-36c9-4b13-9f68-7a3acc1b5148"], "metadata": {"page_label": "246", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "b26ba6c1-9ce5-4cc3-bb19-6fc5dea556b9": {"node_ids": ["a8369808-da1a-472f-864d-5e7c5a640d50", "f94fea48-051b-470a-a19a-0de86eff7b73", "6449eaae-0e1c-4d1c-bd85-c83ed3c005e1"], "metadata": {"page_label": "247", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "dd900cd0-597f-48ad-9805-a97dbcb03071": {"node_ids": ["4774f6eb-f32f-4b3a-9f1b-683869895af4", "25c359c5-81b5-4928-80fb-6c47f4074a0c", "58cda90e-5c88-420f-8829-eb72ff79e9f6", "b4de6e89-0921-4f20-aa7e-d7270cb7ae35"], "metadata": {"page_label": "248", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "4bc0fcc8-190d-4968-892c-df3ca7512fe8": {"node_ids": ["a9f87f9f-2d1c-4cc4-ba38-e9161447ff4f", "22cc2716-bff3-4348-aee1-23518b0c00c1", "1e0166c7-fd61-47c7-a387-935f88dcbf45", "e30a455b-12ae-42a7-b392-71dc0b1d1d04"], "metadata": {"page_label": "249", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "72a1c3c5-1335-4c75-b26b-1803c0d2eaff": {"node_ids": ["489753a0-dc7b-4f3f-b57a-229f5a66a947", "ca053614-ff23-4f9e-adcb-fe7da617b7b3", "0af86f6f-684a-4de2-8456-18785313fd2c", "bc60bb06-4f3e-4669-8a1b-804761b19e9b"], "metadata": {"page_label": "250", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "e652a10a-ba4e-43e4-9d91-6a2c478b54f3": {"node_ids": ["eaad1912-b8bb-435f-92e5-f19148d5e2ab", "6cf3a57d-51db-49d4-92d0-a8b583d09504", "59d995b0-8ede-4b0f-9ad0-b3319356c9fd", "10d8a31a-564c-4924-91ee-30a43a1192aa"], "metadata": {"page_label": "251", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "1bc37f17-7742-409c-8d61-1d45f5c3b01a": {"node_ids": ["9c4a741f-f118-440b-9c73-4bd61d421d1c", "1792aa38-bf95-4e63-b115-b8ce074da9e2", "2ac72ee7-ee20-44c9-8618-7c5a11f4d99e", "e0b63f00-acb3-4148-8865-2ac10f9a491f"], "metadata": {"page_label": "252", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "40fa6b97-cac6-4995-9694-37d6f39324b1": {"node_ids": ["9012f71b-4b25-460c-a8c5-8a7911d01f9a", "8aec57d1-ac7c-4edd-8c17-8148492378cd", "02dee197-b316-4cae-9083-0eca374863b4"], "metadata": {"page_label": "253", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "8d66af4c-ecef-466f-8a33-3db59aff07e8": {"node_ids": ["bd4ded46-0595-4ae8-8643-bc0af6019a4a", "1b66cf91-a05a-41fc-a86a-e9c836adee2a", "7520d7c5-f166-4c97-8b41-58e19ff2289b", "c18d9974-38e4-4edc-bb6e-3ac01e767c4b"], "metadata": {"page_label": "254", "file_name": "ACG 2015 Hereditary GI Cancers.pdf", "file_path": "data/documents/ACG 2015 Hereditary GI Cancers.pdf", "file_type": "application/pdf", "file_size": 490960, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "1dbe19fa-7132-4758-92a4-06c10cebc198": {"node_ids": ["d52c2ab9-dd69-40ba-9edc-36359b6dcafd", "ef65e270-2fbf-48cc-8d14-ec74b2b05f67", "a6c765ba-91bb-4829-b068-8968f3411279"], "metadata": {"page_label": "1043", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}}, "105d7069-5266-4bf2-a3fa-a3b49898b22e": {"node_ids": ["89e7509d-e2b7-4d9a-8ae8-b832c8da1b32", "dcdfdf5e-02f4-49eb-842b-629498b0a089", "5f467e84-1f34-48e4-a634-821228999c5c"], "metadata": {"page_label": "1044", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}}, "e4ce00ce-7ddd-4459-9e54-1411121bbf37": {"node_ids": ["586fe2c3-c535-472f-9189-452f66d382a1", "e358d092-6ea3-4da1-9b0f-86634fe3b3af", "d2910286-7626-47e1-a289-9ee294e2236e", "4e0fe710-2980-4b8f-9586-d2fed5ba51c0"], "metadata": {"page_label": "1045", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}}, "5063b093-a32d-4dd1-bec8-c39a3f8c618b": {"node_ids": ["9dab2bc6-d7d9-4b2b-bdbe-f5860e3a7b39"], "metadata": {"page_label": "1046", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}}, "ad7d0a21-3e29-4e0a-af01-2382c406de2a": {"node_ids": ["658136fc-110c-423b-a2e2-673d30cab125", "49d83f81-a8c4-47ee-836f-82ceabc06c60", "39c7ddb0-fce0-4e67-aea5-69aa567901de", "adb69bec-50f8-44d8-8af5-416182d544ba"], "metadata": {"page_label": "1047", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}}, "9902a8c2-5457-4a78-82c1-b431991caf64": {"node_ids": ["1c229caf-7c30-47d6-8a0a-2a2d3c5514ee", "c42581a4-29c6-4310-903e-8a9dc1dbab99", "6d33e945-d4c0-4691-8ed3-407e23aeb35e", "ae989339-631d-4def-935c-d770077c2933"], "metadata": {"page_label": "1048", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}}, "883fdb2b-3ab4-4258-9211-abfc1afbb23c": {"node_ids": ["d8aa07ea-9972-479e-a448-8334e662da33"], "metadata": {"page_label": "1049", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}}, "db333755-7304-4d6b-9ea7-6a8a3e1e075f": {"node_ids": ["792ab654-96af-43dc-b817-0b3dfc8f9faf", "00a41ff1-4456-45ed-927b-2805c2579936", "d7cccca3-14f9-4572-a46a-e5909620b90e", "5e0a450e-6dc4-42d6-b7b2-6de749c52350"], "metadata": {"page_label": "1050", "file_name": "AGA 2021 IBD CRC Surveillance.pdf", "file_path": "data/documents/AGA 2021 IBD CRC Surveillance.pdf", "file_type": "application/pdf", "file_size": 2753707, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}}, "27e7fbff-4a42-4e21-9625-d7726ea2e19f": {"node_ids": ["b7e13590-8791-4629-b2c5-e1d24c641aaf", "1d5176e3-dbdd-4c66-8ca8-e5874094ee02", "41ff8c99-fa75-489b-9740-41bd06363d24"], "metadata": {"page_label": "137", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "b8663f18-a984-4313-98e9-31be402eb51a": {"node_ids": ["de658d79-ea8d-478f-8692-88cbe424fd65", "80f75769-d5b7-4bd1-8f58-1e7325f29b6a", "cd440220-dccc-4636-98d4-8b2ec3565af7", "ca0da5a0-5b58-487b-be61-1cfddb8488df", "892ba7b3-421f-4771-ae77-73466e2bcfa7", "635a6896-84aa-4c99-9f94-0d498af2f29c", "9c72ad10-f9b4-464e-9195-3bc59dcf1af9"], "metadata": {"page_label": "138", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "fead70f1-cc0a-4faa-a49f-b49c6202bad4": {"node_ids": ["6dcb522b-391f-4d43-a61b-0a0984ab010d", "d7dec904-665d-4332-a297-7797d199e171", "369f5fbe-afa3-4572-96ac-19776ef25b93", "6d92516a-c9e8-4eec-8f3a-aa390d1cd2ac", "8c78b5db-df48-4670-b09b-9167269fa92c"], "metadata": {"page_label": "139", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "c63ea98e-a01c-44b8-9f33-adf025ad6602": {"node_ids": ["908eac1d-4018-4261-bfc4-8277c30745e2", "1248f89d-a96c-4f17-aec9-4e52135023e1", "e3ebdabd-f2a1-47af-9ed7-e92ea87fc650", "b4c100e9-544b-4032-9c7c-a6e44c0128f4"], "metadata": {"page_label": "140", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "00f89055-c291-4589-9e59-c47474e50130": {"node_ids": ["c82ed093-b94f-4309-aa65-eb4686cd5c0f", "9929b247-1a5f-4541-9eb8-e3a1d4e2a7d5", "22f2515c-4e63-4f88-a6de-43c34a996cbc"], "metadata": {"page_label": "141", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "b0e52743-911b-4a5f-a6c4-f12d9edb9289": {"node_ids": ["fc56a0bb-204c-4b36-89e4-276e8254e7a0", "ea6a11d5-11e5-4731-9903-f2f31fc797e0", "ca57c163-69d1-4092-819c-1f383c7e114e", "5b4b8088-844b-43ac-b5c2-f7d46de7710f", "b8f86ef4-8f55-4156-80f5-e20b78d58995"], "metadata": {"page_label": "142", "file_name": "ASCRS 2017 Lynch Syndrome.pdf", "file_path": "data/documents/ASCRS 2017 Lynch Syndrome.pdf", "file_type": "application/pdf", "file_size": 249364, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-16"}}, "c22672c7-9436-4df9-9531-b81e104aedca": {"node_ids": ["f51c627f-6fcd-4938-933d-15664f6a9564", "73e47913-5174-471f-9672-74b4474e3612", "45ef922d-5078-4ed3-a2c2-bb6b07933eac"], "metadata": {"page_label": "1", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}}, "7a475de4-81c7-44f5-8826-c442acb7a396": {"node_ids": ["e7461657-d4cb-4018-9124-570a03386644", "b39189a5-845b-4ce4-9a78-19955830569a", "9ce181c2-d05f-4ef2-8249-9a5662f38dfd"], "metadata": {"page_label": "2", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}}, "e5f12b3b-6830-4f35-913b-592305c682be": {"node_ids": ["b3002bd0-f7f9-48b1-857e-6a29bbee824f", "6df321de-b7ec-4532-8aea-a104a0f4c01a", "031e7b18-e8e3-477d-9849-b5775667473e"], "metadata": {"page_label": "3", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}}, "51b691a2-5a4b-4e7c-a60b-bbc029ff72d9": {"node_ids": ["6e82bcb0-f426-432f-88a7-3ab60aaeeb7e", "8f6fd072-eea0-447c-b81c-da513e2f27d4", "b7838844-e90c-4d4a-928c-594b5bfdf4d8"], "metadata": {"page_label": "4", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}}, "ab015375-8dec-405f-9b23-1e921ebe6904": {"node_ids": ["d5070772-fd4d-450b-9098-4c60f7b0b404", "62d5ae79-716e-4eea-910e-46fb2db0a78d", "2d2acda1-7717-47b4-b288-302caf732c6d", "2703592c-c6ac-4f31-8389-0dee55c47a73"], "metadata": {"page_label": "5", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}}, "d3e15656-ac50-4c58-86f8-bb385546b9d2": {"node_ids": ["db9ca3e5-ad8b-4927-a2b9-ad2c67bbab11", "399c07c0-cd2f-4101-bb7c-e4dc9586421e", "2c027a6f-f532-4c5f-a73a-957e5859a3ae"], "metadata": {"page_label": "6", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}}, "084919ce-227a-4a3e-8f93-78f25e33d762": {"node_ids": ["4abc5c52-20c6-4150-bc64-a4f9f4d08cc5", "8aae1fee-40b5-41a6-b65c-b5550a6ed1fa", "e786b3d0-bd54-4db9-adf6-2f5d4c8b5d97"], "metadata": {"page_label": "7", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}}, "e50b7613-6371-427b-8eef-f34555dd6a3f": {"node_ids": ["1d93f28e-aafe-4c1c-9b30-754af8e7dc61", "d9f562b5-380b-4440-b17d-a77160c751cc", "f253ac9b-bb44-42bf-836b-065957a1bf34"], "metadata": {"page_label": "8", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}}, "e3cd3045-eee6-4846-b02c-478a6e9e8e27": {"node_ids": ["16d5f712-9c20-4c83-ab32-b03c35af0ffe", "0d072b2f-7bf5-4e10-bfde-93f0436daf4f", "d914c8a2-7c2c-440a-92eb-5735fd5a2862"], "metadata": {"page_label": "9", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}}, "4aabf2c9-5a8a-4a57-869f-e3668a4ce6e1": {"node_ids": ["7a2e717f-8e4b-41ca-9ac5-3ed519fe5e2f", "c16f0fce-7bce-478e-bad9-63bc2cf3a153", "22c7b819-396e-4d24-999f-0dfb570ce7e6"], "metadata": {"page_label": "10", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}}, "fc4497c2-ec0a-4405-b523-9c6e940267ae": {"node_ids": ["aa7041af-3aac-456d-b0a1-8a0d827fc4dc", "826083a6-bb32-458d-ae5c-04a0dbab7a1a", "29cd5b70-adf1-4496-a82a-6c6233cd1143"], "metadata": {"page_label": "11", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}}, "aaa3ae17-2f8e-4799-9eca-0349973ab0cf": {"node_ids": ["1d828df3-1379-40e1-8a5a-a28967484883", "9694ecf0-5498-4905-a78a-344dc77f2a05", "f375cf8f-8eea-4f94-b959-9b217d2ceb36", "c53e7cb0-f9f0-4060-81ee-860fceb3d712"], "metadata": {"page_label": "12", "file_name": "MSTF 2017 CRC Screening.pdf", "file_path": "data/documents/MSTF 2017 CRC Screening.pdf", "file_type": "application/pdf", "file_size": 1062131, "creation_date": "2023-11-16", "last_modified_date": "2023-11-15", "last_accessed_date": "2023-11-17"}}}, "docstore/metadata": {"cb06e274-8f84-4c07-9959-21d8a2b43e39": {"doc_hash": "55572bc0c153f2cdf5bafd96fcbc0dd77ad880d41ff9d0eb2dba2ca2f9715d6e", "ref_doc_id": "fed750a1-344b-4cc1-a9e3-43aa3e2a9dc8"}, "2955d200-3d69-4c09-98e8-670107036db7": {"doc_hash": "1842f7d5f9f60310bb15d2ac3d9ca82dc109a917b48a62097eb3ba12c048a62c", "ref_doc_id": "fed750a1-344b-4cc1-a9e3-43aa3e2a9dc8"}, "4474d413-46ca-44b4-9c40-f05b8cc604be": {"doc_hash": "0295503c522f9f8e1a973d7e95701875691057af0af189cb865fcd7c0275858b", "ref_doc_id": "fed750a1-344b-4cc1-a9e3-43aa3e2a9dc8"}, "d57064e5-bb9f-4b7e-a278-8da8bcb5f388": {"doc_hash": "8f7d024556432ddb095cb9c43181f8570da399382e146f54795f41cfaa25ee99", "ref_doc_id": "fed750a1-344b-4cc1-a9e3-43aa3e2a9dc8"}, "d1ebd309-4ec7-4ba8-bdba-a489ece0dae1": {"doc_hash": "d9694a19b3a86f84b4ce4e29be0102fef0944880ab6fd60cad867cb257cfee87", "ref_doc_id": "d03c26b4-5937-40d1-a094-9520d1ab61a8"}, "6c12dc3d-c112-4002-bd73-d1565c54fece": {"doc_hash": "8620a9023889fce4d72d6769cfd8cb61051c028d61879d588e3b077ad391d1b3", "ref_doc_id": "d03c26b4-5937-40d1-a094-9520d1ab61a8"}, "854b4134-fa1e-4e23-9fbd-11ff8ae104ca": {"doc_hash": "40fd279e09f94d871b957868a38e3e548b710c54dee31e86a7cf527f7fdda353", "ref_doc_id": "d03c26b4-5937-40d1-a094-9520d1ab61a8"}, "87a6f675-a8d6-432a-a4b6-88658a2391f2": {"doc_hash": "91328e06477a035cb83565cbfab4e1866895c71411448c5580e8226a8df728c7", "ref_doc_id": "d03c26b4-5937-40d1-a094-9520d1ab61a8"}, "cc477908-57ae-495f-bd09-079fe77a6b72": {"doc_hash": "b130cfbe924b2379c7730f6f9cc6f402556f9d118f0b6ea72e9642ba36997ea4", "ref_doc_id": "2fa71731-7e72-4fac-af86-8692b3ae2854"}, "63a265be-89a6-469f-af2c-54d215aa08fb": {"doc_hash": "e871f50b03c14a407dc53facce722417bedcad43d9919debc32f1840dcf9bd01", "ref_doc_id": "2fa71731-7e72-4fac-af86-8692b3ae2854"}, "de8f7c17-8877-4658-a464-bd0838881033": {"doc_hash": "14b01570e33c1c00b20c3fba8d82e7a11967fe64be801cadb47bb7e73f99dafe", "ref_doc_id": "2fa71731-7e72-4fac-af86-8692b3ae2854"}, "fdf19d33-e750-4aa6-9e49-0069d820ec64": {"doc_hash": "116c3b16e7cbf952779534ed225191062482b5f85ec05ddf26394d4bb4e54343", "ref_doc_id": "2fa71731-7e72-4fac-af86-8692b3ae2854"}, "05d70c96-e99a-49a7-8c15-cd4f4ce6f6b7": {"doc_hash": "8fd7512aeca413b85d9dcb11e2e0270cd86ac1db3bda0fb1cbb7fa792794bee1", "ref_doc_id": "f97a245a-22f1-48a5-8820-a409dcc5d14a"}, "bdaafdfd-7e6b-4488-93eb-894a0f7b7a57": {"doc_hash": "94c477817048efe2a6c869a2d24d0659b57c23183bb7fcb9deac57a60a103e01", "ref_doc_id": "f97a245a-22f1-48a5-8820-a409dcc5d14a"}, "d6f1e6f7-5dc7-4653-a92a-ad0ac99f6431": {"doc_hash": "29c507cdafcc4db65a3919968ae20bc38e7eb164e32b8f9b0b5285ac25e06926", "ref_doc_id": "f97a245a-22f1-48a5-8820-a409dcc5d14a"}, "3395afff-957c-47f1-9f7b-12039009ba12": {"doc_hash": "8bfae5b08a1fa8b98d6ecd90a026b8405a3b5946eb9dfdbc0a588ac8dd8dc3c5", "ref_doc_id": "f97a245a-22f1-48a5-8820-a409dcc5d14a"}, "07abcf04-c899-41b8-9bec-abe37e501058": {"doc_hash": "4f13d7b4bed5368f25fc1e1be4709baec821ab2ab073658eb420849ae98648ec", "ref_doc_id": "febe9185-c2fa-4b8e-95c6-c8a33f8ce111"}, "d82365eb-6434-41f1-87ab-a32788a8a18a": {"doc_hash": "e45efcefec198238f27f65c1e9377d0ecbdcf7f17f9f948b0fe096b060a7aead", "ref_doc_id": "febe9185-c2fa-4b8e-95c6-c8a33f8ce111"}, "55824f6b-09db-4aa6-9a22-ea52f55843a1": {"doc_hash": "cdb63af424085991bc3c9754c3c2d39f823eb4bc38053b6ca0c2aa5db4d9de2e", "ref_doc_id": "febe9185-c2fa-4b8e-95c6-c8a33f8ce111"}, "c5fbf8c2-3522-4942-974b-d2b2e5043896": {"doc_hash": "ed49db4204582f2a07e0fe931e2e27532ef2138f96998ddea8d8d4da52f2496f", "ref_doc_id": "febe9185-c2fa-4b8e-95c6-c8a33f8ce111"}, "4bd15618-7230-4774-8b05-cad67a4861e2": {"doc_hash": "89381a0cd650371c6fcad69bbf45f5ef4658b1c279bd9fa85dce4ec282e8d3e0", "ref_doc_id": "c6a21ca2-90e1-4c65-bdff-b803654ec46f"}, "8597bfbe-72e4-4d0c-80b0-ea9c53f07f8c": {"doc_hash": "e5ca209d9bde3d69f1ff78595ada046533f80fe27fbb81e9200b254c5c5135eb", "ref_doc_id": "c6a21ca2-90e1-4c65-bdff-b803654ec46f"}, "c66dd567-cce5-4bd8-a6af-6889c238978a": {"doc_hash": "1a688dfd55ff6419b45e1d8a0b7cf67d6cdc81a6ae2c32086b60d8fb9c4a11b7", "ref_doc_id": "c6a21ca2-90e1-4c65-bdff-b803654ec46f"}, "4d90953d-8363-4f31-a021-82049fc4b9cc": {"doc_hash": "10d8e0a8b2a139ca2d4cdc13e5ec225b26953bfc861153569d29cc3e93f67422", "ref_doc_id": "c6a21ca2-90e1-4c65-bdff-b803654ec46f"}, "d58abcdd-60d5-4e33-b098-c0d33480cce9": {"doc_hash": "5ef235fa617dd2d67fcb3fc709388fe4c18931833164d6dcd4bb157458448138", "ref_doc_id": "6ebbc63c-01f4-4e3e-b230-558532555d08"}, "620f4262-e455-4c54-8d98-30b7839bf517": {"doc_hash": "a22fd5bffa1fddbd0a54fd63e1fdb6d8c5737fa368e69bdf7c790646a40a0119", "ref_doc_id": "6ebbc63c-01f4-4e3e-b230-558532555d08"}, "041848d4-e1e1-4d6f-b15d-6580c31c7ea2": {"doc_hash": "650d9b22c20c013f477f6e0a19c09b0d8f049d93581ad0635effc6335945bd32", "ref_doc_id": "6ebbc63c-01f4-4e3e-b230-558532555d08"}, "6dcf6419-715b-4a0e-851d-53b3954ad845": {"doc_hash": "1a62ee9998ad8fc4da3698c9d12295da8d891a1831c713e19f733011be034404", "ref_doc_id": "fe5bec53-1f2b-4c3c-829c-8495787e9122"}, "cd92a56f-d2d6-42f2-859a-b5ecdab1521b": {"doc_hash": "5a0ebb17c5621bba5ad009a1c2bdd17b8a5a3745189aba0745e763e49c439602", "ref_doc_id": "fe5bec53-1f2b-4c3c-829c-8495787e9122"}, "c09b5ca2-f7f4-4baa-8cb6-cc280465f100": {"doc_hash": "b4cea3f8ba461e74218d3b74a4ca2fb9bada8c1295f779955b2ee9ccd2109353", "ref_doc_id": "fe5bec53-1f2b-4c3c-829c-8495787e9122"}, "802d5db0-e454-406b-bac6-6546cb040436": {"doc_hash": "7978d8f7e79138f0c0346431628fd3af909fc72942a3a24c13bc260008434598", "ref_doc_id": "fe5bec53-1f2b-4c3c-829c-8495787e9122"}, "2ec04b63-1847-481f-b2be-0982f04d6e0e": {"doc_hash": "69b5303c4090db54edea0977170e97a93637a8bdf54606f0b4f495980c4e7242", "ref_doc_id": "487f0446-65f4-4882-ab3e-bed2586a8214"}, "9c71a7b5-0e2f-4924-b857-0bfebc4c6fec": {"doc_hash": "cba0f0bdd8544d75f708bcb0b572d574173cb1757c51e8c73e33267377462070", "ref_doc_id": "487f0446-65f4-4882-ab3e-bed2586a8214"}, "0c1011a6-d692-4e0b-b417-76e94f50be55": {"doc_hash": "72f5d4170a6979cf28df0cca4b8c15772de807a8ed6fadea54365571de1a0112", "ref_doc_id": "487f0446-65f4-4882-ab3e-bed2586a8214"}, "fc56f9ed-1fc1-45e9-a954-56dbe740f786": {"doc_hash": "8525c595238b4af624be848c616f34fd44e6acf2781b5bc831ff38636c54ad55", "ref_doc_id": "487f0446-65f4-4882-ab3e-bed2586a8214"}, "f463496b-27cc-4727-ba1e-786e7aeddbc8": {"doc_hash": "6d6f66e95eb6f4f4b3e83bd387f8e2896b31e61a98133735212f1f80d255b283", "ref_doc_id": "1dfd9907-68af-43c3-b265-7f4569dd82a8"}, "141b9542-6952-46d6-8405-bf80bc361419": {"doc_hash": "6c269400d315bcccd1b4d9565ed2f75707be9f0ff0f661888fc65c64778f1a10", "ref_doc_id": "1dfd9907-68af-43c3-b265-7f4569dd82a8"}, "4d6ed2bb-755a-41c9-bb05-b466c2676786": {"doc_hash": "f208f254f81a2c434bcf2403cbdda238cadf1caa3a14cf0c61d17b23dbe9f465", "ref_doc_id": "1dfd9907-68af-43c3-b265-7f4569dd82a8"}, "f9a8ad4b-4793-40e6-9d04-18e7afa681c5": {"doc_hash": "ec8fcc752a7fadf49dbbe1676028ae583b70c70aaf9ce3c34076a6981d2c7565", "ref_doc_id": "1dfd9907-68af-43c3-b265-7f4569dd82a8"}, "de2eebaa-da1a-4d63-bc17-3faf7f0291ff": {"doc_hash": "ca319267153c131edf568eac26ec3a8de8892ae40cc6e905a056c6ef19d23bfa", "ref_doc_id": "671cda4e-8944-448f-8054-6c718ccd0db3"}, "e4ac0b38-79c2-4ebb-8ce4-26f3ded5092b": {"doc_hash": "d453b3b288005d8d235767940c76d0f5a7cc30bf6339ae27d992d85fb587cdac", "ref_doc_id": "671cda4e-8944-448f-8054-6c718ccd0db3"}, "ff31a775-0515-49df-a20e-07f9aa15f925": {"doc_hash": "f983e8b0b44e05398bf122cfed98e8cbf66a2407588392211522369f7a4fc44d", "ref_doc_id": "671cda4e-8944-448f-8054-6c718ccd0db3"}, "4c01f901-fcef-4551-9052-b1b98f364fc9": {"doc_hash": "e5077d5cee8379a7089d21649bc87cafdc657cfb970bddfa69364d0f8daad653", "ref_doc_id": "a81e88e8-aa74-4a71-82ae-177cdcfcf648"}, "56c8371c-0e48-4e67-8af5-74f3d90f822f": {"doc_hash": "90f5653559cd4f5e97b146d1215a0fbc6fd4d893f0eff1876e3e3210d4d84527", "ref_doc_id": "a81e88e8-aa74-4a71-82ae-177cdcfcf648"}, "f4f71330-654b-4a21-a5ae-7faab9cdd2f1": {"doc_hash": "c32ee831709d86ef3584d82b8ecdedb8d633483334882c8268be310275558d16", "ref_doc_id": "a81e88e8-aa74-4a71-82ae-177cdcfcf648"}, "b9ac43ff-a56a-49ae-8e24-54eb1b4c7409": {"doc_hash": "4c54e8b7b87e175deeef16ec17affca3634eb88ec35ec4af71c69b98b28d328e", "ref_doc_id": "06ea3c36-f840-4e59-b835-99394dbf217e"}, "e1f26ad7-da83-482e-8443-f5bac68bec65": {"doc_hash": "34e70ceec0c4a6fcc640317ef6c73ea153a94779e4bf995b228b0d69cb7ec97b", "ref_doc_id": "06ea3c36-f840-4e59-b835-99394dbf217e"}, "48f93b99-d093-4b32-9f6c-a5367ff12847": {"doc_hash": "9e68d993daa2c2f710a0740a915d7c332457e5e37742d8cd52aae5b47526e9c0", "ref_doc_id": "06ea3c36-f840-4e59-b835-99394dbf217e"}, "eafe4a13-9bed-40bc-b8a4-751a7724b3a3": {"doc_hash": "f09f54b7dd09ecb6797490c9bb89e668d2632e7b46efc8711c443bc357c10deb", "ref_doc_id": "06ea3c36-f840-4e59-b835-99394dbf217e"}, "476dc7cf-48eb-42f4-ba53-de43ad766c9e": {"doc_hash": "d4b8712f3d2933165fd046d31c444ac634cad81abe95cbbd43b09cb3b4c657ae", "ref_doc_id": "d01648cf-3d66-490f-a813-395c0a26c02d"}, "c968e55d-c2fa-485e-8999-c7081f68652e": {"doc_hash": "fff6ef129e0888d93bc16e33e93ee4cd2486cb4fa39964930f8e82a8bd6add39", "ref_doc_id": "d01648cf-3d66-490f-a813-395c0a26c02d"}, "22d59266-a885-46e5-a73d-35b3c1781020": {"doc_hash": "dbc76a54b6fda16c7711ab93c313d5b144386bcf930eec1386d3922c633c4b57", "ref_doc_id": "d01648cf-3d66-490f-a813-395c0a26c02d"}, "7cb7d23e-c478-4dcd-ba8b-dce5cab26a19": {"doc_hash": "7978d8f7e79138f0c0346431628fd3af909fc72942a3a24c13bc260008434598", "ref_doc_id": "d01648cf-3d66-490f-a813-395c0a26c02d"}, "e8e8c46d-dd70-4e40-a9b7-e1bdb1591c3a": {"doc_hash": "23cf9ebad5d282ea85ec8fef29adb18fd934aeeb574dcadc82441758047894a4", "ref_doc_id": "90a489b0-c353-465c-8d7d-6417983ac5ab"}, "ebcbf99d-187e-4cd3-b16e-08da3f4349c8": {"doc_hash": "99209f906885c0ba37dd08cf1c558d568b3c18324478d29d45c3761a547ae5ad", "ref_doc_id": "90a489b0-c353-465c-8d7d-6417983ac5ab"}, "a953f635-57e9-4769-87ed-42498732ead0": {"doc_hash": "2d4be10cc8e586175db7aef1682a3c36d85c425a11285014f930943989c9571e", "ref_doc_id": "90a489b0-c353-465c-8d7d-6417983ac5ab"}, "ccf1017f-6468-4128-b21b-e83bf9c9e9c9": {"doc_hash": "5a82324d9d6baad7b53bc433635a8d98c6a1d37bff25ed06ee1b280e989a12c4", "ref_doc_id": "90a489b0-c353-465c-8d7d-6417983ac5ab"}, "cde14d95-96fd-4412-9428-83d1e6099c75": {"doc_hash": "bec84dff40643ce0fe1c1617e35cf8646f69ccb5166a11490c24d5144cbae644", "ref_doc_id": "d6049be2-6741-4b9a-962b-62d6b721da5e"}, "f49add44-9e6f-4958-9ffa-7f2e1824d60c": {"doc_hash": "4a45cc6d9d6f5c0c0ab78c0b599d2920324c62f039deaafddf4d54d7528eca1d", "ref_doc_id": "d6049be2-6741-4b9a-962b-62d6b721da5e"}, "3ee8fc74-4fad-4193-aa12-5b53ca22fbef": {"doc_hash": "81847b8ffc79b738c63a91a7f1de8dd89f88fcc8370b490060d1252c74a9b91c", "ref_doc_id": "d6049be2-6741-4b9a-962b-62d6b721da5e"}, "963b95c8-00f9-4576-a88d-382fef51ce00": {"doc_hash": "cd0cad03b4ee535ff67373a7da679c57919298df622922bfcec502c4ec540f70", "ref_doc_id": "d6049be2-6741-4b9a-962b-62d6b721da5e"}, "3725859c-104c-4065-ab66-186b172b7a06": {"doc_hash": "89d71da3d6a61fe74c8a728fbcf5a05223669a8024f09e59fe7c4ff1acb85327", "ref_doc_id": "78617b07-b153-4000-9df0-5f080884cea0"}, "f8a053e7-f657-4e43-af93-4e2d05bd3915": {"doc_hash": "eb1638bc0c06f9718fbbef900c31571a71fa19d4f31484c3cac910756c7e0d7a", "ref_doc_id": "78617b07-b153-4000-9df0-5f080884cea0"}, "40e38f1f-79db-4e41-92c0-2443ac6a0220": {"doc_hash": "62d3e5b47a9dfaddf7cbcd1767a3817fd968447379088a9a74edf4ae6dc4b34c", "ref_doc_id": "78617b07-b153-4000-9df0-5f080884cea0"}, "b355d4a5-913e-4c83-98e7-d9f2db353259": {"doc_hash": "4e448659ebcc71cd27fb9f56ef3d3d178e7781e07f8b075b54f5834b8a4048f6", "ref_doc_id": "78617b07-b153-4000-9df0-5f080884cea0"}, "d4117715-e302-48f9-b207-05a4488f6893": {"doc_hash": "fcbd39fbb85e48d13ab170e0f4f4858b0d6c661d54d3307f13b6c16a5a2fa50d", "ref_doc_id": "997b874e-d73a-4f57-a490-73f63810361c"}, "8eed13dc-c2ce-4f73-b415-a0e666fd4528": {"doc_hash": "9ee713439931e3eb0cd1dc1bef81deaac7f415494c03050202903828b3872464", "ref_doc_id": "997b874e-d73a-4f57-a490-73f63810361c"}, "1eca0253-e991-45ab-80e3-a72c880b2edd": {"doc_hash": "c83c9b270d64c70f712081b33ac663eaa22ccf6beb677a2516db2edb965c8ccc", "ref_doc_id": "997b874e-d73a-4f57-a490-73f63810361c"}, "6bca38d1-1786-47de-aa73-096e654656ce": {"doc_hash": "7978d8f7e79138f0c0346431628fd3af909fc72942a3a24c13bc260008434598", "ref_doc_id": "997b874e-d73a-4f57-a490-73f63810361c"}, "1d047ad8-e150-41c6-a26f-08da210c40b2": {"doc_hash": "6241dfb350b9ba65274b3c0f41fa15c9fd7129c7e0af5fe170c9caafce3a1e40", "ref_doc_id": "6f57cb37-f096-446b-8a86-6ad463f80904"}, "7ae82f89-dd88-48e9-855f-a46e5d60769f": {"doc_hash": "8e07dc3592d83b252ef0b2656cec58dd3dd1561eca56b1a2f684a1a5dd9a331f", "ref_doc_id": "6f57cb37-f096-446b-8a86-6ad463f80904"}, "0ae9e58f-ac3a-4c28-b1b0-a229da57fbc8": {"doc_hash": "fddd68d30f8d1d8d30ff2742e9b558b2f0700c67323d678c584fe752ef2cfd88", "ref_doc_id": "6f57cb37-f096-446b-8a86-6ad463f80904"}, "c7287a59-a6af-411e-b079-a77191b4a239": {"doc_hash": "79db73aaa367ec3544d63c993a78b7cd24d907eaaed5826be73dd260d98eba03", "ref_doc_id": "6f57cb37-f096-446b-8a86-6ad463f80904"}, "c5fc137e-6b97-4966-adc3-10aff0b6b23c": {"doc_hash": "0c46b8dfa6ac2f1cc8f8507801dce2e7e263b5e400579e35f03e7ff025936f8d", "ref_doc_id": "d096f65b-91df-4cab-9a1a-6a2c13173042"}, "340de4aa-0fe2-4627-a123-4f5f617bb42e": {"doc_hash": "ff7c663b506906fdb8c5d2260db168e108bfad0ac3c4d342b24f1da004cabad4", "ref_doc_id": "d096f65b-91df-4cab-9a1a-6a2c13173042"}, "6d50ab8a-5677-4ffd-a5e6-6fb2f805f095": {"doc_hash": "bed43e42b73f423d78894e1a7ffb2f166ee400b3b6f8d1da784c380f82752617", "ref_doc_id": "d096f65b-91df-4cab-9a1a-6a2c13173042"}, "fa75e4a2-58ab-4f47-8711-93fcf4007f00": {"doc_hash": "afd03a0e05a1d3dc3e519bf9968e4f73946b4ecbed0bac3edcf6cfb2ef360d9d", "ref_doc_id": "d096f65b-91df-4cab-9a1a-6a2c13173042"}, "a1818f55-b1ab-4b0f-bbdd-1c5ea96c12ad": {"doc_hash": "777d6de277a861817f7148c31b2d449ff2cb282d2ea6d0e6f346f27bd4e96eaf", "ref_doc_id": "24bc8201-f996-4f23-bb8a-2cd99fc637b9"}, "ad9a7b5b-fdde-4e62-b968-b06043a692b6": {"doc_hash": "a2b78a87beedb7d8684d0c39cf7f89f08d04feb335cbb412aff21f8a019d2fa1", "ref_doc_id": "24bc8201-f996-4f23-bb8a-2cd99fc637b9"}, "7ff59e37-9e3b-450b-bbe9-7c9f50d94d83": {"doc_hash": "48149e62ca68ad4b3079671de39a93e3cb8c8974285e5ad72fbdc0838ac17732", "ref_doc_id": "24bc8201-f996-4f23-bb8a-2cd99fc637b9"}, "37dff770-65ac-4ac7-ba1f-5f948bda8746": {"doc_hash": "77fb6a1fe626119ce7a1f66cf7334e68d2a3a6d08620c269c99e0fe8c7ce18d3", "ref_doc_id": "1c1e7ff5-1978-471d-ba26-cb58841ff89a"}, "83a8276b-53fa-47a4-a3d0-277dba6464ce": {"doc_hash": "40cd5fc4b472fe7a1915baeaab21e94b57c0ad03b41dbba07759d5644791a6a4", "ref_doc_id": "1c1e7ff5-1978-471d-ba26-cb58841ff89a"}, "bd3d098e-f384-4f1a-9448-ebcfa9e06062": {"doc_hash": "408dd5d3a12d3aa357de1c995ee746d9da66ccd79d543ea04bf8980f2ce73055", "ref_doc_id": "1c1e7ff5-1978-471d-ba26-cb58841ff89a"}, "4b5c1ae8-394d-4313-a071-17824ded121d": {"doc_hash": "9b4a6c9a2d2ad495a7604959b8e54e4aee7e9ab526babbcf51c272a797aa0ae8", "ref_doc_id": "66757d82-468d-4e89-bfd6-e6516b4cb324"}, "3c4c990c-c761-4531-beb2-7bb58b960c81": {"doc_hash": "2fa286be9929ea8d845bc389cab8417809d49b94aec274b9ca68289c2f36dc48", "ref_doc_id": "66757d82-468d-4e89-bfd6-e6516b4cb324"}, "1b93cb61-6364-4deb-ad88-f63669693558": {"doc_hash": "655417b7a12e4005e3603352d50bca9d19024a3332d55f5c80c884f4ce32ef6a", "ref_doc_id": "66757d82-468d-4e89-bfd6-e6516b4cb324"}, "da1c4d03-5d64-4763-9dea-e7f397553b08": {"doc_hash": "7d74039b27a74292728e411fe87c70961f672bde780dc197c8fa0c1ffab197b5", "ref_doc_id": "66757d82-468d-4e89-bfd6-e6516b4cb324"}, "eb59f905-005a-4f1d-93b2-369f48816c7f": {"doc_hash": "52a549a1ba38bb6222a1a9170403dc41d19cd760b7d4259eaa04f8703334910c", "ref_doc_id": "3ded5d19-ba3e-431c-8c91-8993af126911"}, "c009e2aa-a2df-4fc2-97b3-8c5dc00559ea": {"doc_hash": "6fda4d2ed804eb1a376979f04e5307c15b7fbe4fd2c73f5f9a45353908dfa6ed", "ref_doc_id": "3ded5d19-ba3e-431c-8c91-8993af126911"}, "0a8a33dd-ac42-4f41-bc47-a86ee0506601": {"doc_hash": "77316ed2255e4374ce1be32a1f6975411b6a599c0a776710916101d06099f2a5", "ref_doc_id": "3ded5d19-ba3e-431c-8c91-8993af126911"}, "952253bb-36c9-4b13-9f68-7a3acc1b5148": {"doc_hash": "1ad66bdcaa7392671f9ef7914411a0d783746dc13c2caa5b4242885c07209293", "ref_doc_id": "3ded5d19-ba3e-431c-8c91-8993af126911"}, "a8369808-da1a-472f-864d-5e7c5a640d50": {"doc_hash": "fe34727683d128d5a8a17dd71b6ea9602bda790254912fef380da8a96394be6c", "ref_doc_id": "b26ba6c1-9ce5-4cc3-bb19-6fc5dea556b9"}, "f94fea48-051b-470a-a19a-0de86eff7b73": {"doc_hash": "301a6ab691863db9d5fc997b92489cfb87db7221454dc67c8ef1c5526e079aef", "ref_doc_id": "b26ba6c1-9ce5-4cc3-bb19-6fc5dea556b9"}, "6449eaae-0e1c-4d1c-bd85-c83ed3c005e1": {"doc_hash": "ac06434e41aa9f13e895ddb31ff3ee3261c2989dee7b945cfb2cbcea34f00622", "ref_doc_id": "b26ba6c1-9ce5-4cc3-bb19-6fc5dea556b9"}, "4774f6eb-f32f-4b3a-9f1b-683869895af4": {"doc_hash": "20d006b2219b4afa0044e94d0e2f1c4b24fbe90556d86028856710fd29b07f01", "ref_doc_id": "dd900cd0-597f-48ad-9805-a97dbcb03071"}, "25c359c5-81b5-4928-80fb-6c47f4074a0c": {"doc_hash": "4881d6e197ec92eb5b8cdb12948033773878307b7502338557388bb4dfef9278", "ref_doc_id": "dd900cd0-597f-48ad-9805-a97dbcb03071"}, "58cda90e-5c88-420f-8829-eb72ff79e9f6": {"doc_hash": "c9c0c89d504d13e1d1e9cf5a18e01a1280972d0bedfeb82179a4ee4738072dd4", "ref_doc_id": "dd900cd0-597f-48ad-9805-a97dbcb03071"}, "b4de6e89-0921-4f20-aa7e-d7270cb7ae35": {"doc_hash": "cf8fac0fb6f4b0156c49bbe3a3bb777efce4c659f20758ec19826645bc85b55e", "ref_doc_id": "dd900cd0-597f-48ad-9805-a97dbcb03071"}, "a9f87f9f-2d1c-4cc4-ba38-e9161447ff4f": {"doc_hash": "cf002d95d5d2fe47e4be5026559094546c93418900531f06ecc5f628c625f1e9", "ref_doc_id": "4bc0fcc8-190d-4968-892c-df3ca7512fe8"}, "22cc2716-bff3-4348-aee1-23518b0c00c1": {"doc_hash": "013a4d2b66c1e0dd2d558630226b81cd5891613a61d3da1ee8e8d9bed40e1c94", "ref_doc_id": "4bc0fcc8-190d-4968-892c-df3ca7512fe8"}, "1e0166c7-fd61-47c7-a387-935f88dcbf45": {"doc_hash": "880033c548fcb11263e9bbc46ea53c0998c8d9d508323fdd3037f61b982900ec", "ref_doc_id": "4bc0fcc8-190d-4968-892c-df3ca7512fe8"}, "e30a455b-12ae-42a7-b392-71dc0b1d1d04": {"doc_hash": "17702c550ebe3e1e1a8eb62a79e7270e5161b43eb8bcc15d004cf2f91b26cd0b", "ref_doc_id": "4bc0fcc8-190d-4968-892c-df3ca7512fe8"}, "489753a0-dc7b-4f3f-b57a-229f5a66a947": {"doc_hash": "fecedac661b53ad6d7b2b145450ab2e43634a01a3039a3a9ad6d9e237ffbd186", "ref_doc_id": "72a1c3c5-1335-4c75-b26b-1803c0d2eaff"}, "ca053614-ff23-4f9e-adcb-fe7da617b7b3": {"doc_hash": "e0260eab0a4c32f77c4b7e54f9d30fb13e4d91ad12c1715cc383d44e9f2f525a", "ref_doc_id": "72a1c3c5-1335-4c75-b26b-1803c0d2eaff"}, "0af86f6f-684a-4de2-8456-18785313fd2c": {"doc_hash": "a4e3634affa33d171c04be0dd00e1178d63d5c1cfdcf9ba11d220971df914f22", "ref_doc_id": "72a1c3c5-1335-4c75-b26b-1803c0d2eaff"}, "bc60bb06-4f3e-4669-8a1b-804761b19e9b": {"doc_hash": "93d9a947ef2f35c2e4c9c9d431f91c1105251408f58978cc1919ebb4a86539e5", "ref_doc_id": "72a1c3c5-1335-4c75-b26b-1803c0d2eaff"}, "eaad1912-b8bb-435f-92e5-f19148d5e2ab": {"doc_hash": "73d4dcdf342723800042acd704dc1edc490120269ffc73081017ad3279672a84", "ref_doc_id": "e652a10a-ba4e-43e4-9d91-6a2c478b54f3"}, "6cf3a57d-51db-49d4-92d0-a8b583d09504": {"doc_hash": "a26c440a63f6a4e9188f4c6af34f6f94f85e18fa29a47a59799b64f92ee1d634", "ref_doc_id": "e652a10a-ba4e-43e4-9d91-6a2c478b54f3"}, "59d995b0-8ede-4b0f-9ad0-b3319356c9fd": {"doc_hash": "df36eb7e59f99349d76df28b9e0722e6324c300a79ee9c20fdc80037003c3376", "ref_doc_id": "e652a10a-ba4e-43e4-9d91-6a2c478b54f3"}, "10d8a31a-564c-4924-91ee-30a43a1192aa": {"doc_hash": "d510c481ad2ee547641af8bec04876b9f767597f1df833b139e95cc143d35fe3", "ref_doc_id": "e652a10a-ba4e-43e4-9d91-6a2c478b54f3"}, "9c4a741f-f118-440b-9c73-4bd61d421d1c": {"doc_hash": "4e8d8db51bd09a57fadafa13924d5c443861d3efb939500fb21e981557cfc543", "ref_doc_id": "1bc37f17-7742-409c-8d61-1d45f5c3b01a"}, "1792aa38-bf95-4e63-b115-b8ce074da9e2": {"doc_hash": "2b30a93fd7e8c36bf61e5c58ec3c832cd4c38088a13b66b6b979b2968ea4ceba", "ref_doc_id": "1bc37f17-7742-409c-8d61-1d45f5c3b01a"}, "2ac72ee7-ee20-44c9-8618-7c5a11f4d99e": {"doc_hash": "4c2d5d64e27e54e349055b8e445a694e410570df40e79abb8b9f3ee56f7add80", "ref_doc_id": "1bc37f17-7742-409c-8d61-1d45f5c3b01a"}, "e0b63f00-acb3-4148-8865-2ac10f9a491f": {"doc_hash": "c19e10cd8f5fe33e686c3a746c51cc30e4691ba1933a98a52d5e680846121d40", "ref_doc_id": "1bc37f17-7742-409c-8d61-1d45f5c3b01a"}, "9012f71b-4b25-460c-a8c5-8a7911d01f9a": {"doc_hash": "b9060e85cbf6261baa0992166c95e30fcaac47904cd43a86ff39e22dee86adb0", "ref_doc_id": "40fa6b97-cac6-4995-9694-37d6f39324b1"}, "8aec57d1-ac7c-4edd-8c17-8148492378cd": {"doc_hash": "8580fe1fe6cbc8a7244e29f91475b304595fbbceda8dc3f4fd38aeba2c2ff02c", "ref_doc_id": "40fa6b97-cac6-4995-9694-37d6f39324b1"}, "02dee197-b316-4cae-9083-0eca374863b4": {"doc_hash": "70d8e22c0b0a83cbeb1a849d7584d6d5a7343971e58437f13dd4103ff20295e0", "ref_doc_id": "40fa6b97-cac6-4995-9694-37d6f39324b1"}, "bd4ded46-0595-4ae8-8643-bc0af6019a4a": {"doc_hash": "01167692e0f299a8abedf8361f2eb2a9c80fb6c5483e3b6ffa4132302ac1ba1e", "ref_doc_id": "8d66af4c-ecef-466f-8a33-3db59aff07e8"}, "1b66cf91-a05a-41fc-a86a-e9c836adee2a": {"doc_hash": "1339535489e12dbd79a2d341a04966f0d231ae642586c8ae0f662bbf06d0902f", "ref_doc_id": "8d66af4c-ecef-466f-8a33-3db59aff07e8"}, "7520d7c5-f166-4c97-8b41-58e19ff2289b": {"doc_hash": "ce3c862927ee022010d862731d2a744aa4398b99b1a6dd0258642c09aa8808e6", "ref_doc_id": "8d66af4c-ecef-466f-8a33-3db59aff07e8"}, "c18d9974-38e4-4edc-bb6e-3ac01e767c4b": {"doc_hash": "1ba63711f65ad6f4dd6b7b6019a4fb63593aa379658dba81da8631d9e03e8727", "ref_doc_id": "8d66af4c-ecef-466f-8a33-3db59aff07e8"}, "d52c2ab9-dd69-40ba-9edc-36359b6dcafd": {"doc_hash": "44b103d62c54b79254979b32bf0599749053564427903971d62d07e5d35d8d8b", "ref_doc_id": "1dbe19fa-7132-4758-92a4-06c10cebc198"}, "ef65e270-2fbf-48cc-8d14-ec74b2b05f67": {"doc_hash": "423650cfce17122ebea8e5143a9bf84082d2ba82bc3dbc1ad179692109f56cba", "ref_doc_id": "1dbe19fa-7132-4758-92a4-06c10cebc198"}, "a6c765ba-91bb-4829-b068-8968f3411279": {"doc_hash": "6083d84f17f08bdfdf9e07b668d1daef7773c06f576de263ab500feea1b1ef6e", "ref_doc_id": "1dbe19fa-7132-4758-92a4-06c10cebc198"}, "89e7509d-e2b7-4d9a-8ae8-b832c8da1b32": {"doc_hash": "e61a993bf88a999195c4983eb86a2579fcdccceda0eacee863969a8d6bb9c941", "ref_doc_id": "105d7069-5266-4bf2-a3fa-a3b49898b22e"}, "dcdfdf5e-02f4-49eb-842b-629498b0a089": {"doc_hash": "ba58754a2b7a1a6f50d2e38cacf228b852192566d25c99039c99a2b7f1e4d4dc", "ref_doc_id": "105d7069-5266-4bf2-a3fa-a3b49898b22e"}, "5f467e84-1f34-48e4-a634-821228999c5c": {"doc_hash": "8940c1e02296316349f059c952c492c269287bc3663f3956986ccd1cc7629400", "ref_doc_id": "105d7069-5266-4bf2-a3fa-a3b49898b22e"}, "586fe2c3-c535-472f-9189-452f66d382a1": {"doc_hash": "c35a7fffb058c8b1ffdbb6c26908078c2db41e064d7420531d9d24870b3dfd7c", "ref_doc_id": "e4ce00ce-7ddd-4459-9e54-1411121bbf37"}, "e358d092-6ea3-4da1-9b0f-86634fe3b3af": {"doc_hash": "c7200dc9d8f4bb1bbd4cbfc62cd1f11da2bf6514f4d2450dd17cebe85088b455", "ref_doc_id": "e4ce00ce-7ddd-4459-9e54-1411121bbf37"}, "d2910286-7626-47e1-a289-9ee294e2236e": {"doc_hash": "536837ec667d5862cc838b64681a7077f93777008e7152bd7767c688d4c8962e", "ref_doc_id": "e4ce00ce-7ddd-4459-9e54-1411121bbf37"}, "4e0fe710-2980-4b8f-9586-d2fed5ba51c0": {"doc_hash": "fcd336470faccbfa46af4395df2af45b72d46065c0f49333be0ea4dbd71fc57a", "ref_doc_id": "e4ce00ce-7ddd-4459-9e54-1411121bbf37"}, "9dab2bc6-d7d9-4b2b-bdbe-f5860e3a7b39": {"doc_hash": "a5928918e6766b98051261a8c0628e5669a5a5904d87252a9b165c70abe714e0", "ref_doc_id": "5063b093-a32d-4dd1-bec8-c39a3f8c618b"}, "658136fc-110c-423b-a2e2-673d30cab125": {"doc_hash": "76251ce4c914951c37f8192a38805ee4a74fb6e55e18bd62ed78b1300a6d4dec", "ref_doc_id": "ad7d0a21-3e29-4e0a-af01-2382c406de2a"}, "49d83f81-a8c4-47ee-836f-82ceabc06c60": {"doc_hash": "2e914907f779271acdb5a727681f8bae2c94f527269ae90e1056b988f524d13c", "ref_doc_id": "ad7d0a21-3e29-4e0a-af01-2382c406de2a"}, "39c7ddb0-fce0-4e67-aea5-69aa567901de": {"doc_hash": "e788a0076d4317772a75ea0852b942594b67e5690267f68e954bf10008699055", "ref_doc_id": "ad7d0a21-3e29-4e0a-af01-2382c406de2a"}, "adb69bec-50f8-44d8-8af5-416182d544ba": {"doc_hash": "b4dfd35e25701b9141767c33b37873b73ad2b7ff08ced267ae2725cabd611bbf", "ref_doc_id": "ad7d0a21-3e29-4e0a-af01-2382c406de2a"}, "1c229caf-7c30-47d6-8a0a-2a2d3c5514ee": {"doc_hash": "c9a2c1da3f738793866b1918d676286d3bf80337e60cbc2bc897a00ebddd9466", "ref_doc_id": "9902a8c2-5457-4a78-82c1-b431991caf64"}, "c42581a4-29c6-4310-903e-8a9dc1dbab99": {"doc_hash": "abd23ce2bb211c2726cb11d2c14b4007c5210f6a3c9b6d9f79aca2a1c7d29310", "ref_doc_id": "9902a8c2-5457-4a78-82c1-b431991caf64"}, "6d33e945-d4c0-4691-8ed3-407e23aeb35e": {"doc_hash": "a8dfebfa8172b5e487567bb77e3ece13f4fea8ff48dbeb11b7ea882294612342", "ref_doc_id": "9902a8c2-5457-4a78-82c1-b431991caf64"}, "ae989339-631d-4def-935c-d770077c2933": {"doc_hash": "8368a7e4b8667c80ecece4e915cd22015556a8263939d0293a8373638ad2e9dd", "ref_doc_id": "9902a8c2-5457-4a78-82c1-b431991caf64"}, "d8aa07ea-9972-479e-a448-8334e662da33": {"doc_hash": "2d6aa0c5247b83431b2c6d1b4049ff74e4f57ba2cf2c5f9cbb769741f564b2bb", "ref_doc_id": "883fdb2b-3ab4-4258-9211-abfc1afbb23c"}, "792ab654-96af-43dc-b817-0b3dfc8f9faf": {"doc_hash": "0cf915c2afe8163331429cd5bf2209363c8deeb28383771a9e0eb08631fa475e", "ref_doc_id": "db333755-7304-4d6b-9ea7-6a8a3e1e075f"}, "00a41ff1-4456-45ed-927b-2805c2579936": {"doc_hash": "16b85419499d6189f727ae6600ac66a02b9ab37415fe9fbd2b8cf41e6742b51c", "ref_doc_id": "db333755-7304-4d6b-9ea7-6a8a3e1e075f"}, "d7cccca3-14f9-4572-a46a-e5909620b90e": {"doc_hash": "fae47570f0ddb40bba292e21d29d5fc8d49cd2148f1d0ddb8c981d81c2506176", "ref_doc_id": "db333755-7304-4d6b-9ea7-6a8a3e1e075f"}, "5e0a450e-6dc4-42d6-b7b2-6de749c52350": {"doc_hash": "b0f3df20cf6a2faef2deaf5d523fe7d402bc54b4e49953ee7e4967f034e1bd6f", "ref_doc_id": "db333755-7304-4d6b-9ea7-6a8a3e1e075f"}, "b7e13590-8791-4629-b2c5-e1d24c641aaf": {"doc_hash": "e75b20cb33cf50527f6a413ce1e764946c1fec14a37a3e1e827fb9ed5e098b6b", "ref_doc_id": "27e7fbff-4a42-4e21-9625-d7726ea2e19f"}, "1d5176e3-dbdd-4c66-8ca8-e5874094ee02": {"doc_hash": "53e4db5c1e6341452b0f129bfc0af1d33fcfa3d40234f7436754dc979ef0244f", "ref_doc_id": "27e7fbff-4a42-4e21-9625-d7726ea2e19f"}, "41ff8c99-fa75-489b-9740-41bd06363d24": {"doc_hash": "44576ac7dc7915d974a3e419af5822f430c7f2e8ace62a4d323519397d1a1a78", "ref_doc_id": "27e7fbff-4a42-4e21-9625-d7726ea2e19f"}, "de658d79-ea8d-478f-8692-88cbe424fd65": {"doc_hash": "4caec64a7f514bc83e4c2680710b61e5c271038daeafc43bcd26e7e6fc637c1b", "ref_doc_id": "b8663f18-a984-4313-98e9-31be402eb51a"}, "80f75769-d5b7-4bd1-8f58-1e7325f29b6a": {"doc_hash": "27f24bc35144541b28c6e40bca8afa07aab3d5ad5a06ae9e18d23a1630cb8200", "ref_doc_id": "b8663f18-a984-4313-98e9-31be402eb51a"}, "cd440220-dccc-4636-98d4-8b2ec3565af7": {"doc_hash": "29839c6da8bc683e8909c263e7f7c0f0088723c62206ffe5be74190d8779af6e", "ref_doc_id": "b8663f18-a984-4313-98e9-31be402eb51a"}, "ca0da5a0-5b58-487b-be61-1cfddb8488df": {"doc_hash": "1fd963dcca355c200d21bfec3f2fcf35f739327d5c27154249b63782f15c1b10", "ref_doc_id": "b8663f18-a984-4313-98e9-31be402eb51a"}, "892ba7b3-421f-4771-ae77-73466e2bcfa7": {"doc_hash": "fb3376c1b6f6a3ac06a73ee955b6627a2f7a24279ee4a660cab4c83bb74fe818", "ref_doc_id": "b8663f18-a984-4313-98e9-31be402eb51a"}, "635a6896-84aa-4c99-9f94-0d498af2f29c": {"doc_hash": "9d96e5114bda6443270fa05860fe706b78db963f1da0d8e15fc409feb68bb123", "ref_doc_id": "b8663f18-a984-4313-98e9-31be402eb51a"}, "9c72ad10-f9b4-464e-9195-3bc59dcf1af9": {"doc_hash": "3e7d4b1ff8e1a3268130139ba3c6e964e922fe0cb82bb73ed7de8be364279b1a", "ref_doc_id": "b8663f18-a984-4313-98e9-31be402eb51a"}, "6dcb522b-391f-4d43-a61b-0a0984ab010d": {"doc_hash": "ff751f95464ffb7c99c0728182cc68a3bd75dec235ca6e74bb44b965dad42d6c", "ref_doc_id": "fead70f1-cc0a-4faa-a49f-b49c6202bad4"}, "d7dec904-665d-4332-a297-7797d199e171": {"doc_hash": "34b3a27c64c57889747baf935f798267cc84932f7110ac03d4d7bd3800b593a4", "ref_doc_id": "fead70f1-cc0a-4faa-a49f-b49c6202bad4"}, "369f5fbe-afa3-4572-96ac-19776ef25b93": {"doc_hash": "11ed3aec4f366073b7466a59d445ce0201423f2f4fe247b28f92877c574f9edc", "ref_doc_id": "fead70f1-cc0a-4faa-a49f-b49c6202bad4"}, "6d92516a-c9e8-4eec-8f3a-aa390d1cd2ac": {"doc_hash": "a01cc48b1267c7461cbdf6645b1fb5597b360d1a753439dab7f0b77d9248a1a5", "ref_doc_id": "fead70f1-cc0a-4faa-a49f-b49c6202bad4"}, "8c78b5db-df48-4670-b09b-9167269fa92c": {"doc_hash": "2ff90a58a3f1e7c05bff229fc0344871c4b699436e08c835302ba00afb2adf7b", "ref_doc_id": "fead70f1-cc0a-4faa-a49f-b49c6202bad4"}, "908eac1d-4018-4261-bfc4-8277c30745e2": {"doc_hash": "90b0266a7c848c8612cd4723c9dbd3866cbf3157b9329ab635624b1d2ab97a47", "ref_doc_id": "c63ea98e-a01c-44b8-9f33-adf025ad6602"}, "1248f89d-a96c-4f17-aec9-4e52135023e1": {"doc_hash": "798e53cb45c187431660b854bdb39be90cd4a5782ca50f5f57684b7fc3ec558b", "ref_doc_id": "c63ea98e-a01c-44b8-9f33-adf025ad6602"}, "e3ebdabd-f2a1-47af-9ed7-e92ea87fc650": {"doc_hash": "55986c071e339e53b8cb2cbfed95b36dfc1904d8cb3c5a97c05c5332719560c4", "ref_doc_id": "c63ea98e-a01c-44b8-9f33-adf025ad6602"}, "b4c100e9-544b-4032-9c7c-a6e44c0128f4": {"doc_hash": "7c0963c716798bca62791cb0372ddc8e3a71415cb6fe26fdf02d6e7b4cc3c175", "ref_doc_id": "c63ea98e-a01c-44b8-9f33-adf025ad6602"}, "c82ed093-b94f-4309-aa65-eb4686cd5c0f": {"doc_hash": "0a7542ef30faa1c6e2f2b42d1f04b8b355e26407a0be4bfcac3b31d73e9bdb5a", "ref_doc_id": "00f89055-c291-4589-9e59-c47474e50130"}, "9929b247-1a5f-4541-9eb8-e3a1d4e2a7d5": {"doc_hash": "3dbf480e67074133706901ac71e75f3cc46698d23fc1ecd010b4e9835739516d", "ref_doc_id": "00f89055-c291-4589-9e59-c47474e50130"}, "22f2515c-4e63-4f88-a6de-43c34a996cbc": {"doc_hash": "f392cc942547a6acf60d2a7187914bf45269553e449c0945856137dd6800cea0", "ref_doc_id": "00f89055-c291-4589-9e59-c47474e50130"}, "fc56a0bb-204c-4b36-89e4-276e8254e7a0": {"doc_hash": "fe3d42702c1d2372ff79ce34ac937778aedb215ebb4c97fdca0a7319e5570460", "ref_doc_id": "b0e52743-911b-4a5f-a6c4-f12d9edb9289"}, "ea6a11d5-11e5-4731-9903-f2f31fc797e0": {"doc_hash": "f6c1669b44e57b3c2c8a673d0231245a50b4847b44f814df54aec276b5bd7d26", "ref_doc_id": "b0e52743-911b-4a5f-a6c4-f12d9edb9289"}, "ca57c163-69d1-4092-819c-1f383c7e114e": {"doc_hash": "4615af224f5a3f274fc651bfc7bd30886b90a1a6b02de4a9f3c843c10712fb08", "ref_doc_id": "b0e52743-911b-4a5f-a6c4-f12d9edb9289"}, "5b4b8088-844b-43ac-b5c2-f7d46de7710f": {"doc_hash": "c5f202560c198865c3358e6fcdee593da20455444d0af3e6b9c82b4926a119e5", "ref_doc_id": "b0e52743-911b-4a5f-a6c4-f12d9edb9289"}, "b8f86ef4-8f55-4156-80f5-e20b78d58995": {"doc_hash": "5629e41427630f2f7e00ffcbc81033c9b307ed2cc7b4df8227f9881dca875b3b", "ref_doc_id": "b0e52743-911b-4a5f-a6c4-f12d9edb9289"}, "f51c627f-6fcd-4938-933d-15664f6a9564": {"doc_hash": "b5f3e91d8f4e6e3b149dfe4a9abc915ed8c212dbeff218f0c17f408cad762fa7", "ref_doc_id": "c22672c7-9436-4df9-9531-b81e104aedca"}, "73e47913-5174-471f-9672-74b4474e3612": {"doc_hash": "2e53eee5c548ae2d3a020a08630418e0e2e35f4e55591f0ff72479db2c4b025d", "ref_doc_id": "c22672c7-9436-4df9-9531-b81e104aedca"}, "45ef922d-5078-4ed3-a2c2-bb6b07933eac": {"doc_hash": "cd3b0507d57b4351304a20bab095345a3b4a8e8a9e6da96047808dfba33f53d0", "ref_doc_id": "c22672c7-9436-4df9-9531-b81e104aedca"}, "e7461657-d4cb-4018-9124-570a03386644": {"doc_hash": "2fcf655b08592b802f0f970bb8858d28bc7b4a1108f81f95c39a4e57d4b87e89", "ref_doc_id": "7a475de4-81c7-44f5-8826-c442acb7a396"}, "b39189a5-845b-4ce4-9a78-19955830569a": {"doc_hash": "66dec63fd03c5b0ff46fd320375d46ad72a6236758a2b2819dc0a10ce35abd04", "ref_doc_id": "7a475de4-81c7-44f5-8826-c442acb7a396"}, "9ce181c2-d05f-4ef2-8249-9a5662f38dfd": {"doc_hash": "a837ec27688351a8a3f587d35243277166da71814457c2f7ed6cdbc37300ce85", "ref_doc_id": "7a475de4-81c7-44f5-8826-c442acb7a396"}, "b3002bd0-f7f9-48b1-857e-6a29bbee824f": {"doc_hash": "70fa667ce23274b356dfbf5f8125ec2486b559c5b3194acc94ea9830a8d11592", "ref_doc_id": "e5f12b3b-6830-4f35-913b-592305c682be"}, "6df321de-b7ec-4532-8aea-a104a0f4c01a": {"doc_hash": "16a37c6679c217ca5511697afa9b87ac5d32b75d60f75fe7ea6595a300ccfb1d", "ref_doc_id": "e5f12b3b-6830-4f35-913b-592305c682be"}, "031e7b18-e8e3-477d-9849-b5775667473e": {"doc_hash": "f477137b00578b25e44bb670fecba7924f91ea2c15e35c82cd24d6bfffef8363", "ref_doc_id": "e5f12b3b-6830-4f35-913b-592305c682be"}, "6e82bcb0-f426-432f-88a7-3ab60aaeeb7e": {"doc_hash": "a0763d678e63126a9aa9a3fa89497f848d2676688845fda7d2af3778583e331d", "ref_doc_id": "51b691a2-5a4b-4e7c-a60b-bbc029ff72d9"}, "8f6fd072-eea0-447c-b81c-da513e2f27d4": {"doc_hash": "8ead42f54aa7c7e253d12d2a9ba4bff8aab5aacf9bd9466949c23f5eb7b79f1e", "ref_doc_id": "51b691a2-5a4b-4e7c-a60b-bbc029ff72d9"}, "b7838844-e90c-4d4a-928c-594b5bfdf4d8": {"doc_hash": "4125b9419732d455682db29dcfafe9e49a700f96a56a872be43d99c7a95ccd36", "ref_doc_id": "51b691a2-5a4b-4e7c-a60b-bbc029ff72d9"}, "d5070772-fd4d-450b-9098-4c60f7b0b404": {"doc_hash": "04f63fb1a2b25a7e412890dc51077c616ec7e093ec845bcb2b6afba3cb1e5c64", "ref_doc_id": "ab015375-8dec-405f-9b23-1e921ebe6904"}, "62d5ae79-716e-4eea-910e-46fb2db0a78d": {"doc_hash": "6f3c3aebc392cf6bc8ab3383e797fb16f634d5f1ed4caa9c94c2b11c8d6f154a", "ref_doc_id": "ab015375-8dec-405f-9b23-1e921ebe6904"}, "2d2acda1-7717-47b4-b288-302caf732c6d": {"doc_hash": "1c0a5bd3722775110b04a838887f5640faee0620c47e9b13491d2a7879edb84a", "ref_doc_id": "ab015375-8dec-405f-9b23-1e921ebe6904"}, "2703592c-c6ac-4f31-8389-0dee55c47a73": {"doc_hash": "6471d737c7537ebf15ca97cebfb643d6251bf383a9b5524475256fe1579a2bc8", "ref_doc_id": "ab015375-8dec-405f-9b23-1e921ebe6904"}, "db9ca3e5-ad8b-4927-a2b9-ad2c67bbab11": {"doc_hash": "e1eb7ae83ffa431289a3aff5dd639d8660f6f5bc51df4d8d64e2ef1435ccbc5b", "ref_doc_id": "d3e15656-ac50-4c58-86f8-bb385546b9d2"}, "399c07c0-cd2f-4101-bb7c-e4dc9586421e": {"doc_hash": "459d19a68a926734785afa0311bdd653118b455f643ab718bedaeb01e1a482d7", "ref_doc_id": "d3e15656-ac50-4c58-86f8-bb385546b9d2"}, "2c027a6f-f532-4c5f-a73a-957e5859a3ae": {"doc_hash": "566ce365b5bdbe9c4551b76783781a02f50da0bde91e623583979299e2366f93", "ref_doc_id": "d3e15656-ac50-4c58-86f8-bb385546b9d2"}, "4abc5c52-20c6-4150-bc64-a4f9f4d08cc5": {"doc_hash": "949298ea0be1e5d457bf34f7f61ad5b3a92195edabe8f95eeb1023704c1bac42", "ref_doc_id": "084919ce-227a-4a3e-8f93-78f25e33d762"}, "8aae1fee-40b5-41a6-b65c-b5550a6ed1fa": {"doc_hash": "4f1e4c2e14ab8117f6da26f6c4152ffd03bd81dab910b0376a80b83fc0d53a80", "ref_doc_id": "084919ce-227a-4a3e-8f93-78f25e33d762"}, "e786b3d0-bd54-4db9-adf6-2f5d4c8b5d97": {"doc_hash": "23a7050f57ef5221ff392a2a317c7ee8636edcb6c254ade1e02bd46b6b28fe0e", "ref_doc_id": "084919ce-227a-4a3e-8f93-78f25e33d762"}, "1d93f28e-aafe-4c1c-9b30-754af8e7dc61": {"doc_hash": "c1d34ee26abb2bd110b14f3bef93d4ef31a415c17114cb0c458ba71bc115670f", "ref_doc_id": "e50b7613-6371-427b-8eef-f34555dd6a3f"}, "d9f562b5-380b-4440-b17d-a77160c751cc": {"doc_hash": "e977523b27c71b067195228585906723737911e6b7bb9326e01459f11bc1dade", "ref_doc_id": "e50b7613-6371-427b-8eef-f34555dd6a3f"}, "f253ac9b-bb44-42bf-836b-065957a1bf34": {"doc_hash": "377e6b6c0f8e87c3256c055ff05b1c1de61cfffc5a5f3a2f1dc0549409d05aed", "ref_doc_id": "e50b7613-6371-427b-8eef-f34555dd6a3f"}, "16d5f712-9c20-4c83-ab32-b03c35af0ffe": {"doc_hash": "cb6b9da0fa6e64bafeb2c034c0c41ea1aa2a73ed2ebcf65c88da3e4aeb8d21a4", "ref_doc_id": "e3cd3045-eee6-4846-b02c-478a6e9e8e27"}, "0d072b2f-7bf5-4e10-bfde-93f0436daf4f": {"doc_hash": "ff95034dd4aec88a8ed9a43dab63531bed36cc0c0e81fda95944373b0bf41e43", "ref_doc_id": "e3cd3045-eee6-4846-b02c-478a6e9e8e27"}, "d914c8a2-7c2c-440a-92eb-5735fd5a2862": {"doc_hash": "33b78dafabacb3620c4cd3e97d18fad8d4b8f7ce4f2256b57e112ead77711a56", "ref_doc_id": "e3cd3045-eee6-4846-b02c-478a6e9e8e27"}, "7a2e717f-8e4b-41ca-9ac5-3ed519fe5e2f": {"doc_hash": "3655a731e6568f88c3e129631757c5fe06d51f15c4e263633cf57c212f15dad5", "ref_doc_id": "4aabf2c9-5a8a-4a57-869f-e3668a4ce6e1"}, "c16f0fce-7bce-478e-bad9-63bc2cf3a153": {"doc_hash": "9e85d8db2a6823b757fe3662fa0270a6ae9a6dd3cc6fb7d532dcb77aee822733", "ref_doc_id": "4aabf2c9-5a8a-4a57-869f-e3668a4ce6e1"}, "22c7b819-396e-4d24-999f-0dfb570ce7e6": {"doc_hash": "25520556547731beb9199fc28db154dfe5173ed1cdcdb0d0f3d31c2e4a8c7bce", "ref_doc_id": "4aabf2c9-5a8a-4a57-869f-e3668a4ce6e1"}, "aa7041af-3aac-456d-b0a1-8a0d827fc4dc": {"doc_hash": "22150bf93e9c2853839e5754bb788ef601bd7af717c5312bf3a125bdd4be2116", "ref_doc_id": "fc4497c2-ec0a-4405-b523-9c6e940267ae"}, "826083a6-bb32-458d-ae5c-04a0dbab7a1a": {"doc_hash": "270941fa34efc09521b0b2294a484b33f387878a61b78d48822bacf4e17b6325", "ref_doc_id": "fc4497c2-ec0a-4405-b523-9c6e940267ae"}, "29cd5b70-adf1-4496-a82a-6c6233cd1143": {"doc_hash": "fce709067b0a52aaa139cedc831f81892c9f75c5be4ac896e94bb3540fec83d5", "ref_doc_id": "fc4497c2-ec0a-4405-b523-9c6e940267ae"}, "1d828df3-1379-40e1-8a5a-a28967484883": {"doc_hash": "3b425542b0fb07d0bd96d651d9c6649a7e099ff49865de64d5867ae5e5483565", "ref_doc_id": "aaa3ae17-2f8e-4799-9eca-0349973ab0cf"}, "9694ecf0-5498-4905-a78a-344dc77f2a05": {"doc_hash": "ec71ab6ac6c60f23e8aa485f5751f0e3ec59c63e82918d12c246330d7dcf3f8c", "ref_doc_id": "aaa3ae17-2f8e-4799-9eca-0349973ab0cf"}, "f375cf8f-8eea-4f94-b959-9b217d2ceb36": {"doc_hash": "f016016310a884f5c896744f3a328bb381a1262c5367fd352c4f931966c4309a", "ref_doc_id": "aaa3ae17-2f8e-4799-9eca-0349973ab0cf"}, "c53e7cb0-f9f0-4060-81ee-860fceb3d712": {"doc_hash": "e22c84e403d9235a1f1e00df8223314a61c9c3cb4aa3f5e3071fe9b814bc63ac", "ref_doc_id": "aaa3ae17-2f8e-4799-9eca-0349973ab0cf"}}}